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Summary
Nicotine is the major psychoactive component in tobacco and specifically activates 
nicotinic acetylcholine receptors (nAChR) present in the brain, ganglia, and at the 
neuromuscular junction. nAChR on nerve terminals in the brain modulate the release of a 
number of neurotransmitters, including dopamine (DA) in the striatum. This research 
project has focused on the in vitro pharmacology of presynaptic nAChR modulation of 
[3H]DA release from striatal synaptosomes and slices.
Pharmacological studies in Chapter 3 demonstrated that, in synaptosomes, the
presumed a7-selective antagonist methyllycaconitine (MLA) was also potent in inhibiting
presynaptic nAChR on DA terminals containing the putative a3/a6(32p3 combination of
subunits. The novel agonist iodo-A-85380 was also examined and results are compatible
with the presence of two populations of nAChR subtypes on dopamine releasing terminals*
in this region of the brain, both of which may include the a4 subunit.
Superfusion experiments in Chapter 4 progressed to striatal slices, to explore the 
functional crosstalk between striatal nerve terminals as a consequence of nAChR 
activation. In slices, nicotine, in combination with a7 nAChR antagonists and ionotropic 
glutamate receptor agonists and antagonists, confirmed and extended the proposal that 
glutamate release from glutamatergic afferents, elicited by activation of an a7 nAChR, can 
enhance release of DA. Preliminary results also demonstrated enhanced co-operativity 
between N-methyl-D-aspartate (NMDA) receptors and nAChR to release [3H]DA from 
striatal slices compared to synaptosomes.
In Chapter 5, the neurochemical interactions detailed in Chapter 4 were examined in 
animals chronically treated with nicotine prior to superfusion. Consistent reductions in 
[3H]DA release were noted in striatal slices from treated animals compared to saline 
treated controls. Application of some of the antagonists used in Chapter 4 suggested that 
the reduction in [3H]DA release may be due to inactivation of the a7 nAChR controlling 
glutamate release. Radioligand binding assays also highlighted regional changes in 
numbers of nAChR that may be relevant to nicotine addiction.
DA release is a Ca2+ dependent process, but the contribution of Ca2+ from intracellular 
stores has not yet been fully explored. In chapter 6, the role of intracellular Ca2+ stores 
was first defined in the SH-SY5Y cell line. Results suggested that nAChR subtypes were 
differentially coupled to specific sources of Ca2+, as activation of nAChR produced 
sustained responses in intracellular Ca2+ levels which were due to activation of VOCCs, 
but also involved Ca2+ release from ryanodine and IP3-dependent stores. Further 
experiments studied [3H]DA release from rat striatal synaptosomes. Caffeine, an activator 
of intracellular Ca2+ stores, increased [3H]DA release but in a Ca2+-sensitive and 
ryanodine-insensitive manner, suggesting that release did not involve activation of 
intracellular Ca2+ stores. Additional assays implied that caffeine increased [3H]DA release 
by antagonism of adenosine receptors, which may tonically modulate DA release in the 
striatum.
These studies have extended our knowledge of the pharmacology surrounding DA 
release in the striatum, and may have implications regarding the role of the a7 nAChR 
subtype in nicotine addiction.
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1.1 Nicotine: from past to present
Addiction to nicotine, the main psychoactive 
component of tobacco, currently affects 1.15 
billion people on the planet (The World Health 
Report, 1999). It is an epidemic that poses a 
growing threat not only to the health of the general 
population but also to economic and 
environmental stability worldwide.
Derived from plants belonging to the genus 
Nicotiana (Figure 1.1), it is believed that nicotine 
serves a variety of natural roles, such as storage 
of nitrogen and a defence against insects.
Historians believe that the plant, as we know it 
today, grew in the Americas c.6000 BC, with 
tobacco smoking practised among the early 
Mayans as part of their religious ceremonies 
(Leavey, 1998). Paper had not yet been invented 
and so they wrapped their tobacco in palm leaves 
or com husks, stuffed it into reed or bamboo, or 
rolled tobacco leaves into crude cigars. The 
following centuries saw tobacco smoking 
proliferate throughout Mexico and the Antilles, and 
it appears to have spread further when tribes 
dispersed northwards via the Mississippi Valley and by sea to Brazil. Later, it was widely 
consumed by native Indians, who used pipes to smoke it and also blended the tobacco 
with other plants to vary its flavour. Tobacco could be said to have been introduced to 
Europe by Columbus, who, in 1492, was offered tobacco leaves as a gift by native Indians 
when he set foot in the New World. Widespread cultivation of the plant occurred during 
the 16th Century, with European traders shipping tobacco to most countries, as it became 
fashionable amongst the more affluent inhabitants of Europe and the United States. 
However, cigars and cigarettes as we know them today did not appear until the late 19th
Figure 1.1 A field of tobacco 
plants in Cuba. Nicotiana tabacum is 
a hardy plant and so is grown in many 
parts of the world, with the two largest 
exporters being the USA and Brazil. 
China is the world’s greatest producer 
of the plant but exports little of what it 
grows. Interestingly, the world’s entire 
production of tobacco is grown in an 
area the size of Denmark.
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century, with tobacco being commercially grown by multinational companies, producing 
millions of cigarettes a year by newly invented rolling machines.
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Figure 1.2 Growth of cigarette consumption and projected deaths due to tobacco 
(The World Health Report, 1999).
Today, the total number of smokers in the world is still growing, especially in low and 
middle income countries, with the occurrence of about 4 million deaths each year 
attributed to smoking related diseases (Figure 1.2).
1.2 A brief view of nicotine addiction
So why is smoking so addictive? The principal reason is that nicotine has a potent 
effect on the neurochemistry of the mammalian brain due to several factors. The first is 
that as nicotine is inhaled on smoke particles, it easily enters the lungs and is rapidly 
absorbed across the bronchial membranes and into the 
bloodstream in the form of the free base (Benowitz, 1986,
1996; Figure 1.3). The second is that it reaches the brain 
in roughly seven seconds. This rapid transport is due to it 
entering the bloodstream, via the pulmonary vein, where 
it is subsequently pumped by the heart through the 
body’s arteries without undergoing first-pass metabolism 
in the liver. This is coupled with nicotine’s ability to pass 
across the blood/brain barrier with ease. Finally, it exerts 
its effect on a group of receptors in the brain, known as 
nicotinic acetylcholine receptors (nAChR), which are 
activated within milliseconds of nicotine binding to them.
Pleasurable and mood-enhancing effects then occur
Figure 1.3 The chemical 
structure of nicotine. Nicotine 
is a water and lipid soluble drug 
which, in the free base form, is 
readily absorbed via respiratory 
tissues, skin, and the 
gastrointestinal tract. At pH 7.4, 




which can further reinforce a high level of dependence, coupled with conditioned 
behaviours associated with the paraphernalia of smoking, such as lighting the cigarette 
itself. Some of these effects are thought to be due to release of the neurotransmitter 
dopamine (DA) in certain areas of the brain, a subject that is discussed in more detail in 
Chapter 5. In addition, without the regular intake of nicotine, unpleasant physical 
withdrawal symptoms manifest themselves in the form of depressed mood, anxiety, 
weight gain and irritability, to name but a few (Russell, 1990; Table 1). Also, other 
compounds present in tobacco smoke may enhance the sensations afforded by nicotine. 
It is the combination of these factors that make smoking so addictive. However, the exact 
underlying neurochemical changes that occur over the weeks and months of smoking are 
still not fully understood, nor are the reasons why individuals resume smoking* months or 
years after previously quitting (more detailed information on nicotine addiction is 
presented in Chapter 5).
1.2.1 Current methods to help smokers quit
When an individual ceases to smoke they experience a variety of withdrawal 
symptoms, most of which peak during the first week of abstinence (Table 1; Russell, 
1990). However, it was reported, as early as 1942, that injections of nicotine alleviated 
these symptoms in individuals who had stopped smoking (Johnston, 1942).










Therefore, until the last couple of years, nicotine replacement therapy has been the 
major form of treatment for helping individuals to abstain from tobacco smoking. The basic 
idea behind this treatment is that delivery of a constant, low concentration of nicotine,
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relieves some of the symptoms that smokers experience when they quit smoking (Table 
1). Nicotine replacement products come in a variety of forms including gum, patch, 
sublingual tablet or lozenge, inhaler, and spray. Although these products have been 
shown to relieve some withdrawal symptoms they are not very effective, as in most large 
scale trials they have only been found to raise your chances of quitting from 10 to -20%  
(reviewed in Lee et al., 1993). Another product that has recently become available 
provides a non-nicotine solution to smoking cessation. Marketed under the name 
Zyban™, the compound bupropion has previously been used as an antidepressant, and in 
several large scale trials was claimed to be of equal or greater benefit than current 
nicotine replacement therapies (Hurt et al., 1997; Balfour, 2001). Future remedies may 
include antagonists or agonists of specific nAChR subtypes or combinations bf nicotinic 
and non-nicotinic drugs (Covey et al., 2000). Nevertheless, cigarette smoking remains the 
most significant cause of preventable death on the planet.
1.3 Nicotine’s target
As mentioned above, nicotine selectively interacts with a group of receptors known as 
nicotinic acetylcholine receptors (nAChR), which form part of a much larger superfamily of 
structurally related ligand gated ion channels, which include the inhibitory GABAa> GABAc 
and glycine receptors and the excitatory 5 HT3 receptor (Ortells and Lunt, 1995). nAChR 
themselves respond to the neurotransmitter acetylcholine (ACh) and have been implicated 
in a variety of physiological processes, including mediation of muscle contraction, 
neuronal development, neuroprotection, and cognitive function (Lindstrom et al., 1996; 
Role and Berg, 1996; Changeux et al., 1998; Dajas-Bailador et al., 2000).
One could say that nAChR were first identified by Langley in 1905, who proposed the 
concept of a 'receptive substance', mediating the effect of nicotine and curare on muscle 
(see Bennett, 2000 for a historic perspective). However, it was only the discovery that the 
electric organs (electroplax) of the sea dwelling rays of the Torpedo species (Figure 1.4) 
contained huge amounts of nAChR that led to the relatively easy purification of milligram 
amounts of the protein and structural characterisation of the nAChR and its subunits. 
Following this work, homologous nAChR subunits were isolated from the vertebrate 
neuromuscular junction. The past 25 years has also heralded the discovery of a multitude 
of neuronal nAChR subtypes, and it is these that the next section mainly concentrates on.
5
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1.4 Identification, cloning and expression of nAChR subunits
To date, a panoply of nAChR subunits have been identified in the vertebrate nervous 
system (for reviews see Sargent, 1993; McGehee and Role, 1995; Changeux et al., 1998; 
Dani, 2001). The nAChR located at the neuromuscular junction has a subunit composition 
of (a1)2pi5/ey (Ortells and Lunt, 1995). One form, containing the y subunit, is expressed in 
embryonic muscle, but during development the homologous e subunit replaces the y 
subunit, resulting in the expression of the second form at the adult neuromuscular junction 
(Takai et al., 1985; Mishina et al., 1986). It is these muscle-type nAChR that are 
analogous to nAChR found in Torpedo electroplax.
Figure 1.4 Photo of the sea-dwelling electric ray, Torpedo califomica. Found on the 
outer continental shelf, in kelp beds, over fine sand bottoms or buried in sand. It feeds on bony 
fishes, mainly herrings and halibuts, attacking its prey with the aid of its electric organ discharge 
or EOD. The EOD of a large individual was measured at 50 V; with a low internal organ 
resistance the power output exceeded 1 kW. However, no human has yet been injured by the 
electric shock, (source: animalplanet.com)
In the vertebrate brain there are now thought to be 9 different alpha subunits (a2-a10; 
Boulter et al., 1986; Goldman et al., 1987; Wada et al., 1988; Boulter et al., 1990; 
Couturier et al., 1990a,b; Elgoyhen et al., 1994; Elgoyhen et al., 2001), although a8 is only 
expressed in avian brain, and 3 beta subunits (p2-p4; Deneris et al., 1988, 1989b; Boulter 
et al., 1990). Subunits are designated a or p on the basis of the presence or absence, 
respectively, of two adjacent cysteine residues present at, or close to, the ACh binding 
site (Karlin and Akabas, 1995). Comparative analysis of the sequences of these genes 
suggests that the first duplication of a nAChR subunit (a9) occurred at least a billion years 
ago, whereas other such events have only taken place in the last 500 million years or so 
(e.g. a3/a6 & p2/p4; Le Novere and Changeux, 1995; Ortells and Lunt, 1995).
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If it were possible that the nAChR subunits discovered to date could combine alone or 
in combination with any other, to form a pentameric nAChR then the number of 
conceivable permutations would number in the thousands. This is not thought to be the 
case, as it is now known that assembly of the nAChR follows certain combinatorial rules. 
Most of these have been deduced from work performed using eggs (or oocytes) from the 
African clawed toad, Xenopus laevis, coupled with electrophysiological recordings. This 
system has proved invaluable in the dissection of nAChR subunit composition, as 
combinations of different a and p subunit mRNA or cDNA molecules injected into the 
oocytes leads to expression of functional nAChR on the surface of the cells.
1.4.1 Assembly and expression studies t
From early experiments performed using the method described above, it has been 
determined that the a2, a3 or a4 subunits will form functional channels when expressed in 
pairwise combinations with either the P2 or p4 subunit, but are unable to form channels 
when expressed alone (reviewed in McGehee and Role, 1995). Moreover, a recent study 
has also shown that expression of a3, P2 and p4 can produce a functional triplet form of 
the nAChR (Colquhoun et al., 1997). Early co-expression studies examining the ct5, a6 
and p3 subunits proved problematic and for a time they were thought to be “orphan” 
subunits. For instance, the a5 subunit failed to form functional channels when co-injected 
with any other a or p subunit (Boulter et al., 1990; Wang et al., 1996; Ramirez-Latorre et 
al., 1996). However, it has now been shown that it can form functional surface receptors 
with triplet combinations of subunits e.g. a3a5p4 (Conroy et al., 1992; Vernallis et al., 
1993; Wang et al., 1996) or a3p2p4a5 (Conroy and Berg, 1995). Although it is thought to 
serve a structural role, rather than contribute to binding of ACh, nAChR containing the a5 
subunit showed increased channel open and burst times (Nelson and Lindstrom, 1999), 
which was not surprising considering that conformational changes after activation of 
nAChR are thought to encompass all the subunits (Unwin, 1995). Likewise, recent studies 
have determined that the a6 subunit can form functional receptors, but only when co­
expressed with an a and a p subunit, with viable combinations including the avian a3a6p4 
and human a6p4p3, a3a6p2, and a4a6p2 (Gerzanich et al., 1997; Fucile et al., 1998; 
Kuryatov et al., 2000). Until recently, the role the P3 subunit played in the nAChR proved 
to be a conundrum, as it does not participate in the formation of functional nAChR in 
oocytes when co-injected in pairwise combinations with a2, a3, a4 or a7 subunit mRNA
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(Deneris et al., 1989a; McGehee and Role, 1995; Palma et al., 1999). However, 
Forsayeth and Kobrin (1997) demonstrated for the first time that the p3 subunit can 
assemble with the a4 in rat brain and with the a4 and p2 subunits in transfected COS 
cells. In addition, they also omitted each subunit in turn from the transfection procedure, 
with results suggesting that the p3 subunit acts as a linker between the a4|32 and the 
a4(34 heterodimers, thus forming a nAChR with a a4p2|33a4 subunit combination. 
However, no data were provided that these receptors were functional. The following year, 
Sivilotti and colleagues revaluated expression of the P3 subunit in oocytes, but with the 
inclusion of a reporter mutation in the subunit (V273T) which would increase the agonist 
sensitivity of a functional receptor if incorporation occurs (Groot-Kormelink et al., 1998).
i
This mutation allowed them to determine that functional nAChR can be formed when the 
p3 co-assembles with the a3 and p4 subunits. The expression studies described here 
have aided the elucidation of possible native nAChR subunit combinations, and are 
especially relevant to Chapter 3 of this thesis, where the composition of subtypes of 
nAChR that modulate DA release in the striatum is discussed.
In contrast to the heteromeric nAChR outlined above, the mRNA or cDNA for the a7 
and a8 subunits are able to be solely expressed in oocytes to form what are presumably 
homomeric receptors (Couturier et al., 1990a; Seguela et al., 1993; reviewed in McGehee 
and Role, 1995). They display functional responses to ACh and are inhibited by a peptide 
toxin called a-bungarotoxin (a-Bgt), derived from the venom of the snake Bungarus 
multicinctus (see sections 1.10.1.2 and 1.12.1.3.2 for more detailed information on this 
compound). The a8 subunit has only been found in chick brain (Scheopfer et al., 1990) 
whilst the a7 subunit is present in both chick and vertebrate. Thus, the chick brain 
contains both a7* and a8* nAChR and a minor nAChR population consisting of both a7 
and a8 subunits (Schoepfer et al., 1990; Britto et al., 1992; Keyser et al., 1993).
In mammalian preparations, a7 subunits have been isolated (Vernallis et al., 1993) but 
in the absence of a3, a5, p2, or p4 subunits (Chen and Patrick, 1997; Rangwala et al., 
1997), again suggesting they form homomeric receptors in vivo. Indeed, the rapid decay 
of the responses obtained with a7 in oocytes appear to be qualitatively similar to certain 
a-Bgt sensitive currents in chick ciliary ganglia (Zhang et al., 1994). However, there was, 
and to a certain extent, still is, confusion over whether they actually are homomeric in 
nature. Due to their ability to bind a-Bgt with high affinity, a7 nAChR were among the first 
neuronal nAChR purified and from initial studies they appeared to be composed of
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subunits of differing molecular weights (Kemp et al., 1985; Whiting and Lindstrom, 1987). 
Later, when radioligand binding of [3H]cytisine was compared between a7 nAChR 
expressed in oocytes and those expressed in stably transfected cell lines, a 50 fold 
difference in the binding affinity of the radioligand was found (Anand et al., 1993). Several 
explanations have been put forward to explain these incongruities, including proteolytic 
cleavage or incomplete processing of the subunits. Some timely reports have gone some 
way in clarifying the situation. One reported that a7 subunits can fold into two different 
conformations (Rakhilin et al., 1999), whilst another found that a7 subunits in rat PC12 
cells are differentially processed, only after which can a functional receptor form (Drisdel 
and Green, 2000). The authors of this last study also state that, due to the similar
t
characteristics, a7 nAChR from rat brain are probably homomeric pentamers containing 
differentially processed subunits (hence the previously determined differences in 
molecular weight). Lately, another report has also demonstrated that the chick a l  receptor 
can co-assemble with the 03 subunit, but produces a complex that is insensitive to ACh 
(Palma et al., 1999).
Finally, the a9 nAChR subunit can form functional homomeric receptors on its own, 
whereas the a10 subunit cannot (Elgoyhen et al., 1994; Elgoyhen et al., 2001). No 
neuronal expression of these subunits has been found but they have been localised to 
some sensory end organs, including the hair cells of the cochlea, where they may be 
involved in cholinergic efferent innervation of the hair cells (see section 1.10.3 for more 
details on the localisation of these subunits). Electrophysiological and pharmacological 
analysis of oocytes expressing the a9 subunit has provided evidence that the nAChR 
formed are unusual, as they display both nicotinic and muscarinic properties (Elgoyhen et 
al., 1994). For example, nicotinic agonists ACh, DMPP, and the muscarinic agonist 
oxotremorine M can activate the receptor, whereas moderate concentrations of d- 
tubocurarine, a-Bgt, nicotine, muscarine, and atropine inhibited ACh evoked currents. 
Furthermore, a recent report has shown that when these two subunits are co-expressed 
they can combine to form a functional channel (Elgoyhen et al., 2001). However, the 
pharmacological profiles of the a9 homomer and the a9a10 heteromer are essentially 
indistinguishable from each other, but closely match those reported for the receptors 
found in the cochlea hair cells mentioned above.
These multiple combinations of nAChR subunits possess distinct pharmacological and 
physiological properties, some of which are described in section 1.9. However, an 
important question in the study of nAChR subunit expression is, “Does the manner in
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which oocytes translate and assemble the nAChR subunit mRNA in vitro correspond to 
the same processes that occur in vivo to produce native nAChR?”.
1.4.2 Comparison of nAChR expressed in vitro with native nAChR
All the functional nAChR subunit combinations described so far respond to ACh to 
varying degrees (McGehee and Role, 1995). In an attempt to define the subunit 
composition of native nAChR, characteristics may be compared to the heterologously 
expressed nAChR described in section 1.4.1. From results gained from experiments on 
the muscle-type nAChR, mouse muscle nAChR expressed in oocytes displayed similar 
single-channel currents to those reported for the same receptors expressed in BC3H-1 
cells (Luetje and Patrick 1991; reviewed by Lingle et al., 1992). *
However, in several studies no correlation between native and expressed nAChR could 
be found. For example, in the medial habenula the channel conductance of nAChR 
closely resembled that of a3p4 receptors expressed in oocytes, but the rank order of 
potency for agonists in the habenula did not match that determined for the heterologously 
expressed a3|34 nAChR nor any of the other expressed combinations (Mulle et al., 1991; 
Luetje and Patrick, 1991). In addition, we are only now discovering that native receptors 
may be composed of triplet and even quadruplet combinations of different nAChR 
subunits, and that the inclusion of just one different subunit can dramatically alter the 
properties of the channel (Ramirez-Latorre et al., 1996; Nelson and Lindstrom, 1999).
Therefore, it seems likely that only the injection of multiple a/p subunit mRNA 
combinations into oocytes may produce channels that resemble those seen in vivo, 
although the expression work performed to date has certainly been of great help in 
uncovering the identity of native nAChR.
In concert with studies identifying and examining expression of nAChR subunits, the 
examination of the structure, organisation, membrane topology, and biophysical properties 
of the nAChR have also been the subject of intense research.
1.5 Subunit structure and organisation
The nAChR is a large (-290 kDa) glycoprotein complex formed from five membrane 
spanning subunits (Figure 1.5; see Corringer et al., 2000 for a detailed review). The a and 
p nAChR subunits have similar primary structures with significant sequence homologies. 
Their composition may be divided into 6 different regions, as illustrated in Figure 1.5 A.
10
Chapter 1
1. A small signal peptide that is removed during translocation.
2. A large, hydrophilic, N-terminal domain that is relatively conserved and contains 
one or more glycosylation sites, a 15 residue cysteine loop, and a portion of the 
ACh binding site.
3. Three hydrophobic membrane spanning domains of 19 to 27 amino acids (M1, M3 
and M4).
4. An amphipathic a-helical M2 domain that lines the channel of the receptor.
5. A large and variable hydrophilic intracellular cytoplasmic loop of about 100-200 
amino acids in length located between M3 and M4, containing consensus 
serine/threonine and tyrosine phosphorylation sites. *
6. A small hydrophilic C-terminal segment of around 10-20 amino acids.
Much of the work examining the secondary structure of the nAChR has been 
performed on the Torpedo nAChR and so one cannot directly extrapolate the features 
described below to nAChR from other species. Nevertheless, some valuable insights have 
been obtained into the structure of the receptor. For instance, a combination of infrared 
spectroscopy (Gorne-Tschelnokow et al., 1994), CD measurements (Corbin et al., 1998), 
and secondary structure predictions (Le Novere et al., 1999a) has suggested a melange 
of cx/p components in the M1-M4 transmembrane domains. The same techniques propose 
that the cytoplasmic domain is formed by two amphipathic a-helices joined together by a 
stretch of amino acids that do not seem to have any defined structure. Electron 
microscopy has revealed that a dense, rod-like region, protrudes from each subunit, and 
this could, perhaps, correspond to one of the predicted a-helices (Miyazawa et al., 1999). 
These observations can, perhaps, offer some indications of the possible secondary 
structure features of mammalian nAChR.
Early data for the quaternary subunit organisation of the nAChR relied on the use of 
molecular weight estimates and there now seems to be a general consensus that the 
nAChR complex is assembled from five transmembrane polypeptide subunits which are 
arranged in a pentameric ring (Figure 1.5 B; Cartaud et al., 1973; Cooper et al., 1991; 
Grutter and Changeux, 2001). Visualisation of the overall receptor structure has been 
realised by low resolution electron microscopy of the Torpedo nAChR. The nAChR 
appears to be a pentameric transmembrane structure that projects -65 A into the synaptic 
cleft and -20 A into the cytoplasm, and forms a central pore of about 25 A diameter at the
11
Chapter 1
synaptic side which then narrows towards the cytoplasmic side (Figure 1.5 C; Toyoshima 









Figure 1.5 Structure of the nAChR.
(A) Transmembrane topology. The four transmembrane domains can be clearly seen (M1 -  M4). A 
large hydrophilic sequence (-200 amino acids) at the amino terminus contributes to the 
neurotransmitter binding site. A large hydrophilic portion (100 -  200 amino acids), that is variable in 
sequence, links the M3 and M4 domains. It is important with regard to intracellular signalling, as it 
contains phosphorylation sites (P).
(B) Putative arrangement of the nAChR subunits described in (A) around a five-fold axis of 
pseudosymmetry, resulting in the creation of the ion channel. The 3 transmembrane domains, M1, 
M3 and M4 are hydrophobic, but M2 is amphipathic and lines the ion pore throughout the length of 
the receptor.




1.6 Ligand binding site
nAChR are thought to have either 2 or, in the case of a7, a8, and a9 homomers, 5 
binding sites for ACh. In addition, the affinity for ACh, and binding of other nAChR ligands 
varies depending on subunit composition and species. Therefore, there is great interest in 
modelling the ACh binding sites in order to determine residues involved and their spatial 
arrangement. Not only would this contribute to the understanding of the structure of the 
receptor but it would also be invaluable in the design of subtype selective ligands.
Figure 1.6 Neurotransmitter binding 
sites on nAChR. The models to the left 
show the quaternary structures of the muscle 
type, heterooligomehc a4p2 type and homo- 
oligomeric a l  type nAChR with the location 
of ACh binding sites at the subunit interfaces 
represented by the yellow capsules. The 
loops that contribute to the principal 
component are labelled A, B and C and 
those that form the complementary 
component are labelled D, E and F 
(Corringer et al., 2000).
Initial labelling experiments were performed on nAChR purified from Torpedo using 
competitive antagonists of different chemical structures (summarised in Corringer et al., 
2000) and also expression of different pairwise subunits in cell lines (Blount and Merlie, 
1989). Results showed that all the ligands labelled the a1 subunit, with secondary binding 
to the y and 5 subunits. Additionally, only expression of the a1 subunit with either the 5 or 
y subunits yielded an ACh binding site - all other combinations failed to bind ACh. 
Together, these results suggest that the ACh binding site is asymmetric with the a1 
subunit forming what is now known as the principal binding component and the 8/y 
subunits forming the complementary component (Figure 1.6; Corringer et al., 1995).
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A more detailed analysis of the binding sites for ACh, led to the identification of the 
amino acid residues of these subunits that are essential to binding of nAChR ligands. 
Again labelling by competitive ligands was exploited but coupled with supplementary 
mutational analysis. Overall, residues that took part in binding ACh were grouped into 6 
loops named A, B, C, D, E and F, with loops A, B and C residing on the a1 subunit and 
loops D, E, and F located on the 6/y subunit (Figure 1.6 & Figure 1.7; reviewed in 
Corringer et al., 2000).
Figure 1.7 Representation of the nAChR ligand binding site. Residues identified by 
affinity labelling and site-directed mutagenesis are indicated on the primary site present on ci­
ty pe subunits and on the complementary site present on 8 /  y subunits of muscle nAChR, or on 
the a subunits of homomeric nAChR (e.g. a l), or on the a / 0  subunits of heteromeric nAChR.
These initial studies were performed on nAChR purified from the Torpedo species, so 
the obvious question is, “Do the same loops occur in neuronal nAChR?”. The answer may 
be gained from sequence comparisons with the neuronal subunits themselves (Galzi et 
al., 1991b; Corringer et al., 1995). These seem to show a high conservation for loops A, 
B, and C in the a2-8 subunits, whilst examination of the loops in the complimentary 
component shows that loop D seems to be conserved in the p2 and p4 and a7 and a8 
subunits. However, loop E seems to be highly variable whilst loop F doesn't seem to be 
present in p2 and p4 but is present in y, 5, e, and a7 subunits. Mutational analysis of 
residues contained within these loops in the a7 nAChR and to a a7-5HT chimera has 
identified the amino acids that contribute to the ACh binding site (Galzi et al., 1991a; 
Corringer et al., 1995). These studies show that, in the case of the a7 nAChR, each 
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these analyses, one can conclude that binding sites in neuronal nAChR are probably 
formed between the interface of an a and a p subunit, or in the case of a l  and a8, 
between two a subunits.
In contrast to the depiction of the ACh binding sites above, studies performed by Unwin 
have uncovered cavities contained within the two a subunits (Unwin, 1993). Until recently, 
these were believed to be ACh binding pockets and higher resolution examination of 
these pockets seemed to support this argument, as it revealed that they were connected 
to the vestibule by tunnels, thus providing a possible access route for ACh (Figure 1.11; 
Miyazawa et al., 1999). However, evidence has come to light recently that suggests that 
these interpretations are invalid. In two elegant studies, Sixma and colleagues describe 
the isolation of a small protein that binds ACh (AChBP) from the glial cells of a snail 
(Lymnaea stagnalis). It appears to be released into the synaptic cleft in response to ACh, 
thus providing regulation of neurotransmission (Smit et al., 2001). But one may ask, “How 
can a protein from a snail be compared to the vertebrate nAChR?”. The answer is 
provided by the x-ray crystallographic structure of this protein, which has been determined 
to 2.7 A (Brejc et al., 2001), and is homologous to the extracellular N-terminal domain of 
the nAChR subunits described above. It also has a homopentameric structure (Figure 1.8) 
and an amino acid sequence most closely 
related to the a subunits of the nAChR family, 
but does not have the transmembrane and 
intracellular domains shown in Figure 1.5.
Moreover, pharmacological analysis of the 
AChBP demonstrated that it bound several 
nicotinic ligands, including ACh and nicotine, 
with high affinity (Smit et al., 2001). The 
crystal structure of the AChBP also reveals 
that the binding site is formed by a series of 
loops on the principal and complementary 
components (ball-and-stick representations;
Figure 1.8) and these correspond to the 
amino acids that have previously been 
biochemically shown to be responsible for 
ligand binding in the nAChR (Unwin, 1993;
Valenzuela et al., 1994). On the basis of
Figure 1.8 The pentameric structure 
of AChBP. In this representation each 
protomer has a different colour. Subunits 
are labelled anti-clockwise with A-B, B-C, C- 
D, D-E and E-A forming the principal and 




these observations, the most likely access routes to these ligand binding sites are from 
above or below the double cysteine containing loop that buries the region from the 
solvent. This seems to contradict Unwin’s previously suggested hypothesis that access is 
from the central pore, as this would apparently require major structural rearrangements, 
which are less likely (see above; Miyazawa et al., 1999; Brejc et al., 2001). In addition, 
future computational models, utilising the high resolution structure of this novel protein, 
will hopefully provide valuable insights into the processes pertaining to activation and 
desensitisation of the nAChR.
1.7 The ion channel
When activated, the nAChR allows the passage of the cations, Na+, K*, and Ca2+. The 
ions can flux in both directions down their respective electrochemical gradients, through a 
pore formed by the pentameric arrangement of subunits. Several approaches have been 
taken to identify the residues involved in controlling ion flux through the receptor and the 
secondary structures formed. It is known from photoaffinity labelling experiments that the 
M2 segments of each subunit form the lining of the channel, and that they probably form 
a-helices (Le Novere et al., 1999a). Additional data obtained by electron microscopy of 
the open channel showed 5 rods bordering the ion channel (Unwin, 1995), and these have 
been ascribed to the same M2 helical segments.
The residues lining these segments have also been documented (Figure 1.9; Hucho et 
al., 1986; Imoto et al., 1988; Charnet et al., 1990; Revah et al., 1990; Pedersen et al., 
1992; Akabas et al. 1994) but of, perhaps, greater interest is the determination of those 
residues that form the so-called “gate” of the nAChR. This possesses the pivotal function 
of occluding the ion channel when the receptor is in the resting or desensitised states. 
Unwin (1993) proposed that the gate lies midway along the M2 segments, formed by the 
side chains of the L251 residues, but when these residues were replaced results were not 
consistent with this hypothesis (Filatov et al., 1995; Labarca et al., 1995). Other studies 
discovered that mutations in two rings of aligned residues (S240 and T244; Figure 1.9) at 
the cytoplasmic end of the channel altered the conductance and selectivity of the channel, 
suggesting that these residues form the narrowest part of the channel (Imoto et al., 1991; 














Figure 1.9 A diagram representing the structure of the nAChR 
ion channel. The M2 helices from two a l  subunits are shown with the 
numbered residues forming rings that line the channel. The upper portion 
of the channel (blue) is believed to act as a water pore with the lower loop 
components (yellow) acting as the selectivity filter controlling the lumenal 
flow of ions through the receptor. (Adapted from Corringer et al., 2000)
A more definitive region for the gate in the resting state has been isolated using a 
technique known as the substituted-cysteine-accessibility method or SCAM (Akabas et al., 
1994; Pascual and Karlin, 1998). This procedure entails mutating each residue of the M2 
domain to a cysteine one at a time, after which small, positively charged sulfhydryl- 
specific reagents are added from the extracellular side. The procedure was performed in 
the absence and in the presence of ACh with results showing that with the receptor in the 
closed state, the reagents reacted with cysteine residues up to, and including T244C, 
which lies near the intracellular end of the channel. Furthermore, rate constants for most 
of the substitution reactions were greater in the presence of ACh than in the absence, 
apart from some cysteine residues (L245C and S248C) close to the intracellular end of 
the channel, where rate constants were similar both in the presence and absence of ACh 







Figure 1.10 Receptor channel structure of the mouse muscle type 
nAChR. The diagram above shows a detailed view of the closed ‘gate’ of the 
nAChR in the resting state, determined by exposure of cysteine mutated 
residues 240-244, to a sulphidryl-specific reagent in both the open and closed 
receptor states (adapted from Wilson and Karlin, 1998).
A more precise evaluation of the residues that form the gate in the resting state was 
performed by Wilson and Karlin (1998), where the SCAM method was applied to six 
consecutive residues (S239 to T244) mutated to cysteine and expressed in HEK 293 cells 
or Xenopus oocytes. Sulfhydryl-specific reagents were added both extracellularly and 
intracellularly. They found that when the channel was closed, a barrier was formed 
between residues G240 and T244, that prevented entry of the reagents added from either 
side. Application of ACh removed this barrier and so the conclusion was that these 5 
residues line the narrow part of the channel where the gate is located (Figure 1.10). 
Lately, the SCAM method has been used to extend our knowledge of the nAChR channel 
in the stable desensitised state, with the discovery that residues in the closed gate extend 
further into M2, from 240 to 251 (Wilson and Karlin, 2001).
If one summarises these results, a picture of the nAChR channel emerges in which the 
upper element is formed by a-helices and acts as a water pore, whereas the lower portion 
is not a-helical, and is instead formed by loops which are able to selectively filter ions. 
Residues 240 to 244 form the gate in the resting state (Figure 1.9) and residues 240 to 
251 are involved in the stable desensitised state. However, this model becomes more 
complicated when one takes into account observations performed by Unwin in 1999. He
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proposed that direct flux of ions through the receptor channel appeared to be obstructed 
not only by the protein rapsyn, but also by parts of the receptor itself (Figure 1.11). These 
additional narrow openings, lined with negatively charged residues, were observed in the 
cytoplasmic portion of the receptor, where they are believed to act as filters to exclude 
anions from the region around the pore.
Figure 1.11 Putative model o f cation movement through the open, muscle type, 






1.8 Sequential or concerted?
Originally the nAChR was thought to open and close in a manner similar to that of an 
enzyme or more precisely, binding of an agonist causes the receptor to open. This 
scheme is known as the ‘sequential model’. However, evidence suggests that this kind of 
transition does not occur. Instead, in 1965, Monod, Wyman and Changeux proposed that 
the nAChR spontaneously isomerises between discrete states via a series allosteric 
transitions, where binding of the ligand is at a site distinct from the site of activity i.e. the 
ion channel. This model has been termed the ‘concerted allosteric model’ (Figure 1.12; for 
reviews see Corringer et al., 2000 and Changeux and Edelstein, 2001). Indeed, the 
distance between the ion channel and ACh binding site has been determined to be in the 
range of 20-40 A, making direct contact impossible (Miyazawa et al., 1999). Other 
experimental evidence supports this model, as mutations that alter the receptor’s structure 
and function can be found throughout the protein and not just in defined zones, thus 
indicating that transitions are a product of global, rather than local, changes in receptor 
structure (Edelstein et al., 1997). In addition, the L247T mutation that converts competitive 
antagonists into agonists can only be explained by the concerted model and not the
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sequential one (Revah et al., 1991). Finally, spontaneous open states have been 
observed by single channel recording in the absence of agonist, and the incidence of 
these is increased by the global mutations previously described (Grosman and Auerbach,
2000). If binding of agonist were required to induce activation of the channel, as stated in 
the sequential model, then these openings would not be observed.
R A
Figure 1.12 Diagram representing the minimal four state model of allosteric transitions 
of the nAChR. From rapid mixing experiments performed on Torpedo membranes rich in 
nAChR, a model with a minimum of four states was developed. R is the low-affinity resting state 
that occurs in the absence of agonist, A represents the active receptor state, and D and I are 
desensitised states. For the Torpedo nAChR, the timescales of some of the transitions are as 
follows: R to A = jus to ms, towards D -  ms to 100 ms, towards I = up to a minute.
So from a physiological point of view, a pulse of ACh into the synaptic cleft would 
stabilise the A state before proceeding to stabilise the higher affinity I and D states. 
However, a low concentration of ACh would match the high affinity of the I and D states 
thus shifting the equilibrium in that direction. In this way ACh could act as both an 
activator or inhibitor depending on the concentration present at the nAChR.
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1.9 Biophysical characteristics of neuronal nAChR
As mentioned in section 1.7, nAChR channels are permeable to Na+, K+, and Ca2+. 
Originally, it was thought that the ability of the monovalent cations to control the 
membrane potential in neurones was of paramount significance. Over the last decade, 
however, there has been a realisation that Ca2+ entry through nAChR is also pertinent, 
due to the ability of Ca2+ to regulate intracellular signal transduction pathways.
The Ca2+ permeability of most of the functional neuronal nAChR subunit combinations 
has been investigated and is usually given as a permeability ratio of Ca2+:Na+ or PcJPua 
(for reviews see McGehee and Role, 1995; Role and Berg, 1996). In electrophysiological 
terms, this ratio is a function of the size of the shift in reversal potential determined by the
t
relative permeability of the nAChR to Ca2+ versus Na+. For most of the neuronal 
combinations of nAChR this ratio is in the range of 1-1.5 (McGehee and Role, 1995). 
However, the a7 homomeric nAChR has a Pca/PNa close to 20, almost three times that of 
the NMDA receptor (Seguela et al., 1993). By acting, in effect, as a ligand gated Ca2+ 
channel, a7 nAChR may be important in several cellular processes, such as modulation of 
cell survival (Dajas-Bailador et al., 2000) and activation of intracellular Ca2+ stores 
(Chapter 6 ). It must also be noted that although the a7 is highly permeable to Ca2+, it is 
also the most quickly desensitising, which could decrease the magnitude of ion flux 
through the channel. In contrast to the a7 nAChR, the receptor found at the 
neuromuscular junction is the least permeable to Ca2+ exhibiting a Pca/PNa of about 0 .2  
(Bertrand et al., 1993).
Another parameter of the nAChR that has been subjected to extensive scrutiny is the 
rate of desensitisation, which also varies according to subunit composition (Role, 1992). 
The term “desensitisation” describes the process by which the nAChR (or any other type 
of receptor) fails to evoked a response as a consequence of a prolonged or repeated 
stimulus. A summary of the channel open times of several nAChR subtypes is presented 
in Table 2 (Nelson and Lindstrom, 1999; Mike et al., 2000). It can be seen that the a3|34 
nAChR desensitises relatively slowly whereas the a7 has an extremely rapid timescale of 
desensitisation. There is also evidence that both a  and p subunits can determine the time 
course of desensitisation (Gross et al., 1991; Cachelin and Jaggi, 1991; Wang et al., 
1996; Gerzanich et al., 1998). For example, insertion of the a5 subunit increased the 




Table 2  Single channel properties of nAChR subtypes. The multiple channel open times 
are thought to be due to flexibility in the stoichiometry of the nAChR channels or as a result of 
postranslational modifications to the subunits (from Nelson and Lindstrom, 1999).
nAChR Subtype Channel Open Times
a3p4 1.4 and 6.5 ms
ot3|32 0.71 & 3.5 ms
cc7 108.6 jlis
a3a5(32 0.5 & 2.1 & 5.5 ms
a3a5|34 1.6 & 6.4 & 22 ms
Application of a low concentration of agonist can cause desensitisation without 
activation, as the desensitised receptor has a higher affinity for agonist than the resting or 
open receptor. Consideration of this process is highly relevant when one considers 
sustained nicotine intake during tobacco smoking (Dani and Heinemann, 1996), where 
smokers exhibit a steady-state nicotine level of around 0.1 pM (Russell, 1990). A more 
detailed discussion of this phenomena is presented in Chapter 5.
1.10 Distribution and localisation of nAChR subunits
Mapping the distribution of the neuronal nAChR has been an ongoing task for the past 
twenty years or so. Over that time a variety of methods have been developed that may be 
employed to locate nAChR (reviewed by Wonnacott et al., 2001).
1. The use of labelled nAChR ligands which can be bound to homogenates or 
histological brain sections. This method is quick and easy to perform and is very 
sensitive but has the drawback that there are very few nAChR ligands that are 
specific for a certain subtype of nAChR.
2. Immunohistochemistry using subunit selective antibodies. These mostly have good 
specificity and sensitivity and have been employed in numerous studies at both the 
light and electron microscopy level. They show distribution of subunits rather than 
particular nAChR subtypes.
3. In situ hybridisation using molecular probes that are specific for certain nAChR 
subunits. These only detect the mRNA of the subunits and so cannot give any 
quantitative information on the amount of protein expressed.
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4. Use of positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). These techniques are employed in vivo using specially 
synthesised tracers based on nAChR ligands and have the major advantage of 
being non-invasive and can therefore be used in humans. However, ligand 
specificity and time and space resolution both need to be improved.
The first section describes some of the nicotinic ligands that have been employed in 
radioligand binding studies. Pharmacological properties of the ligands are dealt with in 
section 1 .1 2 .1 .
1.10.1 Ligand binding studies
In order to gain an insight into the distribution of nAChR, early ligand binding studies 
used tritiated forms of nicotine (Yoshida and Imura, 1979; Romano and Goldstein, 1980; 
Marks and Collins, 1982) and ACh (Schwartz et al., 1982) and iodinated forms of the 
snake toxin, a-bungarotoxin (a-Bgt) (Schmidt et al., 1977). Then, in 1985, Clarke et al. 
undertook a major autoradiographic study comparing the regional binding of all three 
ligands in the rat brain. They found the binding pattern of nicotine and ACh differed from 
that of a-Bgt, suggesting that a-Bgt was labelling a population of nAChR distinct from 
those labelled by the other two radioligands. These novel findings, coupled together with 
the other studies led to the classical division of neuronal nAChR into those that bind 
nicotine with high affinity and those which bind a-Bgt with high affinity.
1.10.1.1 High affinity [3H]nicotine binding sites
Nicotine will bind to all nAChR, although different subtypes have different affinities for 
it. It has been established that there are two groups of [3H]nicotine binding sites (Romano 
and Goldstein, 1980), those which have high affinity for the ligand i.e. those with a KD in 
the nanomolar range or less (Wonnacott, 1987) and a variety of lower affinity binding sites 
that are presumed to correspond to the binding sites for [125l]a-Bgt. The naturally occurring 
form of nicotine is the (-) form and this has been found to bind to brain membranes with a 
potency 80 times that of the (+) isomer (Wonnacott, 1987). With relevance to this thesis, 
results in Chapter 5 compare levels of [3H]nicotine binding between naTve rats and rats 
chronically treated with nicotine.
As mentioned earlier, the autoradiographic analysis performed by Clarke et al. (1985) 
revealed the regional distributions of [3H]nicotine, [3H]ACh and [125l]a-Bgt binding sites in
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the rat brain. The pattern of [3H]nicotine and [3H]ACh binding was very similar with the 
highest densities of binding in the interpeduncular nucleus, thalamic nuclei, superior 
colliculus, medial habenula, presubiculum, cerebral cortex (layers I and lll/IV) and the 
substantia nigra/ventral tegmental areas. However, the distribution of [125l]a-Bgt binding 
was strikingly different, with only some overlap of binding in the superior colliculus and 
layer I of the cerebral cortex. In the following year, Collins and colleagues (1986) 
compared binding of the same radiolabelled ligands between mouse and rat brain. They 
found a variety of regional differences in the distribution of binding sites but confirmed that 
[3H]nicotine and [3H]ACh bound to the same sites in both rat and mouse brain, whereas 
[125l]a-Bgt bound to a different population of sites (Marks et al., 1986).
So what is the identity of the receptor complex that binds [3H]nicotine with such high 
affinity? The initial answer to this came from immunoprecipitation experiments, where the 
monoclonal antibody mAb270 (an antibody raised against the chick (32 nAChR subunit) 
was used to demonstrated that the high affinity [3H]nicotine binding sites in rat brain 
membrane were composed of a4 and (32 subunits alone (Whiting and Lindstrom, 1986, 
1987). Complementing this work, Flores et al. (1992) used antisera to a4 and p2 fusion 
proteins to show that immunoprecipitation of either subunit from rat brain also removed 
virtually all of the other. However, the picture may be more complicated after the finding 
that a5 can co-assemble with a4 subunits in chicken brain (Conroy et al., 1992), and so 
the possibility exists that some a4a5|32 sites may also be present. In recent years the use 
of knockout mice has added to these findings (see Cordero-Erausquin et al. (2000) for 
review on nAChR subunit null mutant mice). In brain tissue from (32 null mutant mice, high 
affinity [3H]nicotine binding completely disappears (Picciotto et al., 1995) and is almost 
completely eliminated in a4 knockouts, apart from a few brain nuclei (Marubio et al.,
1999). Thus, in mammalian brain, the majority of high affinity [3H]nicotine binding sites are 
cx4(32* nAChR with a small subset of (32 containing receptors that do not contain the a4 
subunit.
1.10.1.2 High affinity a-bungarotoxin binding sites
a-Bungarotoxin (a-Bgt) is an 8  kDa protein isolated from the venom of the snake 
Bungarus multicinctus (Figure 1.22). During the 1970s, several groups acquired evidence 
that the toxin binds with high affinity to a number of autonomic ganglia (Greene et al., 
1973; Fumagalli et al., 1980) and could be displaced by ligands selective for nAChR. As 
mentioned previously, [125l]a-Bgt binding sites do not correlate with high affinity
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[3H]nicotine binding sites. In an autoradiographic study of rat brain dense labelling was 
revealed in the inferior colliculus, cerebral cortex (layer VI), hypothalamus, and 
hippocampus, areas that were found not to contain any high affinity sites for [3H]nicotine 
or [3H]ACh. Definitive evidence has again come from null mutant mice, where no 
detectable [125l]a-Bgt binding was seen in any brain region in those mice lacking the a7 
subunit (Orr-Urtreger et al., 1997). In addition to a7 nAChR, a-Bgt will also bind to the 
avian a8  nAChR and mammalian a9 subtype found in cochlear hair cells (Luetje et al., 
1990; Elgoyhen et al., 1994) but, as yet, no interactions have been found to occur with 
other heteromeric combinations of nAChR.
The last decade has seen the development of additional radiolabelled nAChR ligands 
that have extended our understanding of the distribution and diversity of nACjhR. These 
will now be briefly discussed.
1.10.1.3 [3H]Epibatidine
[3H]Epibatidine is a radiolabelled version of the most potent nAChR agonist known (see 
section 1.12.1.1.2). It will bind to the a4|32* nAChR subtype with very high affinity and with 
low non-specific binding, but will also bind to other a/p heteromeric nAChR subtypes with 
affinities which, although lower, are still within the nM range (Houghtling et al., 1995; Perry 
and Kellar, 1995). Immunoprecipitation experiments in rat trigeminal ganglia also indicate 
that [3H]epibatidine binds to two populations of nAChR, one containing the a4 and (32 
subunits and the other containing the a3 and (34 subunits (Flores et al., 1996). Marks et al. 
(1998) also showed that [3H]epibatidine bound to two sites in mouse brain and that they 
could distinguish between them by use of cytisine. These features of [3H]epibatidine are 
useful for the characterisation of nAChR binding sites that are not sensitive to some of the 
other radiolabelled nAChR ligands available, such as [3H]nicotine and [125l]a-Bgt. In 
addition, an iodinated version of the ligand ([125l]epibatidine) with higher specific activity 
has recently been synthesised (Davila-Garcia et al., 1997) and has proved useful in 
differentiating a minor population of nAChR binding sites in mouse brain (Whiteaker et al., 
2 0 0 0 a).
1.10.1.4 [3H]Cytisine
Cytisine is an alkaloid compound derived from the seeds of the plant Laburnum 
anagyroides (Figure 1.13) and has a binding pattern in rat brain almost identical to that of 
[3H]nicotine and [3H]ACh (Pabreza et al., 1991) with all three ligands thought to bind to the
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same population of nAChR (Anderson and Americ, 1994). The immunoprecipitation 
experiments performed by Flores et al. (1992), mentioned above, also resulted in the 
removal of >90% of high affinity [3H]cytisine binding sites from rat brain extracts, 
suggesting a a4p2* nAChR. [3H]Cytisine binding is also distinguished from other 
radioligands by virtue of its higher affinity (roughly 6  fold) and lower non-specific binding.
Figure 1.13 Laburnum anagyroides and the chemical structure of cytisine
1.10.1.5 [125l]a-Conotoxin Mil
The nAChR ligand a-conotoxin Mil (a-CTx Mil) is a peptide toxin isolated from the 
venom of the cone snail Conus magus, (see section 1.12.1.3.1 and Figure 1.20). It has 
been demonstrated to be a potent and selective antagonist of a3p2* nAChR expressed in 
oocytes (Cartier et al. 1996) but has recently been shown to bind to a6 * nAChR in the 
striata of mice (Champtiaux et al., 2002).
The peptide has been radiolabelled with the radioactive isotope iodine-125 and its 
selective nature exploited in a ligand binding study in mouse brain (Whiteaker et al., 
2000b). [125l]a-CTx Mil binding sites were of a unique distribution, with the most densely 
labelled areas being the superficial layers of the superior colliculus, nigro-striatal pathway, 
optic tract, olivary pretectal, and mediolateral and dorsolateral geniculate nuclei. The 
unlabelled ligand potently competed with a subset of [3H]epibatidine binding sites but 
exhibited a weak ability to displace [3H]nicotine and [125l]a-Bgt binding.
Another study has exploited the capacity of the toxin to label a novel population of 
nAChR receptors in the nigrostriatal pathway to examine the effects of MPTP lesioning in 
monkey brain as a model of Parkinson’s disease (Quik et al., 2001). The distribution of 
binding sites was comparable between the two species (mouse and monkey) but there 
were regions in the monkey brain that differed in their intensity of [125l]a-CTx Mil binding, 
with the greatest intensity seen in the habenular-interpeduncular system. The authors 
note that this disparity may be due to the altered importance of various neuronal systems 
between the two species e.g. the visual system as opposed to the olfactory system.
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In Chapter 3 of this thesis [125l]a-CTx Mil binding has been examined in the rat striatum 
to aid in unravelling the pharmacology of a-CTx Mil-sensitive receptors in this region. In 
conclusion, [125l]a-CTx Mil represents a novel radioligand that should prove extremely 
useful in extending our understanding of nAChR distribution in neuronal systems.
1.10.1.6 [3H]Methyllycaconitine
In recent years a tritiated version of the a7 antagonist methyllycaconitine (MLA) has 
become available (see section 1.12.1.3.3 for pharmacological details). MLA is a 
competitive nicotinic antagonist with approximately 1 0 0 , 1 0 0 0  and 1 0 ,0 0 0  fold higher 
affinity for a7 nAChR, compared with a3p2, a4|32 and muscle nAChR, respectively (Ward 
et al., 1990; Alkondon et al., 1992; Drasdo et al., 1992; Wonnacott et al., 1993). The 
pharmacology and distribution of [3H]MLA binding sites in rodent brain tissue corresponds 
well with that of [125l]a-Bgt binding sites (Davies et al., 1999; Whiteaker et al., 1999). To 
this end, it has been employed in Chapter 5 to analyse levels of a7 in rats that have been 
chronically treated with nicotine.
However, one enigma that remains is that in rat brain Davies et al. (1999) found a small 
component of a-Bgt insensitive [3H]MLA binding sites which was not detected in 
autoradiographs of mouse brain. Several explanations are offered for this phenomena, but 
the most plausible is that the a-Bgt insensitive component comprises nAChR receptors to 
which [3H]MLA can bind, but a-Bgt cannot due to restricted access (a-Bgt is a much larger 
molecule than MLA). The reason that these are not seen in the mouse brain may be due 
to the different preparations used (membrane homogenates, as opposed to brain slices). 
Results presented in Chapter 3 may also point towards the identity of this a-Bgt 
insensitive component.
1.10.2 Immunohistochemical localisation of nAChR
The technique of mapping the location of nAChR by use of antibodies is known as 
immunohistochemistry. It relies on the highly specific and robust interaction between a 
specific epitope on the receptor and an antibody raised against the amino acid sequence 
of the epitope, or even the entire receptor. The antibody may then be visualised by use of 
a secondary antibody that binds to the first but is coupled to a tag of some sort. The tag 
used depends on the level of visualisation which may either be at the light/confocal or 
electron microscopic (EM) level.
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Initial studies in the 1980s used iodinated monoclonal antibodies to examine the 
distribution of a4 and (32 nAChR subunits in both rat and chicken brain (Swanson et al.t 
1987). Additional research at the light level has utilised antibodies with a horseradish 
peroxidase (HRP) label. This enzyme cleaves the compound diaminobenzidine to produce 
a dark reaction product enabling the location of the antibody to be visualised. To date, this 
technique has been used to map the (32 (Hill et al., 1993; Sorenson et al., 1998), a4 
(Nakayama et al., 1995, Nakayama et al., 1997, Sorenson et al. 1998, Arroyo-Jimenez et 
al. 1999), and a l  (Del Torro et al., 1994, Lubin et al., 1999) subunits in various regions of 
the rodent brain. More recently the distribution of the a3 subunit has been examined in 
different brain regions and also during development (Yeh et al., 2001).
t
The invention of the confocal microscope has extended the use of antibodies directed 
against the nAChR. The laser light can be focused through a shallow depth of field (0.5 -
1.5 pm) enabling visualisation of a defined ‘slice’ of the sample. The antibodies used in 
this technique are conjugated to fluorescent tags, which when excited emit light of certain 
wavelengths. As the laser light is directed at a defined section, only those tagged 
antibodies present in that section will fluoresce. In contrast, in a light microscope, 
antibodies throughout the section would fluoresce. The upshot of this is an elimination of 
out of focus fluorescence with a concurrent increase in contrast and clarity.
Confocal studies have localised the cx6  receptor in the substantia nigra and ventral 
tegmental area (Goldner et al., 1997), whereas the colocalisation of a4 and (32 with a 
marker for dopaminergic terminals, tyrosine hydroxylase, has been performed in the SNc 
(Sorenson et al., 1998, Arroyo-Jimenez et al., 1999). An additional study demonstrated 
that the a4 (but not a3/a5) subunits colocalised with the 5-HT3 receptor on rat striatal 
synaptosomes (Nayak et al., 2000) and in the hippocampus, double labelling with 
synaptotagmin (a presynaptic marker) and an antibody against the a l  nAChR showed 
that the two labels colocalised, consistent with a presynaptic role for a l  nAChR (Zarei et 
al., 1999).
At the level of the synapse, light microscopy does not have the resolution that enables 
visualisation of any details. In such cases use of electron microscopy is required, with a 
number of studies employing this technique using antibodies directed against several 
different nAChR subunits. Changeux and colleagues have mapped the ultrastructural 
localisation of the a4 subunit in the rat substantia nigra, with distinct labelling of 
postsynaptic densities (Arroyo-Jimenez et al., 1999). However, they did not investigate
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whether there was any presynaptic labelling. The ultrastructural localisation of the a7 
subunit has also been characterised in hippocampus (Fabian-Fine et al., 2001).
Experiments in our laboratory have also shown 02 subunit immunoreactivity in striatal 
nerve terminals (Wonnacott et al., 2000). On further investigation immunogold labelling 
against the 0 2  subunit colocalised with antibodies directed against tyrosine kinase, a 
marker of dopaminergic neurones (Jones et al., 2001). Interestingly, not all the 02 labelled 
boutons were positive for TH labelling, indicating the presence of 02 nAChR on non- 
dopaminergic terminals (possibly 5-HT boutons). These results are indicative of the 
presynaptic presence of the 0 2  subunit in nigro-striatal dopaminergic neurones 
(Chapter 3).
1.10.3 In situ hybridisation studies
In the last 15 years the powerful technique of in situ hybridisation has been used to 
map the majority of nAChR subunits in the rat brain (Wada et al., 1989; Wada et al., 1990; 
Boulter et al., 1990; Deneris et al., 1989b;*Seguela et al., 1993; Elgoyhen et al., 1994; Le 
Nov&re et al., 1996; Elgoyhen et al., 2001). However, it should be noted that the process 
of in situ hybridisation purely shows the location of mRNA transcripts for each nAChR 
subunit and so cannot be used as a reliable method to localise the protein produced i.e. 
whether protein remains in the cell body or is transported to the terminal fields and also 
the amount of protein present. Nevertheless, a wealth of information has been gathered 
from these studies enabling us to make the general assertion that some nAChR subunits 
seem to be widely dispersed throughout the brain whilst others are concentrated in certain 
nuclei. For example, Wada et al. (1989) noted a widespread hybridisation pattern for the 
a4 and 02 subunits, which concurs with the distribution of [3H]nicotine and [3H]ACh in 
radioligand binding assays (Clarke et al., 1985). A wide dispersal pattern is also seen with 
the a7 subunit in the rat brain, with particularly high concentrations in the hippocampus, 
forebrain, amygdala and olfactory tubercle (Seguela et al., 1993). The 04 subunit is not as 
widely distributed as the 0 2  subunit but was still found in relatively high levels in the 
hippocampus, interpeduncular nucleus, medial habenula, olefactory regions and forebrain. 
In contrast, the a2 and a3 subunits have a more conservative expression pattern (Wada 
et al., 1989). Hybridisation signals for the a2 subunit were only found in the 
interpeduncular nucleus with a3 subunit mRNA being slightly more widespread, with 
expression in the thalamus, motor cortex, locus coeruleus and certain areas of the 
hippocampus. Of significance to some of the work presented in this thesis, the
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dopaminergic neurones that project from the substantia nigra and ventral tegmental area 
display high levels of a5, a6  and 03 subunit mRNA expression, which may be important in 
the dissection of the subunit combinations that occur in these neurones (Wada et al., 
1990; Le Novere et al., 1996). Finally the a9 and a10 subunits seem to display a rather 
remarkable expression pattern, as no mRNA transcripts for either of them were found in 
any region of the rat CNS. Instead, expression of these subunit mRNA was restricted to 
the inner and outer cochlear hair cells, in addition to other unusual regions, such as the 
tongue and nasal epithelium (Elgoyhen et al., 1994,2001).
With reference to primate species, a recent study of nAChR subunit mRNA expression 
in the monkey brain concluded that the distribution of a3, a4, a5, a6 , 02, 03, and 04 
subunits was essentially the same as in rodent brain (Han et al., 2000). The only major 
differences were the expression of a2 mRNA, which was widely seen throughout the 
monkey brain, and a l  mRNA, which was localised in areas not previously observed in 
rodents.
1,10.4 In vivo PET and SPECT studies
The application of PET and SPECT to examine nAChR distribution and function in the 
brain began in the early 1990’s. Both these systems are non-invasive methods that use 
radiolabelled ligands to study the regional distribution of nAChR. PET utilises ligands 
labelled with positron emitting isotopes (e.g. 11C, 13N) whilst SPECT uses y or photon 
emitting isotopes (e.g. 123l, 99mTc). Initial studies used a carbon-11 labelled form of nicotine 
but this was found to be a far from ideal tracer, as there were problems concerning its 
specificity and rapid metabolism, which limited its usefulness in vivo (Nyback et al., 1994). 
The discovery of the potent nAChR agonist epibatidine renewed interest in the area of 
nAChR imaging, with the primary tracer compounds based upon it displaying excellent 
selectivity. However, there were problems concerning its narrow therapeutic index, which 
made it unsuitable for use in humans. Recent developments in the field have proved more 
promising with the synthesis of a family of 3-pyridyl ethers that display picomolar affinity 
for nAChR (Abreo et al., 1996). Our group has also conducted an in vitro pharmacological 
study of one of the latest analogs of this family - a novel, non-radiolabelled, version of 
[123l]-A-85380 (l-A-85380). Data, together with a more detailed description of l-A-85380 
are presented in Chapter 3.
In summary, the techniques of PET and SPECT imaging, in combination with novel 
subtype selective tools for the nAChR, hold great potential as diagnostic and mapping
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tools for unravelling the in vivo pathology of a variety of conditions, such as Alzheimer’s 
and Parkinson’s disease.
1.11 The nAChR and human neurological disorders
This section outlines some of the major neuropathological illnesses involving nAChR 
that affect humans (reviewed recently by Paterson and Nordberg, 2000).
1.11.1 Alzheimer’s disease
The progressive neurodegenerative disorder known as Alzheimer’s disease (AD) 
affects almost 1 in 10 individuals over the age of 65 and accounts for over 50% of cases 
of senile dementia (Selkoe, 1999). In total there are thought to be 11 million sufferers 
worldwide (WHO World Health Day Report, 2001).
The disease itself is characterised by various pathological changes in the brain, 
producing a devastating decline in mental function, especially in learning and memory. 
Early correlates of the disease are the accumulation of (3-amyloid peptide in neuritic 
plaques, coupled with a marked loss of cholinergic innervation to the cortex and 
hippocampus (Coyle et al., 1983), and concurrent loss of activity of choline 
acetyltransferase in these regions. There have been a number of studies examining the 
binding of nAChR ligands in AD patients, with the most significant changes observed in 
the temporal, parietal, and occipital cortices (Paterson and Nordberg, 2000). One recent 
study examined [3H]nicotine, [3H]epibatidine, [3H]cytisine, and [3H]vesamicol binding in 
brains from AD patients (Sihver et al., 1999). Significant reductions in the binding of all the 
ligands were seen in AD patients compared to age-matched controls. The majority of 
these receptors may be presynaptic in nature, as a correlation has been found with the 
reduction of [3H]epibatidine binding sites and a decrease in synaptophysin, a presynaptic 
marker (Sabbagh et al., 1998). Treatments for this debilitating disease mainly rely on 
therapies that use acetylcholinesterase inhibitors to increase levels of ACh, thus the 
potential of nAChR ligands in the treatment of AD is currently being explored.
A recent development in the field has been the discovery that the (3-amyloid peptide 
can antagonise the activation of a7 currents in hippocampal interneurones (Pettit et al., 
2001; Liu et al., 2001). It was already known that (3-amyloid is able to selectively and 
competitively bind to a7 nAChR (Wang et al., 2000) but these novel results suggest an 
additional functional mechanism by which further impairment of cholinergic function could 
occur. These studies suggest that the a7 nAChR may also be an important component of
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AD, and a relevant target for drug treatment of the disease. Therefore, the future 
development of nAChR subtype selective ligands may provide another avenue for the 
improvement of cognitive function in AD patients (see section 1.12.1.2.).
1.11.2 Epilepsy
Epilepsy is a brain disease characterized by repeated seizures or “fits” which may 
manifest themselves in many forms, ranging from the short lapses of attention to severe 
and frequent convulsions. There are thought to be multiple causes, e.g. trauma to the 
brain, infections such as encephalitis, parasites, alcohol or exposure to other toxic 
substances. However, in half of the cases, the origins of the disease remain unknown. 
One form of epilepsy is characterised by brief seizures that occur during light sfeep and is 
known as autosomal dominant frontal lobe epilepsy (ADNFLE). The cause is a genetic 
mutation in the gene encoding the a4 nAChR subunit, which results in replacement of the 
serine 247 residue with a phenylalanine (Weiland and Steinlein, 1996). As the mutation 
occurs in the M2 region lining the channel, it interferes with desensitisation resulting in a 
receptor that desensitises more rapidly and remains in that state for a longer period. A 
second mutation can occur with the insertion of a leucine at position 259, but this is 
relatively well tolerated (Steinlein, 1995).
1.11.3 Parkinson’s disease
The symptoms of Parkinson’s disease (PD) are the result of degradation of DA- 
secreting neurones in the brain, causing the pivotal symptom of akinesia, in addition to the 
other well-known indicators of tremor or trembling in the limbs. With great relevance to 
nAChR, one environmental factor that has proven to affect a persons susceptibility to the 
disease is whether he or she smokes. Smoking, rather than promoting the onset of the 
disease, actually decreases an individual’s chance of developing PD by 50% (for review 
see Fratiglioni and Wang, 2000). Smoking or NRT use has also been observed to reduce 
PD symptoms (Fagerstrom et al., 1994). These unusual observations suggest therapies 
that include nAChR ligands may benefit PD sufferers, with supporting evidence from 
animal models of the disease, where nicotine and the a4p2* nAChR selective agonist, 
SIB-1508Y (see section 1.12.1.2.1 for description) both reduced DAergic 
neurodegeneration (Janson et al., 1988, 1992; Cosford et al., 1996; Schneider et al., 




The psychiatric disorder known as schizophrenia is characterised by the manifestation 
of a range of profound psychoses that usually begin in late adolescence or early 
adulthood, although the inheritance pattern appears to be complex (reviewed by McEvoy,
2001). The actual cause of the disease is not fully understood but one hypothesis 
suggests that overproduction of DA may be a possible reason. The involvement of nAChR 
has also been considered, as a high percentage of schizophrenics are heavy smokers 
compared to the general population (Lohr and Flynn, 1992). Binding studies examining 
levels of [3H]cytisine and [125l]a-Bgt binding sites in the CA3 regions of the hippocampus 
and also a study examining a7 receptor protein in the frontal cortex found that levels of 
binding and protein were reduced in schizophrenics. Connected to this are the 
observations that nicotine gum alleviates some of the abnormalities in patients with 
schizophrenia, but only at high doses (6  mg; three pieces of gum; Adler et al., 1992, 
1993). This evidence again implicates the a7 nAChR in schizophrenia, as it is activated at 
relatively high concentrations of nicotine, compared to other subtypes of nAChR.
1.11.5 Tourette’s syndrome
Gilles de la Tourette syndrome (TS) is a psychiatric disorder of unknown etiology which 
is characterised by persistent motor and verbal tics in addition to frequent hyperactivity, 
anxiety, phobias and compulsive disorders. The disorder is treated by neuroleptic drugs 
such as haloperidol, but these have undesirable side effects. Interestingly, studies have 
reported that when neuroleptics are combined with nicotine delivered via a patch or gum 
their effect is potentiated (Sanberg et al., 1988). The mechanisms through which nicotine 
exerts its beneficial effects remain unknown but may include modulation of DA release. 
The low level of nicotine provided by the transdermal patch may desensitise nAChR 
present presynaptically on DA terminals, thus normalising the release of DA and 
stabilising the hyperactive neurones. These observations indicate that further research is 
warranted into the role of nAChR in this illness.
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1.12 Presynaptic nAChR and modulation of neurotransmitter
Presynaptic neuronal nAChR are known to be located on nerve terminals themselves 
with comparatively less evidence for preterminal receptors (Role and Berg, 1996; 
Wonnacott, 1997; Vizi and Lendvai, 1999; Figure 1.14).
The definition of a presynaptic locus of action dictates that the enhancement by a 
nAChR agonist should be Ca2+ dependent (as Ca2+ are required in exocytosis) but 
insensitive to the sodium channel blocker, tetrodotoxin (TTx). Occurrence of TTx- 
sensitivity in the absence of relevant cell bodies, suggests a preterminal localisation of 
nAChR (L6 na et al., 1993).
Figure 1.14 Possible locations of neuronal nAChR. nAChR at presynaptic locations can 
modulate neurotransmitter release by depolarising the nen/e terminal to activate voltage 
operated Ca2+ channels, e.g. DA release from nigro-striatal terminals. nAChR at preterminal 
sites may depolarise the neuronal process and cause an enhancement of sEPSC frequency 
that is dependent on the induction of axon potential firing e.g. GAB A release from dispersed IPN 
neurones. Somatodendritic nAChR may indirectly enhance basal firing rates e.g. in nigro-striatal 















Presynaptic nAChR are considered to modulate neurotransmitter release directly, or to 
influence the probability that an action potential will result in exocytosis. There is less 
experimental evidence for preterminal receptors, one proposal is that they may exist on 
axons and modulate ACh release from motor-nerve terminals (Wessler, 1996). Additional 
studies on dissociated neurones from rat interpeduncular nucleus and slices of chick 
spiroform nuclei showed that nAChR agonists increased the frequency of postsynaptic 
responses in a tetrodotoxin sensitive manner, thus implicating a preterminal nAChR in 
these preparations (Lena et al., 1993; McMahon et al., 1994). Albuquerque and 
colleagues have also shown TTx sensitivity in GABAergic neurones in the CA1 field of the 
hippocampus, with insensitivity to MLA and a-Bgt (Alkondon et al., 1997b). This implicates 
a non-a7 preterminal nAChR in the modulation of GABA release from these neflrones.
The exact function of some subtypes of nAChR is an enigma, but evidence suggests 
some act as autoreceptors for ACh whereas others are responsible for modifying the 
release of a variety of other neurotransmitters. The putative a9a10 containing nAChR 
found in cochlear hair cells are unusual in that they are thought to have a role distinct from 
other subtypes of nAChR, with possible involvement in the control of the sensitivity and 
tuning of the auditory nerve fibres with concurrent modulation of auditory encoding 
(Elgoyhen et al. 1994; Vetter et al. 1999).
Undoubtedly, modulation of neurotransmitter release is only one of the roles that 
nAChR perform in the CNS. Other functions that have been suggested are the 
maintenance of normal transmission in impaired situations or serving as a signalling 
mechanism for informing or modulating other aspects of nerve terminal function (e.g. 
neurite outgrowth).
1.12.1 Subtype selective tools and the study of presynaptic nAChR
Previously, the wide variety of nAChR subtypes, combined with the relative dearth of 
subtype selective compounds, has proved to be a stumbling block in the study of 
presynaptic nAChR. However, the last decade has heralded the discovery and 
development of a variety of novel subtype selective tools which should help to advance 
our understanding of the diversity of nAChR and aid in the development of novel drugs for 
medicinal use.
In general, putative subtype selective agents have been evaluated on the basis of their 
activity at heterologously expressed nAChR in Xenopus oocytes. Compounds that display 
selectivity are then characterised in tests of general or defined behaviour (e.g.
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ant I nociception). This section will outline the major agonists and antagonists that have 
been characterised so far in addition to those that are relevant to this thesis.
1.12.1.1 nAChR agonists
Nature has provided a panoply of agonists from a wide variety of sources that have an 
intrinsic action at the nAChR. These have been utilised in some of the experiments 
presented in this thesis and are described below.
1.12.1.1.1 Nicotine
As mentioned at the beginning of this thesis, nicotine is an alkaloid formed naturally in 
plants from the genus Nicotiana and has been used extensively in th§ study of 
presynaptic nAChR in superfusion assays and electrophysiological experiments. In 
cultured rat hippocampal neurones, nicotine evoked type II currents, indicative of an 
a4p2* nAChR, with an EC50 of 10.8 pM (Alkondon and Albuquerque, 1993). In 
comparison, an EC50 of 27 pM was obtained with type IA currents, suggesting that 
nicotine is less potent at a7 nAChR. It has been used to evoke release of all the 
neurotransmitters mentioned in section 1.12.2 and is utilised in Chapters 3-6 to evoke DA 
release from both striatal synaptosomes and slices. More detailed information regarding 
various aspects of its action in these preparations is described therein.
1.12.1.1.2 Epibatidine
Epibatidine is azabicycloheptane alkaloid, initially isolated from the skin of the 
Ecuadorian tree frog, Epipedobates tricolor (Figure 1.15; Spande et al., 1992). It is now 
synthesised commercially, with both enantiomers being pharmacologically equipotent, and 
behaving as extremely potent full agonists at nAChR subtypes from a number of species 
expressed in Xenopus oocytes. These include chicken (a3p2, a3p4, a4p2, a7 and a 8 ) 
and human (a3p2, a3|34 and a7) with comparatively less potency at human muscle 
nAChR (Gerzanich et al., 1995). With a view to its action at native nAChR, both isomers 
were tested in cultured rat hippocampal neurones, with (+) and (-)epibatidine evoking type 
IA currents with EC50 values of 2.9 and 4.3 pM respectively and type II currents with EC50 
values of 19 and 15 nM, respectively. This suggests an extremely potent action at the 
cc4|32* nAChR with relatively less effect at the a7 nAChR (Alkondon and Albuquerque, 
1995). In assays of DA release from rat striatal slices it was 150 times more potent than 
nicotine and also considerably more efficacious (Sullivan et al., 1994).
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Figure 1.15 The Ecuadorian tree frog Epipedobates tricolor and the structure of 
epibatidine, the most potent nAChR agonist. The frog itself is found to the West of the Andes 
Mountains from middle elevations (around 600 m) to highlands and cloud forests (elevation 
~ 1,700 m). It adapts well and thrives in cleared areas around plantations, grassy environs 
around small steams and in meadows keep wet by irrigation runoff (source: animalplanet.com).
Epibatidine also displays potent, non opioid, analgesic activity in vivo via a neuronal 
nicotinic mechanism (Spande et al., 1992; Qian et al., 1993; Damaj et al., 1994; reviewed 
by Decker and Meyer, 1999). Although epibatidine has antinociceptive properties, the 
compound also produces profound hypothermia and ataxia and, therefore, has limited 
clinical use.
However, the extreme potency of epibatidine does provide a structural basis for the 
design and synthesis of novel compounds as high affinity, selective, probes for specific 
nAChR subtypes within the brain. Such compounds, if proved to be without the toxic side- 
effects of epibatidine in clinical trials, may be useful as safe and efficacious non-opioid 
analgesic therapies that would overcome the unwanted side effects of narcotic analgesics 
(e.g. sedation and dependence). They may also function as potential drugs for the 
treatment of pathological conditions involving neuronal nAChR (see sections 1.11 and 
1 .12 .1.2 ).
1.12.1.1.3 Anatoxin-a
Anatoxin-a is a naturally occurring compound produced by the freshwater 
Cyanobacterium, Anabaena flos aquae (Figure 1.16), and is now able to be synthesised 
de novo (Koskinen and Rapoport, 1985; Huby, 1990). Of its two stereoisomers the (+) 
form is roughly 150 times more potent than the (-) form (NB: in this thesis anatoxin-a 
refers to racemic (±) form). It is a potent agonist in functional assays and has been used in
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several studies of neurotransmitter release mediated by presynaptic nAChR, including 
ACh (Wilkie et al., 1996; Grady et al., 2001), noradrenaline (Clarke and Reuben, 1996), 
and DA release from synaptosomes (Soliakov et al., 1995; Kaiser et al., 1998). It has also 
been used to evoke DA release from slices, where the existence of an a7 component has 
been uncovered (Chapter 5; Kaiser and Wonnacott, 2000). It has a rigid ring structure, 
which provides the scope for structural modifications to be made.
Figure 1.16 A dark-field image of the cyanobacterium, Anabaena flos aquae 
(magnification - X  57) together with the chemical structure of anatoxin-a. The anatoxins 
are a group of low molecular weight neurotoxic alkaloids, including anatoxin-a, homoanatoxin-a 
and anatoxin-a(s). Homoanatoxin-a also acts at nAChR whereas anatoxin-a(s) is an 
acetylcholinesterase inhibitor. Source: The Cya nosite - http://www-cyanosite.bio.purdue.edu.
1.12.1.1.4 UB-165
This is a novel synthetic anatoxin-a/epibatidine hybrid, containing the 
azabicyclononene ring of anatoxin-a and chloropyridyl moiety of epibatidine (Figure 1.17; 
Wright et al., 1997). In binding assays UB-165 has been shown to discriminate between 
a4p2*/a3p2* and a7 nAChR with a 10,000 fold difference in potency (Sharpies et al.,
2000). Functional studies show a complex pharmacology, as it displays partial agonism at 
a4p2* nAChR but is a full agonist at a-CTx Mil sensitive nAChR (Sharpies et al., 2000). 
These results and others presented in the paper led to the proposition that a4p2* nAChR 
are involved in the presynaptic modulation of DA release in the striatum. The partial 
agonism of this compound has also been exploited in Chapter 3, to further dissect the 







Figure 1.17 The chemical structure of the anatoxin-epibatidine hybrid, UB-165.
1.12.1.1.5 Choline
Choline is a selective agonist at the a 7 nAChR with an EC50 of 1.6 mM in cultured 
hippocampal neurones (Papke et al., 1996; Alkondon et al., 1997a). Furthermdre, choline 
exhibits differential actions depending on the concentration used. At concentrations above 
200 pM it can activate a7 nAChR, whilst at lower concentrations (35 jxM) it desensitises 
them.
The physiological role of choline, if one exists, is unclear at present. One theory is that 
if choline accumulates near synapses (e.g. by the hydrolysis of ACh) it may desensitise 
a7 nAChR, and thus control the amount of signal transmitted via activation of these 
receptors. This may be important in synapse development (Alkondon et al., 1997a). 
However, the local concentrations of choline in the brain are presently unknown, and so 
until these are determined the endogenous role of choline is a matter of debate. 
Nevertheless, choline has proven to be a useful and inexpensive tool for the in vitro study 
of the a7 subtype of nAChR.
1.12.1.2 Synthetic nAChR ligands with therapeutic potential
1.12.1.2.1 Compounds selective for the a4p2* nAChR
The chemical structure of ABT-594 is based on epibatidine and has high affinity for the 
a4p2* nAChR subtype but exhibits 4000 times lower affinity than epibatidine for the 
neuromuscular nAChR (Donnelly-Roberts et al., 1998). As a result it has a much wider 
therapeutic index and less adverse side-effects than epibatidine. Phenotypically, it 
displays potent antinociceptive activity, similar to that of morphine but without the side 
effects of withdrawal and physical dependence (Bannon et al., 1998).
The second compound, known as RJR-2403, is derived from nicotine and may have 
potential use as a cognitive enhancer. Although it has a selectivity for a402* vs. a7 
nAChR that is equal to nicotine, it does not stimulate ion flux in PC12 ganglionic cells or
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TE671 neuromuscular cells, suggesting a marked selectivity for CNS nAChR (Bencherif et 
al., 1996). Moreover, in animals, RJR-2403 was less potent than nicotine in evoking side 
effects such as changes in blood pressure, heart rate, locomotion and body temperature 
(Lippiello et al., 1996).
As mentioned in section 1.11.3, SIB-1508Y is another derivative of nicotine that is 
targeted for use in PD patients, as it is more efficacious in evoking DA release from rat 
striatal synaptosomes than nicotine and is effective in animal models of PD. (Cosford et 
al., 1996). Consequently, it may be able to ameliorate some of the symptoms found in PD 
patients by reversing the DAergic deficits due to the disease.
\= N  ABT-594 IN RJR-2403
SIB-1508YCH.
Figure 1.18 Chemical structures of commercially synthesised a4p2* nAChR selective 
compounds
1.12.1.2.2 Compounds selective for the a7 nAChR
The spirooxazolidinone, AR-R17779, is a recently synthesised compound that displays 
extreme selectivity for the a7 subtype of nAChR, roughly 35000 fold more than nicotine 
(Mullen et al., 2000). Moreover, it is 5 times as potent as nicotine at the a 7 nAChR.
The nAChR agonist, GTS-21 (also known as DMXB) is an agonist that has been 
evaluated as a treatment for Alzheimer’s disease (section 1.11.1). Its selectivity is 
demonstrated by partial agonism at human and rat a 7 homomers, in comparison to 
negligible activity at human and rat a4[32 nAChR expressed in oocytes (de Fiebre et al., 
1995). It has been established that chronic administration of GTS-21 enhances learning 
and memory and endows protection against the effects of |3-amyloid neurotoxicity, with 
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Predatory cone snails are members of the genus Conus which utilise peptide toxins in 
their venom to capture and immobilise their prey (Figure 1.20). The number of different 
toxins produced by all members of this genus has been estimated to be around 50,000, of 
which only a small fraction have been purified and characterised.
Figure 1.20 Photo of a cone snail (Conus textile). Various elements of the snail’s 
physiology can be seen. The extended siphon (upper -  black and orange stripes) is a sensory 
element that detects movement and prey. The venom-laden proboscis (lower -  orange) 
extends out of the snail's ‘mouth’ to harpoon its prey and inject the venom. The eye stalks are 
just visible either side of the proboscis (white). (Source: The Conotoxin Homepage, 
http://grimwade. biochem. unimelb. edu. au/cone)
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A specific subset <if peptide toxins produced by members of the genus Conus have 
been found to affect nAChR. Several of them inhibit the muscle-type nAChR and at least 
eight members of the a-conotoxin family have been isolated and characterised for their 
action at neuronal nAChR (reviewed by McIntosh et al., 1999; Arias et al., 2000). These 
conotoxins may be divided into different subfamilies, depending on their structure. Most 
have 4 cysteines that are conservatively arranged within the family, with the (X3/5 subfamily 
arranged CCX3CX5C, the 0 ^ 3  subfamily CCX4CX3C, and the 0 4 7  subfamily CCX4CX7C. 
Only one a-conotoxin has been found with three disulphide bonds, a-conotoxin SI I, and 
belongs to the a3/5/3 subfamily. A fifth subfamily, aA, has a core sequence that is 
completely different to the other families and represents an entirely novel class of
t
competitive nAChR antagonists. A final, sixth subfamily of non-competitive nAChR 
antagonists has also been isolated. Derived from the venom of C. purpurascens, the \j/- 
conotoxin FINE is unrelated to any of the other nAChR antagonists and has 3 disulphide 
bonds.
To date, the conotoxins that target neuronal nAChR have all been members of the 
a-conotoxin family. The most well-characterised of these are outlined in Table 3, with the 
following section concentrating on those conotoxins that are relevant to this thesis.
Table 3 a-Conotoxins and their specificity for different subtypes of neuronal nAChR 
(McIntosh et al., 1999)
































This was the first a-conotoxin to be isolated and characterised (McIntosh et al., 1994; 
Figure 1.21 A) and was determined to be a selective inhibitor of rat a7 nAChR expressed 
in Xenopus oocytes, with an IC50 of 2 2 0  nM (Johnson et al., 1995). It also inhibits native
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a l  nAChR in rat hippocampal neurones in a competitive and voltage dependent nature 
(Pereira et al., 1996). The authors found that the action of a-conotoxin Iml (a-CTx Iml) 
was specific for a-Bgt-sensitive nAChR, with 5 min pre-exposure to a-CTx Iml producing a 
competitive, reversible, concentration-dependent decrease in the peak amplitude of a7 * 
a-Bgt-sensitive currents. Additional experiments showed that a-CTx Iml had no effect on 
glycine, GABA, NMDA, kainate or quisqualate-gated currents. Experiments in bovine 
adrenal chromaffin cells have produced similar evidence. Lopez et al. (1998) showed that 
a-CTx Iml inhibited the release of catecholamines (IC50 100 nM) elicited by brief pulses of 
ACh to the same extent as a-Bgt. However, in the subsequent year Broxton et al. (1999) 
found that in the same cell type, a-CTx Iml was a potent inhibitor of nicotine stimulated, a- 
Bgt insensitive responses (IC50 2.4 pM), results that indicate the inhibition of an a3{34 
nAChR, not previously detected in Xenopus oocytes (Johnson et al., 1995). This last 
result may be due to a species difference, as rat subunits were expressed in the oocytes. 
Alternatively, the reason why Lopez et al. did not detect inhibition of a-Bgt insensitive 
responses may be that they used brief pulses of agonist (5 s) and lower concentrations of 
a-CTx Iml (< 1 pM). 
a-Conotoxin Mil
As mentioned in section 1.10.1.5, a-CTx Mil (Figure 1.21 B) is a potent antagonist at 
a3p2 nAChR expressed in Xenopus oocytes, with inhibition of responses occurring in the 
subnanomolar range (Cartier et al., 1996). Since its isolation from the venom of the fish- 
hunting cone snail, Conus magus, it is now synthesised commercially and has been used 
in several functional studies in native systems (Chapter 3; Kulak et al., 1997; Kaiser et al., 
1998). In chick ciliary ganglia, a-CTx Mil has been used to elucidate nAChR that have 
differing kinetic properties, as it was able to selectively block the slowly decaying current 
in these neurones, whereas a-CTx Iml only blocked the rapidly decaying responses 
(Tavazoie et al., 1997). Of great relevance to this thesis are the studies examining DA 
release from rodent striatal dopaminergic neurones where use of a-CTx Mil has led to the 
identification of two distinct populations of nAChR (Kulak et al., 1997; Kaiser et al., 1998). 
Recently, a3|32p3 triplet nAChR expressed in oocytes also displayed sensitivity to low nM 
concentrations of a-CTx Mil (McIntosh et al., 2000), furthermore, no [125l]a-CTx Mil 
binding was observed in the brains of a6  null mutant mice (Champtiaux et al., 2002). 
Thus, the selectivity of a-CTx Mil may be more complicated than originally thought and 




This peptide toxin (Figure 1.21 C) was isolated relatively recently from the venom of a 
mollusc hunting snail (Conus aulicus) and displays selectivity for a3p4* nAChR expressed 
in Xenopus oocytes. Data from functional studies demonstrate that it inhibits 
[3H]noradrenaline release in hippocampus (Luo et al., 1998) and [3H]ACh release from 
IPN but fails to inhibit [3H]DA release from striatum (Grady et al., 2001).
Figure 1.21 The 3D structures of a-conotoxin Iml (A), and a-conotoxin Mil (B), and a- 
conotoxin AulB (C), as solved by NMR (For a-CTx Iml, Lamthanh et al. (1999), protein 
databank entry 1G2G; for a-CTx Mil, Shon et al. (1997), protein databank entry 1M2C; for a- 
CTx AulB, Cho et al. (2000), protein databank entry 1DG2).
1.12.1.3.2 a-Bungarotoxin
As mentioned in section 1.10.1.2, a-Bgt is isolated from the venom of the snake 
Bungarus multicinctus (Figure 1.22) and is a potent (Kj -  1 nM; Davies et al., 1999) and 
selective pseudoirreversible antagonist at a7 nAChR. a-Bgt has been used to inhibit a7 
nAChR in a wide variety of functional studies, ranging from superfusion (Kaiser and 
Wonnacott, 2000) to electrophysiology (Gray et al., 1996; Alkondon et al., 1998). The only
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disadvantage of its use in functional studies is the long preincubation time needed (1 h) 
when using low nanomolar concentrations, which may adversely affect some tissue 
preparations. However, this problem may be overcome be increasing the concentration of 
a-Bgt, the result being a shorter preincubation time whilst still achieving a selective 
blockade of a7 nAChR.
Figure 1.22 The Taiwanese banded krait, Bungarus multicinctus and the 3D structure 
of one of its toxin components, a-bungarotoxin, as determined by NMR. Multicinctus 
belongs to the krait family of highly venomous snakes found throughout Southeast Asia and is 
readily identified by its alternating black and yellow/white bands. In common with other kraits, it 
also has a row of hexagonal scales along the ridge of its back (Source: animalplanet.com; 
Structure, Scarselli et al., 2002, protein databank entry 11K8)
1.12.1.3.3 Methyllycaconitine
Plants of the Delphinium spp. are known to contain numerous toxic compounds, 
including deltaline, nudicauline, barbinine and the hexacyclic norditerpenoid, 
methyllycaconitine (MLA; Figure 1.23). The latter generates neurotoxic effects in both 
vertebrates and invertebrates. Of great interest to researchers in the field of nAChR, is the 
ability of MLA to bind to neuronal a7 nAChR with high affinity (see section 1.10.1.6). It 
also exhibits potent in vitro pharmacological behaviour, as picomolar amounts antagonise 
a7 homomeric nAChR expressed in oocytes (Palma et al., 1996) and type IA responses in 
hippocampal neurones (Alkondon et al., 1992). In recent years, MLA has been used in 
several behavioural studies, due to its ability to cross the blood-brain barrier. In particular 
those examining the addictive properties of nicotine (e.g. Lecca et al., 2000; Grottick et al., 
2000a; Nomikos et al., 2000) and subsequent withdrawal (Nomikos et al., 1999).
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However, there is a caveat here that should be noted. As the local concentrations of MLA 
in the brain are not precisely known, antagonism of other subtypes of nAChR may occur. 
At certain concentrations (> 50 nM) MLA may interact with other subtypes of nAChR 
(Alkondon and Albuquerque, 1993), hence the window of selectivity at the a7 nAChR is 
quite small. Consequently, results from these behavioural studies should be interpreted 
cautiously. More information concerning the pharmacological properties of this compound, 










Figure 1.23 The chemical structures o f the nAChR antagonists, methyllycaconitine 
(left) and DH/3E (right).
1.12.1.3.4 Dihydro-p-erythroidine
Derived from seeds of the Erythrina spp., many pharmacological studies have 
employed this compound as a selective antagonist at a4p2* nAChR (Figure 1.23; 
Alkondon and Albuquerque, 1993). However, its selectivity at this subtype of nAChR is 
questionable as it has been shown that DHpE will inhibit other subtypes of heteromeric 
nAChR expressed in Xenopus oocytes within a concentration range of 0.19 to 1.3 pM 
(Harvey et al., 1996). On the other hand, at concentrations below 10 pM it does not seem 
to affect a7 responses (Alkondon and Albuquerque, 1993), so it could be defined as an 
antagonist at non-a7 nAChR. In addition, it displays least potency at a3p4* nAChR 
(Harvey et al., 1996), so may be of use in studies examining this subtype of nAChR. In 
common with MLA, DHpE is able to cross the blood-brain barrier and has been used in 
several behavioural studies examining the addictive process and working memory
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(Corrigall et al., 1994; Felix and Levin, 1997; Grottick et al., 2000a; Bancroft and Levin,
2000).
1.12.2 Presynaptic nAChR and neurotransmitter release
For some time synaptic transmission was thought to be purely a process during which 
a neurotransmitter crossed the synapse and interacted with receptors on the postsynaptic 
membrane. This theory was modified by Koelle in 1961 (see below) who coined the term 
presynaptic receptor as a receptor located on a nerve terminal that modulates the release 
of the neurotransmitter contained within. Broadly speaking, presynaptic receptors can be 
classified as either autoreceptors, responding to a neurotransmitter released from the 
same terminal on which they reside, or heteroreceptors, responding to a neurdtransmitter 
not released from the same terminal on which they reside. Information on the changes 
that occur during chronic treatment with nicotine, with regard to the neurotransmitters 
described below, is located in Chapter 5.
1.12.2.1 Acetylcholine (ACh)
In 1906, Hunt and Taveau were the first to synthesise ACh, whilst in the same year 
Dixon performed experiments on the vagus inhibition of the heart, identifying a substance, 
which he called ‘inhibitin’, that caused the heart to cease functioning. It was only after the 
First World War that Loewi demonstrated that chemical transmission between the vagus 
nerve and the heart was mediated by a substance that he called ‘Vagusstoff’. 
Subsequently, he and others produced sufficient evidence that Vagusstoff and ACh were 
one and the same. Dale and colleagues then went on to prove that ACh was the 
transmitter acting on the ‘receptive substance’ first discovered by Langley at the 
neuromuscular junction.
ACh, the endogenous activator of the nAChR, was the first neurotransmitter proposed 
to elicit its own release (Koelle, 1961), thus developing the concept of the presynaptic 
receptor. In the last couple of decades, studies examining the role of presynaptic neuronal 
nAChR in ACh release have mainly examined release from rodent tissue using the 
technique of superfusion. In this method radiolabelled ACh is produced in situ by loading 
synaptosomes with [3H]choline. The perfusate then contains a mixture of released 





Figure 1.24 A sagital section through the rat brain showing the major cholinergic 
pathways. OB, olfactory bulb; ICj, islands of Calleja; BF, basal forebrain; SN, substantia nigra; 
Hyp, hypothalamus; IP, interpedunclular nucleus; DR, dorsal raphe; CB, cerebellum
Initial evidence for the presynaptic involvement of neuronal nAChR in the release of 
ACh was derived from a study examining nicotine-evoked ACh release from mouse 
cortical synaptosomes (Rowell and Winkler, 1984). Release of ACh by nicotine was 
blocked by hexamethonium and partially dependent on Ca2+. Subsequent studies were 
concerned with the further characterisation of this release. Using rat synaptosomes, 
several studies have determined that [3H]ACh release is sensitive to DHpE, 
mecamylamine and neuronal-bungarotoxin, but insensitive to a-Bgt and MLA (Lapchak et 
al., 1989; Ochoa and O’Shea, 1994; Wilkie et al., 1996). This suggests an absence of an 
a7 nAChR component. A recent study examining release in mouse IPN found that a-CTx 
Mil did not inhibit [3H]ACh release but addition of the a3p4* nAChR antagonist a-CTx 
AulB blocked release by -  50% (Grady et al., 2001). In addition, release was unchanged 
in assays using mice homozygous for the p2 subunit null mutation. However, when 
compared to ACh release from other brain regions there were some interesting 
differences. Wilkie et al. (1996) reported that in hippocampal synaptosomes cytisine 
behaved as a full agonist and was equipotent to nicotine, whilst DHpE was a more potent 
antagonist than mecamylamine. Alternatively, in mouse IPN synaptosomes, although 
cytisine was also a full agonist it was substantially more potent than nicotine. Moreover, 
DHpE was considerably less potent than mecamylamine in inhibiting release in this 
region. These results indicate that there may be some diversity in the subunit composition 




Synthesis of DA itself begins with the amino acid tyrosine, which is taken up by 
dopaminergic neurones from the bloodstream (Figure 1.25). Production of the 
neurotransmitter occurs within the cell body or terminals via a synthetic pathway that 
converts tyrosine to 3,4-dihydroxyphenylalanine (DOPA) which is subsequently converted 
to DA. This newly synthesised DA is protected from degradation by an efficient vesicular 
uptake system. The same vesicular transporters responsible for this process also function 
to counteract the ‘leak’ of DA from stores into the cytoplasm.
Figure 1.25 Characteristics of a dopaminergic synapse. Tyrosine (Tyr) is converted to 
dopamine (DA) by the sequential action of the enzymes tyrosine hydroxylase (TH) and L- 
aromatic amino acid decarboxylase (AADC). Uptake of DA into storage vesicles is performed by 
the vesicular monoamine transporter. Once DA is released it can interact with the post-synaptic 
D1 receptors or the presynaptic D2 autoreceptor. The DA reuptake transporter acts to terminate 
the action of DA by removing it from the synaptic cleft.
DA release is initiated by depolarisation of the nerve terminal with influx of calcium 
through voltage- and receptor-operated Ca2+ channels. Ca2+ efflux from intracellular stores 
may also contribute to this release (Chapter 6 ; Bonanno et al., 2000). Once released, DA 
interacts with postsynaptic dopamine D1/D2 receptors, and D2 autoreceptors located on 
the DA terminal itself. In fact, DA receptors may be divided into the D1-like family (D1, D5) 
and the D2-like family (D2, D3, D4). The D1-like receptors show moderate affinity for 
typical DA agonists (e.g. apomorphine), with D1 found at high concentrations in the
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striatum, substantia nigra, nucleus accumbens, and olefactory tubercle. The expression of 
the D5 receptor is much more restricted and its function is not yet fully understood. 
Members of the D2-like receptor family display high affinity for drugs such as haloperidol, 
with the D2 receptor the most prominent subtype in the brain, being found in such DA rich 
areas as the nucleus accumbens and striatum. Much lower levels of D3 and D4 receptors 
exist and are found predominately in the limbic areas of the brain.
The main mechanism responsible for terminating the interaction of DA with these 
receptors is active re-uptake into the presynaptic nerve terminal by a transport molecule 
that is selective for DA. Despite this efficient uptake system, some extracellular DA is able 
to diffuse away from the region of synaptic transmission and may eventually be broken 
down to form a variety of metabolites by the enzymes monoamine oxidase and/or 
catechol-O-methyltransferase.
There have been a multitude of studies concerned with the involvement of presynaptic 
nAChR in the release of DA, with most examining release from rodent striatal preparations 
(synaptosomes and slices) using superfusion (see section 1.13.1 and all chapters in this 
thesis). This brain region contains the dopaminergic terminals of neurones whose cell 
bodies are located in the substantia nigra and ventral tegmental areas (Figure 1.26; see 








Figure 1.26 A sagital section through the rat brain showing the major dopaminergic 
pathways. FC, frontal cortex; ACC, anterior cingulated cortex; LC, locus coeruleus; ST, striatum; 
ME, median eminence; OT, optic tract; SN, substantia nigra; VTA, ventral tegmental area; PIT, 
pituitary gland; RRF, retrorubral field
Regarding the pharmacology of release, there is increasing evidence of heterogeneity 
amongst presynaptic nAChR located on striatal DA terminals. The selective antagonist ot- 
CTx Mil, used at a concentration that causes a maximal block of a3p2* nAChR, inhibits 
40-60 % of the nicotinic agonist-evoked DA release from striatal terminals, whereas the
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non-selective antagonist mecamylamine almost completely inhibits release (Chapter 3; 
Kulak et al., 1997; Kaiser et al., 1998).
It has been shown that agonist-evoked DA release is Na+ and Ca2+ dependent (Rowell 
et al., 1987; Soliakov et al., 1995). Release is almost completely blocked by removal of 
Ca2+ from the buffer and also by addition of the non-specific Ca2+ channel blocker, 
cadmium chloride (Soliakov et al., 1995; Soliakov and Wonnacott, 1996). Investigations 
into the subtypes of Ca2+ channels involved in agonist-evoked DA release have shown 
sensitivity to the N-type blocker, o-conotoxin GVIA and to the P/Q and N-type blocker, co- 
conotoxin-MVIIC (Soliakov and Wonnacott, 1996; Kulak et al., 2001) but insensitivity to 
the selective P-type blocker, co-agatoxin IVA (Soliakov and Wonnacott, 1996) and to the L 
and T type blockers diltiazem and nickel (Harsing et al., 1992). Moreover, recent 
investigations into the functional coupling of subtypes of nAChR to discrete subtypes of 
VOCCs using a-conotoxin Mil have shown that synaptosomes containing a3p2* nAChR 
may be coupled to P/Q type channels, but not to N-type channels (Kulak et al., 2001). 
Conversely the authors suggest that another population of nAChR, possibly a4p2*, may 
be coupled to N-type channels and yet another population, again possibly a402*, could be 
associated with P/Q type channels. Results suggest that these associations must occur in 
different groups of synaptosomes, implying the existence of three different pathways in 
three different populations of synaptosomes.
A final point of note is that, in several studies, other components of tobacco (Dwoskin 
et al., 1995) and metabolites of nicotine itself have been found to elicit DA release in vitro 
(Teng et al., 1997). Included in this is the major metabolite of nicotine, cotinine, which 
evoked [3H]DA release from rat striatal slices in a Ca2+ and mecamylamine sensitive 
manner (Dwoskin et al., 1999). These phenomena may contribute to the 
neuropharmacological effects of nicotine and tobacco smoking, and this concept is 
discussed in Chapter 5.
1.12.2.3 Noradrenaline
Noradrenaline (NA) is synthesised in the same enzymatic pathway as DA, with the final 
stage being the production of noradrenaline from DA via the enzyme dopamine-p- 
hydroxylase. In the last decade there have been several studies concerned with the 
characterisation of NA release from hippocampal synaptosomes (Clarke and Reuben, 
1996; Kulak et al., 1997; Luo et al., 1998), slices (Sacaan et al., 1995, 1996; Sershen et 





Figure 1.27 A sagiial section through the rat brain illustrating the major noradrenergic 
pathways. LC, locus coeruleus; MFB, medial forebrain bundle; Hyp, hypothalamus
Studies performed in synaptosomes are most pertinent when one is concerned with 
delineation of the subtypes of nAChR that modulate NA release. In 1996, Clarke and 
Reuben compared the release of [3H]NA and [3H]DA, elicited by variety of agonists and 
found that several agonists (nicotine and anatoxin-a) were more potent in releasing DA 
than NA. In addition, the nAChR antagonists DHpE and MLA were more potent at 
inhibiting [3H]DA release than [3H]NA release. They concluded that the presynaptic 
nAChR that modulate DA and NA release differ pharmacologically and made the initial 
suggestion that hippocampal NA release is modulated by an a3p4* nAChR. Furthermore, 
NAergic neurones that project from the locus coeruleus to various parts of the brain are 
known to express mRNA for the a3, a4, and p4 subunits (Wada et al., 1988). A paper 
published in the subsequent year demonstrated that a nAChR containing the a3p2 
combination of subunits can be excluded, as a-CTx Mil had no effect on nicotine-evoked 
NA release from hippocampal synaptosomes (Kulak et al., 1997). The pharmacological 
examination of NA release was extended with the advent of the selective a3p4* nAChR 
antagonist, a-CTx AulB. McIntosh and colleagues (1998) used this novel tool to show that 
it was effective at reducing [3H]NA release from hippocampal synaptosomes, thus 
confirming the previous conclusion put forward by Clarke and Reuben (1996). 
Furthermore, the results from synaptosomal preparations seem to be comparable to those 
obtained from hippocampal and thalamic slices (Sacaan et al., 1995, 1996) with additional 
pharmacological evidence indicating the probable absence of an a7 component due to the 





Compared with the other neurotransmitters described in this section, there have been 
few investigations into the existence of presynaptic nAChR on serotonergic terminals. 
Some papers report that nAChR agonists can induce 5-HT release in slices (e.g. Yu and 






Figure 1.28 A sagital section through the rat brain showing the major serotonergic 
pathways. OB, olfactory bulb; St, striatum; Hyp, hypothalamus; SN, substantia nigra; VTA, ventral 
tegmental area; CB, cerebellum
To date, only two studies have reported the direct effect of nAChR agonists on the 
release of 5-HT (Reuben and Clarke, 2000; Cordero-Erausquin and Changeux, 2001). In 
the first of these, using superfused rat striatal synaptosomes, nicotine, ACh, epibatidine 
and cytisine all elicited a dose-dependent increase in 5-HT release which was blocked by 
mecamylamine, submicromolar concentrations of DHpE, and concentrations of MLA 
greater than 100 nM (Reuben and Clarke, 2000). In the same study, no significant release 
was seen from hippocampal or cortical preparations. On the basis of the activities of the 
various antagonists used, the authors concluded that a4p2* but not a7 nAChR mediate 5- 
HT release, but they note that the agonist profiles obtained may implicate a more complex 
isoform or mixed population of nAChR.
The second study, performed in slices of mouse spinal cord, revealed three different 
populations of nAChR affecting 5-HT release (Cordero-Erausquin and Changeux, 2001). 
Although the situation is more convoluted in the slice, by using an array of antagonists the 
authors were able to dissect out the contribution and possible locations of the various 
nAChR populations. They concluded that one population of nAChR is located 
presynaptically on the 5-HT neurone and is tonically active. The other two populations are 
putatively situated on inhibitory GABA/glycine neurones, with one group tonically active 
and the other inactive and sensitive to MLA (Figure 1.29). In addition, 5-HT release was
53
Chapter 1
unchanged in (32 and a4 knockout mice, suggesting that neither of these subunits are 
present in the populations of nAChR described above.
Figure 1.29 Minimal anatomical c ircu it for acetylcholine (ACh) and nicotine regulation 
o f serotonin (5-HT) release in the mouse spinal cord (modified from Cordero-Erausquin 
and Changeux, 2001)
1.12.2.5 y-Aminobutyric acid (GABA)
GABA is the major inhibitory neurotransmitter in the brain, and has a widespread 
distribution, occurring in both local interneurones and in projection neurones. GABA 
release is known to be negatively modulated by GABAa and GABAb autoreceptors but 
there is also a large body of evidence for the involvement of presynaptic nAChR in both 
avian and mammalian systems.
GABA release has been measured by both superfusion and electrophysiological 
means. Superfusion of hippocampal synaptosomes in our laboratory has shown that 
nicotine-evoked [3H]GABA release is sensitive to DHpE, but not a-Bgt, suggesting the 
absence of an a7 nAChR (Wonnacott et al., 1989). A comprehensive study of [3H]GABA 
release from mouse synaptosomes demonstrated that nicotine-evoked release was Ca2+ 
dependent, blocked by mecamylamine and DHPE, but not by a-Bgt (Lu et al., 1998). 
Dose-response curves were also presented for a multitude of nAChR agonists and 
revealed that cytisine and epibatidine were the most potent at eliciting [3H]GABA release, 
with the highest release occurring in the striatal and thalamic areas. There was also a 












different brain areas and levels of [3H]nicotine binding, thus implicating an a4(32* nAChR. 
Finally, nicotine was unable to evoke [3H]GABA release from synaptosomes prepared 
from the brains of (32 knockout mice, an observation which again points to a |32-containing 
nAChR. Using superfused hippocampal slices, a recent study has also noted that 
[3H]GABA release is sensitive to TTx, a-Bgt, and MLA but not a nanomolar concentration 
of DHPE, implying that preterminal a7 nAChR may be involved in this area of the brain 
(Kofalvi et al., 2000).
Differences in the synaptic location of nAChR that modulate GABA release in different 
regions of the brain have also been noted using electrophysiological techniques. In one 
study in mouse thalamus using patch-clamp recordings, the authors showed that nAChR 
agonists increased the frequency of GABAergic currents in a tetrodotoxin insensitive 
manner (Lena and Changeux, 1997) and that, in agreement with Collins and co-workers
(1998), these were absent in (32 knockout mice. In the rat hippocampus, Albuquerque and 
colleagues also found that nicotinic agonist-evoked GABA release from CA1 
interneurones was insensitive to TTx, suggesting a presynaptic location for the nAChR 
involved (Alkondon et al., 1999). Moreover, by applying ACh and the a7 selective agonist, 
choline, they discovered that a single CA1 interneurone can display two pharmacologically 
distinct currents. One of these is mediated by the a7 nAChR and causes fast excitation of 
the interneurone. The other contains a4(32 nAChR subunits and mediates slow excitation. 
A different location of nAChR was provided by Lena et al. (1993) with the detection of 
TTx-sensitive synaptic currents evoked by nicotine from GABAergic terminals in the rat 
interpeduncular nucleus, implying a preterminal location for nAChR in this brain region. A 
similar situation was also seen in GABAergic neurones in the hippocampus (Alkondon et 
al., 1997b).
1.12.2.6 Glutamate
The high temporal resolution of electrophysiological recordings, coupled with a fast 
perfusion system for agonist application (Pereira et al., 1999) has enabled the detection of 
a nAChR modulation of glutamate release via rapidly desensitising a7 nAChR. Examples 
of presynaptic a7 nAChR capable of modulating glutamate release have been described 
in rat hippocampus (Gray et al., 1996), olfactory bulb (Alkondon et al., 1996) and VTA 
(Mansvelder and McGehee, 2000). The unambiguous assignment of the a7 subtype as 
the nAChR responsible is due to the application of several a7-selective antagonists (a- 
Bgt, MLA and a-CTx Iml), plus the recognition that choline preferentially activates a7
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nAChR (Alkondon et al., 1997a). More direct evidence to support the role of presynaptic 
a7 nAChR in hippocampal neurones was provided by Gray et al. (1996). In parallel with 
electrophysiological recordings of postsynaptic currents, increases in intracellular Ca2+ in 
response to nicotine were demonstrated in large mossy fibre terminals loaded with the 
Ca2+ sensitive dye, fura-2. Thus, nAChR activation could increase the probability of 
transmitter release and hence increase the rate of quantal release, reflected in an 
increase in the frequency of postsynaptic currents.
Radcliffe and Dani (1998) observed a second type of nAChR modulation of glutamate 
release in hippocampal cultures. This was also attributed to a l  nAChR, but in this case 
the effect lasted for minutes rather than seconds, persisting after the nicotinic stimulus 
had been removed. These properties prompted the suggestion that presynaptic a l  
nAChR may contribute to glutamatergic synaptic plasticity. This concept has been 
advanced recently by Mansvelder and McGehee (2000) who showed that under 
appropriate conditions of repetitive postsynaptic electrical stimulation, co-application of 
nicotine could induce a long lasting increase in the amplitude of postsynaptic currents, in 
response to subsequent standard stimulation conditions. The increased amplitude reflects 
an enhanced amount of transmitter release in response to a given stimulus, and this 
persisted for at least 40 minutes, consistent with the induction of an LTP-like 
phenomenon. The most parsimonious interpretation of the data is that nicotine acts at 
presynaptic a l  nAChR on glutamatergic terminals; pairing nicotine application with 
presynaptic electrical stimulation did not result in any change in amplitude of postsynaptic 
currents (Mansvelder and McGehee, 2000).
The rapid desensitisation of a7-type nAChR has foiled attempts to directly demonstrate 
the nAChR modulation of glutamate release using superfusion. However, from 
experiments performed in our laboratory, evidence has been obtained for the nAChR 
modulation of glutamate release from rat striatal slices; again this effect appears to 
mediated by a a7-type nAChR (Kaiser and Wonnacott, 2000; Chapter 4). In this 
preparation, [3H]DA release elicited by nAChR the agonist anatoxin-a includes a 
component that is blocked by a-Bgt, a-CTx Iml, MLA and ionotropic glutamate receptor 
antagonists. Our current interpretation of these results is that nicotinic stimulation of 
glutamate release via an a7-type nAChR on cortico-striatal neurones can activate 
AMPA/Kainate ionotropic glutamate receptors located on the DAergic terminals, thus 
indirectly enhancing [3H]DA release. In Chapter 4 this concept is discussed in greater
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detail and results are presented that replicate and extend this analysis using nicotine as 
the agonist instead of anatoxin-a.
1.13 Measurement of neurotransmitter release
In order to measure the release of the neurotransmitters from the diverse preparations 
described above, a variety of methods have been developed. Each has their own 
advantages and disadvantages and may be more suitable for the study of one type of 
neurotransmitter than another, with some techniques being applied in vivo whilst others 
are only performed in vitro.
1.13.1 Superfusion
Transmitter release from brain preparations (synaptosomes or slices) in vitro is typically 
measured by superfusion. The term "superfusion" was coined by H.E. Gaddum in 1953, 
although the principle had been applied in earlier studies. It refers to the flow of liquid, 
typically physiological buffer, over tissue (as opposed to perfusion in which liquid flows 
through the tissue). Usually several samples are superfused in parallel, and serial 
fractions of superfusate are collected for analysis of released transmitter. After 
establishing a stable baseline, transmitter release can be evoked by drug application or 
electrical stimulation, in the presence or absence of antagonists or other drugs. 
Automated superfusion systems, designed for brain slices, are produced commercially. A 
customised system, with sub-second time resolution, has been developed for 
synaptosomes (Turner et al., 1989) but there have been no published reports yet of 
nicotine-evoked transmitter release measured over such brief timescales. Recently, a 
higher throughput release assay has been described (Anderson et al., 2000). This is a 
static release system carried out in 96 well filter plates equipped with a support membrane 
to separate tissue slices from the bathing medium (containing the released transmitter) 
that can be removed by vacuum filtration. The pharmacological data presented for 
nicotine-evoked [3H]DA (Puttfarcken et al., 2000) and [3H]noradrenaline release 
(Anderson et al., 2000) are comparable to results from conventional superfusion systems. 
This method should prove extremely useful for rapid screening of novel ligands.
Convenient assay methods for endogenous transmitter are generally too insensitive to 
detect amounts in the individual fractions of superfusate, although amperometry with 
carbon fibre microelectrodes can detect small changes in chemical concentration at the 
surface of preparations in vitro (e.g. nicotine-evoked catecholamine secretion from
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individual bovine adrenal chromaffin cells (Cahill and Wightmann, 1995) and DA release 
from striatal slices (Zhou et al., 2001) has been detected by this method). Most commonly, 
tissue is loaded with radiolabelled transmitter prior to superfusion, and the release of 
radioactivity is measured. Thus, as previously stated, nAChR agonists have been shown 
to stimulate the release of [3H]DA (reviewed by Rowell, 2001), [3H]noradrenaline (Sacaan 
et al., 1995; Clarke and Reuben, 1996), [3H]GABA (Lu et al., 1998), and [3H]5-HT 
(Reuben and Clarke, 2000). Alternatively, radiolabelled precursors may be used, allowing 
the tissue to convert this into transmitter. It has been argued that the latter method 
ensures that physiological pools of releasable radiolabelled transmitter will be formed. 
This approach is necessary for ACh, as there is no uptake mechanism for the transmitter 
itself; most of the [3H]choline taken up is converted into [3H]ACh and the release of tritium 
evoked by nAChR agonists can be attributed to the transmitter (Wilkie et al., 1996; Grady 
et al., 2001). Similarly, [3H]tyrosine has been used to label DA in studies of presynaptic 
nAChR function (Giorguieff et al., 1977; Cheramy et al., 1996). In this case the 
preparation is continuously superfused with the [3H]tyrosine, hence it is necessary to 
chromatographically separate the precursor from the product in each fraction of 
superfusate collected. In general there is good agreement between studies using 
[3H]tyrosine and [3H]DA to examine the effects of nicotinic drugs on striatal DA release 
(c.f. Cheramy et al., 1996 and Kaiser and Wonnacott, 2000).
Absent from the above list is the measurement of nicotine-evoked glutamate release: 
this has proved refractory using [3H]glutamate or [3H]aspartate. Fluorimetric (Nicholls, 
1989) and bioluminescent (Fosse et al., 1986) methods exist, but have apparently not 
been applied to study nicotine-evoked responses. If glutamate release is primarily 
regulated by a7* nAChR, a superfusion system with fast application and high temporal 
resolution may be crucial for discerning responses. A component of nAChR-evoked DA 
release elicited by a7-mediated glutamate release has been inferred in vitro (Chapter 4; 
Kaiser and Wonnacott, 2000; Wonnacott et al., 2000) and in vivo (Schilstrom et al., 1998b, 
2000).
1.13.1.1 Slices or synaptosomes?
Slices or minces (c.a. 250 pm thick) are conventionally prepared using an automated 
device, such as a Mcllwain tissue chopper. The advantages of such preparations are their 
speed and ease of preparation, and the preservation of local connectivity, making the slice 
more representative of the intact brain. The latter aspect may also be a disadvantage, as
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indirect effects on transmitter release, via synaptic connections, can complicate the 
interpretation of results. The protocol typically used to study the effects of presynaptic 
metabotropic receptors on transmitter release from slices is to determine S2/S1 ratios. In 
this paradigm a stimulus (e.g. electrical or KCI depolarisation) is given first with standard 
buffer (S1) and then repeated in the presence of test agonist or antagonist (S2). The 
S2/S1 ratio of amounts of transmitter released gives the degree of stimulation or 
antagonism. Thus each individual experiment has its own internal standard (S1). This 
protocol is unsuitable for studying nAChR effects on transmitter release because (a) 
nAChR modulate basal release, and (b) 
nAChR desensitise so readily that successive 
stimulations with a nAChR agonist can 
produce large decrements in responses that 
compromise the comparison of ratios (e.g. 
see Wilkie et al., 1996). Instead, absolute 
values of transmitter release (in cpm or 
fmoles, typically expressed as a % of 
baseline or of total radiolabel originally 
accumulated by the preparation) are 
determined and comparisons made between 
parallel chambers with and without various 
concentrations of drug of interest. Slice 
studies have been particularly used for the 
pharmacological characterisation of nAChR- 
mediated [3H]DA release in striatum (e.g.
Dwoskin et al., 1995; Marshall et al., 1996;
Kaiser and Wonnacott, 2000; Wonnacott et 
al., 2000), [3H]noradrenaline release in 
hippocampus (Sacaan et al., 1995; Sershen 
et al., 1997), and [3H]5-HT release from 
spinal cord (Cordero-Erausquin and 
Changeux, 2001).
Isolated nerve terminals are generated when brain tissue is homogenised under 
appropriate conditions (Gray and Whittaker, 1962). These structures have been given the 
name synaptosomes. These structures retain all the features of the intact nerve ending
Figure 1.30 Electron micrograph 
showing the uitrastructurai morphology 
of striatal slices used in superfusion 
experiments in this thesis. An asymmetric 
(A) and symmetric synapse (B) are indicated 
by arrows and a dentritic spine (S) can be 
clearly seen (electron microscopy performed 
by Dr. Ian Jones in our group).
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and enable aspects of nerve terminal function to be studied in isolation. Crude 
synaptosome preparations, produced by differential centrifugation, include free 
mitochondria and plasma membranes. Highly purified preparations can be prepared by 
density gradient centrifugation, for example four-step Percoll gradients separate 
synaptosomes from membrane fragments 
and mitochondria (Dunkley et al., 1988).
Superfusion of synaptosomes avoids cross­
talk between nerve terminals, and modulation 
of transmitter release reflects a direct effect 
via presynaptic receptors. However, 
preparations are rather frail, being prone to 
osmotic or mechanical damage.
Nevertheless, synaptosomes have been 
somewhat more popular than slices for the 
neurochemical examination of presynaptic 
nAChR mediating the release of various 
neurotransmitters from different brain regions 
(Kaiser and Wonnacott, 1998). Typically, a 
single stimulation with nAChR agonist is 
given, and different agonist concentrations or 
the effect of antagonists or other drugs 
compared in parallel chambers, as for slices.
1.13.2 In vivo neurochemical methods
In vivo microdialysis has been widely used to measure transmitter release; with respect 
to nicotine, most studies have focused on monitoring DA overflow. This technique has the 
benefit that it can provide results from the functioning brain in conscious, freely moving 
animals. It has high anatomical precision, enabling small, adjacent structures (such as the 
core and the shell of the accumbens) to be examined independently. On the negative 
side, in vivo microdialysis has poor temporal resolution (in vivo voltametry offers higher 
temporal resolution; Nisell et al., 1997) and it is impractical for detailed dose-response 
relationships. Moreover, drug concentrations reaching the nAChR can only be estimated.
Infusion of nicotine directly into the terminal field (striatum, nucleus accumbens or 
frontal cortex) elicited DA overflow detected by microdialysis (Marshall et al., 1997). This
Figure 1.31 Electron micrograph of
the ultrastructure of striatal 
synaptosomes used in superfusion 
experiments in this thesis. Single 
synaptosomes containing synaptic vesicles 
can be clearly seen (electron microscopy 
performed by Dr. Ian Jones in our group)
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was blocked by mecamylamine but no further pharmacological analysis was carried out to 
determine which nAChR subtypes are responsible. However, the data are consistent with 
local stimulation of nAChR (on presynaptic terminals or interneurones) being able to elicit 
DA release in vivo. In the mouse, nicotine-evoked DA overflow in the striatum was 
abolished in animals lacking the (32 subunit (Picciotto et al., 1998); the locus of action of 
nicotine was not established in these studies. Clearly further work is needed to resolve the 
relative contributions of different nAChR subtypes, and of presynaptic versus 
somatodendritic nAChR, to DA release in vivo.
1.13.3 Electrophysiological approaches
Because nerve endings are too minute to record from (with the exception of certain 
calyces, Coggan et al., 1997), presynaptic nAChR activity is inferred from a modulation of 
transmitter release detected as postsynaptic currents. nAChR modulation at glutamate 
and GABA synapses has been the major focus of this approach (Radcliffe et al., 1999; 
Pereira et al., 1999). Nicotine increases the frequency of miniature postsynaptic currents 
without affecting their amplitude, consistent with an enhancement of transmitter release 
rather than direct activation of a distinct population of postsynaptic nAChR. This is 
confirmed by blockade of currents by glutamate or GABA antagonists. As mentioned at 
the start of section 1.12, TTx is routinely applied to determine whether modulation occurs 
at a presynaptic location.
To study these responses in neurones, systems have been developed that allow fast 
application and removal of nAChR agonists coupled with imaging apparatus to examine 
the Ca2+ dynamics that occur in the nerve terminals (Pereira et al., 1999). Using these 
techniques, Albuquerque and co-workers (1993) identified a variety of whole-cell currents 
due to the assorted nAChR subtypes present on neurones in the hippocampus. When 
activated by ACh, they discovered that hippocampal neurones displayed currents that had 
differing decay kinetics and sensitivities to agonists and antagonists and subsequently 
classified these responses into 4 different types. The first of these, type IA currents, were 
sensitive to blockade by a-Bgt, MLA or a-CTx Iml, showed an inward rectification that 
depends on the intracellular level of Mg2+, display rundown that can be prevented by the 
presence of ATP-regenerating compounds in the intracellular solution and are sensitive to 
modulation by extracellular concentration of Ca2+. Type II currents were only found in 10% 
of the cultured hippocampal neurones and had slowly decaying currents that are sensitive 
to blockade by DH0E. Type III responses occurred in only 2% of the neurones examined
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and were sensitive to mecamylamine. Finally, some 10% of neurones examined displayed 
mixed characteristics (termed type IB) and were only partially inhibited by MLA or DH|3E 
alone but completely blocked by both. To determine the nAChR subunit combinations that 
underlie these responses, the characteristics of each type of response were compared 
with the properties of subunits expressed in Xenopus oocytes. Results suggested that 
type IA, type II and type III responses were produced by a7 nAChR, a4f32* nAChR and 
a3f34* nAChR respectively (Alkondon and Albuquerque, 1993). This original classification 
of the nAChR mediated responses recorded from cultured hippocampal neurones has 
since been expanded (Table 4; Zoli et al., 1998).
Table 4 Electrophysiological classification of nAChR according to Zoli et al., 1998.
nAChR Type Characteristics
Type 1 a-Bungarotoxin and MI_A sensitive, low affinity for nAChR agonists, 
desensitise very rapidly, a7 containing
Type 2 Most nAChR ligands bind to this subtype with nanomolar affinity, 
insensitive to low nM concentrations of MLA, [3H]nicotine binding 
eradicated in (32 -/- mice, contain a4(32
Type 3 Bind [3H]epibatidine with high affinity, insensitive to low nM 
concentrations of MLA, desensitise slowly, do not contain |32, possible 
composition a3|34 (?+a5)
Type 4 Bind [3H]epibatidine and [5H]cytisine with high affinity, insensitive to low 
nM concentrations of MLA, possible composition a4f34±a5 and/or 
a3a5(34
In this thesis, DA release has been examined from superfused striatal synaptosomes 
(Chapters 3 and 6 ) and slices (Chapter 4 and 5) in vitro. Synaptosomes were used to 
dissect the direct presynaptic action of nAChR on DA terminals, whilst slices provided a 
more integrated preparation for the study of the involvement of presynaptic nAChR in the 
indirect modulation of DA release by glutamate release. Changes in the latter preparation 
were also examined after chronic nicotine treatment.
1.14 The aims of this thesis
It is now apparent that nAChR can modulate the release of many neurotransmitters 
and cellular processes in the brain. In particular, the involvement of presynaptic nAChR in 
neurotransmitter release has been the subject of extensive study, with DA release from
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the striatum a prime example. However, the composition of nAChR that modulate DA 
release in this region and the contribution of other transmitter systems in the vicinity has 
been poorly characterised. Therefore, the overall aim of this thesis is to improve the 
definition of the roles and subtypes of nAChR, in vitro, in different neuronal preparations.
In the first instance, the involvement of nAChR in the neurochemistry of DA and 
glutamate terminals in the striatum was investigated in naTve rats and in rats treated 
acutely or chronically with nicotine.
•  Chapter 3. To examine the nAChR subtypes involved in DA release from striatal 
synaptosomes. During the course of the investigation of a glutamate-mediated 
component of nAChR-mediated DA release (Chapter 4), pharmacological 
characterisation of the nAChR antagonist MLA and the novel agonist iodo-A-85380 
was undertaken. This was prompted by studies that reported discrepancies in MLA- 
sensitive responses, raising the possibility that MLA inhibits a non-a7 population of 
neuronal nAChR. The allegedly a402* nAChR selective compound iodo-A-85380 was 
also characterised in its usefulness in the dissection of the subunit composition of the 
nAChR present on DA terminals.
•  Chapter 4. To extend the understanding of the enhancement of DA release by 
glutamate. Previous work in our laboratory has proposed an indirect enhancement of 
DA release by glutamate as a consequence of nAChR stimulation by the agonist, 
anatoxin-a in striatal slices. These results are confirmed and extended using the 
prototypic nAChR agonist nicotine in combination with various subtype selective 
nAChR and ionotropic glutamate receptor agonists and antagonists.
•  Chapter 5. To examine striatal DA-glutamate interactions in rats that have been 
chronically treated with nicotine. Although the mechanisms through which nicotine 
produces dependence have been studied in great depth we are still a long way from 
determining the exact neurochemical changes that occur. Nicotine may also release 
glutamate in the striatum, as described above, implicating this neurotransmitter in the 
addiction process. Therefore, any changes in DA-glutamate interactions after chronic 
treatment with nicotine will be investigated by superfusion and radioligand binding. 
These will provide an insight into some of the processes that occur after nicotine 
treatment which may be relevant to nicotine addiction in humans.
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•  Chapter 6 . Exploration of intracellular Ca2+ dynamics in SH-SY5Y cells and their 
involvement in DA release from striatal synaptosomes. Nicotine increases Ca2+ in 
SH-SY5Y cells due to Ca2+ influx through nAChR and VOCCs. The subtypes of 
nAChR and their differential coupling to specific sources of Ca2+ are examined, and 
whether stimulation of nAChR may also induce Ca2+ release from ryanodine- and 
inositoltriphosphate-dependent intracellular stores. Following definition of this system, 
preliminary experiments were initiated to explore the possibility that intracellular Ca2+ 
stores may also be involved in DA release.
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2.1 Superfusion of striatal synaptosomes and slices
2.1.1 Optimisation of superfusion technique
At the beginning of this project several steps were taken to optimise the superfusion 
method to prevent the build up of contaminants in various components of the superfusion 
apparatus and to generally improve the procedure. These were as follows:
•  Concentrated stock solutions were stored at 4°C and used in the preparation of the 
Krebs buffer.
•  Disposable glass tubes were used to hold the agonist/antagonist solutions and were 
discarded after each experiment, as opposed to the previous regime of cleaning the 
tubes after each experiment.
•  Cleaning of the superfusion tubing and chambers was performed more rigorously. 
After each experiment a 70 % ethanol wash was performed followed by distilled 
water. Once a week, tubing was washed in methanol (five minute soak) and then 
thoroughly washed with distilled water. Chambers for slices were also left to soak 
overnight in methanol and then washed with distilled water the following day.
•  It was found that if responses were consistently low or there were fluctuations in the 
baseline, the [3H]DA or pargyline had degraded and was replaced.
2.1.2 Materials
Male Sprague-Dawley (SD) rats, (250-350 g, University of Bath breeding colony) were 
used. [7,8-3H]dopamine ([3H]DA; specific activity, 45-49 Ci/mmol, 1.67-1.81 TBq/mmol, 
stored at -20°C in 1 mM ascorbic acid) was purchased from Amersham International 
(Amersham, Bucks, UK). a-Amino-3-hydroxy-5-methyl-4-isoxazo!e propionic acid (AMPA), 
(±)anatoxin-a, a-conotoxin Mil (a-CTx Mil), methyllycaconitine (MLA), 6,7- 
dinitroquinoxaline-2,3-dione (DNQX), D-phosphonopentanoic acid (D-AP-V) kynurenic 
acid (Kyn A) and ZM-241385 were obtained from Tocris Cookson (Bristol, UK). (-)- 
Nicotine hydrogen tartrate, a-bungarotoxin (a-Bgt), caffeine, a-conotoxin Iml (a-CTx Iml), 
(±)epibatidine, dihydro-p-erythroidine (DHpE), mecamylamine, N-methyl-D-aspartate 
(NMDA), pargyline and nomifensine were obtained from Sigma Chemical Co. (Poole, 
Dorset, UK). UB-165 was synthesised by Prof. T. Gallagher (University of Bristol, UK) as
66
___________________________________________________________________________________ Chapter 2 1
previously described (Wright et al., 1997). Iodo-A-85380 was a gift from NIDA (USA). All 
other chemicals used were of analytical grade and obtained from standard commercial 
suppliers.
2.1.3 Dissection and preparation of striata
Male Sprague-Dawley rats (250-350 g) were sacrificed by cervical dislocation, 
decapitated and the brain removed. Striata (80-120 mg wet weight) were rapidly dissected 
into ice cold sucrose-HEPES buffer (0.32 M sucrose, 5 mM HEPES, pH 7.4), for 
preparation of synaptosomes or slices (see Figure 2.1 for summary).
Dissection Of Brain Region
Homogenise tissue, 
differential centrifugation Chop tissue
Figure 2.1
A brie f summary o f 
the superfusion 




Load Preparation With [3H]Dopamine
Perfuse with buffer, containing 
inhibitors of re-uptake and enzymatic 
degradation, with or without antagonists
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P2 synaptosomes were prepared by differential centrifugation as previously described 
(Soliakov et al., 1995; Kaiser et al., 1998). Briefly, tissue was homogenised using a glass- 
Teflon homogeniser (12 strokes at 500 rpm) and centrifuged at 1,000 x g for 10 minutes. 
The supernatant was decanted and centrifuged at 12,000 x g for 20 minutes. The 
supernatant was then discarded and the P2 pellet re-suspended in Krebs buffer of the 
following composition: 118 mM NaCI, 2.4 mM KCI, 2.4 mM CaCI2) 1 .2  mM MgS04, 1.2 
mM KH2P04, 25 mM NaHC03 and 10 mM glucose, buffered to pH 7.4 with 95 % 0 2/5 % 
C02 and supplemented with 1 mM ascorbic acid, 8  pM pargyline (0.5 pM nomifensine was 
added after the synaptosomes had been loaded with [3H]DA, to inhibit DA re-uptake) and 
re-centrifuged at 12,000 x g for 10 minutes. The final pellet was re-suspended in 1.5 ml 
Krebs buffer and synaptosomes loaded with radiolabelled neurotransmitter by incubation 
with [3H]DA (0.1 pM, 0.132 MBq/ml) for 15 min at 37°C. Synaptosomes were then 
superfused onto a double thickness of Whatman GF/B filters in 12 homemade open 
superfusion chambers (Figure 2.2) made from truncated chromatography columns. The 
remainder of the superfusion experiment was performed in Krebs bicarbonate buffer 










Figure 2.2 The superfusion machine configured for superfusion of synaptosomes.
Arrows indicate direction of buffer flow. Inset: Detail of the open superfusion chamber showing 
the double layer of Whatman GF/B filters (grey) and direction of buffer flow.
Striatal, prism shaped tissue slices of 0.25 mm thickness were prepared as previously 
described (Marshall et al., 1996; Kaiser and Wonnacott, 2000) using a Mcllwain tissue 
chopper. The striata from three rats were chopped once in one direction after which the
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platform holding the tissue was rotated 45° and the tissue chopped again. The resulting 
prism shaped striatal slices were separated by pipetting up and down, 10 times, in 6.5 ml 
of Krebs bicarbonate buffer (without nomifensine). The slices were allowed to settle, 5 ml 
of buffer were removed and the above procedure repeated. After the final removal of 
buffer, slices (in 1.5 ml of Krebs buffer, without nomifensine) were incubated with [3H]DA 
(0.1 pM, 0.185 MBq/ml) for 15 min. To remove excess radioactive label, 5 ml of Krebs 
buffer (with nomifensine from this point onwards) was added and the slices allowed to 
settle (~ 2 min). The 5 ml of buffer was then removed, discarded, and the procedure 
repeated. After the final removal of buffer, slices were left in a volume of 1.5 ml. An 
additional 1.5 ml of Krebs buffer was added and aliquots of the slice suspension pipetted 
into 12 closed superfusion chambers (200 pl/chamber; 40-50 mg tissue). A nylon mesh 
and GF/B filter were placed at each end of the chamber to prevent slices from flowing out 
of the apparatus (Figure 2.3). The remainder of the superfusion experiment was 






Figure 2.3 The superfusion machine configured for superfusion of slices. Arrows 
indicate direction of buffer flow. Inset: Detail of the closed superfusion chamber showing the 
position of Whatman GF/B filters (grey), nylon meshes (black) and direction of buffer flow.
Superfusion of synaptosomes (open chambers) or slices (closed chambers) was 
performed as previously described (Soliakov et al., 1995; Marshall et al., 1996) in a 
Brandel superfusion apparatus using Krebs bicarbonate buffer at a flow rate of 0.5 ml/min 
and a temperature of 37°C; fractions were collected every two minutes using an 










After a 20 min washout period, synaptosomes or slices were superfused for a further 
10 min in Krebs buffer with or without antagonist (except in the case of a-Bgt, which was 
present in the perfusate for 1 h). Agonists were then applied for 40 s, separated from the 
bulk buffer flow by 1 0  s air bubbles in the presence or absence of antagonist (for summary 
see Table 5). After stimulation, synaptosomes or slices were superfused for a further 10 
min in Krebs buffer with or without antagonist. Additionally, when caffeine or other 
adenosine receptor antagonists were included (Chapter 6 ) stimulation was for 180 s, 
unless otherwise indicated.
t
Table 5 Time Course of a Typical Experiment








collector, set to 








2.1.5 Quantification of radioactivity
To estimate the amount of radioactivity remaining in the synaptosomes at the end of 
the experiment, the GF/B filters were placed in scintillation vials and radioactivity counted. 
To estimate the amount of radioactivity remaining in the slices at the end of the 
experiment, superfusion was continued for 30 min with 0.01 M HCI to lyse the slices. From 
a total of 15 ml of lysate per chamber, 1 ml aliquots were counted for radioactivity.
Optiphase Safe™ scintillation fluid was added (4 ml/vial) to the fractions and vials 
vortexed prior to counting for radioactivity in a Packard Tricarb 1600 liquid scintillation 
counter (counting efficiency 48 %).
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2.1.6 Superfusion data analysis
The baseline was derived by fitting the following double exponential decay equation to 
the data, using the program SigmaPlot (v 2.0) for Windows 3.1:
y  = a e bx + ce^*
where a and c are initial (at x = 0 ) release in each phase, b and d are the decay constants 
in each phase, and x is the fraction number. Evoked [3H]DA release was calculated as the 
area under the peak after subtraction of the baseline and expressed as a percentage of 
the total radioactivity present in the synaptosomes or slices at the time of stimulation 
(fractional release). This was taken to be the sum of subsequently released [3H]DA plus 
that on the filters (synaptosomes) or in the total lysate (slices).
*
Data are presented as either fractional release or, more commonly, fractional release 
as a percent of a corresponding control, run in parallel in the absence of antagonist. 
Values in histograms and concentration-response curves represent the mean ± S.E.M. of 
the number of independent experiments carried out, with each experiment consisting of 2  
or 3 replicate chambers for each condition.
Where concentration-response relationships were examined, curves were calculated 
and plotted and EC50 values determined by fitting data to the Hill equation (see below) 
using the non-linear least squares curve fitting function of SigmaPlot
Percent Release= -----------------„
( [Drug] V"
I  E C =o J
Where nH is the Hill number, [Drug] is the concentration of the agonist, and EC50 is the 
concentration at which half-maximal [3H]DA release by the agonist was obtained. 
Statistical significance was determined using unpaired Student’s t-test or one-way ANOVA 
and Tukey’s post-hoc test, as stated in the figure legends. Values of p<0.05 or p<0.01 
were taken to be statistically significant.
2.2 Surgical procedures
All surgical procedures that are described in this section conform to UK Home Office 
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2.2.1 Materials
Male Sprague-Dawley (SD) rats, 245-255 g, from the University of Bath breeding 
colony were used. Heparin, chlorhexidine digluconate, (-)nicotine ditartrate and (-)nicotine 
base were obtained from Sigma Chemical Co. (Poole, Dorset, UK). Alzet™ osmotic 
minipumps (Model 2002) were purchased from Charles River Laboratories (UK). Wound 
clips were from Scientific Laboratory Supplies (Nottingham, UK). Other miscellaneous 
surgical equipment and chemicals were obtained from standard sources.
2.2.2 Chronic nicotine treatment of rats by injection
Male SD rats were chronically treated by subcutaneous injection with either phosphate 
buffered saline (PBS; 150 mM NaCI, 8 mM K2HP04>2 mM KH2P04, pH 7.4) or*(-)nicotine 
ditartrate in PBS, pH 7.4 (equivalent to 0.4 mg (-)nicotine base/kg). Rats were divided into 
pairs with one rat receiving PBS (control) and one rat receiving nicotine (treated). Rats 
were injected once a day, in the afternoon, for seven days. Behaviour was monitored for 
30 min after each injection by visual inspection. On the eighth day, rats were killed and the 
striata dissected for superfusion, as described in section 2.1. The remainder of the brain 
(minus striatum and cerebellum) was frozen for later use in radioligand binding assays. 
Where multiple pairs of rats were treated, the injection regime was staggered so that each 
pair of control and treated rats were assayed on subsequent days.
2.2.3 Chronic nicotine treatment of rats by osmotic minipumps
Male SD rats were chronically treated by (-)nicotine delivered via osmotic minipumps 
for 14 days, 4 mg (-)nicotine base/kg/day. Minipumps were loaded with either PBS or 
nicotine base in PBS with the pH adjusted to 7.4 with conc. HCI. The concentration of 
nicotine in the pump was calculated according to the following formula:
4 mg/kg/day x estimated weight of rat on day 7 
24 x Pumping Rate of Minipump/hr (in ml)
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Minipumps were implanted under halothane 
anaesthesia (4% halothane: 1 l/min 0 2 induction,
2% halothane: 1 l/min 0 2 maintenance), dorsally,
2-3 cm behind the shoulder blades. The area was 
shaved with a pair of electric clippers and 
swabbed with a solution of 70 % ethanol/0.5 % 
chlorhexidine digluconate. A 1.5 cm incision was 
made and blunt dissection performed to create a 
subcutaneous skin pocket large enough to 
accommodate the minipump. The minipump was 
then swabbed with isopropanol and inserted into 
the skin pocket with the delivery portal facing 
towards the tail of the animal. Antibiotic powder 
(Cicatrin™) was puffed into the wound and the incision closed with two wound clips. 
Behaviour was monitored throughout the 14 days in the first group of animals. 
Experiments not involving withdrawal were performed as follows. At the end of the 14th 
day the animal was sacrificed and superfusion performed on the striata, as outlined in 
section 2.1. For studies examining withdrawal, animals were anaesthetised at the end of 
the 14th day, as described above, and minipumps were removed through a second 
incision made lower down on the back of the animal with the wound secured with two 
wound clips. After 1 or 7 days withdrawal the animals were sacrificed and superfusion 
performed as in section 2.1. The remainder of the brain (minus striatum and cerebellum) 
was frozen for later use in radioligand binding assays. In a separate trial, using 3 pairs of 
rats treated with either nicotine or PBS as above, superfusion was not carried out so that 
radioligand binding assays could be performed on striatum and frontal cortex.
2.3 Radioligand binding studies
2.3.1 Materials
• [3H](-)Nicotine (81.5 Ci/mmol in ethanol; stored at -20°C in a ten fold molar excess 
of mercaptoacetic acid) and [3H]AMPA (40.9 Ci/mmol; stored at -20°C) were 
provided by Dupont NEN (Stevenage, Herts, UK)
• [3H]Methyllycaconitine ([3H]MLA; 25-50 Ci/mmol; stored at -20°C) was from Tocris- 
Cookson (Avonmouth, Bristol, UK)
(3) Drug solution is 
expelled via 
delivery portal







Figure 2.4 Operation of the 
Alzet™ osmotic minipump
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2.3.2 Reagents
For [3H]nicotine and [3H]MLA binding
• Sucrose solution was composed of 0.32 M sucrose, 1 mM EDTA, 0.1 mM PMSF 
and 0.01% (w/v) sodium azide, pH 7.4
• Phosphate buffered saline (PBS) was composed of 150 mM NaCI, 8 mM K2HP04j
2 mM KH2HP04, 1 mM EDTA, 0.1 mM PMSF, 0.01% (w/v) NaN3, pH 7.4. For
washing, PBS was prepared as above but without the addition of PMSF and EDTA
• Krebs Ringer Tris-HEPES buffer (KRTH) was composed of 118 mM NaCI, 4.8 mM
KCI, 2.5 mM CaCI2, 20 mM HEPES, 20 mM Tris, 0.1 mM PMSF and 0.01% NaN3,




• Tris-citrate-sucrose (TCS) buffer was composed of 0.32 M sucrose, 50 mM Tris, 1 
mM EDTA and 1 mM EGTA, pH 7.4 (adjusted with citric acid)
• Tris-citrate buffer 50 mM Tris, 1 mM EDTA and 1 mM EGTA, pH 7.4
• Tris-citrate binding buffer 50 mM Tris, 1 mM EDTA, 1 mM EGTA, 100 mM KSCN, 
pH 7.4
2.3.3 Tissue preparation
Preparation of brain tissue for use in [3H]MLA and [3H]nicotine radioligand binding 
assays was performed according to a modification of the method used by Davies et al.
(1999) and is essentially the same method used to prepare synaptosomes for use in 
superfusion. For [3H]AMPA binding the procedure was based on that of Dev et al. (1995). 
Brain tissue from chronically treated rats (minus cerebellum and striatum or striatum and 
frontal cortex alone) was stored at -20°C. Subsequently, brain samples from individual 
rats were thawed in cold sucrose solution, weighed and homogenised separately, but in 
parallel, using a glass-Teflon homogeniser (12 strokes at 500 rpm). The homogenate was 
centrifuged at 1000 x g for 10 minutes at 4°C in a Sorvall RC-5B centrifuge using an SM- 
24 rotor, after which the supernatant (S1) decanted and retained on ice whilst the pellet 
(P1) was discarded. The supernatant was then centrifuged at 12000 x g for 20 min at 4°C. 
The supernatant was discarded and the pellet (P2) re-suspended in PBS and re­
centrifuged as above. This step was repeated before the final pellet was re-suspended (4 
ml/g original wet weight of tissue) after which samples were stored at -20°C prior to 
binding experiments.
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A slightly different procedure was followed for preparation of tissue for use in [3H]AMPA 
binding assays. Brain tissue from chronically treated rats (minus cerebellum and striatum) 
was stored at -20°C. Subsequently, brains were thawed, weighed and homogenised in 
ice cold TCS buffer. Again, brains from individual rats were homogenised separately but in 
parallel. The homogenate was subjected to differential centrifugation to prepare a P2 
pellet as described for [3H]nicotine and [3H]MLA binding. However, instead of re- 
suspending the final pellet, it was frozen on dry ice, thawed, washed in Tris-citrate buffer 
and centrifuged (12,000 x g, 20 min, 4°C). This step was repeated twice before the final 
pellet was re-suspended (4 ml/g wet weight) after which samples were stored at -20°C 
prior to binding experiments. This freeze-thawing procedure is apparently required in 
order to lyse any glutamate containing vesicles and wash away the subsequently release 
glutamate, which could interfere with the binding of [3H]AMPA.
2.3.4 Protein estimation
Protein was determined using the Biorad protein
assay kit, which essentially uses the method of 0.6 ■
Bradford (Bradford, 1976). The assay reagent was S 0 .5 -<
6 „ .




Whatman filter paper. A standard protein curve was f  0 .2 -
constructed using triplicate samples of bovine serum 
albumin, dissolved in PBS, over a concentration
8
<  0.1 -
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
range of 0.2 -  1.2 mg/ml (Figure 2.5). Brain samples
BSA concentration (mg/ml)
were diluted 1:4, 1:8 and 1:16, in PBS, in triplicate.
Figure 2.5 A typical protein
Each sample (10 pi of BSA standards or diluted brain standard curve. Points represent
samples) was added to LP4 tubes and 1 ml of the the mean absorbance ±  S.E.M.
assay reagent added to each tube. Protein was obtained at 595 nm using increasing
determined by measurement of optical density at 595 concentration of BSA (0.2 -  1.2
nm versus blank (buffer plus reagent) using a Helios mg/ml) assayed in triplicate using
Gamma spectrophotometer. the Biorad protein assay.
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2.3.5 [3H]Nicotine and [3H]MLA binding protocol
The density of [3H]nicotine binding sites present in brain tissue from chronically treated 
animals was determined by a modification to a protocol previously used in this laboratory 
(Rowell and Wonnacott, 1990). [3H]MLA binding was essentially the method of Davies et 
al. (1999) developed in this laboratory. Triplicate LP4 tubes were set up for total and non­
specific binding. Membranes were diluted in Krebs-Ringer-Tris-HEPES (KRTH) buffer to 
give 0.1 to 1 mg protein/ml and 250 pi of diluted membranes added to each tube along 
with 10 pi distilled water to tubes for total binding or 10 pi of 27 mM nicotine ditartrate 
(final concentration 1 mM) or 10 pi of 27 pM unlabelled MLA (final concentration 1 pM) to 
measure non-specific binding. [3H]Nicotine (540 nM) or [3H]MLA (540 nM) was added to 
all tubes using a repeating pipette to give a final concentration of 20 nM in both cases. 
Tubes were vortexed and incubated at room temperature for 1 hour prior to transfer to the 
cold room for 30 min. In order to separated bound from unbound ligand, samples were 
filtered on a Brandel Cell Harvester, under vacuum, through a double thickness of 
Whatman GF A/E filters (pre-soaked in 0.3% (w/v) polyethyleneimine). Filters were 
washed four times with 4 ml PBS, transferred to maxi scintillation vials (Packard- 
Canberra) and 5 ml Optiphase Safe scintillation fluid added. In order to relate the 
radioactivity counts obtained from binding experiments to the actual amount of bound 
radioligand present, 10 pi of either 540 nM [3H]nicotine or [3H]MLA stock were applied to 
moist filters in scintillation vials and 5 ml scintillation fluid added.
2.3.6 [3H]AMPA binding protocol
The number of [3H]AMPA binding sites present in brain tissue from chronically treated 
animals was determined based on the method of Honore et al. (1982). Triplicate tubes 
were set up for total and non-specific binding. Membranes were diluted in Tris-citrate 
binding buffer to give 0.25 protein/ml. Aliquots of diluted membranes (250 pi) were added 
to each LP4 tube along with 10 pi distilled water to tubes for total binding or 10 pi of 27 
mM L-glutamate (final concentration 1 mM) to measure non-specific binding. [3H]AMPA 
(10 pi) was added to all tubes using a repeating pipette to give a final concentration of 10 
nM. Tubes were vortexed and incubated at 4°C for 1 hour. In order to separate bound 
from unbound ligand, samples were filtered as above, except filters were washed four 
times with 4 ml Tris-citrate buffer. Total counts were determined by applying 10 pi of 270 
nM [3H]AMPA stock to moist filters in scintillation vials.
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2.3.7 Data analysis
Radioactivity counts (cpm) from binding assays were converted into amount of 
radioligand bound per mg protein for presentation in histograms. Values represent the 
mean specific binding ± S.E.M. of triplicate results from at least one experiment. Statistical 
analysis of radioligand binding levels obtained from control and treated rats was 
determined using the unpaired Student’s t-test, as stated in the figure legends. Values of 
p<0.05 or p<0.01 were taken to be statistically significant.
2.4 Quantitative autoradiography of [125l]a-CTx Mil binding
Experiments performed by Dr. Paul Whiteaker in Chapter 3 assessed [125l]a-CTx Milt
binding by quantitative autoradiography. The methods used were similar to those detailed 
in Whiteaker et al. (2000) and are briefly outlined in the following section.
Tissue sections (20 ^m thick) were prepared from male Sprague-Dawley rats (300- 
350 g), and mounted onto microscope slides. Before incubation with [125l]a-CTx Mil, 
sections were incubated in binding buffer (NaCI, 144 mM; KCI, 1.5 mM; CaCI2, 2 mM; 
MgS04, 1 mM; HEPES, 20 mM; bovine serum albumin, 0.1% (w/v); pH 7.5) containing 
PMSF (1 mM; to inactivate endogenous serine proteases) at 22°C for 15 min. For all 
[125l]a-CTx Mil binding reactions, the standard binding buffer was also supplemented with 
5 mM EDTA, 5 mM EGTA, and 10//g/ml each of aprotinin, leupeptin trifluoroacetate, and 
pepstatin A to protect the ligand from endogenous proteases.
Saturation binding experiments were performed by incubation of six series of sections 
with concentrations of [125l]a-CTx Mil varying between 0.05 nM and 2.5 nM to determine 
total binding at each concentration for 2 h at 22°C. Non-specific binding (in the presence 
of 10 mM (-)-nicotine) was determined in a series of adjacent sections, and receptor- 
specific binding was determined as the difference between total and non-specific binding 
at each concentration. The ability of MLA to inhibit [125l]a-CTx Mil binding was determined 
by co-incubation of sections with 0.5 nM [125l]a-CTx Mil and varying concentrations of 
MLA (1 nM -  1000 nM) for 2 h at 22°C. Following incubation with [125l]a-CTx Mil, the 
slides were washed and dried overnight
Mounted, desiccated sections were apposed to film (3 days, Amersham Hyperfilm p- 
Max film). To allow quantitation, each film was also exposed to radioactive microscales. 
After the films had been exposed they were developed and signal intensity in selected 
brain regions was measured by digital image analysis. Films were illuminated using a
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Northern Light light box, and autoradiographic images of the sections and standards were 
captured using a CCD imager camera. Signal intensity was determined using NIH-image 
1.61. Six independent measurements from different tissue sections were made for 
nucleus accumbens and striatum, under each incubation condition, for each rat. The 
optical density measurements for each brain area were averaged, and the mean optical 
density was used to calculate the degree of labelling by reference to the relevant standard 
curve.
2.4.1 Analysis of autoradiography experiments
Results for saturation binding experiments were calculated using the Hill equation:
B = BmaxLn/ ( L n + Kdn) where B is the binding at the free ligand concentration L,*Bmax is the 
maximum number of binding sites, K<j is the equilibrium binding constant, and n is the Hill 
coefficient. Values of Bmax, Kj, and n were calculated using the non-linear least squares 
fitting algorithm of Sigma Plot V5.0 (Jandel Scientific, San Rafael, CA). Results for 
inhibition of [125l]a-CTx Mil binding were calculated using a one-site fit: B = b0/(1 + (I/IC5o)
where B is ligand bound at inhibitor concentration I, B0 is the binding in the absence of 
inhibitor, and IC50 is the concentration of inhibitor required to reduce binding to 50% of B0. 
Values for Kj (inhibition binding constant) were derived by the method of Cheng and 
Prusoff (1973): Ki = ICso /1 + (L / Kd) •
2.5 Fluorimetric measurement of nicotine-evoked changes in 
intracellular Ca2+ concentration
2.5.1 Materials
Tissue culture media, serum and plasticware were obtained from Gibco BRL (Paisley, 
Renfrewshire, Scotland). Media supplements, a-bungarotoxin (a-Bgt), cadmium chloride, 
(-)nicotine hydrogen tartrate, nifedipine, caffeine, cyclopiazonic acid (CPA), ryanodine and 
mecamylamine were purchased from The Sigma Chemical Co. (Poole, Dorset, UK). 
Xestospongin-c and a-conotoxin Iml (a-CTx Iml) were from Calbiochem (Nottingham, 
UK). a-Conotoxin Mil (a-CTx Mil) was from Tocris Cookson (Bristol, UK). Fluo-3 AM and 
pluronic F127 were purchased from Molecular Probes (Oregon, USA). a-Conotoxin AulB 
(a-CTx AulB) was a gift from Dr B. Livett (University of Melbourne, Australia). The 
concentrations of nAChR antagonists, VOCC blockers and ryanodine and IP3 receptor 




based on previous studies (Kaiser et al., 1998, for a-CTx Mil; Johnson et al., 1995, 
Pereira et al., 1999, for a-CTx Iml; Sharma and Vijayaraghavan, 2001, for CdCI2; Taylor 
and Peers, 1999, for nifedipine; Gafni et al., 1997, and Gueorguiev et al., 2000, for 
xestospongin-c; Shoop et al., 2001, for ryanodine).
2.5.2 Cell culture
Human neuroblastoma SH-SY5Y cells (ECACC, Salisbury, UK; passages 14-20) were 
cultured as previously described (Sharpies et al. 2000; Ridley et al. 2001, 2002). In brief, 
cultures were maintained in 175 cm2 tissue culture flasks and maintained in Dulbecco’s 
modified Eagle’s media (DMEM:F12), supplemented with 15% foetal bovine serum, 2 mM 
L-glutamine, 1% non-essential amino acids and 190 U/ml of penicillin and 0.2 mg/ml of 
streptomycin, until confluent. Cells were plated (1:5 dilution from flask) into 96 well 
Primaria plates (Falcon, New Jersey, USA) and experiments performed 72 h afterwards 
with confluent cultures.
2.5.3 Calcium fluorimetry
After removal of the medium from the confluent cultures, SH-SY5Y cells were washed 
twice with Tyrode’s Salt Solution (TSS: 137 mM NaCI, 2.7 mM KCI, 1.0 mM MgCI2, 1.8 
mM CaCI2, 0.2 mM NaH2P04, 12 mM NaHC03l 5.5 mM glucose; pH 7.4) and incubated 
with the membrane permeable Ca2+-sensitive dye fluo-3-AM (10 pM) and 0.02 % pluronic 
(to facilitate fluo-3 dispersal and loading) for 1h at room temperature in the dark. Cells 
were then washed twice with TSS, before adding 80 pi buffer, with or without added 
drugs, per well. After 15 min pre-incubation (or 30 min in the case of a-Bgt) at room 
temperature in the dark, changes in fluorescence (excitation 485 nm, emission 538 nm) 
were measured using a Fluoroskan Ascent fluorescent plate reader (Labsystems, 
Helsinki, Finland).
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Basal levels of fluorescence were monitored for 5 s (short term protocol) or 20 s (long 
term protocol) before addition of nicotine (20 pi; final concentration 30 or 100 pM) using 
an automatic dispenser. After stimulation, changes in fluorescence were monitored for 
20 s (initial increase; short term protocol) or 10 min (sustained response; long term 
protocol). For normalising fluo-3 signals, responses from each well were calibrated by 
determination of the maximum and minimum fluorescence values. At the end of each 
experiment, addition of 0.2 % Triton (F max) was followed by 40 mM MnCI2 (F min). The 
mean F min / F max ratio was 0.24 ± 0.03 (mean ± SEM, n = 32) and 0.26 ± 0.04 (mean ± 
SEM, n = 30) for short- and long-term measurements respectively; these values were 
consistent with those reported for this dye in other systems (Minta et al., 1989; Sharma 
and Vijayaraghavan, 2001). According to previous studies, the manganese-saturated 
fluorescence corresponds to an intracellular Ca2+ concentration of 100 nM (Minta et al., 
1989). The average baseline fluorescence normalised to F min was 1.15 ± 0.02 (n = 25). 
Data were calculated as a percentage of F max - F min. Values in the presence of 
blockers were expressed as a percentage of the control response to 30 pM nicotine 
(included in all experiments), unless otherwise stated. Maximum responses to nicotine 
were approximately 20 % of the F max -  F min, thus not close to saturation of the dye. No 
significant effects on basal levels of fluorescence were observed after incubation with any 
of the antagonists or blockers used, with the exception of CdCI2. Incubation with CdCI2 
produced a rather slow but sustained increase in basal fluorescence, which precluded its 
use in long-term measurements.
2.5.4 Statistics
Data represent the mean ± S.E.M. of 3 or more independent experiments (each with 4 
replicates). Statistical significance was determined using the unpaired Student’s t-test or 
one-way ANOVA and Tukey’s post-hoc test, as stated in the figure legends. Values of 
p<0.05 and p<0.01 were taken to be statistically significant.
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3 Pharmacology of Presynaptic nAChR on
Dopamine Terminals in the Rat Striatum
3.1 Introduction
The nicotinic stimulation of dopamine (DA) release from the terminal fields of the nigro- 
striatal pathway has been well documented, and is modulated by presynaptic nAChR on 
striatal DA terminals (see section 1.12.2.2; Rapier et al., 1988; Grady et al., 1992; Clarke 
and Reuben, 1996; Zhou et al., 2001). Somato-dendritic nAChR on DA neurones in the 
substantia nigra (Clarke et al., 1987; Reuben et al., 2000; Klink et al., 2001) are also likely 
to influence striatal DA release (Picciotto et al., 1998; see Di Chiara, 2000a). The 
nigrostriatal system has merited attention because of its relevance to the motor stimulant 
and addictive properties of nicotine and because these nAChR represent therapeutic 
targets for the treatment of Parkinson’s disease (see Chapter 4 for a description of this 
disease).
Determination of the subunit composition of native nAChR presents a major challenge. 
This endeavour is hampered by a lack of subtype-selective nicotinic ligands, the majority 
of those available are antagonists derived from natural products. As described in section 
1.12.1.3.1, a-conotoxin Mil (a-CTx Mil) belongs to a family of peptide toxins elaborated by 
Conus spp. and directed against particular nAChR subtypes (McIntosh et al., 1999). From 
studies of functional nAChR expressed in Xenopus oocytes, a-CTx Mil was originally 
defined as a specific antagonist of nAChR composed of a3 and p2 subunits (Cartier et al., 
1996; Harvey et al., 1997) and [125l]a-CTx Mil labels a unique population of nicotinic 
binding sites in mouse and monkey brain (Whiteaker et al., 2000b; Quik et al., 2001). This 
toxin partially blocks [3H]DA release from rat striatal synaptosomes stimulated with 
nicotine (Kulak et al., 1997) or anatoxin-a (Kaiser et al., 1998): this was interpreted as 
evidence for the heterogeneity of presynaptic nAChR on DA terminals, with one 
population containing an a3p2 interface (although in light of a recent report, the population 
may contain an a6p2 interface; Champtiaux et al., 2002). Studies with the novel partial 
agonist UB-165 led to the proposal of an a4p2* nAChR subtype as a candidate for the 
other nAChR population present on striatal DA terminals (Figure 3.1; Sharpies et al.,
2000). These subunit assignments are consistent with the localisation of p2 nAChR 
subunit immunoreactivity in most DAergic terminals in the dorsal striatum (Jones et al.,
2001) and the absence of nicotine-evoked DA release from striatal synaptosomes or
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slices prepared from p2 null mutant mice (Grady et al., 2001; Zhou et al., 2001). However, 
the subunit composition of presynaptic nAChR is likely to be more complex than pairwise 
combinations of subunits and this is denoted by the asterisk (Lukas et al., 1999).
Midbrain DA neurones express most nAChR subunits (Charpantier et al., 1998; Klink et 
al., 2001), including a particularly high expression of mRNA corresponding to the a6 and 
P3 nAChR subunits, which have a very limited distribution in the brain (Le Nov6re et al., 
1996). Patch clamp recording and single cell PCR analysis of rat midbrain DA neurones, 
and comparison with data from transgenic mice deficient in a particular nAChR subunit, 
led to the tentative subunit compositions a4a6/<x3a5(p2)2 and (oc4)2a5(p2)2 for two major 
nAChR subtypes found on cell bodies of these neurones in the substantia nigra and VTA 
(Klink et al., 2001; Figure 3.1).
Somatodendritic a4a6a5(p2)2 & 
nAChR a4a5(p2)2





tegmental area (showing release o f DA)
Figure 3.1 Putative nAChR subtypes and their locations in nigrostriatal neurones
For nAChR subtypes at DAergic terminals, Kulak et al., 1997; Kaiser et al., 1998; Sharpies et 




Typical fast desensitising a7-type nAChR currents are also observed in some midbrain 
DA neurones (Pidoplichko et al., 1997; Klink et al., 2001), but a l*  nAChR do not appear to 
mediate [3H]DA release from striatal synaptosomes as the a7-selective antagonists 
a-bungarotoxin (a-Bgt) and a-conotoxin Iml (a-CTx Iml) are without effect (Rapier et al., 
1990; Grady et al., 1992; Kulak et al., 1997). However, it has previously been noted that 
50 nM methyllycaconitine (MLA), a potent, a7-selective antagonist, produced a partial 
inhibition of anatoxin-a-evoked [3H]DA release from striatal synaptosomes (Kaiser and 
Wonnacott, 2000), in agreement with the earlier observation of Clarke and Reuben 
(1996). In avian neuronal preparations some discrepancies between MLA- and a-Bgt- 
sensitive responses have also been reported (Yum et al., 1996; Guo et al., 1998, Yu and
t
Role, 1998). Recently, Klink et al. (2001) have also shown that low nanomolar 
concentrations of MLA inhibit a population of non-a7 nAChR currents, correlated with the 
tentative subunit composition a4a6a5(p2)2 in rat mesencephalic DA neurones. It is 
possible that minority populations of non-a7, neuronal nAChR with particular subunit 
combinations show sensitivity to MLA.
The novel a4|32* selective nAChR agonist, 5-iodo-3- 
(2(S)-azetidinylmethoxy)pyridine (l-A-85380; Figure 3.2) is 
also used here to further explore the nAChR subtypes that 
regulate [3H]DA release from striatal synaptosomes. This 
compound is the latest progression arising from a family of 
3-pyridyl ethers that display picomolar affinity for nAChR 
(Abreo et al., 1996). The most noteworthy contender from 
this series is 3-(2(S)-azetidinylmethoxy)pyridine or 
A-85380, which exhibits high affinity for a4(32* nAChR. Several halogenated and 
radiolabelled derivatives of A-85380 have now been synthesised for use in PET and 
SPECT studies (Koren et al., 1998). For instance, a version of A-85380 labelled with 
iodine-123 has been successfully used in SPECT experiments in monkeys and baboons 
with results demonstrating the high specificity and low toxicity of the compound (Chefer et 
al., 1998; Horti et al., 1999; Musachio et al., 1999). With reference to the radioligand 
binding experiments in Chapter 5, last year witnessed the first in vivo imaging by SPECT 
of upregulation of nAChR following chronic nicotine treatment using [123l]-A-85380 
(Kassiou et al., 2001). In vitro binding studies performed with [123l]-A-85380 show that it 
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compared with a3(34*, a7 and muscle nAChR, respectively (Mukhin et al., 2000). No 
binding was detected in the brains of mice homozygous for a mutation in the (32 nAChR 
subunit. These data suggest that the non-radiolabelled version of this compound, (Figure 
3.2), may be of additional assistance in the dissection of nAChR subunits involved in 
striatal DA release.
Therefore, in this chapter the MLA-sensitive portion of nAChR-mediated [3H]DA release 
from striata! synaptosomes is pharmacologically characterised using the superfusion 
technique (see section 2.1). It was determined that low nanomolar concentrations of MLA 
inhibit the same nAChR population as a-CTx Mil. Using [125l]a-CTx Mil to label nAChR 
directly, we confirm that MLA potently interacts with this site. Additional information
t
regarding the subunit composition of nAChR involved is disclosed by use of the putative 
a4|32* selective compound, l-A-85380. The relationship between presynaptic and 
somatodendritic nAChR on DA neurones, with respect to subunit composition, is also 
discussed.
3.2 Results
3.2.1 MLA partially inhibits nicotine-evoked [3H]DA release from 
striatal synaptosomes
Nicotine-evoked [3H]DA release from rat striatal synaptosomes was monitored in the 
presence and absence of a variety of nicotinic antagonists. Nicotine (10 pM; delivered as 
a 40 s pulse) elicited a peak of radioactivity above basal release, and this was almost 
totally abolished in the presence of the general nAChR antagonist mecamylamine (10 pM; 
Figure 3.3 A). The residual release was equivalent to the non-specific release observed 
when agonist was replaced with buffer. In the presence of MLA (50 nM), a small decrease 
in the amount of nicotine-evoked [3H]DA release was consistently observed (Figure 3.3 A 
& B). MLA had no effect on the basal release of [3H]DA.
The concentration response relationship for the effect of MLA on [3H]DA release 
evoked by 10 pM nicotine (Figure 3.3 B) showed a significant (p<0.05, n=4) inhibition of 
the response between 30 and 100 nM MLA. Higher concentrations of MLA were not 
examined as MLA becomes non-selective above 100 nM and would interact with various 
non-a7 subtypes of nAChR (Drasdo et al., 1992; Wonnacott et al., 1993). At 10 nM MLA, 
a concentration frequently used to inhibit a7 nAChR, there was a small but non-significant 
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Figure 3.3 Inhibition by MLA of nicotine-evoked fHJDA release from striatal 
synaptosomes. Synaptosomes were loaded with fH ]DA and superfused as described in 
section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity. Antagonist was 
introduced into the perfusing buffer 10 min prior to stimulation for 40 s with nicotine.
(A) Release of fHJDA over time, showing the response to 10 pM nicotine in the absence ( • )  
and presence (u) of 50 nM MLA, or 10 pM mecamylamine (A). Evoked fH]DA release is 
expressed as a percent of the mean basal release; values are the mean ±  S.E.M. of the 
triplicate chambers from a representative experiment.
(B) Effect of increasing concentrations of MLA on nicotine-evoked fH]DA release. 
Synaptosomes were stimulated with 10 pM nicotine, in the presence and absence of MLA 
Results are expressed as a percentage of the response to 10 pM nicotine alone. Error bars 
indicate the S.E.M. from four separate experiments, each consisting of two or more replicate 
chambers (** p<0.01, * p<0.05 significantly different from control response; one-way ANOVA 
and Tukey’s post-hoc test).
MLA (50 nM) was compared with other a7-selective nAChR antagonists for inhibition of 
nicotine-evoked [3H]DA release from rat striatal synaptosomes (Figure 3.4). Nicotine at a 
maximally effective (100 pM) and a submaximal concentration (10 pM; see insert, Figure
3.4) were compared. At the higher concentration, nicotine elicited approximately 50% 
more [3H]DA release than 10 pM nicotine; in both cases the responses were decreased to 
the level of a buffer control in the presence of mecamylamine (10 pM). MLA significantly 
inhibited [3H]DA release evoked by 10 pM nicotine, by 16.3 ± 5.8 % (p<0.05, n=4) but had 
no significant effect on release evoked by the higher concentration of nicotine (Figure 3.4).
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However, maximally effective concentrations of the a7-selective nAChR antagonists a-Bgt 
(40 nM) and a-CTx Iml (1 pM; Johnson et al., 1995; Pereira et al., 1996) did not diminish 
[3H]DA release from striatal synaptosomes stimulated with either concentration of nicotine.
Log10[nico«ne]((iM)
Nic + a-Bgt + MLA + a-CTx + Mec Nic + a-Bgt + MLA + a-C Tx + Mec
Iml Iml
+ 10 nM Nicotine + 100 jiM Nicotine
Figure 3.4 The effect of the a7-selective antagonists on nicotine-evoked fH]DA  
release from striatal synaptosomes. Synaptosomes were loaded with fH]DA and superfused 
as described in section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity. 
Antagonist was introduced into the perfusing buffer 10 min prior to stimulation for 40 s with 
nicotine, except in the case of a-Bgt, where synaptosomes were incubated with it for 1 h prior to 
addition of agonist. The effect of the a7-selective antagonists a-Bgt (40 nM), MLA (50 nM), a- 
CTx Iml (1 pM) and the general nAChR antagonist, mecamylamine (10 pM), were compared for 
their effect on fH]DA release evoked by 10 pM nicotine or 100 pM nicotine. Values are 
expressed as a percentage of the response to 10 pM nicotine, in the absence of antagonist, 
determined in parallel. Inset: concentration response relationship for nicotine-evoked fHJDA 
release from striatal synaptosomes. Values are the mean ±S.E.M. from at least three separate 
experiments, each consisting of two or more replicate chambers (* p<0.05, significantly different 
from control response, Student’s t-test).
The inhibition by MLA, but not by the other a7 nAChR antagonists, suggested that MLA 
was interacting with a non-a7 nAChR. To explore this possibility, other nAChR 
antagonists were used to clarify the subtype of nAChR involved. In the presence of 100 
nM a-CTx Mil, a concentration that has been shown to selectively and maximally inhibit
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a3p2* nAChR (Cartier et al., 1996; Kaiser et al., 1998), [3H]DA release evoked by 10 nM 
nicotine was decreased by 35.5 ± 8.6 % (p<0.01, n=6; Figure 3.5). MLA also partially 
inhibited nicotine-evoked [3H]DA release, consistent with previous experiments (above), 
but when co-applied with a-CTx Mil no additional inhibition of [3H]DA release was 
observed (26.2 ± 5.9 % inhibition, p<0.01, n=5; Figure 3.5).
120 n
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Figure 3.5 Inhibition of nicotine-evoked [*H]DA release from striatal synaptosomes
by MLA and non-a7 antagonists. Synaptosomes were loaded with ?H]DA and superfused as 
described in section 2.1. Antagonists (50 nM MLA; 100 nM a-CTx Mil; 1 pM DHpE) were 
introduced into the perfusing buffer, either singly or in combination, 10 min prior to stimulation 
for 40 s with 10 juM nicotine. Evoked fH]DA release in the presence of antagonist is expressed 
as a percentage of the response to 10 pM nicotine alone. Values are the mean ±  S.E.M. from at 
least three independent experiments, each consisting of two or more replicate chambers 
(**p<0.01, *p<0.05 significantly different from control response, one-way ANOVA and Tukey’s 
post-hoc test; f t  p<0.01, significantly different from responses obtained with nicotine alone and 
in combination with a-CTx Mil, MLA and a-CTx MII+MLA, one-way ANOVA and Tukey’s post- 
hoc test.)
The antagonist DHpE has a broad specificity for neuronal nAChR, but is more selective 
for non-a7 containing nAChR at low concentrations (1 pM, Harvey et al., 1996). At 1 |^ M, 
DHpE produced a substantial inhibition (62.7 ± 9.4 %) of [3H]DA release evoked by 10 pM 
nicotine. Neither a-CTx Mil (100 nM) nor MLA (50 nM) in combination with DHpE (1 pM) 
showed any additivity with respect to the extent of inhibition observed (Figure 3.5).
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Subtype-selective agonists which activate only one of the nAChR subtypes present on 
striatal DA terminals would provide another approach to characterising the action of MLA 
on striatal synaptosomes. The recent characterisation of the novel synthetic agonist UB- 
165 (Sharpies et al., 2000), showed it was a partial agonist in releasing [3H]DA from 
striatal synaptosomes, as it predominately activated the a-CTx Mil-sensitive nAChR 
subtype. From the effects of MLA on nicotine-evoked [3H]DA release (Figure 3.4 & Figure
3.5), we predicted that UB-165-evoked [3H]DA release should also be sensitive to low 
nanomolar concentrations of MLA. Two concentrations of UB-165 were compared: a 
maximally effective concentration (1 pM) and one that approximates to its EC50 value (0.2 
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Figure 3.6 Sensitivity to MLA of fhiJDA release evoked by UB-165. Synaptosomes 
were loaded with fH]DA and superfused as described in section 2.1. Antagonist (50 nM MLA; 
100 nM a-CTx Mil; 10 pM mecamylamine) were added to the perfusing buffer 10 min prior to 
stimulation for 40 s with nicotine (10 pM) or UB-165 (0.2 pM or 1 pM). Results are expressed as 
a percentage of the response to 1 pM UB-165. Values are the mean ±  S.E.M. from at least 
three independent experiments, each consisting of two or more replicate chambers (** p<0.01, 
significantly different from responses obtained with 1 pM UB-165, one-way ANOVA and Tukey’s 
post-hoc test; f t  p<0.01, f  p<0.05, significantly different from responses obtained with 0.2 pM 
UB-165, one-way ANOVA and Tukey’s post-hoc test).
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[3H]DA release evoked by 0.2 pM and 1 pM UB-165 was 20 % and 29 %, respectively, 
of that elicited by 10 pM nicotine (Figure 3.6). Mecamylamine (10 pM) reduced the 
responses of both concentrations of UB-165 to a similar level, approximately 7 % of the 
nicotine response. a-CTx Mil (100 nM) and MLA (50 nM) inhibited [3H]DA release evoked 
by 0.2 pM UB-165 to a similar extent (38.9 ± 3.3 % and 37.1 ± 4.8 % inhibition 
respectively), compared with 53.9 ± 7.0 % and 61.3 ± 5.3 % inhibition by DHpE and 
mecamylamine respectively (Figure 3.6). Co-application of a-CTx Mil and MLA produced 
no additive effect. At the higher agonist concentration (1 pM UB-165), a-CTx Mil and 
DHpE continued to inhibit the response (by 40.0 ± 5.7 % and 57.0 ± 5.5 % respectively) 
but MLA no longer exerted any significant effect, consistent with a competitive mode of 
inhibition.
3.2.2 Inhibition by MLA of [125l]a-CTx Mil binding
The effects of MLA on nicotinic agonist-evoked [3H]DA release suggest that it acts 
competitively at the same nAChR subtype as a-CTx Mil. To address this proposition, 
experiments were performed by Dr Paul Whiteaker (University of Colorado, USA). [125l]a- 
CTx Mil was used to label nicotinic sites in rat striatum and nucleus accumbens and the 
ability of MLA to displace this specific binding was investigated. [125l]a-CTx Mil displayed 
saturable specific binding to striatum and nucleus accumbens (Figure 3.7 A), with Bmax 
values of 9.8 ±1.3  and 16.5 ± 4.6 fmol /  mg protein and Kd values of 0.63 ±0.19 and 0.83 
± 0.55 nM, respectively. Competition assays with serial dilutions of MLA over the range 1 
nM -  1 pM were carried out by Dr Paul Whiteaker using 0.5 nM [125l]a-CTx Mil, a 
concentration approximating to its Kd. MLA was able to fully displace specific binding of 
the radioligand to both striatum and nucleus accumbens (Figure 3.7 B), with K* values of 
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Figure 3.7 Inhibition by MLA of [1251]a-CTx Mil binding to rat striatum and nucleus 
accumbens (experiments performed by Dr Paul Whiteaker).
(A) Saturation binding of [ 125l]a-CTx Mil. Total and non-specific binding of [ 125l]a-CTx Mil (0.05 - 
2.5 nM) to serial sections of rat brain was determined by quantitative autoradiography as 
described in section 2.4. Non-specific binding was measured in the presence of 10 mM nicotine 
in adjacent series of sections for each [125l]a-CTx Mil concentration. Binding to striatum and 
nucleus accumbens was determined from optical density measurements of labelling in those 
regions. Non-specific binding was linear with concentration, reaching 18.5 ±  1.1 and 14.6 ±2.1  
fmol m g 1 (protein) at 2.5 nM [125l]a-CTx Mil, for striatum and nucleus accumbens, respectively. 
Specific binding was calculated as the difference between total and non-specific values for each 
radioligand concentration. Data points indicate the mean ±  S.E.M. of determinations from 3 
animals, and are fitted to the Hill equation. Bmax values of 9.8 ±  1.3 and 16.5 ±  4.6 fmol m g 1 
(protein), and Kd values of 0.63 ±  0.19 and 0.83 ±  0.55 nM were derived for striatum and 
nucleus accumbens, respectively.
(B) Inhibition by MLA. Serial sections of rat brain were incubated with 0.5 nM [125l]a-CTx Mil in 
the presence of increasing concentrations of MLA (1-1000 nM), in the presence and absence of 
10 mM nicotine to define non-specific binding, as described in section 2.4. Data points indicate 
the mean specific binding ± S.E.M. of determinations from 3 animals, and are fitted to single-site 
Hill inhibition equation. IC50 values for inhibition by MLA are 59.1 ±  23.2 nM and 55.5 ±  22.1 nM 
for striatum and nucleus accumbens, respectively.
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3.2.3 Further demonstration of the competitive nature of MLA
The results presented in Figure 3.4, 3.6 and 3.7 suggest MLA is competitive in nature. 
To analyse this further, the inhibition of [3H]DA release by low nanomolar concentrations 
of MLA at different concentrations of nicotine could be examined. This would be a time 
consuming process using superfusion, so an additional functional technique was 
employed. Ca2+ fluorimetry experiments were performed in 96 well plates using SH-SY5Y 
cells (see Chapter 6 for more information regarding this technique). Although these cells 
lack the a4 nAChR subunit, they express the a3, a5, a7, p2 and p4 subunits, and MLA is 
known to inhibit responses from them (Ridley et al., 2002). Thus, this method should allow 
the investigation of the competitive activity of MLA. Ca2+ fluorimetry was used to monitor 
increases in fluorescence evoked by three concentrations of nicotine (10, 30 and 100 nM) 
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Figure 3.8 MLA inhibits increases in fluorescence evoked by different 
concentrations of nicotine. SH-SY5Y cells were loaded with fluo-3 AM, as described in 
section 2.5. Cells were stimulated with 10, 30, or 100 pM nicotine alone and in the presence of 
increasing concentrations of MLA (1, 3, 10, 30, 50, or 100 nM). Fluorescence was monitored at 
538 nm for 20 s. The response to the nicotine control in the absence of MLA was taken as 
100% and all other values expressed as a percentage of this. All values are the mean ±  S.E.M. 
from 3 separate experiments with quadruplicate repeats. (** p<0.01, * p<0.05 significantly 
different from responses of the respective nicotine control, one-way ANOVA and Tukey’s post- 
hoc test). Curves were not fitted to the Hill equation due to the likely contribution of multiple 
nAChR subtypes (see Chapter 6).
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Generally, the ability of lower concentrations of MLA to inhibit the response to nicotine 
increased as the concentration of nicotine decreased (Figure 3.8). The highest 
concentration of MLA (100 nM) significantly inhibited (p<0.01, n=3) the increases in 
fluorescence evoked by all three concentrations of nicotine (Figure 3.8). Conversely, 3 
and 10 nM MLA only caused significant inhibition (p<0.01, n=3) of increases in 
fluorescence evoked by the lowest concentration of nicotine (10 pM; Figure 3.8). These 
results demonstrate that MLA acts as a competitive inhibitor, in this assay.
3.2.4 Pharmacological evaluation of the nAChR agonist lodo-A-85380
The novel agonist l-A-85380 is highly selective for a4p2* nAChR (Mukhin et al., 2000), 
a receptor combination thought to exist at the terminals of nigrostriatal dopaminergic 
neurones (Sharpies et al., 2000). It was, therefore, employed here to extend the 
examination of nAChR subtypes involved in [3H]DA release from striatal synaptosomes. 
Initial results are presented in Figure 3.9 A and show representative superfusion profiles 
of [3H]DA release evoked by increasing concentrations of l-A-85380 (1, 10 or 100 nM; 
delivered as a 40 s pulse). Both the 10 and 100 nM concentrations of l-A-85380 elicited 
peaks of radioactivity above basal release with maximal responses twice that of [3H]DA 
released by 10 pM nicotine (c.f. Figure 3.3 A & Figure 3.9 A). To assess the potency of I- 
A-85380 at nAChR present in the synaptosomes, further experiments examined the 
concentration-response relationship of the agonist. l-A-85380 displayed potent activity in 
evoking [3H]DA release from synaptosomes, with an apparent EC50 value of 13.5 nM 
(Figure 3.9 B), similar to that of epibatidine (2.4 nM; Sharpies et al., 2000). The overall 
profile of [3H]DA release from synaptosomes was bell-shaped (Figure 3.9 B), suggesting 
that the highest concentrations of l-A-85380 desensitised, or channel blocked, a 
proportion of the nAChR in the preparation.
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Figure 3.9 Responses to l-A-85380 determined in striatal synaptosomes. I-A-85380- 
evoked pHJDA release was examined in synaptosomes loaded with pHJDA and superfused as 
described in section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity.
(A) Release of pHJDA over time, showing the response to 1 ( ), 10 (M) or 100 nM (A) l-A- 
85380. Evoked pH]DA release is expressed as a percent of the mean basal release. Values are 
the mean ±  S.E.M. of the triplicate chambers from a representative experiment.
(B) Concentration-response relationship and a-CTx Mil sensitivity of l-A-85380-evoked pHJDA 
release from striatal synaptosomes. Antagonist (100 nM a-CTx Mil; ) was added to the 
perfusing buffer 10 min prior to stimulation for 40 s with l-A-85380 (1-3000 nM; %). The a-CTx 
Mil-sensitive component of l-A-85380-evoked pHJDA release was estimated by subtraction of 
a-CTx Mil-insensitive fHJDA release from that evoked by l-A-85380 alone (A). Results are 
expressed as a percentage of the response above basal. Values are the mean ±  S.E.M. from at 
least three independent experiments, each consisting of two or more replicate chambers. 
Concentration-response curves were fitted to the Hill equation. For pHJDA release evoked by I- 
A-85380 alone EC50 = 13.5 ±4 .2  nM, for a-CTx-insensitive pHJDA release, EC50 = 12.7 ±4 .2  
nM, for a-CTx sensitive pHJDA release, ECso -  34.4 ±  36.2 nM. (** p<0.01, * p<0.05, 
significantly different from responses of the respective concentration of l-A-85380 in the 
absence of a-CTx Mil, Student’s t-test).
To determine the striatal nAChR population that l-A-85380 was affecting (i.e. the a-CTx 
Mil-sensitive or insensitive population), the concentration-response curve was repeated in 
the presence of the a3/a6p2 selective nAChR antagonist, a-CTx Mil (100 nM; Figure 3.9 
B). In this case, an EC50 value of 12.7 nM was obtained, which was not significantly
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different to that seen with l-A-85380 alone (13.5 nM; Figure 3.9 B). Although the EC50 
values were not dissimilar, a-CTx Mil partially and significantly inhibited [3H]DA release 
evoked by concentrations of l-A-85380 between 3 and 1000 nM (p<0.01, p<0.05, n>3). By 
subtracting [3H]DA release in the presence of a-CTx Mil from the release evoked by l-A- 
85380 alone, the estimated response profile of the a-CTx Mil-sensitive nAChR population 
was revealed (Figure 3.9 B). The calculated EC5o value of 34.4 nM was almost three fold 
higher than the EC5o for a-CTx Mil-insensitive [3H]DA release (12.7 nM), and the profile 
was bell-shaped.
The sensitivity of l-A-85380-evoked [3H]DA release to the a3p2* selective nAChR 
antagonist, a-CTx Mil warranted further pharmacological examination. Two different 
concentrations of l-A-85380 were used, one approximating the overall EC50 value (10 nM) 
and another that corresponded to the concentration that elicited maximal release of 
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Figure 3.10 Pharmacological analysis of the nAChR subtypes involved in fhiJDA 
release evoked by l-A-85380. Synaptosomes were loaded with fHJDA and superfused as 
described in section 2.1. Antagonists (50 nM MLA; 100 nM a-CTx Mil; 1 pM DHpE) were added 
to the perfusing buffer 10 min prior to stimulation for 40 s with (A) 10 nM or (B) 300 nM l-A- 
85380. Results are expressed as a percentage of the response above basal. Values are the 
mean ±  S.E.M. from at least two independent experiments, each consisting of two or more 
replicate chambers. (** p<0.01, * p <0.05 significantly different from l-A-85380 control, one-way 
ANOVA and Tukey’s post-hoc test; f t  p<0.01 significantly different from all other conditions, 
one-way ANOVA and Tukey’s post-hoc test. Statistics were not performed in (B) as n=2).
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[3H]DA in the presence of 100 nM a-CTx Mil, 50 nM MLA and 1 pM DHpE (Figure 3.10 A 
& B; a-CTx Mil data from Figure 3.9 B).
All the antagonists caused inhibition of [3H]DA release. However, DHpE consistently 
reduced [3H]DA release evoked by both concentrations of l-A-85380 to an amount similar 
to that obtained with a buffer pulse (-0 .5  %). In addition, at the higher concentration of l-A- 
85380 (300 nM), the extent of inhibition by MLA and, in particular, a-CTx Mil was 
increased. Interestingly, the inhibition of l-A-85380-evoked [3H]DA release by 50 nM MLA 
was not surmountable with the higher concentration of 300 nM l-A-85380, in contrast to 
the results in Figure 3.4 and Figure 3.6.
The activity of l-A-85380 was also investigated using a different neuronal preparation
i
which does not express a4p2* nAChR, namely SH-SY5Y cells (see Chapter 6; Lukas et 
al., 1993). Results from these assays are shown in Figure 3.11, and demonstrate that l-A- 
85380 displayed a potent ability to evoke Ca2+-induced increases in fluorescence in SH- 
SH5Y cells (EC50 value = 387.3 nM).
Figure 3.11 Responses to l-A-85380 
determined in SH-SY5Y cells. SH-SY5Y 
cells were loaded with fluo-3 AM, as 
described in section 2.5, and stimulated 
with l-A-85380 (1-30000 nM).
Fluorescence was monitored at 538 nm 
for 20 s. The response to the 1000 nM I- 
A-85380 control was taken as 100 % and 
all other values expressed as a 
percentage of this. All values are the 
mean ±  S.E.M. from at least 2 separate 
experiments with quadruplicate repeats. 
The concentration-response curve was 
fitted to the Hill equation (EC50 value = 
387.3 ±  123.3 nM).
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3.3 Discussion
The results presented in this chapter demonstrate that the presumed a7-selective 
compound MLA may antagonise other nAChR subtypes located on striatal DAergic nerve 
terminals, at concentrations frequently used to selectively block a7 nAChR. The ability of 
50 nM MLA to partially inhibit nicotinic agonist-evoked [3H]DA release was consistently 
observed at low concentrations of nicotine and UB-165, but was surmountable at higher 
agonist concentrations suggesting a competitive mode of action. As none of the other a7- 
selective compounds examined (a-Bgt and a-CTx Iml) had any effect on nicotine-evoked 
[3H]DA release from striatal synaptosomes, this strongly argues that MLA is not acting 
through an a7 nAChR. Moreover, the lack of additivity with a-CTx Mil suggest that both 
antagonists act at the a-CTx Mil-sensitive nAChR subtype. Confirmation of this interaction 
was provided by the ability of low nanomolar concentrations of MLA to displace [125l]a-CTx 
Mil binding to rat striatum and nucleus accumbens. Additional information on the 
interactions of MLA with nAChR were gained from experiments in SH-SY5Y cells. The 
ability of MLA to inhibit fluorescence responses in these cells decreased as the nicotine 
concentration was increased, supporting a competitive mode of action.
The absence of a discernible a7 nAChR-mediated component in nicotine-evoked 
[3H]DA release from striatal synaptosomes is well documented (Rapier et al., 1990; Grady 
et al., 1992; Kulak et al., 1997), and substantiated by the lack of effect of a-Bgt and a-CTx 
Iml in the present study (Figure 3.4). In contrast we have previously shown that these 
agents, as well as MLA, antagonise nicotine-evoked [3H]DA release from striatal slices, 
interpreted as evidence for the involvement of an indirect a7 nAChR-mediated component 
in the slice (see Chapter 4; Kaiser and Wonnacott, 2000). In the present study, [3H]DA 
release from striatal synaptosomes was examined in order to focus on presynaptic nAChR 
localised on the DA terminals.
The inhibition by 50 nM MLA of [3H]DA release evoked by either nicotine or UB-165 
was surmountable (Figure 3.4 & Figure 3.6), consistent with a competitive interaction. 
Similarly, Clarke and Reuben (1996) observed a surmountable inhibition by MLA of 
nicotine-evoked [3H]DA release from striatal synaptosomes. These authors demonstrated 
complete inhibition by MLA with an IC50 value of 38 nM, whereas nicotine-evoked 
[3H]noradrenaline release was notably less sensitive to MLA (IC50 = 1 pM). Full dose- 
response curves for [3H]DA release were not determined here due to time constraints. 
However, a more extensive analysis of the competitive action of MLA was performed in
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SH-SY5Y cells (Figure 3.8). Although the composition of nAChR in this cell line differs 
somewhat to those in expressed in nigrostriatal neurones (e.g. a l  and {34 are present 
whilst a4 is absent), the results demonstrate that MLA can compete with lower 
concentrations of nicotine to inhibit increases in fluo-3 fluorescence, whilst at higher 
agonist concentrations only the maximum concentration of MLA (100 nM) inhibited such 
responses (Figure 3.8). MLA (50 nM) also partially inhibited (by 37 %) [3H]DA release from 
striatal synaptosomes stimulated with 1 uM anatoxin-a, but had no effect when the agonist 
concentration was increased to 25 pM (Kaiser and Wonnacott, 2000). Thus, MLA potently 
and competitively inhibits a portion of striatal [3H]DA release elicited by a number of 
nicotinic agonists acting at presynaptic nAChR.
t
MLA appears to interact with a-CTx Mil-sensitive nAChR, as inhibition by the two 
toxins of nicotine- or UB-165-evoked [3H]DA release is not additive when they are applied 
together (Figure 3.5 & Figure 3.6). This inference is supported by the ability of MLA to 
potently displace [125l]a-CTx Mil binding. [125l]a-CTx Mil labelled a small population of 
specific sites in rat striatum and nucleus accumbens, with a sub-nanomolar binding affinity 
(Figure 3.7). The density of sites (10 and 16 fmol/mg protein, respectively) agrees well 
with numbers of specific binding sites reported for the corresponding brain regions in 
mouse (Whiteaker et al., 2000b) and monkey (Quik et al., 2001), assuming 1 mg protein 
corresponds to 10 mg tissue. In the monkey caudate putamen, more than 95% of specific 
[125l]a-CTx Mil binding sites were lost in MPTP-lesioned animals. Together with the 
correlation with DA transporters, this strongly supports the localisation of [125l]a-CTx Mil 
binding sites to DAergic terminals in these brain regions (Quik et al., 2001). a-Bgt (1 pM) 
failed to inhibit [125l]a-CTx Mil binding to mouse striatum, and conversely a-CTx Mil, at 
concentrations up to 1 pM, did not compete for [125l]a-Bgt binding to mouse brain 
membranes (Whiteaker et al., 2000b). Thus the ability of MLA to fully displace [125l]a-CTx 
Mil binding (Fig. 4) with a K of -33 nM reflects a non-a7 nAChR activity for this ligand.
The observations in the present study parallel the findings of Klink et al. (2001) for 
nAChR responses recorded electrophysiologically from DA cell bodies in the rat midbrain. 
These authors showed that in most (75 %) DA neurones, ACh or nicotine evoked slow 
whole cell currents that were partially blocked by low nanomolar concentrations of MLA 
and a-CTx Mil in a non-additive manner.
This raises the question of the subunit composition of nAChR subtype(s) with which 
MLA potently interacts. The majority of rat midbrain DA neurones express the a3, a4, a5,
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a6, p2 and P3 subunits (Klink et al., 2001). a-CTx Mil was originally defined as a selective 
antagonist of nAChR composed of a3 and |32 subunits, with no activity at other pairwise 
nAChR subunit combinations or a7 nAChR expressed in Xenopus oocytes (Cartier et al., 
1996; Harvey et al., 1997; Kaiser et al., 1998). As binding of a-CTx Mil to one a3p2 
interface would be sufficient for functional inhibition, the toxin specificity was extended to 
include a3p2-containing (or a3p2*) nAChR (Kulak et al., 1997; Kaiser et al., 1998). 
However, the a3 subunit shares high sequence identity with the a6 subunit (Le Novere 
and Changeux, 1995) that is highly expressed in DA neurones (Le Novdre et al., 1996; 
Goldner et al., 1997; Klink et al., 2001). Deletion of a6 subunit expression by in vivo 
administration of antisense oligonucleotides decreased nicotine-induced effects on
t
locomotor activity (Le Novere et al., 1999b), consistent with a role in motor functions 
executed by the striatum. The a6 subunit is reluctant to form functional nAChRs in 
pairwise combination with a p subunit, supporting its participation in more complex subunit 
assemblies, and the efficient expression of a variety of combinations has been 
demonstrated in heterologous systems (Fucile et al., 1998; Kuryatov et al., 2000). 
Immuno-isolated a6-containing nAChR from chick retina display high affinity for a-CTx Mil 
(K = 66 nM), but relatively low affinity for MLA (1.3 pM; Vailati et al., 1999). Very recently, 
data from a6 knockout mice have been published, with [125l]a-CTx Mil binding absent in 
the brains of these rodents, confirming that a-CTx Mil can also act at a6* nAChR 
(Champtiaux et al., 2002).
Expression of the P3 subunit is also limited to a few brain regions, notably 
catecholaminergic areas (Deneris et al., 1989b) where it co-localises with a6 nAChR 
subunit expression in the rat brain (Le Novere et al., 1996). Functional nAChR comprised 
of rat a3, f32 and p3 subunits and expressed in Xenopus oocytes retain high sensitivity to 
a-CTx Mil (Luo et al., 2000), while transgenic mice lacking expression of the P3 nAChR 
subunit are deficient in specific binding sites for [125l]a-CTx Mil in the striatum (Booker et 
al., 1999). However, chicken immunoisolated p3-containing nAChR that are devoid of a6 
subunits do not exhibit high affinity for a-CTx Mil or MLA (Vailati et al., 2000). 
Consequently, the p3 subunit may not confer sensitivity to a-CTx Mil or MLA to nAChR 
but is crucial for the formation, targeting or stability of a-CTx Mil-sensitive nAChR in basal 
ganglia in vivo. Klink et al. (2001) propose that the p3 subunit is targeted to terminal 
regions of DAergic neurones and does not participate in somatodendritic nAChR: thus 
nAChR at these two locations could exhibit pharmacological (Reuben et al., 2000) and
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biophysical differences. Indeed, Klink et al. (2001) reported that 1 nM MLA was maximally 
effective in blocking cell body responses, which is more potent than predicted from the 
neurochemical measurements of [3H]DA release summarised above, or its K, for 
interaction with [125l]a-CTx Mil binding sites (Figure 3.7). While this discrepancy may 
reflect methodological differences, it could also arise from distinct nAChR subtypes at cell 
body and terminal locations.
These considerations lead to the proposition that a-CTx Mil and MLA sensitive 
presynaptic nAChR mediating striatal [3H]DA release are comprised of a3 and/or a6 
subunits together with (32 and (33 subunits. Klink et al. (2001) proposed the subunit 
composition a4a6a5((32)2 for a-CTx Mil- and MLA-sensitive somatodendritic nAChR.
t
Inclusion of the a4 subunit was based on the absence of responses in midbrain slices 
from a4 null mutant mice. No direct evidence is available for the participation of the a4 
subunit in the a-CTx Mil and MLA sensitive nAChR, therefore experiments were 
undertaken with the putative a4(32-selective agonist l-A-85380 to examine this possibility.
The functional pharmacology of the supposed a4(32 selective nAChR ligand l-A-85380 
has not been reported, although it is assumed to mirror the features of the parent 
compound, A-85380 (Abreo et al., 1996), which has also proved useful in identifying a 
novel population of nAChR in mouse brain (Whiteaker et al., 2000a). Radioligand binding 
studies with the iodinated form of A-85380 show an extreme selectivity for a4(32* nAChR 
compared to a3(34, a l  and muscle nAChR subtypes, although a3(32* nAChR were not 
examined (Muhkin et al., 2000). Therefore, initial experiments tested the potency of this 
compound for agonist activity in two different neuronal preparations. I-A-85280 was 30 
times more potent in evoking increases in [3H]DA release from striatal synaptosomes 
(EC50 13.5 nM; Figure 3.9 B) compared to stimulation of increases in fluorescence in 
SH-SY5Y cells (EC50 387.3 nM; Figure 3.11), which do not express the a4 nAChR subunit 
(see Chapter 6; Lukas et al., 1993). One could conclude from these results that the 
absence of a4p2* nAChR in SH-SY5Y cells, and presence of such a subtype in striatal 
synaptosomes are the reasons for the differences in potency. It also suggests that l-A- 
85380 is stimulating another subtype of nAChR in SH-SY5Y cells, possibly the a3(34* 
subtype, as this was the subunit combination with the next highest affinity for l-A-85380 
(Mukhin et al., 2000). Conversely, the extreme potency (EC50 = 13.5 nM) of l-A-85380 in 
evoking [3H]DA release from synaptosomes may be due to action at an a4(32* nAChR. 
However, the ability of a-CTx Mil to partially inhibit the responses suggests that in one
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population of nAChR l-A-85380 may also be acting at an a3/a6p2* interface (Figure 3.9 B 
& Figure 3.10). These observations are in agreement the view of Klink et al. (2001) who 
stated that the a4 subunit is present in the same nAChR as a3/a6p2 (see discussion 
above; Figure 3.12). The profile of l-A-85380-evoked [3H]DA release that is sensitive to a- 
CTx Mil was estimated by subtraction of the responses evoked by l-A-85380 in the 
presence of a-CTx Mil from the responses elicited by agonist alone (Figure 3.9 B). l-A- 
85380 was less potent in evoking a-CTx Mil-sensitive responses (EC50 = 34.4 nM) 
compared to the response that were insensitive to the toxin (EC5o = 12.7 nM). In addition, 
a-CTx Mil-sensitive responses occurred over a relatively narrow concentration range of 
10 to 3000 nM, resulting in a bell-shaped curve. This is in contrast to the a-CTx Mll- 
insensitive component, which only began to decline at the highest concentration of l-A- 
85380 (Figure 3.9 B). The differences in the profiles of the CTx-sensitive and -insensitive 
components may reflect the desensitisation of nAChR that make up these responses. This 
observation also provides the reasoning for inclusion of the a5 subunit in the a-CTx Mil- 
insensitive population, as inclusion of a5 in heterologously expressed nAChR produced 
receptors with increased channel opening and burst times (Nelson and Lindstrom, 1999).








•  Potently activated by 
l-A-85380
This inhibition of l-A-85380-evoked [3H]DA release by a-CTx Mil was investigated 
further using additional antagonists (MLA and DHpE; Figure 3.10 A & B). DHpE 
dramatically reduced [3H]DA release to that evoked by a buffer pulse, whilst MLA caused 
a consistent and partial inhibition of [3H]DA release evoked by both concentrations of l-A- 
85380. In contrast to the results obtained with nicotine and UB-165 (Figure 3.4 & Figure
3.6) the inhibition of [3H]DA release by MLA was not surmountable using a higher
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concentration of l-A-85380 (300 nM). This may be explained by the fact that the 
concentrations of 100 pM nicotine and 1 pM UB-165 are well along their respective dose- 
responses curves (Sharpies et al., 2000). Although 300 nM is a maximally effective 
concentration of l-A-85380 (Figure 3.9 B), an even higher concentration may be required 
to overcome the inhibition by MLA in a similar manner to the other agonists used in this 
chapter. The percentage of inhibition induced by MLA is also similar to that in Figure 3.5, 
although further experiments are required to confirm that MLA and a-CTx Mil are acting at 
the same nAChR. Low micromolar concentrations of DHpE can potently inhibit nAChR 
containing the a4|32 and a3p2 subunit combinations (Harvey et al., 1996). The effect of 
this antagonist on [3H]DA release (Figure 3.10) suggests that both of these subunit
t
combinations may be involved in the response to l-A-85380. This mirrors the observations 
of Klink et al. (2001), who noted that 2 pM DHpE inhibited the responses from both 
subtypes of nAChR in midbrain DA neurones. In summary, the blockade of [3H]DA release 
stimulated by l-A-85380 by MLA supports the proposition that the antagonist is acting at a 
non-a7 nAChR, possibly one containing an a4p2 interface.
3.4 Conclusions
•  MLA inhibits an a-CTx Mil-sensitive nAChR on dopaminergic terminals in the 
striatum at concentrations previously used to selectively block a7 nAChR.
•  The inhibition by MLA is overcome by increasing the concentration of agonist, 
consistent with a competitive mode of action.
•  l-A-85380 potently evokes [3H]DA release from striatal synaptosomes and this 
response is partially blocked by a-CTx Mil and MLA, suggesting that l-A-85380 
interacts with 2 subtypes of nAChR.
•  Lower potency is displayed by l-A-85380 in eliciting fluorescence responses in 
SH-SY5Y cells, a system lacking a4p2* nAChR.
One implication of these and related studies is that sensitivity to low nanomolar 
concentrations of MLA should not be considered diagnostic of a l  nAChR, at least in 
studies of rodent basal ganglia. This is particularly pertinent for in vivo studies, where drug 
concentrations reaching the nAChR are not known (e.g. Schilstrom et al., 1998b; Panagis 
et al., 2000). Despite these concerns, the variability of the nAChR subtype selectivity of 
MLA may also be exploited for the differentiation of minority subtypes of nAChR, by 
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4 Nicotinic Modulation of Dopamine Release
from Rat Striatal Slices
In the previous chapter, experiments were performed using synaptosomes with the 
specific purpose of examining the presynaptic nAChR modulation of striatal DA release. 
To study the interactions between neurotransmitters in the striatum a more intact 
preparation is required. Therefore, in this chapter DA release from striatal slices is 
considered. This is primarily to confirm and extend previous results (Kaiser and 
Wonnacott, 2000) surrounding the pharmacology of striatal DA-giutamate interactions 
after stimulation of presynaptic nAChR.
4.1 The Basal Ganglia
The striatum belongs to a group of anatomically distinct structures that are collectively 
known as the basal ganglia. Other members of this group include the subthalamic 
nucleus, the globus pallidus, and the substantia nigra, which themselves, may be further 
subdivided into functionally different components (Figure 4.1). These structures were 
identified as early as 1664, when the first clear description of distinct subcortical 

























Figure 4.1 Diagram of the 
neuronal circuitry of the basal 
ganglia. Red lines represent inhibitory 
pathways whilst green lines signify 
excitatory pathways. The DAergic input 
from the SNpc may be excitatory or 
inhibitory depending on the postsynaptic 
receptor involved. Abbreviations: GPe, 
globus pallidus pars externa; STN, 
subthalamic nucleus; GPi, globus 
pallidus pars intema; SNpc, substantia 
nigra pars compacta; SNpr, substantia 
nigra pars reticulata; SC, superior 
colliculus; MEA, midbrain extrapyramidal 
area; VAA/L, ventralis anterior/latralis; IL, 




It is generally agreed that the basal ganglia participate in the control of movement for 
several reasons. Firstly, many of the inputs and outputs of the basal ganglia are 
connected with motor areas. Secondly, the activation of basal ganglia neurones correlates 
with movement. Thirdly, lesioning of the basal ganglia pathways results in severe 
disruption of movement.
The basal ganglia are thought, therefore, to be implicated in the planning and execution 
of complicated motor strategies. In this section the functions of the major components of 
the basal ganglia are outlined.
4.1.1 Subthalamic nucleus
This region receives the excitatory glutamatergic input from motor areas of*the cortex 
and inhibitory GABAergic input from the GPe. The output from the STN is excitatory in 
nature and composed of glutamatergic neurones that project to the GPi, SNpr and GPe.
4.1.2 Globus pallidus
The globus pallidus is divided into the internal (GPi) and external (GPe) segments in 
primates, whilst in rodents the GPi lies within the internal capsule and is known as the 
entopeduncular nucleus. The principal inputs to the GPi are from the striatum and the 
STN. The input from the striatum is GABAergic in nature and terminates around a single 
neurone in a dense formation, whilst making sparse contact with other neurones. In 
contrast, the input from the STN is glutamatergic and, therefore, excitatory in nature and 
synapses onto many neurones in the GPi. Output from the GPi is composed of inhibitory, 
GABAergic neurones which pass to the thalamus and then onto the motor, premotor, and 
supplementary motor areas. The supplementary motor area also provides major input to 
the basal ganglia, and so there is a loop between this area and the basal ganglia. The 
GPe passes information within the basal ganglia, in particular to the STN.
4.1.3 Substantia nigra
This area may also be divided into two regions, one being the substantia nigra pars 
compacta (SNpc) and the other the substantia nigra pars reticulata (SNpr). The SNpc 
provides DA input to all of the striatum and also receives GABAergic inputs from the same 
area. The neurones contain a substance known as neuromelanin, a dark pigment, which 
endows the neurones with a dark appearance and is the basis for their name, substantia 
nigra (nigra means black in Latin).
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In common with the SNpc, the SNpr also receives GABAergic input from the striatum 
and excitatory glutamatergic input from the STN, whilst providing inhibitory projections to 
three regions of the thalamus, namely the ventral lateral, ventral anterior and mediodorsal 
nuclei. These thalamic nuclei in turn project to the prefrontal and the premotor cortices. An 
additional inhibitory projection exists to the superior colliculus (SC) and, together with the 
projection to the mediodorsal thalamic nucleus, is connected to brainstem and cortical 
areas that control eye movement.
4.1.4 Striatum
This region is the main entrance of cortical information to the basal ganglia circuitry and 
is comprised of the caudate nucleus, putamen and nucleus accumbens. For a more 
detailed description of the structure of the striatum see section 4.3.
Historically, two major pathways of information flow from the striatum to the GPi and 
SNpr (Figure 4.2). The first is the direct pathway, which arises from a subset of striatal 
projection neurones enriched in substance P/dynorphin and Di DA receptors, and 
terminates directly in the GPi and SNpr. The second is the indirect pathway, which 
originates from striatal neurones enriched in enkephalin and D2 DA receptors, is inhibitory 
in nature, and terminates in the GPe. In turn, GPe neurones provide inhibitory GABAergic 
input to the STN, which relays signals to the basal ganglia output nuclei. Increased activity 
in the direct pathway causes a decrease in GPi/SNpr output, whilst increased activity in 










representing the direct and 
indirect pathways that project 
from the striatum. Red
pathways are inhibitory and 
green pathways are excitatory. 
See text for description
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A loop also exists that projects from the striatum to the SNpc and back to the striatum, 
with the latter pathway dopaminergic in nature. It is the release of DA from this pathway 
that excites the direct pathway but inhibits the indirect pathway. Imbalance in this system, 
due to degradation of the nigro-striatal neurones, is thought to underlie some of the motor 
dysfunctions associated with Parkinson disease.
4.2 Diseases of the basal ganglia
Components of the basal ganglia have been implicated in several diseases, with the 
most well-known being Parkinson’s disease.
In 1817 a British doctor, James Parkinson, published a paper entitled "An Essay on the 
Shaking Palsy" where he described the major symptoms of the disease that would later 
bear his name. Then, in the early 1960s, researchers identified the root of the disease. 
They established that the DAergic neurones in the substantia nigra (SN) were selectively 
degraded. In addition to the loss of SN neurones, studies have also found a loss of 
cholinergic cells in the basal forebrain coupled with a reduction in high-affinity [3H]nicotine 
binding sites. The symptoms of Parkinson's disease (PD) are the result of this 
degeneration, and can be divided into four groups; postural instability, impaired balance 
and coordination; resting tremor or trembling in legs, hands, arms, jaw, and face; rigidity 
or stiffness of the limbs and trunk; and slowness of movement (bradykinesia). As these 
symptoms become more pronounced, patients may have difficulty walking, talking, or 
completing other simple tasks.
The cause of the cell death is not yet known but several theories have been put 
forward in an attempt to explain the origin of the disease. One theory is based on the fact 
that there are a number of compounds, such as the toxin 1-methyl-4-phenyl-1,2,3,6,- 
tetrahydropyridine (MPTP), and neuroleptic drugs, that are known to induce parkinsonian 
symptoms in humans. This suggests that PD may occur when either an external or an 
internal toxin selectively destroys the dopaminergic neurones mentioned above. However, 
apart from cases that have a genetic derivation, no research has provided conclusive 
proof of the cause of the disease, although the compound MPTP has been utilised as a 
tool in experimental studies to simulate PD in animal models of the disorder. Interestingly, 
one environmental factor that has been proven to affect a persons susceptibility to the 
disease is whether he or she smokes. Smoking, rather than promoting the onset of the 
disease, actually decreases an individual’s chance of developing PD by ~ 50 % (for review 
see Fratiglioni and Wang, 2000). Smoking or NRT use has also been observed to reduce
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PD symptoms (Fagerstrom et al., 1994). These unusual observations suggest therapies 
that include nAChR ligands may be of benefit to PD sufferers.
Currently, treatments for PD in widespread use are still based on the drug levodopa (L- 
DOPA; L-3,4-dihydroxyphenylalanine). Dopaminergic cells can utilise L-DOPA to 
manufacture DA and thus replenish the brain's dwindling supply. L-DOPA is usually 
combined with carbidopa, which delays the conversion of levodopa into DA until it reaches 
the brain, thus preventing or diminishing some of the side effects that often accompany 
L-DOPA therapy and also reducing the amount of L-DOPA needed. The therapy delays 
the onset of some of the debilitating symptoms and extends the period of time during 
which parkinsonian patients can lead relatively normal, productive lives.
Prior to the introduction of L-DOPA, anticholinergic drugs were the main treatment for 
PD. However, other experimental therapies have examined nicotine treatment in mouse 
models of the disease. Acute nicotine administration has been found to reduce 
dopaminergic neurodegeneration caused by MPTP but interestingly chronic nicotine 
enhanced the MPTP induced toxicity (Janson et al., 1992). Moreover, in monkeys, using 
the same MPTP model, administration of the a4|32* nAChR selective agonist, SIB-1508Y, 
improved cognitive and motor performance but only when combined with L-DOPA 
(Cosford et al., 1996; Schneider et al., 1998a,b). Finally, a recent study has examined the 
levels of mRNA for a4, a6, a7 and (32, (33, (34 subunits in monkey SN before and after 
MPTP treatment (Quik et al., 2000). Results demonstrated that after lesioning, levels of 
the a6 transcript increased whilst (33 decreased, suggesting that levels of nAChR 
containing these subunits may be altered during PD. With relevance to smoking, the 
authors also demonstrated that exposure of cultured mesencephalic dopaminergic 
neurones to nicotine, 24 h prior to exposure to MPP+ was neuroprotective.
In addition to PD, several other diseases have their origins in the basal ganglia.
•  Huntington’s disease (or Huntington’s chorea) is a genetically based degenerative 
disease in humans that is caused by the loss of specific striatal neurons. Sufferers 
exhibit frequent, brief, random, involuntary movements that involve all parts of the 
body. However, voluntary movements are much slower than normal. A possible 
mechanism for the disease is that disinhibition of the GPe causes inhibition of the STN 
which decreases the activity of the GPi, resulting in hyperactivity of motor cortical and 
brainstem circuits (Albin et al., 1989).
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•  Ballism is associated with damage to the subthalamic nucleus. Again, brief involuntary 
movements are observed but these tend to be much larger in amplitude, producing 
flinging like motions. Voluntary movements are normal.
•  Tardive dyskinesia is related to changes in DAergic receptors, causing hypersensitivity 
to DA. It causes abnormal involuntary movements, particularly of the face and tongue.
4.3 Structure of the striatum
The word striatum is derived from the Latin stria, meaning a furrow, and is due to the 
large number of myelinated axons that run through the region, giving it a conspicuous, 
lined appearance. As mentioned above, the striatum serves as the input centre for the 
basal ganglia. Excitatory glutamatergic input arrives from both the cerebral cortex and 
thalamic nuclei, whilst the SNpc and ventral tegmental area (VTA) are the two main 
sources of DA projections to the dorsal and ventral striatum, respectively. It is these 
pathways that are of particular interest in this thesis. Additional sources of innervation of 
the striatum include the GPe, the STN, the dorsal raphe and the tegmental 
pedunculopontine nucleus (TPP). The physical arrangement of some of these inputs is 
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The main targets of these striatal afferents are the GABAergic medium sized spiny 
projection neurones, which account for roughly 95 % of the total neuronal population of 
the striatum (Smith and Bolam, 1990). They possess large dendritic trees and extensive 
local axon collaterals. Several types of striatal intemeurones have also been identified by 
their differential content in neurotransmitter, neuropeptides and calcium binding proteins 
(Calabresi et al., 2000; see Table 6). Albeit less massively innervated than spiny neurons, 
interneurones also receive direct cortical, thalamic and nigral inputs (Bolam et al., 2000).





Medium spiny neurones GABA Account for -95% of the total neuronal 
population. Possess large dendritic trees 
and extensive local axon collaterals.
Aspiny neurones ACh Interneurones that form synapses with 
medium spiny neurones. Constitute 1-2% 
of the striatal population.
Medium aspiny cells Somatostatin Also contain neuropeptide Y and nitric 
oxide synthase.
Parvalbumin- and calretinin- 
containing neurones
GABA Local inhibitory interneurones.
4.4 Acetylcholine in the striatum
As stated above, there are cholinergic interneurones present in the striatum that 
presumably provide the endogenous stimulation of nAChR in the region. They are 
tonically active (Bennett and Wilson, 1999), but the action of the released ACh is not well 
understood. As mentioned in section 1.12.2.1, nicotine can enhance ACh release from 
cortical and hippocampal synaptosomes (Rowell and Winkler, 1984; Wilkie et al., 1996) 
with a recent microdialysis study mirroring these results in vivo (Tani et al., 1998). 
However, in the latter study, no release of striatal ACh could be evoked by systemically 
administered nicotine. This situation is replicated in vitro, as it was observed that the 
nicotinic agonist methylcarbamylcholine was unable induce ACh release from 
preparations of striatum (Lapchak et al., 1989).
It is also known that DA can modify ACh release. Originally, it appeared that 
dopaminergic afferents from the SN exert an inhibitory influence on cholinergic
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interneurones, with ACh release from striatal slices reduced by application of DA (e.g. de 
Belleroche et al., 1982). However, with the advent of selective Di and D2 DA receptor 
compounds, this is now not thought to be the case, as activation of Di receptors 
stimulates, while activation of D2 receptors reduces ACh release (Di Chiara et al., 1994). 
This control appears symmetrical in basal conditions, since blockade of both receptors or 
inhibition of DA synthesis does not change ACh release in vivo (Bertorelli et al., 1992). A 
timely report has also indicated that endogenous cholinergic activity can regulate DA 
release in the striatum and, with relevance to Chapter 5, is inhibited by concentrations of 
nicotine similar to those present in the blood of smokers (Zhou et al., 2001). With these 
studies in mind, it is important to consider the effect that endogenous ACh release may 
have on DA release from slices. *
4.5 nAChR and glutamate release in the striatum
As detailed in Chapter 3, presynaptic nAChR are present on DAergic terminals in the 
striatum. However, nicotine has also been shown to increase glutamate levels in vivo, 
(Toth et al., 1993), an effect that is blocked by the non-competitive nicotinic antagonist 
mecamylamine. Glutamate also stimulates DA release in vivo, but it has only been in 
recent years that detailed analysis of DA release has been performed in vitro, including 
the subtypes of neurotransmitter receptors involved (Vizi and Lendvai, 1999). Release of 
glutamate in this context may be especially important, as it could initiate or sustain some 
of the longer term changes that are associated with the development of nicotine addiction 
and dependence.
4.5.1 Metabolism of glutamate
As glutamate is unable to cross the blood-brain barrier, glutamate in neurones must be 
generated solely from local processes (Figure 4.4). Two pathways exist to synthesise 
glutamate. The first process can occur in the Krebs cycle where glutamate is formed 
during the normal oxidative metabolism of glucose through the transamination of a- 
ketoglutarate. The second process involves glial cells, where glutamine may be 
transported into nerve terminals where it is converted locally into glutamate by a 
phosphate-activated glutaminase (PAG). After glutamate is released it undergoes rapid 








Figure 4.4 A representation of a glutamatergic synapse and the processes (black 
arrows) and structures (orange arrows) involved in the metabolism of glutamate. Gin, 









At this point it is also necessary to consider the targets of glutamate, with reference to 
many of the experiments described in this chapter and Chapter 5.
4.5.2 lonotropic glutamate receptors (iGluR)
These ligand gated ion channels can be found throughout the mammalian central 
nervous system and are excitatory in nature. Intensive research in this area was 
accomplished between 1989 and 1992 and involved the cloning of cDNAs encoding the 
glutamate receptor subunits, resulting in the discovery of multiple subtypes (Hollmann and 
Heinemann, 1994; Dingledine et al., 1999). It is now believed that Ca2+ entry through 
iGluRs is one of the underlying processes involved in development and learning but 
iGluRs have also been implicated in a variety of neurological disorders including epilepsy, 
schizophrenia, ischemic brain damage and neurodegenerative disorders. iGluRs may also 
have a role in the spinal nervous system involving pain accompanying inflammation 
(Bleakman and Lodge, 1998; Dingledine et al., 1999). iGluRs can be divided into 3 broad 
categories AMPA, kainate and NMDA receptors, a nomenclature based on their specific 
agonists. From the figure below (Figure 4.5), one can see that multiple subunits exist that 
can be grouped into various families. In common with the nAChR, a similar scenario could 
occur with thousands of different subunit combinations generating a multitude of different
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receptor subtypes. However, it is now generally accepted that an iGluR subunit will only 
assemble with others within its family. Nevertheless, little is known about the exact 
composition of these receptors in their native forms.
Figure 4.5 The ionotropic glutamate receptor family
^  lonotropic Glutamate Receptors J
NMDAAMPA Kainate
GluR5-7 KA1,2 NR1 NR2A-D NR3A
To date 3 families of glutamate receptor subunits have been discovered -  GluR1-7, 
KA1-2, and NR1 -  3A (Figure 4.5). Each subunit is formed from approximately 900 amino 
acids with 4 predicted transmembrane regions (M1 to M4; Figure 4.6; reviewed in 
Dingledine et al., 1999). These subunits can then complex, forming what is thought to be 
either a tetrameric or pentameric structure, similar to the nAChR. However, the glutamate 
receptor complex is much larger than that of the nAChR, mainly due to the large 
extracellular region. Originally each subunit was thought to have 4 domains that 
completely transverse the membrane but this was disproved by several molecular and 
biochemical studies in the mid-1990’s that revealed that the M2 region does not 
completely cross the membrane and instead ‘kinks’ and re-enters the cytoplasm (see 
Bennett and Dingledine, 1995; Figure 4.6).
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Figure 4.6 Diagram of the 
transmembrane organisation of 
the ionotropic glutamate receptor.
In contrast to the nAChR, the M2 
transmembrane domain is thought to 
form a kink in the membrane that 
causes the loop between M2 and M3 
to become cytoplasmic along with 
the carboxy terminus. The positions 
of the two ligand binding domains 
(S1 and S2) and the flip/flop 
alternatively spliced exon of the 
AM PA receptor are also shown 
(after Dingledine et al., 1999).
4.5.2.1 AMPA receptors
Subunits GluR1-4 form the family of iGluR that respond to the agonist AMPA (Figure 
4.5). The individual AMPA subunits are roughly 900 amino acids in length and show 65- 
75% homology (Hollmann and Heinemann, 1994). Two sequences of 150 amino acids 
(S1 and S2 regions; Figure 4.6) are separated by the M1 -  M3 membrane domains and 
form the ligand binding site, although it is possible that the other subunits contribute to the 
binding domain. The C-terminus contains certain motifs for intracellular binding proteins 
such as GRIP, NSF and PICK1 (Dingledine et al., 1999), consistent with its cytoplasmic 
location (Figure 4.6).
Functional diversity of AMPA receptors can occur, as all four AMPA receptor subunits 
can be alternatively spliced into two different isoforms, flip and flop (Figure 4.6; Sommer et 
al., 1990; Dingledine et al., 1999). The alternative splice site is located just before the M4 
domain (Figure 4.6) and is composed of a 38 amino acid sequence encoded by exons 14 
and 15. Only a few amino acids are altered, but this has a remarkable effect on the 
receptors that are formed, with regard to their desensitisation profiles, as receptors 
containing the flip isoform desensitise less rapidly than those that include the flop isoform.
Heterologous expression studies have revealed that the permeability of the AMPA 
receptor to Ca2+ is determined by the GluR2 subunit, through post-transcriptional editing 
of a single amino acid in the M2 region of the channel protein (described in detail by 
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to a positively charged arginine (R) results in the occurrence of two receptor isoforms. The 
GluR2(Q) isoform is permeable to Ca2+, whilst GluR2(R) is not. There are certain areas in 
the brain where electrophysiological investigations have revealed the existence of these 
Ca2+ permeable AMPA receptors. For example, in a subset of hippocampal neurones (lino 
et al., 1990) and cerebellar Purkinje neurones (Brorson et al., 1992).
AMPA receptors are ubiquitously expressed throughout the CNS, where they are 
thought to mediate fast synaptic transmission, but regional differences in the distribution 
have been observed (for review see Ozawa et al., 1998). In particular, the hippocampus 
seems to be rich in [3H]AMPA binding sites (Olsen et al., 1987), with in situ hybridisation 
studies showing abundant GluR1, GluR2, GluR3 mRNA expression with less GluR4 
mRNA expression (Keinanen et al., 1990). With relevance to this chapter, the localisation 
of AMPA receptors has been described in detail in the striatum (Bernard et al., 1997). 
Receptor subunits had a widespread distribution with concentrations of subunits observed 
on the postsynaptic membrane of asymmetric, possibly glutamatergic, synapses, although 
the authors do note that extrasynaptic receptors were also present.
4.5.2.2 Kainate receptors
The glutamate receptors formed from GluR5-7 and KA1&2 subunits are collectively 
known as kainate receptors and are grouped separately from the AMPA and NMDA 
receptors (Figure 4.5; see Chittajallu et al., 1999). They possess many of the same 
structural features as the other iGluRs, with the ligand binding domain formed in the same 
fashion as described for the AMPA receptor above. In addition, the kainate receptor 
subunits GluR5&6 can undergo RNA editing at the Q/R site, again giving rise to receptors 
with differing permeabilities to Ca2+ (Bleakman and Lodge, 1998).
Although kainate receptor subunits are widely expressed in the mammalian central 
nervous system, little is known about their function. However, emerging evidence 
suggests that kainate receptors are involved in synaptic plasticity at developing 
thalamocortical synapses, as it has recently been reported that during LTP in this region, 
kainate receptor-mediated transmission is reduced and is concurrent with an increase in 
the contribution of AMPA receptors (Kidd and Isaac, 1999). Current information also 
indicates that activation of presynaptic kainate receptors facilitates the induction of NMDA 
receptor-independent LTP at the mossy fibre synapse in the CA3 region of the 
hippocampus (Lauri et al., 2001). Finally, a role for kainate receptors in the regulation of 
glutamate and DA release in the striatum has also been identified (Jin, 1997; Hashimoto 
et al., 2000).
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4.5.2.3 NMDA receptors
The final group of iGluR, known as NMDA receptors (NMDA R) have been implicated 
in aspects of development, learning and memory, and this is partly due to some of the 
unusual properties of the receptor that are described below. Three gene families encode 
two groups of subunits, NR1 and NR2A-D, that form the NMDA R with functional channels 
only formed when a subunit from each group is expressed (Figure 4.5; Dingledine et al., 
1999). This is due to the location of the glutamate binding domain at the interface formed 
between the NR1 and NR2 subunits. However, the number of binding sites and exact 
subunit stoichiometry of the NMDA R are currently unknown.
Receptor diversity is not only produced by the insertion of various NR2 subunits into 
the receptor complex, but also through the existence of multiple splice variants of NR1 
subunits (Dingledine et al., 1999). Splice sites are located in one exon at the N terminus 
(N1 cassette) and in two exons at the C terminus (C1 and C2 cassettes), with splicing 
thought to regulate the interaction of the NMDA R with intracellular proteins. For example, 
the C1 cassette contains protein kinase C phosphorylation sites and can bind to 
calmodulin, whereas the C2 cassette can interact with postsynaptic density (PSD)-95 
proteins.
The unusual properties of the NMDA R alluded to at the beginning of this section are 
associated with the participation of the receptor in the induction of a phenomenon known 
as long-term potentiation (LTP). This is a complex process, first identified in 1973 by Bliss 
and Lomo, that can induce long-lasting changes in synaptic function. As detailed in 
Chapter 6, occurrence of LTP does not only involve the NMDA R, as Ca2+ channels and 
metabotropic GluR are also implicated in some areas of the brain. The properties of the 
NMDA R that associate it with development of LTP are as follows. NMDA R are inactive at 
normal resting membrane potentials due to a voltage-dependent blockade of the channel 
pore by Mg2+. There are three main requisites for the flow of ions to occur. Firstly, 
glutamate must be present to activate the receptor by binding to a pocket on the NR2 
subunit. Secondly, there must be sustained depolarisation of the nerve terminal by, for 
instance, a series of nerve impulses arriving at the presynaptic terminal. The subsequent 
depolarisation of the postsynaptic membrane then relieves the Mg2+ block of the NMDA R 
channel. The third requirement for receptor activation is the presence of the co-agonist 
glycine, which binds to a site located on the NR1 subunit (Figure 4.5). Functional 
modulation of the NMDA R may also occur through binding of polyamines to a separate 
site on the NR2B subunit (Figure 4.5). In addition to K+ and Na+, NMDA R are highly
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permeable to Ca2+, and it is the sustained Ca2+ influx through the NMDA R into the 
postsynaptic cell after activation that is thought to be crucial for the development of LTP.
4.5.3 iGluR agonists
All types of iGluR can be activated by the endogenous agonist D-glutamate, but it is 
also thought that the amino acid D-aspartate can exclusively activate the NMDA R. As 
mentioned above, activation of the NMDA R is also dependent on the presence of glycine 
at submicromolar levels. AMPA and kainate receptors were originally thought to respond 
exclusively to either AMPA or kainate (not endogenous ligands), but it is now known that 
some members of each class are activated by both agonists. Therefore, there has been 
an ongoing search to find selective agonists that will activate each class of receptor. 
Those that will selectively activate the AMPA receptor are mainly based on the structure 
of AMPA itself (Figure 4.7) or a compound known as Willardiine.
Table 7 Selective agonists of AMPA receptors
Analogs of AMPA Compounds Based 
on Willardiine
Natural Neurotoxins
AC PA 5-fluorowillardiine Domoic acid
(S)APPA p-N-methylamino-L-alanine 
(also active at GluR5&6)
No agonist has yet been reported that is selective for any specific subtype of AMPA 
receptor. However, subtypes of kainate receptors have been found to be more 
heterogeneous in their responses to agonists.
Table 8 Selective agonists of kainate receptors
Analogs of AMPA Compounds Based 
on Willardiine
Miscellaneous
ATPA (potent at GluR5
weakly active at
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4.5.4 iGluR antagonists
In the case of non-NMDA receptors, the quinoxalines and quinoxalinediones (e.g. 
CNQX, NBQX and DNQX; Figure 4.7) are considered to be first generation antagonists, 
displaying poor selectivity between AMPA and kainate receptors (Honore et al., 1988; 
Watkins et al., 1990). Classical competitive antagonists for the NMDA receptor include 
phosphono derivatives of short chain amino acids, such as AP-5 and AP-7. These 
compounds act at the glutamate site whereas halogenated quinoxalinediones and 
kynurenic acid target the glycine site of the receptor (Watkins et al., 1990).
The past 5 years has seen an effort to develop more selective compounds (reviewed in 
Dingledine et al., 1999), for example LY293558 and LY294486. In addition several non­
competitive blockers have become available, including the AMPA selective compounds, 
CFM-2 & SYM 2206 and the AMPA/kainate blocker, GYKI 52466 (Bleakman and Lodge, 
1998). Non-competitive antagonists also exist for the NMDA R and these include 
ifenprodil, ethanol, and some highly basic toxins from marine snails of the Conus sp. 
which appear to act at the polyamine sensitive sites of the receptor.
AMPA HO NMDA






















Figure 4.7 Structures of iGluR agonists and antagonists whose use is described in 
this chapter. Agonists: AMPA and NMDA. Antagonists: the general iGluR antagonist kynurenic 
acid, the AMPA/kainate selective antagonist DNQX, and the NMDA receptor antagonist AP-V.
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4.6 The modulation of striatal DA release by glutamate
The first evidence of glutamate-evoked DA release was observed by Glowinski and
colleagues using a striatal slice preparation (Giorguieff et al., 1977). Release was
insensitive to TTx, suggesting a presynaptic locus of action for glutamate. In the past
decade the presynaptic location of iGluR in the striatum has been further investigated
using synaptosomal preparations. Glutamate, AMPA and kainate alone were all able to
evoke substantial DA release that was inhibited in the presence of DNQX and CNQX
(Desce et al., 1992; Cheramy et al., 1994). However, NMDA was only able to stimulate
DA release in the absence of Mg2+ ions, and this release was prevented by the NMDA
selective antagonists AP-V and MK-801 (Krebs et al., 1991; Cheramy et al., 1994). Other
*
studies in synaptosomes have demonstrated a co-operativity between nAChR and 
NMDA-R on striatal DAergic terminals, as co-application of 1 mM NMDA with either 
nicotine or ACh in the presence of 1 jliM glycine resulted in enhanced DA release 
(Cheramy et al., 1996). These results suggest that the depolarisation resulting from 
activation of presynaptic nAChR is able to relieve the Mg2+ block of the NMDA R resulting 
in an increased release of DA.
Studies have also been performed using more holistic techniques. For example, using 
in vivo microdialysis, infusion of glutamate (Segovia et al., 1997), AMPA (Kendrick et al., 
1996; Smolders et al., 1996; Sakai et al., 1997) kainate (Hashimoto et al., 2000) or NMDA 
(Keefe et al., 1992; Morari et al., 1993; Kendrick et al., 1996) have all been shown to 
increase striatal DA overflow in vivo. A recent study has also reported that infusion of the 
AMPA receptor agonist, domoic acid, increased DA release from striatum, an effect that 
was blocked by co-infusion of DNQX (Quintela et al., 2000). Local application of NMDA 
antagonists to the terminal regions of the nigrostriatal (Toth et al., 1992) pathways has 
also been shown to dramatically decrease the ability of locally applied nicotine to elicit DA 
release in vivo.
Electrophysiological studies have also implicated nAChR in the modulation of 
glutamate release, specifically nAChR sensitive to MLA and a-Bgt (McGehee et al., 1995; 
Gray et al., 1996; Mansvelder and McGehee, 2000). Furthermore, in the striatum and 
frontal cortex, locally applied nicotine has been shown to increase levels of excitatory 
amino acids, including glutamate, in a mecamylamine-sensitive manner (Toth et al., 
1993). Elsewhere in the brain, intrategmental infusion of NMDA receptor antagonists 
(Schilstrom et al., 1998a) reduced nicotine-evoked DA release in the nucleus accumbens, 
whilst local infusion of MLA also blocked the increase in glutamate overflow in the VTA
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elicited by systemic nicotine (Schilstrom et al., 2000). In retrospect, the implication of an 
a l  nAChR is perhaps unwise due to the questions surrounding the selectivity of MLA 
(results in Chapter 3). It has been proposed that nicotine can act at presynaptic a l  nAChR 
on glutamatergic nerve terminals to release glutamate, which in turn stimulates the 
release of DA via presynaptic glutamate receptors (AMPA/NMDA) on DAergic neurones, a 
conclusion consistent with in situ electrophysiological recordings from striatum (Garcfa- 
Munoz et al., 1996).
In addition to nicotinic heteroreceptors on DA terminals, neurochemical evidence 
obtained in our laboratory suggests that an indirect nicotinic modulation of [3H]DA release 
from rat striatal slices can occur, through release of glutamate. Using the nicotinic agonist 
anatoxin-a, dose-response curves for [3H]DA release were constructed ‘that were 
monophasic in synaptosomes but biphasic in slices (Kaiser and Wonnacott, 2000). On 
investigation of this phenomenon, the second phase of the dose-response curve in slices 
appeared to be mediated by an a7-type nAChR, as a l  selective antagonists (a-CTx Iml, 
a-Bgt, and MLA) all blocked a similar portion of [3H]DA release from slices elicited by 
anatoxin-a (Kaiser and Wonnacott, 2000). Additionally, glutamate receptor antagonists 
blocked [3H]DA release to the same extent, and this inhibition was not increased when 
they were co-applied with the a l  antagonists mentioned above.
In this chapter, results are presented that support and extend those obtained with 
anatoxin-a (Kaiser and Wonnacott, 2000). Experiments were performed using the 
prototypic nicotinic agonist nicotine, as this agonist has seen more widespread use than 
anatoxin-a, with more known regarding its pharmacology in rodent brain preparations (e.g. 
Grady et al., 1992; Alkondon and Albuquerque, 1993; Kulak et al., 1997). In addition, use 
of nicotine is relevant with regard to tobacco smoking, as more defined information 
regarding the pharmacology of this alkaloid and its cellular responses may allow us to 
uncover some of the underlying causes of nicotine addiction. Therefore, in this chapter 
nicotine was used to examine the interactions in vitro between nAChR, iGluR and DA 
release in the striatum. Through the use of selective nicotinic and glutamatergic agonists 
and antagonists, results are consistent with the indirect modulation of DA release from 
striatal slices via an a l  nAChR on glutamatergic nerve terminals. These data also provide 
a baseline for the comparison of changes in this system induced by chronic nicotine 




In comparison to superfusion of synaptosomes, the procedure for superfusion of striatal 
slices is somewhat different and is described in detail in section 2.1. Briefly, after 
dissection of rat striata, instead of the homogenisation procedure used to create 
synaptosomes, striatal slices were prepared using a Mcllwain tissue chopper. These were 
loaded with [3H]DA and aliquoted into closed superfusion chambers, as opposed to open 
chambers used for synaptosomes. Superfusion was then performed as for synaptosomes. 
Unlike synaptosomes, radioactivity remaining in the slices at the end of the experiment 
could not be counted directly. Therefore, radioactive totals were determined after lysis of 
the tissue with 0.01 M HCI.
4.7.1 Typical response profiles
After optimisation procedures had been performed, initial superfusion experiments 
were performed to examine [3H]DA release from striatal slices evoked by 10 pM nicotine. 
Preliminary results showed that it was robust, reproducible and sensitive to 
mecamylamine. Representative profiles showing the responses from one assay are 
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Figure 4.8 Representative profiles of fH]DA release from striatal slices. Striatal slices 
were loaded with fHJDA and superfused as described in section 2.1; 2 min (1 ml) fractions were 
collected. Antagonist (mecamylamine ▲; 10 pM) was added to the perfusing buffer 10 min prior 
to stimulation with 10 juM nicotine for 40 s. Responses were determined in parallel samples in 
the absence of antagonist (•). Release is presented as (A) raw CPM or (B) percentage of the 
mean basal release. Error bars indicate the S.E.M. from 3 separate chambers.
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Comparison of the traces in Figure 4.8 to those showing [3H]DA release from 
synaptosomes (Figure 3.3; Chapter 3), demonstrates that the total amount of nicotine- 
evoked [3H]DA release from striatal slices is roughly 5 times higher than that evoked from 
synaptosomes by an equivalent concentration of nicotine (10 pM).
4.7.2 Concentration-response curves for agonist-evoked [3H]DA
release from rat striatal slices
To initially define nicotine-evoked [3H]DA release from striatal slices, superfusion 
experiments were performed to construct concentration-response curves (Figure 4.9). 
(±)Epibatidine was also included for comparison, as this compound is currently one of the 
most potent nAChR agonists known, and has not been previously examined in the slice. 
Mecamylamine (10 pM) was also present in combination with some of the higher 
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Figure 4.9 Concentration-response curves showing ^HJDA release from rat striatal 
slices evoked by increasing concentrations of nicotine ( • )  and epibatidine (♦). Striatal 
slices were loaded with fH]DA and superfused as described in section 2.1 prior to stimulation 
with a 40 s pulse of agonist. Mecamylamine (A ; 10 juM) was introduced into the perfusion 
buffer 10 min before, during and after stimulation with nicotine. Data points for both 
concentration-response curves were fitted to the single-site Hill equation, as described in 
section 2.1.6. Values represent the mean response above basal ±  S. E M. expressed as a 
percentage of the total radioactivity present in the slices at the time of stimulation from at least 
three separate experiments, each consisting of two or more replicate chambers.
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The dose-response curves obtained for both nicotine and epibatidine appeared 
monophasic with apparent EC5o values of 2.4 ± 0.4 pM and 0.019 ± 0.005 pM, 
respectively. The non-specific release of DA, as determined in the presence of 10 pM 
mecamylamine, was 0.33 ± 0.05 % above basal release, for concentrations of nicotine 
between 1-100 pM. As the level of non-specific release was consistently low, it is 
represented in subsequent graphs as a dashed red line. Where appropriate, the level of 
non-specific release in experiments involving synaptosomes is shown and is derived from 
Chapter 3. It is roughly twice that seen in slices.
Further experiments were performed to compare the efficacy of a variety of agonists 
with respect to stimulation of [3H]DA from striatal slices (Figure 4.10). Epibatidine, 
(±)anatoxin-a, nicotine and UB-165 were all used at maximally effective concentrations. Of 
these four compounds, 300 nM epibatidine was undoubtedly the most efficacious, 
releasing 8.4 ± 2 % [3H]DA above basal levels (Figure 4.10). Nicotine (10 pM) was slightly 
more efficacious than 25 pM anatoxin-a (5.1 ± 0.3 % and 4.3 ± 0.4 % release above 
basal, respectively; Figure 4.10). However, from previous work in synaptosomes,
300 nM (+/-)Epibatidine 
25 |.iM Anatoxin-a 




Figure 4.10 Comparison of [ 3H]DA release evoked by maximally effective 
concentrations of epibatidine, anatoxin-a, nicotine and UB-165. Striatal slices were loaded 
with fHJDA and superfused as described in section 2.1 prior to stimulation with a 40 s pulse of 
agonist at concentrations indicated. Values represent the mean ±S.E.M. of the response above 
basal release from at least two separate experiments, each consisting of two or more replicate 
chambers. The dotted red line indicates the level of non-specific ?H]DA release determined in 
Figure 4.9 in the presence of 10 pM mecamylamine.
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anatoxin-a is known to be more potent than nicotine (Sharpies et al., 2000). Finally, 
although the anatoxin-a-epibatidine hybrid, UB-165, is more potent than anatoxin-a 
(Sharpies et al., 2000), it was much less efficacious then any of the other agonists, 
evoking only 2.3 ± 0.5 % [3H]DA release above basal (Figure 4.10).
4.7.3 lonotropic glutamate receptors and modulation of DA release
Previous studies performed by our group (Kaiser and Wonnacott, 2000) have indicated 
that release of glutamate may be involved in the indirect modulation of anatoxin-a-evoked 
[3H]DA release from striatal slices (see section 4.6 in this chapter).
To determine whether release of glutamate contributes to nicotine-evoked [3H]DA 
release from striatal slices, experiments were performed in the presence and absence of 
the general glutamate antagonist kynurenic acid (Kyn A, 500 pM), and the AMPA/Kainate 
selective antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX, 100 pM; Figure 4.11). A 
concentration of 100 pM nicotine was chosen to stimulate [3H]DA release, as from the 
concentration-response curve (Figure 4.9) this was a maximally effective concentration 
and likely to activate all subtypes of nAChR present in the slice.
Mecamylamine (10 pM) caused an almost total blockade of [3H]DA evoked by either 10 
or 100 pM nicotine (Figure 4.11). The remaining [3H]DA release was comparable to the 
non-specific release evoked by a buffer pulse (Figure 4.11). However, both kynurenic acid 
and DNQX reduced [3H]DA release evoked by the higher concentration of nicotine (100 
pM) by 35.9 ± 13.3 % and 58.1 ± 21.4 % (p<0.05, n=5) respectively (Figure 4.11). In 
addition, when the two iGluR antagonists were combined a similar reduction of 35.9 ±
19.2 % (p<0.05, n=3) was observed. The absence of any additive effect implies that both 
antagonists are acting at the same iGluR i.e. an AMPA/kainate subtype. These data are 
consistent with previous reports that iGluR are involved in the positive modulation of DA 
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Figure 4.11 Comparison of the effects of ionotropic glutamate receptor antagonists 
on nicotine evoked [ 3H]DA release. Striatal slices were loaded with fH]DA and superfused as 
described in section 2.1. Antagonists (kynurenic acid, Kyn A, 500 pM; DNQX, 100 pM; 
mecamylamine, 10 p M ) were added to the perfusing buffer 10 min prior to stimulation for 40 s 
with 100 pM nicotine. Results are expressed as a percentage of the response to 10 pM nicotine 
alone, determined in parallel. Values are the mean ±  S.E.M. from at least three independent 
experiments, each consisting of two or more replicate chambers (** p<0.01 or * p<0.05, 
significantly different from response of 100 pM nicotine, one-way ANOVA and Tukey’s post-hoc 
test).
Kynurenic acid and DNQX were also tested in their capacity to inhibit [3H]DA release 
evoked by lower concentrations of nicotine -  specifically 1 and 10 pM nicotine (Figure 
4.12). At 10 pM nicotine kynurenic acid (500 pM) significantly inhibited [3H]DA release by
21.0 ± 5.5 % (p<0.05, n=5; Figure 4.12). The reduction seen in the presence of DNQX 
was non-significant (14.8 ± 3.4 %). Compared with the effects of the same antagonists on 
[3H]DA release evoked by 100 pM nicotine, the extent of inhibition was lower (Figure 
4.11). At 1 pM nicotine, [3H]DA release was greatly reduced and DNQX (100 pM) caused 
no inhibition of the response to 1 pM nicotine alone (Figure 4.12). These results are 
consistent with nicotine eliciting a significant glutamate contribution, which enhances 
[3H]DA release, at nicotine concentrations of 10 pM and above. Therefore, it would appear 
that the nAChR that mediates glutamate release is relatively insensitive to nicotine.
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Figure 4.12 Comparison of the effects of ionotropic glutamate receptor antagonists 
on fHJDA release nicotine evoked by lower concentrations of nicotine. Striatal slices were 
loaded with fHJDA and superfused as described in section 2.1. Antagonists (kynurenic acid, 
Kyn A, 500 pM; DNQX, 100 pM) were added to the perfusing buffer 10 min prior to stimulation 
for 40 s with 10 or 1 pM nicotine. Results are expressed as a percentage of the response to 10 
pM nicotine alone, determined in parallel. Values are the mean ±  S.E.M. from at least three 
independent experiments, each consisting of two or more replicate chambers. (* p<0.05, 
significantly different from response of 10 pM nicotine, one-way ANOVA and Tukey’s post-hoc 
test)
4.7.4 Determination of possible non-specific effects of iGluR 
antagonists on nAChR
As with all drugs, there is the possibility that they may act non-specifically at other 
targets. To resolve whether the iGluR antagonists kynurenic acid and DNQX could be 
inhibiting nAChR directly, control experiments were performed in two different neuronal 




The first group of assays examined [3H]DA release from striatal synaptosomes (Figure 
4.13 A; see Chapter 3 for nAChR subtypes). This preparation consists of isolated nerve 
terminals, with no possibility of enhancement of [3H]DA release by release of glutamate. 
Therefore, any effects of iGluR antagonists on nicotine-evoked [3H]DA release would be 
due to direct action at the nAChR (glutamate receptors would not be active and, therefore, 
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Figure 4.13 Comparison of the effects of iGluR antagonists on nicotine-evoked fHJDA 
release from striatal synaptosomes and on nicotine-induced Ca2+ influx in SH-SY5Y cells.
(A) Synaptosomes were loaded with fHJDA and superfused as described in section 2.1. 
Antagonists (kynurenic acid, Kyn A, 500 pM; DNQX, 100 pM) were introduced into the perfusing 
buffer 10 min prior to stimulation for 40 s with 100 pM nicotine. Results are expressed as a 
percentage of the response to 10 pM nicotine alone, determined in parallel. Values are the 
mean ±  S.E.M. from at least 3 independent experiments, each consisting of two or more 
replicate chambers. No significant inhibition of nicotine-evoked fHJDA release was observed 
(one-way ANOVA).
(B) Calcium fluorimetry was performed on SH-SY5Y cells as described in section 2.5. The iGluR 
antagonists kynurenic acid (Kyn A; 500 pM) and DNQX (100 pM) were incubated with the cells 
for at least 15 min prior to stimulation with 100 pM nicotine. The general nAChR antagonist 
mecamylamine (Mec; 10 pM) was included as a positive control. The response to the nicotine 
control in the absence of antagonist was taken as 100% and all other values expressed as a 
percentage of this. All values are the mean ±  S.E.M. from at least 4 separate experiments with 
quadruplicate repeats. Neither kynurenic acid nor DNQX caused any significant inhibition of 
nicotine induced Ca2+ influx (one-way ANOVA).
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Results in Figure 4.13 A illustrate that neither kynurenic acid nor DNQX caused any 
significant decrease in [3H]DA evoked by 100 pM nicotine (responses of 10 pM nicotine 
control of 138.4 ±11.8 %, 138.7 ± 16.8 % and 123.2 ± 18.6 % for 100 pM nicotine alone 
and in combination with DNQX, kynurenic acid, respectively).
A second set of experiments was performed using the SH-SY5Y human neuroblastoma 
cell line (Figure 4.13 B). These cells are known to express the a3, a5, a7, p2 and (34 
nAChR subunits with the possibility for a number of combinations to occur (see Chapter 6 
for more information), and offer an alternate way of assessing whether compounds act at 
nAChR. Again, no significant decrease in Ca2+ influx evoked by 100 pM nicotine was 
observed with either kynurenic acid or DNQX (decreases of 6.1 ± 9.6 % and 8.9 ± 6.3 %,
t
respectively; Figure 4.13 B). The general nicotinic antagonist mecamylamine, however, 
caused an almost total blockade of Ca2+ influx (decrease of 95.1 ± 0.4 %; Figure 4.13 B).
4.7.5 Pharmacology of AMPA-evoked [3H]DA release from striatal 
slices
The sensitivity of nicotine-evoked [3H]DA from striatal slices to the AMPA/Kainate iGluR 
antagonist DNQX (Figure 4.11) and evidence in the literature (Desce et al., 1992; 
Cheramy et al., 1994) suggest that either one of these subtypes of iGluR may be present 
on the DA terminal. To further investigate this, rather than using selective antagonists, a 
selective agonist was used, in this case the prototypic agonist AMPA. This was applied 
alone and in combination with nicotine to investigate the effect on [3H]DA release from 
striatal slices (Figure 4.14).
Comparison of the trace in Figure 4.14 A to those showing [3H]DA release evoked by 
10 pM nicotine (Figure 4.8) demonstrates that the peak amount of [3H]DA released by 1 
mM AMPA from striatal slices was roughly half that evoked by nicotine (10 pM). The 
concentration-response curve obtained for AMPA stimulated [3H]DA release was 
monophasic but did not reach a plateau, even approaching a concentration of 10 mM 
(Figure 4.14 B). Higher concentrations could not be tested due to solubility limitations. To 
extend the characterisation of AMPA-evoked [3H]DA release, additional experiments were 
carried out in combination with nicotine (Figure 4.15 A & B). A concentration of 1 mM 
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Figure 4.14 AMPA-evoked fHJDA release from striatal slices. Striatal slices were loaded 
with fHJDA and superfused as described in section 2.1; 2 min (1 ml) fractions were collected.
(A) Representative profiles of fHJDA release from striatal slices. Antagonist (DNQX ( ); 100 
pM) was added to the perfusing buffer 10 min prior to stimulation with 1 mM AMPA for 40 s. 
Responses were determined in parallel samples in the absence of antagonist (•). Release is 
presented as a percentage of the mean basal release. Error bars indicate the S.E.M. from 3 
separate chambers.
(B) Concentration dependence of AMPA-evoked fHJDA release from striatal slices. Striatal 
slices were loaded with fHJDA and superfused as described in section 2.1. Slices were 
stimulated for 40 s with AMPA (0.001 -  3 mM). Results are expressed as a percentage of the 
response to 1 mM AMPA alone, determined in parallel. Values are the mean ±  S.E.M. from 
three independent experiments, each consisting of two or more replicate chambers. Data points 
were fitted to the Hill equation as described in section 2.1.6. As no plateau was obtained, an 
ECso value could not be calculated.
Compared to the [3H]DA release elicited by 10 jiM nicotine, which is taken as 100 %, 1 
mM AMPA increased [3H]DA release by 57.3 ± 4.8 % above basal (Figure 4.15 A). When 
both agonists were co-applied, an additional, significant, increase in [3H]DA release of 
36.6 ± 5.6 % (p<0.01, n=3) above nicotine-evoked release was observed (Figure 4.15 A). 
The application of DNQX in combination with 1 mM AMPA inhibited evoked [3H]DA 
release by 72.9 ± 10.7 % (p<0.01, n=3; Figure 4.15 B), to a level equivalent to the non­
specific release of [3H]DA evoked by a buffer pulse. These novel observations suggest 
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Figure 4.15 Pharmacology of AMPA receptors in the modulation of fHJDA release 
from striatal slices. Striatal slices were loaded with fHJDA and superfused as described in 
section 2.1.
(A) Slices were stimulated for 40 s with either 10 pM nicotine, 1 mM AMPA, or 10 pM nicotine + 
1 mM AMPA. Results are expressed as a percentage of the response to 10 pM nicotine alone, 
determined in parallel. Values are the mean ±S.E.M. from three independent experiments, each 
consisting of two or more replicate chambers. (** p<0.01 significantly different from 10 pM 
nicotine control, one-way ANOVA and Tukey’s post-hoc test, f t  p<0.01, significantly different 
from 1 mM AMPA alone, one-way ANOVA and Tukey’s post-hoc test).
(B) Antagonist (DNQX, 100 pM) was introduced into the perfusing buffer 10 min prior to 
stimulation for 40 s with 1 mM AMPA. Results are expressed as a percentage of the response 
to 1 mM AMPA alone, determined in parallel. Values are the mean ±  S.E.M. from 3 independent 
experiments, each consisting of two or more replicate chambers. (** p<0.01, significantly 
different from 1 mM AMPA control, Student’s t-test)
4.7.6 Involvement of presynaptic a7 nAChR in the modulation of 
[3H]DA release from striatal slices
To further characterise the pharmacology of [3H]DA release in the slice, the 
involvement of the a7 subtype of nAChR was investigated, as evidence exists that [3H]DA 
release evoked by a maximal concentration of anatoxin-a (25 nM) is sensitive to a7 
nAChR antagonists (Kaiser and Wonnacott, 2000). To address this hypothesis using a 














presence of 3 different antagonists selective for the a l  subtype of nAChR (a-conotoxin 
Iml, a-CTx Iml, 1 pM; a-bungarotoxin, a-Bgt, 40 nM, and methyllycaconitine, MLA, 50 
nM). Additional experiments were performed where a7 nAChR antagonists were applied 
in combination with DNQX (100 pM) to explore the notion that a l  nAChR are indeed 
involved in the indirect enhancement of [3H]DA release by glutamate. Figure 4.16 
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Figure 4.16 Effects of antagonists on fHJDA release from striatal slices. Striatal slices 
were loaded with fHJDA and superfused as described in section 2.1. a7 nAChR antagonists (a- 
CTx-lml, 1 fjM; MLA, 50 nM) alone or in combination with the iGluR antagonist (DNQX, 100 pM) 
were added to the perfusing buffer 10 min prior to stimulation for 40 s with 100 pM nicotine, 
except in the case of a-Bgt (40 nM), where slices were incubated and perfused with it for 1 h 
prior to addition of agonist. Results are expressed as a percentage of the response to 10 pM 
nicotine alone, determined in parallel. Values are the mean ±  S.E.M. from at least three 
independent experiments, each consisting of two or more replicate chambers (** p<0.01 or * 
p<0.05 significantly different to 100 pM nicotine control, one-way ANOVA and Tukey’s post-hoc 
test).
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Results showed that the a7 antagonists, a-CTx Iml and MLA reduced [3H]DA release 
evoked by 100 pM nicotine to a similar extent, by 50.7 ± 11.7 % and 59.7 ± 13.4 % 
(p<0.05, n=5), respectively. a-Bgt caused a slightly greater reduction in [3H]DA release 
(77.7 ± 17.6 %, p<0.05, n=3) than either a-CTx Iml or MLA, but this may be due to the 
longer period of incubation (1 h) needed with this ligand or the lower number of 
experiments performed. The inhibition of nicotine-stimulated [3H]DA release achieved with 
a-Bgt (40 nM) and MLA (50 nM) alone (Figure 4.16; reductions of 77.7 ± 17.6 % and 59.7 
± 13.4 %, respectively) was not significantly different when compared to the decrease in 
[3H]DA release after co-application of DNQX (100 juM) with either 40 nM a-Bgt (79.5 ±
13.0 % reduction), or 50 nM MLA (43.6 ± 15.5 % reduction). These data indicate that the 
a7 nAChR and the AMPA/kainate receptor may exist in series on different nerve terminals 
rather than in parallel on the same terminal (see Figure 4.20).
As a7 nAChR antagonists were shown to significantly reduce [3H]DA release, an 
alternative approach was attempted to further investigate the role of this nAChR subtype 
in the modulation of [3H]DA release. Instead of using other antagonists, the selectivity of 
the a7 agonists, choline and AR-R17779, was exploited (Figure 4.17). Choline was used 
at 10 mM, a concentration previously shown to fully and selectively activate fast-decaying, 
type-IA, whole cell currents in hippocampal neurones, indicative of a7 nAChR (Alkondon 
et al., 1997a). The functional activity of the alleged a7 selective compound AR-R17779 
has only been investigated in oocytes expressing a7 nAChR where it was relatively potent 
in eliciting responses with an EC50 of 21 pM. Therefore, in the assays described in Figure 
4.17, a presumably maximally effective concentration of 200 pM was used.
[3H]DA release evoked by both 10 mM choline and 200 pM AR-R17779 was extremely 
low (0.58 ± 0.1 % and 0.68 ± 0.19 % above basal, respectively) compared, for example, to 
the response evoked by a maximally effective concentration of 100 pM nicotine (5.4 ± 0.3 
% above basal; Figure 4.9). The responses were also not significantly different from the 
non-specific response obtained in the presence of mecamylamine (10 pM). Although it 
appears that both MLA (50 nM) and mecamylamine (10 pM) inhibited the responses to 
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Figure 4.17 Evaluation o f fHJDA evoked by  a7 agonists. Striatal slices were loaded with 
fHJDA and superfused as described in section 2.1. Antagonists (MLA, 50 nM; mecamylamine, 
Mec, 10 pM) were added to the perfusing buffer 10 min prior to stimulation for 40 s with 10 mM 
choline. 1 pM atropine was included throughout the experiment to inhibit muscarinic receptors. 
fHJDA release evoked by the synthetic a l  selective agonist, AR-R17779 (200 pM), was also 
compared (n=1). Results are expressed as a percentage of the of the total radioactivity present 
in the synaptosomes at the time of stimulation. Values are the mean ±  S.E.M. from one 
(AR-R17779) or three (choline) independent experiments, each consisting of two or more 
replicate chambers. There were no significant differences between conditions (one-way 
ANOVA)
4.7.7 Investigation of the involvement of the NMDA subtype of iGluR
Up to this point, this study has focused on AMPA/kainate iGluR. In view of the evidence 
in the literature for the presence of NMDA R on DA terminals (e.g. Cheramy et al., 1996), 
experiments were extended to specifically examine the contribution of the NMDA R to 
[3H]DA release from the striatal slice. To facilitate the investigation of the co-operativity 
between the NMDA receptor and nAChR on striatal DAergic nerve terminals, NMDA and 
nicotine were applied, alone and in combination, under a variety of conditions (Figure 4.18 
& Figure 4.19). Initial studies were carried out in synaptosomes in an attempt to replicate 
the results obtained by Cheramy et al. (1996) but using the superfusion system in our
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laboratory. In addition, much shorter stimulation times of 40 s were used, as opposed to 
15 minutes (Cheramy et al., 1996). Superfusion experiments were performed in the 
presence and absence of the NMDA R co-agonist glycine (1 jjM) and also with Mg2+ 
omitted from the buffer.
A summary of the results obtained is presented in Figure 4.18. In the experiments, 1 
mM NMDA applied alone in the absence (Figure 4.18 A) or presence (Figure 4.18 B) of 
glycine (1 pM), was unable to increase [3H]DA release above the level of a buffer control 
(Figure 4.11). However, in Figure 4.18 C, when Mg2+ was removed from the perfusing 
buffer, NMDA significantly increased the level of [3H]DA to 39.0 ± 5.0 % above basal 
release (p<0.05, n=4). This is in agreement with Cheramy et al. (1996), who determined 
that NMDA-evoked [3H]DA release decreased in the presence of ‘ increasing 
concentrations of Mg2+, due to blockade of the NMDA R channel (section 4.5.2.3).
When NMDA was co-applied with 10 pM nicotine in the absence of glycine (Figure 4.18 
A) no significant increases in [3H]DA release were seen. However, in the presence of 1 
pM glycine and Mg2+, a non-significant increase in [3H]DA release of 16.9 ± 7.3 % was 
observed compared to the control response (Figure 4.18 B, n=4). A similar increase of
12.2 ± 5.2 % was seen in the presence of glycine when Mg2+ was absent from the 
perfusing buffer (Figure 4.18 C, n=4). These increases were not significantly different from 
the response evoked by 10 pM nicotine alone due to the small sample size. Nevertheless, 
addition of the selective NMDA R antagonist AP-V reduced [3H]DA release evoked by 10 
pM nicotine in combination with NMDA in all experiments, with non-significant decreases 
in Figure 4.18 B and Figure 4.18 C of 25.6 ± 6.3 % and 23.0 ± 7.5 % respectively.
These results suggest that NMDA R are present on DA terminals and, under the 
appropriate conditions, may be selectively activated by a much shorter pulse of nicotine 
than previously described (Cheramy et al., 1996), thus contributing to the overall release 
of [3H]DA. Experiments then proceeded to evaluate the co-operativity of nicotine and 
NMDA in evoking [3H]DA release from the more intact environment of the striatal slice, a 
paradigm that has not previously been attempted.
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Figure 4.18 Initial evidence that functional NMDA receptors exist on DA terminals. Striatal 
synaptosomes were loaded with fHJDA and superfused as described in section 2.1. The NMDA R 
antagonist AP-V (100 pM) was added to the perfusing buffer 10 min prior to stimulation for 40 s 
with 10 pM nicotine alone or in conjunction with 1 mM NMDA. (A) Experiments performed in the 
absence of both glycine and strychnine. (B) Experiments performed in the presence of both glycine 
(1 pM) and strychnine (1 pM). (C) Experiments performed in the presence of both glycine (1 pM) 
and strychnine (1 pM) but in the absence of Mg2*. Results are expressed as a percentage of the 
response to 10 pM nicotine alone, determined in parallel. Values are the mean ±  S.E.M. from four 
independent experiments, each consisting of two or more replicate chambers. (* p<0.05, 
significantly increased over the non-specific release evoked by 10 pM nicotine in the presence of 
mecamylamine, Student’s t-test).
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4.7.8 Investigation of the involvement of the NMDA subtype of iGluR 
-  Slices
A preliminary analysis of the putative co-operativity between iGluR and nAChR on 
striatal DAergic nerve terminals was also performed in slices. Results are presented in 
Figure 4.19. M  experiments were performed in the presence of 1 pM glycine and 1 pM 
strychnine.
In Figure 4.19 A, 1 mM NMDA alone caused no significant increase of [3H]DA above 
that of a buffer pulse. For comparison with the results in synaptosomes, specifically those 
in Figure 4.18 B, initial experiments utilised a concentration of 10 pM nicotine (Figure 4.19 
A). When this was co-applied with NMDA (1 mM) in slices, a significant increaste of 28.8 ±
7.1 % (pcO.01, n=4) was observed compared to the 10 pM nicotine control, and this was 
blocked by AP-V (100 pM) to the level of the control response. In Figure 4.19 B, a lower 
concentration of nicotine (3 pM) in combination with 1 mM NMDA caused only a slight, 
non-significant increase in [3H]DA release which, nevertheless, was still reduced by the 
application of 100 pM AP-V.
A different situation is seen in Figure 4.19 C. Using a concentration of nicotine that 
evoked a maximal response in the slice, 1 mM NMDA in combination with 100 pM nicotine 
did not enhance [3H]DA release when compared to the response evoked by 100 pM 
nicotine alone. However, the response of nicotine plus NMDA was inhibited to some 
extent by AP-V, although this reduction was non-significant. Interestingly, there was a 
significant (p<0.05, n=4) reduction in the response of 100 pM nicotine alone by addition of 
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Figure 4.19 Co-operativity between nAChR and NMDA receptors in striatal slices.
Striatal slices were loaded with pHJDA and superfused as described in section 2.1. All 
experiments were performed in the presence of 1 pM glycine and 1 pM strychnine. NMDA R 
antagonist AP-V (100 pM) was added to the perfusing buffer 10 min prior to stimulation for 40 s 
with 3, 10 or 100 pM nicotine alone or in conjunction with 1 mM NMDA. Results are expressed 
as a percentage of the response to 10 pM nicotine alone, determined in parallel. Values are the 
mean ±  S.E.M. from at least three independent experiments, each consisting of two or more 
replicate chambers. (* p<0.05, **p<0.01 significantly different from 10 pM nicotine control, one­
way ANOVA and Tukey’s post-hoc test; t  p<0.05, f t  p<0.01, significantly different from 
indicated condition, one-way ANOVA and Tukey’s post-hoc test).
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4.8 Discussion
Previously in our group, the nicotinic agonist anatoxin-a has been used to demonstrate 
the possibility that glutamate may be released via activation of a putative presynaptic a7 
nAChR and contribute to the enhancement of [3H]DA release from striatal slices (Kaiser 
and Wonnacott, 2000). In this chapter, [3H]DA release from striatal slices was examined 
using the superfusion technique, but rather than using anatoxin-a to evoke release, 
nicotine was used to confirm and extend the results previously obtained (Wonnacott et al., 
2000). Nicotine elicited a concentration-dependent increase in [3H]DA release that was 
reduced to the level of a buffer pulse by the general nAChR antagonist mecamylamine. 
Release evoked by a maximal concentration of nicotine was partially inhibited by iGluR 
and a7 selective nAChR antagonists. In addition the iGluR agonist AMPA selectively 
increased [3H]DA release and was additive when combined with nicotine.
4.8.1 Nicotine-evoked [3H]DA release
As described in detail in the introduction to this chapter, the striatum receives 
dopaminergic input from the SNpc in addition to glutamatergic input from cortical areas. It 
is known from ultrastructural studies (Smith and Bolam, 1990; Wonnacott et al., 2000) that 
terminals of these neurones are positioned in mutual close proximity around dendritic 
spines, an arrangement that would facilitate interactions between their respective 
neurotransmitters. From a functional point of view, we have also noticed that anatoxin-a- 
evoked [3H]DA release from synaptosomes is lower than from slice preparations, thus 
suggesting the existence of additional components in the slice that can augment the 
release of DA (Kaiser et al., 1998; Kaiser and Wonnacott, 2000).
Nicotine was able to elicit a robust, concentration dependent, increase in [3H]DA 
release from superfused striatal slices that was almost completely blocked by the general 
nicotinic antagonist mecamylamine (Figure 4.8 and Figure 4.9). The concentration- 
response curve for nicotine had an EC50 value of 2.4 pM, which compares well to that 
previously determined for [3H]DA release from rat striatal slices (3.7 pM, Sacaan et al.,
1995). The curve was also monophasic, compared to the biphasic curve obtained with 
anatoxin-a (Kaiser and Wonnacott, 2000). This difference could signify that the different 
subtypes of nAChR in the slice respond to nicotine over quite a narrow concentration 
range, in such a manner that their responses overlap one another. In contrast, anatoxin-a 
is more potent than nicotine at the non-a7 nAChR present on the DA terminal, with EC50
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values for [3H]DA release of 110 nM and 134 nM obtained in this laboratory from
synaptosomes (Soliakov et al., 1995; Kaiser and Wonnacott, 2000). In contrast, nicotine
has a much greater EC50 value of 1.5 pM in this system (Sharpies et al., 2000). In
addition, the ability of the two agonists to evoke type IA responses (a-Bgt sensitive) in rat
hippocampal neurones gave EC50 values of 3.9 pM for anatoxin-a and 27.2 pM for
nicotine (Alkondon and Albuquerque, 1993). The EC50 value for anatoxin-a is also
consistent with that of the putative a7 component in striatal slices (EC50 value = 5.1 pM;
Kaiser and Wonnacott, 2000). Although one cannot really compare DA release from
synaptosomes with electrophysiolgical responses from hippocampal neurones, it is
interesting that the difference in EC50 values for anatoxin-a is greater than that of nicotine
*
(Table 9). It seems, therefore, that in the case of anatoxin-a there is a sufficient difference 
for two phases to be discerned in the dose-response curve.
Table 9 Data from studies regarding the potency of the agonists nicotine and
anatoxin-a in rat striatal synaptosomes and hippocampal neurones
EC50 for DA release from 
synaptosomes 
(a3p2 & a4p2 nAChR)




Nicotine 1.6 nM1'1 27.2 jiMl3i -1 7  fold
Anatoxin-a 0.1101!!1& 0.134 3.9 nM® -3 3  fold
[1] Sharpies et al. (2000)
[2] Soliakov et al. (1995)
[3] Alkondon and Albuquerque (1993)
4.8.2 iGluR and [3H]DA release from slices
As mentioned in section 4.6 of this chapter, there is evidence indicating the presence of 
presynaptic iGluR on DA terminals in the striatum (e.g. Desce et al., 1992; Cheramy et al.,
1996). Previous experiments using anatoxin-a suggest that glutamate acts through these 
receptors to enhance DA release (Kaiser and Wonnacott, 2000). In Figure 4.11 the
general iGluR antagonist, kynurenic acid, and the AMPA/kainate selective antagonist
DNQX both inhibited nicotine-evoked [3H]DA release to a similar extent by 35.9 % and
58.1 % respectively. In addition, when the two iGluR antagonists were combined a similar, 
non-additive, reduction of 38.4 % was noted. These results follow the same pattern as 
previously seen with 25 pM anatoxin-a (Kaiser and Wonnacott, 2000). Also, when lower 
concentrations of nicotine were applied, the degree of inhibition by kynurenic acid and
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DNQX was reduced, and at 1 pM nicotine no inhibition was seen at all (Figure 4.12). This 
suggests that the lower the nicotine concentration, the less glutamate is released, and 
again points toward mediation by a nAChR with a lower affinity for nicotine.
Another interesting point regarding the application of iGluR antagonists, is that they 
had no effect on the basal release of DA. This suggests that glutamate does not tonically 
regulate the release of [3H]DA, at least in the in vitro slice preparation examined here. 
Studies examining this question in vivo have also presented results that imply that there is 
no tonic regulation of DA release by glutamate (Keefe et al., 1992; Morari et al., 1993; 
Segovia et al., 1997). However, other studies have reported contradictory data that 
glutamate can exert either a facilitatory (Smolders et al., 1996) or an inhibitory influence 
(Keefe et al., 1992; Kendrick et al., 1996) on the tonic release of DA in the‘striatum. It 
would seem, therefore, that further analysis is required to answer the question as to 
whether or not glutamate tonically modulates striatal DA release.
The release of [3H]DA by AMPA has previously been examined in synaptosomes 
(Cheramy et al., 1994), slices (Jin, 1997) and in the striatum of freely moving rats (Sakai 
et al., 1997). In all of these studies release was inhibited by addition of quinoxalinediones.
In this chapter AMPA was shown to evoke [3H]DA release in a dose-dependent manner 
(Figure 4.14 B) from rat striatal slices, but using stimulation times that were much shorter 
than those used previously (40 s as opposed to 20 minutes used by Cheramy et al., 
1994). AMPA-evoked [3H]DA release was also completely blocked by addition of DNQX 
(Figure 4.14 A & Figure 4.15). Release evoked by AMPA was also additive with 10 pM 
nicotine. This novel result suggests that both nicotinic and AMPA receptors can 
individually contribute to DA release in such a manner that one receptor system does not 
impinge on the other. Interestingly, this is in contrast to a recent study that reported oc3p4 
nAChR and P2X2 channels influence each other when co-activated resulting in non­
additive responses (Khakh et al., 2000).
4.8.3 Role of the a 7  nAChR
It has been determined that nicotinic stimulation of DA release from striatal 
synaptosomes is insensitive to a7 nAChR selective antagonists (Kulak et al., 1997; Kaiser 
et al., 1998; Kaiser and Wonnacott, 2000; Chapter 3). However, [3H]DA release from 
striatal slices evoked by anatoxin-a is sensitive to a-Bgt, MLA, and a-CTx Iml (Kaiser and 
Wonnacott, 2000), and these results, together with others presented in that paper, 
suggested that a7 nAChR exist on non-DAergic, possibly glutamatergic terminals. In this
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chapter, the same a7 selective antagonists inhibited [3H]DA release evoked by 100 pM 
nicotine (Figure 4.16), by a similar magnitude as obtained previously. Further experiments 
suggest that the a7 nAChR is, indeed, located on glutamatergic terminals in the striatum, 
as no further decrease of [3H]DA was observed when a7 antagonists were applied in 
combination with the iGluR antagonists kynurenic acid and DNQX (Figure 4.16).
These observations are consistent with a l  nAChR modulating the release of glutamate 
that in turn enhances striatal DA release (Table 10).
Table 10 Summary of the effect of iGluR and a7 nAChR antagonists on nicotine- 
evoked fHJDA release from striatal slices
Nicotine-evoked [3H]DA release in the presence of iGluR (Figure 4.11) and/or a7 
antagonists (Figure 4.16). Data presented as percent of 10 pM nicotine control
(% reduction of 100 pM nicotine)
iGluR antagonists a7 nAChR antagonists a7 + iGluR antagonists
100 pM nicotine 
alone
150.7 ±14.7% 100 pM nicotine 
alone
154.3 ±12.5% 100 pM nicotine 
alone
154.3 ±12.5%
+ Kyn A 108.0 ±13.3 + a-CTx Iml 103.6 ±11.7
(n=3) (-28.3%) (n=4) (-32.9%)
+ DNQX 86.2 ±21.4* + a-Bgt 77.7 ±17.6* + a-Bgt + DNQX 74.8 ±13.0”
(n=5) (-42.8%) (n=3) (-49.6%) (n=3) (-51.5%)
+ Kyn A + DNQX 106.0 ±19.2* + MLA 94.7 ±13.4* + MLA + DNQX 110.7 ±15.5
(n=2) (-29.7%) (n=5) (-38.6%) M ) (-28.3%)
* p<0.05, ** p<0.01, significantly different from the response of 100 pM nicotine alone
(one-way ANOVA and Tukey’s post-hoc test)
In addition to a7 nAChR antagonists, two a7 selective agonists were also employed. 
Choline was chosen as it selectively evokes a-Bgt and MLA sensitive type IA responses in 
cultured hippocampal neurones (Alkondon et al., 1997a). However, stimulation with a 
maximally effective concentration of 10 mM choline for 40 s only produced a small, non­
significant increase in [3H]DA release of 0.58 % above basal (Figure 4.17). This was 
unexpected as one might anticipate that an a7 agonist would evoke a level of [3H]DA 
release equivalent to the level of inhibition caused by a-Bgt, MLA and a-CTx Iml (Figure
4.16). Nevertheless, the small amount of [3H]DA released by choline was able to be
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blocked, in a non-significant manner, by MLA and the general nicotinic agonist 
mecamylamine, which does suggest a small degree of activation of the a7 nAChR (Figure
4.17). One other experiment was performed with the a7 selective compound AR-R17779 
used at a maximally effective concentration of 200 pM (Mullen et al., 2000). Again, [3H]DA 
release was only slightly increased by 0.68 ± 0.19 % above basal (Figure 4.17).
One explanation for these findings is that there may be another, non-a7, subtype of 
nAChR present on glutamate terminals that must be simultaneously activated before 
glutamate release is initiated. A possible mechanism for this could be that Ca2+ influx 
through the a7 nAChR alone may not be sufficient to trigger exocytosis but combined with 
Ca2+ entry elicited by another nAChR, Ca2+ levels may be raised enough to evoke release 
of glutamate. There is evidence for non-a7 nAChR on glutamate terminals in other areas 
of the brain (Girod et al., 2000) but the relationship between these and a7 nAChR has yet 
to be explored.
4.8.4 Contribution of the NMDA subtype of iGluR
In all the previous experiments discussed so far, the NMDA receptor is unlikely to be 
able to contribute to DA release as glycine was not added to the superfusion medium. 
Endogenous glycine, present at concentrations ~ 1 pM (Ferraro and Hare, 1985), would 
also be rapidly removed by the constant perfusion of buffer during the superfusion 
procedure. This amino acid is essential in the activation of NMDA R as it acts as a co­
agonist (Johnson and Ascher, 1987). However, when 1 pM glycine is added to the buffer 
(in conjunction with 1 pM strychnine to block glycine receptors) 1 mM NMDA has been 
shown to evoke DA release from isolated striatal nerve terminals (Desce et al., 1992) and 
slices (Krebs et al., 1991). Using a much shorter stimulation time of 40 s, the results from 
the latter study were replicated in Figure 4.18 C, as 1 mM NMDA in the presence of 
glycine and in Mg2+-free buffer was able to evoke [3H]DA release from synaptosomes.
It is also believed that a synergistic relationship can exist between neurotransmitter 
receptors on the DA terminal. Such interactions have been shown between AMPA and 
NMDA receptors and also nicotinic and NMDA receptors (Desce et al., 1992; Cheramy et 
al., 1996). The result of these interactions is that depolarisation of the nerve terminal by 
nicotine, ACh, or AMPA can relieve the Mg2+ block of the NMDA receptor (Desce et al., 
1992; Cheramy et al., 1994). These results were also replicated to a certain extent in 
Figure 4.18 B & C (Table 11), where co-application of nicotine and NMDA in the presence 
of glycine produced additive increases in [3H]DA release. However, these increases were
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not as substantial as those observed by Glowinski and colleagues (1996) and may reflect 
the differences in stimulation times (15 min versus 40 s in this study). Nevertheless, the 
increases in Figure 4.18 B & C were reduced by addition of the NMDA selective 
antagonist AP-V.
Experiments then progressed to the preliminary examination of the co-operativity of 
nAChR and NMDAR in the striatal slice (Figure 4.19 & Table 11). This has not been 
previously studied, and is, perhaps, more pertinent to the situation that occurs in vivo.
In the first graph (Figure 4.19 A) the experiments performed in synaptosomes in Figure
4.18 B were replicated in the presence of 1 pM glycine and Mg2+. Again, NMDA alone was 
not sufficient to trigger a significant release of [3H]DA but co-application of the agonist with 
10 pM nicotine produced a significant increase of 28.8 % over and above the fevel of the 
nicotine control. This was a much greater release compared to that seen in synaptosomes 
(16.9 %; Figure 4.18 B). The increase was blocked by AP-V, which itself had no effect on 
the [3H]DA evoked by nicotine alone, ruling out non-specific action at the nAChR (Figure
4.19 A). The only difference between these two experiments was the tissue preparation 
used. An explanation for the enhanced response the slice may be that in this preparation, 
nicotine is able to release other neurotransmitters that can enhance the magnitude and 
time-span of depolarisation of the DAergic nerve terminal. For example, nicotine is able to 
evoke 5-hydroxytryptamine release from striatal nerve terminals (see Chapter 1) and 
release of DA by 5-HT has been demonstrated in the striatum (de Deurwaerdere et al., 
1997; Lucas et al., 2000). A lower concentration of 3 pM nicotine combined with NMDA, 
provoked a smaller, non-significant increase in DA compared to 3 pM nicotine alone 
(Figure 4.19 B), supporting this hypothesis.
Some interesting results were obtained when the set of conditions in Figure 4.19 A 
were repeated using a higher concentration of 100 pM nicotine. Firstly, no significant 
increase in [3H]DA release was found when NMDA was applied in combination with 
nicotine, although application of AP-V inhibited the release to just above the level of the 
10 pM nicotine control. Also, when AP-V was applied with the higher concentration of 
nicotine in the absence of NMDA it also caused a similar level of inhibition. This last result 
suggests that, perhaps, 100 pM nicotine causes a release of endogenous glutamate that 
is able to activate the NMDA R in place of NMDA. It also explains why NMDA did not 
enhance the release of [3H]DA when co-applied with 100 pM nicotine, as the NMDA R 
was already activated by the release of endogenous glutamate.
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Table 11 Summary of the effects of nicotine, NMDA, and APV on fHJDA release from 
striatal slices
Co-operativity between nAChR and NMDA R in eliciting [3H]DA release from striatal 
synaptosomes (Figure 4.18) and slices (Figure 4.19) - % of 10 pM nicotine control
Synaptosomes
(all 10 pM nicotine)
-glycine / -strychnine/ 
+Mg2*
+glycine / +strychnine/ 
+Mg2*
•(■glycine / +strychnine/ 
-Mg2*
+ NMDA 16.0 ±2.5% 20.5 ±5.1 % 39.0 ± 4.5 %
Nicotine + NMDA 106.2 ±6.1 % 116.9 ±11.8% 112.3 ±6.6%
Nicotine + NMDA + APV 85.3 ±4.4% 91.2 ±7.5% 85.5 ±11.7%
Slices
+glycine/ +strychnine/ +l\/ g2* i
3 pM nicotine 10 pM nicotine 100 pM nicotine
Nicotine alone 54.6 ± 5.2 % 100.0 % 138.7 ±16.7%
Nicotine + NMDA 72.8 ± 7.6 % 128.8 ±7.1 % 148.6 ±18.5%
Nicotine + NMDA + APV 59.6 ± 5.7 % 90.0 ±6.7% 122.1 ±21.2%
Nicotine + APV - 95.9 ± 9.5 % 94.5 ± 5.1 %
4.8.5 Selectivity of drugs
Complementary experiments were initiated to demonstrate that nicotine-evoked [3H]DA 
release from synaptosomes was not blocked by kynurenic acid or DNQX, indicating that 
these are unlikely to exert a direct effect on nAChR present on the DA terminal (Figure 
4.13). In addition, the glutamate antagonists did not reduce nicotine-stimulated Ca2+ influx 
in SH-SY5Y cells. However, there has been a recent report that kynurenic acid, at 
concentrations greater than 100 nM, can act as a non-competitive antagonist of a7 
nAChR (Hilmas et al., 2001). If this is true then it would indicate that kynurenic acid may 
be inhibiting both iGluR and a7 nAChR in the slice. In system described in this chapter 
one cannot say if this is true, as blockade of both receptors would produce the same 
reduction in [3H]DA release as inhibition of just one of them (see Figure 4.20). However, 
the ability of DNQX to reduce the release evoked by both AMPA and 100 pM nicotine 
suggest that AMPA/kainate receptors are at least involved, and to date there have been 
no questions concerning the selectivity of DNQX at AMPA/kainate receptors (Honore et 
al., 1988; Bleakman and Lodge, 1998).
In Chapter 3, results using synaptosomes showed that 50 nM MLA can inhibit another 
nAChR subtype (in addition to the a7 subtype) situated directly on DA terminals. However, 
the inhibition was not seen using a higher concentration of nicotine (100 pM), due to the
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surmountable nature of MLA inhibition. Therefore, one can say that in Figure 4.16, the 
reduction by 50 nM MLA of [3H]DA release from slices evoked by 100 |iM nicotine should 
reflect the selective antagonism of the a7 nAChR.
4.9 Conclusions
Results presented in this chapter have provided supporting evidence for the hypothesis 
that a7-containing nAChR mediate glutamate release in the rat striatum, which can then 
activate AMPA/kainate iGluR on terminals of nigro-striatal neurones to enhance DA 
release. In addition, a contribution of the NMDA subtype of iGluR has been dissected, and 
in the presence of glycine, a7 nAChR mediated glutamate released is also able to 
enhance DA release via activation of NMDA receptors. A schematic diagram of these 
interactions is shown below (Figure 4.20).
Figure 4.20 Neuronal 
interactions in the rat 
striatum. Schematic cartoon 
showing the putative relationship 
between nAChR, iGluR and 
presynaptic boutons in the rat 
striatum. The cortico-striatal 
glutamatergic input, (RED), 
forms an asymmetric synapse 
with a GABAergic medium spiny 
neurone, (GREEN). A nigro- 
striatal dopaminergic input, 
(BLUE), forms a symmetric 
synapse with the neck of the 
spine.
This clear demonstration of two subtypes of iGluR mediating nicotine-DA interactions in 
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5 Neurochemical Effects of Chronic Nicotine 
Treatment in the Rat Striatum
5.1 Smoking, nicotine and addiction
Addiction to a drug may be defined as a chronically, relapsing disorder that is 
characterised by (Koob et al., 1998):
•  Compulsion to seek and take the drug
•  Loss of control in limiting intake
•  Emergence of negative emotional states when access to the drug is prevented
Figure 5.1 Sagittal section through the rat brain depicting the anatomical pathways 
implicated in the reinforcing effects of drugs of abuse. Projections of the mesolimbic 
dopaminergic system to the nucleus accumbens (NAcc) are in orange, and are thought to be 
critical for psychomotor stimulation reward. They originate in the ventral tegmental area (VTA) 
and project to the NAcc, olfactory tubercle (OT) and ventral striatal domains of the caudate 
putamen (CP). Green pathways indicate opioid peptide containing neurones that may be 
involved in opiate and ethanol reward. GABAa receptor brain areas are shown in blue, and are 
thought to mediate some of the sedative/hypnotic rewards of ethanol. VP, ventral pallidum; SNr, 
substantia nigra pars reticulata; DMT, dorsal medial thalamus; PAG, periaqueductal gray; FC, 
frontal cortex; AMG, amygdala (modified from Koob, 1999).
Originally, the self-administration of drugs of abuse was thought to occur to relieve the 
aversive symptoms that arose when the drug was withheld, a so-called “negative 
reinforcement” model of addiction (reviewed by Wise, 1996, 2000). More recent theories 
have emphasised the role of the CNS in mediating positive reinforcement and euphoria. In 
particular, neuropharmacological studies have established that the mesolimbic
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dopaminergic system is intimately involved in the acute reinforcing effects of many drugs 
of abuse (e.g. cocaine, amphetamine and nicotine; Koob et al., 1998). The circuitry of this 
system is illustrated in Figure 5.1, and it is the effect of chronic nicotine treatment on the 
dopaminergic pathways that forms the focus of this chapter, with relevance to tobacco 
smoking.
The history of how tobacco was introduced to the Western world is described in 
Chapter 1. Use of tobacco and related products is a habit that is extremely persistent and 
resistant to change and, until the last thirty years or so, was seldom regarded as a form of 
drug dependence and certainly was not equated with morphine, cocaine or alcohol 
addiction. Over the last couple of decades the situation has changed, with the view now 
that tobacco use is a form of addiction that has enslaved millions of people to*smoking a 
substance that is the largest single cause of premature death in the developed world 
today (Peto et al., 1999). It is recognised that most smokers have attempted to quit 
tobacco smoking and failed due, primarily, to the neuropharmacological action of nicotine 
in tobacco smoke that provides the driving force behind the continued use of the product.
Initially, the sensory and pharmacological effects of nicotine are aversive, however, 
tolerance soon develops to the nicotine and smoke components. The smoker is then able 
to exquisitely regulate their nicotine intake by self-titration, thus circumventing the 
negative physiological effects caused by high nicotine levels, whilst preventing symptoms 
of withdrawal (reviewed by Russell, 1990). This behaviour results in ‘peaks’ and ‘troughs’ 
of nicotine levels in the blood. Smokers can then be profiled into those who smoke to 
maintain a constant level of nicotine in their blood, presumably to stave off withdrawal 
effects (“trough maintainers”), and those who smoke to generate transient, high, plasma 
nicotine concentrations after each cigarette (“peak seekers”). Individuals achieve this, not 
only by the number of cigarettes they smoke, but also by the number and duration of puffs 
they take from each individual cigarette, and the depth of inhalation. Overnight, however, 
levels of nicotine drop allowing the nAChR that have become desensitised during the day 
to resume activity and so the cycle begins again (Dani and Heinemann, 1996).
As mentioned briefly in Chapter 1, the pharmacokinetics and metabolism of nicotine 
are well-understood. The inhalation of tobacco smoke provides a rapid delivery 
mechanism by which nicotine is transported into the lungs, from where it is absorbed into 
the arterial circulation and rapidly distributed throughout the body, including the brain. The 
resulting concentrations of nicotine in blood plasma vary between smokers from between 
10 to 90 ng/ml (0.06 -  0.55 pM), but average at around 40 ng/ml (~ 0.25 pM; Russell,
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1990). In humans, the elimination half-life of nicotine averages 2-3 h and so levels can 
accumulate throughout the day with regular smoking (Benowitz and Jacob, 1991). 
However, the terminal half-life of nicotine is 20 h or more, and is possibly due to the slow 
release of nicotine from various bodily tissues. The persistence of low levels of nicotine in 
the bloodstream could well be a factor contributing to addiction. To complicate matters, 
studies of the pharmacokinetics of nicotine in rats have shown that levels of nicotine in the 
brain averaged about three times higher than that in the blood (Sastry et al., 1995; Rowell 
and Li, 1997). Whether a similar situation occurs in humans is unknown at present.
The liver is the primary site for the metabolism of nicotine, the breakdown of which 
leads to the generation of at least eight different metabolites (Kyerematen et al., 1990). 
These are structurally related to nicotine and there is some evidence that the/ may have 
pharmacological activity that could contribute to the effects attributed to nicotine in 
humans. The principal metabolite is cotinine, which has a much longer half-life than 
nicotine (16 -21  h), with average cotinine levels 15 times higher than those of nicotine 
(Benowitz, 1996). It was originally thought that cotinine was inactive at nAChR (Abood et 
al., 1983) but there is now increasing evidence that it can impinge on these receptors. 
However, studies have provided conflicting results with one reporting inhibition of nAChR 
function (Vainio et al., 1998) whilst another has demonstrated that cotinine can elicit 
release of [3H]DA from rat striatal slices in a mecamylamine and Ca2+ sensitive manner 
(Dwoskin et al., 1999). The authors of the latter study have also reported that nornicotine 
increased [3H]DA release from superfused slices of striatum and nucleus accumbens 
(Dwoskin et al., 1993, Green et al., 2001). The question of whether the actions of these 
metabolites are additive to the neurochemical effects of nicotine is still a matter of 
discussion.
The view of nicotine as a harmful compound is not completely valid, as it is the 
carcinogens and other toxic compounds in tobacco smoke that are responsible for the 
detrimental effects of smoking. Nicotine, and nicotinic agonists, have been shown to 
improve learning and memory in a variety of animals studies and can reverse deficits in 
several models of cognitive performance, including radial-arm maze performance after 
ibotenic acid lesions of the basal forebrain (Levin, 1992; Levin and Simon, 1998). In fact, 
nicotine and related compounds have already shown the potential to be valuable 
pharmacological agents for the treatment of diseases such as Alzheimer’s and 
Parkinson’s (see Chapters 1 & 3; Donnelly-Roberts and Brioni, 1999). Studies in vitro 
have also shown nicotine to be an effective neuroprotective agent, for example in the
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protection of neuronal cell cultures against excitotoxic cell death (e.g. Marin et al., 1994; 
Dajas-Bailador et al., 2000).
The persistent presence of nicotine in the body during cigarette smoking is thought to 
be one of the contributing factors to the addictive nature of tobacco use. Conversely the 
low levels of nicotine provided by nicotine replacement products attempt to relieve some 
of the withdrawal symptoms people suffer when they quit smoking (Lee et al., 1993). 
However, it is the effect of nicotine derived from cigarette smoking that has been the main 
driving force behind research examining chronic nicotine treatment on nAChR 
themselves, with experiments mainly performed in rodents, using a variety of treatment 
regimes.
«
5.2 Nicotine-induced changes in the brain
5.2.1 Radioligand binding studies
Normally, chronic exposure to an agonist results in downregulation of the receptor 
involved. The behaviour of the nAChR does not follow this doctrine, as upregulation of 
nAChR occurs after chronic exposure to nicotine. This phenomenon has undergone
extensive study in both in vivo and in vitro situations (reviewed in Wonnacott, 1990) and
may be associated with the withdrawal symptoms that appear after tobacco use has 
ceased (Dani and Heinemann, 1996; Dani et al., 2001).
Changes in numbers of nAChR after nicotine treatment have been monitored by some 
of the radiolabelled ligands described in section 1.10.1 of Chapter 1, with the most widely 
used being [3H]nicotine. A wealth of rodent studies have employed this ligand to 
demonstrate that chronic nicotine treatment leads to an increase in [3H]nicotine binding 
sites. For example, in rats, twice daily injections of nicotine (0.5 to 2 mg/kg) have been 
shown to cause upregulation (Schwartz and Kellar, 1985; Ksir et al., 1987; Collins et al., 
1988; el-Bizri and Clarke, 1994). In the same species, a constant infusion of 4 mg/kg/day 
nicotine, mirroring the levels seen in the blood of smokers, also causes upregulation in 
certain brain regions (Sanderson et al., 1993; results in this chapter). With relevance to 
the method of nicotine delivery in humans, rats exposed to cigarette smoke, 1 hour a day 
over a 13 week period, displayed significant increases in [3H]nicotine binding to striatal, 
cortical and cerebellar regions, providing more evidence for a relationship between 
cigarette smoking and nAChR upregulation in vivo (Yates et al., 1995). Indeed, less is 
known about the relationship between tobacco use and nAChR levels in humans, 
although several studies have documented increased [3H]nicotine binding in the brains of
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tobacco smokers, compared to non-smokers, that correlates to the number of packs of 
cigarettes smoked per day (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999). 
Thus, similar mechanisms of nAChR upregulation may occur in both rodents and humans.
Regarding subtypes of nAChR, the increases in [3H]nicotine binding described above 
suggest an upregulation of an a402* nAChR (see section 1.10.1.1). Additional evidence 
that the upregulated nAChR contains the a4 and 02 subunits was provided in a study by 
Flores et al. (1992), where levels of immunoprecipitated nAChR containing the a4 and 02 
subunits were increased in rats that received twice daily injections of nicotine (0.7 mg/kg 
free base). Upregulation of [125l]a-Bgt binding sites, thought to be representative of an a l  
nAChR, has also been observed in mice (Marks et al., 1985; Pauly et al., 1991). However, 
compared to [3H]nicotine binding, upregulation of [125l]a-Bgt binding was generally only 
seen at higher nicotine doses and in fewer brain loci.
The time course of nAChR upregulation has also been investigated. Marks et al. (1985) 
used a constant infusion of nicotine in mice to examine upregulation of [3H]nicotine 
binding in the major brain areas over 14 days. Within 4 days they found that numbers of 
[3H]nicotine binding sites increased and that this correlated with the development of 
maximum tolerance to the physiological effects of nicotine (e.g. effects on heart rate and 
body temperature). Additionally, in that study, and also in others (Schwartz and Kellar, 
1985; Collins et al., 1988, 1990), the upregulation produced by nicotine was not 
permanent, as [3H]nicotine binding levels returned to control values after cessation of 
nicotine treatment. This effect is paralleled in humans, where [3H]nicotine binding in post­
mortem brains of smokers who had quit smoking returned to levels observed in individuals 
who had been life-long non-smokers (Breese et al., 1997). A recent study has also 
reported a significant upregulation of [3H]nicotine binding in polymorphonuclear cells from 
the blood of smokers (Benhammou et al., 2000). This novel observation may prove useful 
as a marker of smoking cessation, with analysis of nAChR numbers over time possible, 
something that has previously been unfeasible in post-mortem tissue.
In rodents, the dose of nicotine that is administered also affects the degree of nAChR 
upregulation. This was demonstrated in an elegant study by Rowell and Li (1997) using 
different dosing regimes and concentrations of nicotine. Although increasing doses of 
constantly infused nicotine resulted in increases in nAChR density (measured by 
[3H]cytisine binding), significant increases were only observed at doses above 1.2 
mg/kg/day. Interestingly, 2 injections of a high concentration of nicotine a day were more 
effective at increasing the density of nAChR than 8 injections of a lower dose of the drug,
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a lack of effect that the authors attributed to stress responses to the more frequent 
injections (Rowell and Li, 1997).
Other radioligands have been employed in studies of this type. A comprehensive
autoradiographic study of the effects of chronic nicotine infusions in mice was performed
by Pauly et al. (1991) using [3H]nicotine, [125l]a-Bgt and the muscarinic acetylcholine
receptor ligand [3H]quinuclidinyl benzilate ([3H]QNB). Increases in the density of
[3H]nicotine and [125l]a-Bgt binding sites occurred in almost two thirds of the mouse brain
regions, with no change in binding of [3H]QNB binding, thus discounting a non-specific
action of nicotine on muscarinic AChR or the cholinergic system in general. Kellar and
colleagues have also utilised the tritiated form of the potent nicotinic ligand epibatidine to
*
measure nAChR binding in brains from smokers (Perry et al., 1999). As epibatidine 
displays high affinity for multiple subtypes of nAChR, it was possible to compare 
[3H]epibatidine binding to the binding of other nicotinic radioligands. This allowed the 
authors to uncover subtle differences in the density of nAChR in brain areas such as the 
temporal cortex, which may reflect upregulation of a discrete subtype of nAChR.
5.2.2 Mechanisms of upregulation
In an attempt to determine the cellular processes that result in upregulation of nAChR, 
studies have examined the effects of chronic nicotine treatment in vitro. Upregulation of 
nAChR has been observed in cell lines, including M10 cells (a4^2 nAChR; Bencherif et 
al., 1995; Whiteaker et al., 1998) and SH-SY5Y cells (a3* and a7* nAChR; Peng et al., 
1997; Ridley et al., 2001) and also in Xenopus oocytes (a4|32 nAChR; Peng et al., 1994a; 
Fenster et al., 1999). However, no study has so far provided a conclusive answer to 
exactly how nAChR upregulation occurs. We do know that upregulation is not due to the 
enhancement of the affinity of the receptor for the radioligand, as determined from K<j 
values in binding assays (Marks et al., 1983; Bencherif et al., 1995). Neither is it the result 
of increased nAChR gene transcription, as mRNA levels remain constant (Marks et al., 
1992; Peng et al., 1994a; Pauly et al., 1996). Upregulation is probably not due to specific 
factors present in neurones -  if these were required then upregulation would not occur in 
Xenopus oocytes. A recent study has suggested that nAChR desensitisation is required 
(Fenster et al., 1999). There have also been suggestions that upregulation results from 
decreased receptor turnover (Peng et al., 1994a), increased recruitment from intracellular 
pools of nAChR (Bencherif et al., 1995), or altered translation rates (Gopalakrishnan et al.,
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1997). Whether nAChR upregulation is the result of one or a combination of these 
processes has yet to be elucidated.
5.2.3 State of upregulated nAChR
Chronic nicotine administration increases numbers of [3H]nicotine binding sites. But are 
the nAChR that these sites represent functional, non-functional or composed of a mixed 
population of the two? A loss of in vivo nicotine-induced activity during nicotine treatment 
was demonstrated in several studies (Marks et al., 1985; Marks et al., 1987; Lapin et al., 
1987), suggesting that at least some nAChR exist in a non-functional state. It is known 
that exposure of nAChR to nicotine results in activation followed quickly by desensitisation 
(see Chapter 1), and this has been studied in many different neuronal systems, including 
rat striatal synaptosomes (Grady et al., 1994; Rowell and Hillebrand, 1994) and in living 
animals using in vivo microdialysis (Balfour and Benwell, 1994). Desensitisation is not 
permanent, as when nicotine is subsequently removed the receptors are able to recover 
the majority of their function (Grady et al., 1994; Marks et al., 1994). However, it is known 
that prolonged nicotine treatment can result in a more extensive decrease in nAChR 
function which cannot be explained by desensitisation alone (Aoshima, 1984; Lukas, 
1991; Galzi and Changeux, 1995; Rowell and Duggan, 1998). Entitled ‘inactivation’, this 
has been demonstrated in vitro using [3H]DA release from striatal terminals (Rowell and 
Duggan, 1998). Interestingly, low nanomolar concentrations of nicotine only caused 
desensitisation whilst high nanomolar and low micromolar concentrations produced both 
desensitisation and inactivation. The authors hypothesised that concentrations achieved 
by cigarette smoking could cause some degree of inactivation of neuronal nAChR. It 
would, therefore, seem plausible that there may be a mixed population of active, 
desensitised and inactive nAChR that are in a constant state of flux depending on the 
levels of nicotine present in the bloodstream of the smoker.
5.2.4 Neurotransmitter release and chronic nicotine
Nicotine, through a primary action at the nAChR, can modulate the release of a variety 
of neurotransmitters (Chapter 1). It is now clear that chronic nicotine intake evokes 
changes in several of these systems, with the following section focusing on the release of 
the 3 main monoamines, 5-HT, noradrenaline and DA.
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5.2.4.1 5-HT
Stimulation of nAChR can elicit 5-HT release in vitro (Reuben and Clarke, 2000) but 
compared to other neurotransmitters, 5-HT has received less attention regarding its role in 
nicotine addiction. Various studies have shown that biosynthesis and levels of this 
neurotransmitter are selectively decreased in the hippocampus of rats chronically treated 
with nicotine (Benwell and Balfour, 1979; Benwell and Balfour, 1982) and that an acute 
dose of nicotine after chronic pre-treatment also results in a decrease in the overflow of 5- 
HT from this region (Balfour and Ridley, 2000). These observations may be relevant to the 
tobacco smoking habit, as concentrations of 5-HT and its major metabolite 5- 
hydroxyindoleacetic acid were also selectively decreased in the hippocampus of post-
i
mortem tissue from human smokers (Benwell et al., 1990). The serotonergic neurones 
that project to the hippocampus have been implicated in the anxioaenic responses to 
withdrawal (e.g. of benzodiazapenes; Andrews et al., 1997) and it is suppression of 5-HT 
release from these neurones that may explain the anxiolytic responses induced by 
nicotine that contribute to the rewarding effects sought by smokers (reviewed by File et 
al., 2000). Recently, a402* nAChR may be implicated in these responses, as infusion of 
DHpE into the dorsal raphe nucleus of rats, antagonised the anxiolytic effects of nicotine 
as measured by the social interaction test (Cheeta et al., 2001). Moreover, these 
serotonergic neurones may also be involved in the development of the symptoms of 
depression experienced by some smokers during the withdrawal process (Balfour and 
Ridley, 2000). With some relevance to this chapter, [3H]5-HT release has also been 
examined in vitro from striatal slices of nicotine treated rats (Yu and Wecker, 1994). In this 
case, there was an increase in [3H]5-HT release in response to stimulation by nicotine.
5.2.4.2 Noradrenaline
Another neurotransmitter that is released in response to nicotine is noradrenaline (NA).
In vitro, Yu and Wecker (1994) found no difference in nicotine-evoked striatal [3H]NA 
release in rats chronically treated with nicotine by injection compared with saline treated 
controls. In contrast, nicotine-stimulated catecholamine release from nicotine treated 
bovine adrenal chromaffin cells was reduced compared to controls (Bullock et al., 1994).
In vivo studies of the effects of chronic nicotine treatment on the turnover of NA have been 
equally conflicting and sporadic (reviewed in Balfour, 1990). One study has reported that 
continuous infusion of nicotine via osmotic minipumps decreased concentrations of NA in 
the frontal cortex (Kirch et al., 1987) whilst another reported daily injections of nicotine
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enhanced NA turnover in the hippocampus (Mitchell et al., 1989). In addition, a recent 
report has decribed the measurement of NA release in the hypothalamic paraventricular 
nucleus (PVE) in rats chronically self-administering nicotine (Fu et al., 2001). During 
acquisition and early maintenance of self-administration, NA levels were greatly 
increased, although during later maintenance levels these declined but were still above 
those of controls. In addition, as the day progressed, the number of occurrences of 
nicotine self-administration also declined, consistent with the progression of nAChR 
desensitisation. Fu et al. (2001) also showed that the initial self-administration event of the 
day produced the highest increases in NA levels. This parallels some aspects of human 
smoking, including the observation that the first cigarette of the day induces greater 
responses in humans than those smoked afterwards (Parrot, 1994). These results 
suggest that NA responses in the PVE region may reflect those that occur during human 
cigarette smoking.
5.2.4.3 Dopamine
In contrast to the other neurotransmitters described in this section, there has been 
extensive study of the release of dopamine (DA) in rodents after both acute and chronic 
administration of nicotine. In particular, release of DA in vivo from mesolimbic 
dopaminergic neurones has been examined. The rationale behind this partly originates 
from the results of experiments by Olds and Milner in the 1950s. By electrically stimulating 
areas of rats’ brains they revealed that discrete centres exist that support self-stimulation, 
consistent with a role in reward functions. The mesolimbic dopaminergic system has been 
subject to special scrutiny, as it was determined to be one of these ‘reward centres’ and 
was particularly sensitive to electrical stimulation. Specifically, DA transmission from the 
nucleus accumbens (NAcc) not only occurs in response to natural rewards, such as food, 
water and sex, but also to drugs of abuse such as cocaine, amphetamine and nicotine. 
Repeated exposure to the addictive drug leads to the development of complex 
behaviours, such as dependence, tolerance, sensitisation and craving. It is these 
phenomena that are believed to motivate drug seeking behaviour and lead to withdrawal 
syndromes.
The link to nicotine addiction was gained from rodent studies of self-administration. In 
these experiments, nicotine self-administration was abolished by the lesioning of 
mesolimbic dopaminergic pathways (Figure 5.1) and also by the application of D^  and D2 
DA receptor antagonists (Corrigall and Coen, 1991; Corrigall et al., 1992; reviewed by Di 
Chiara, 2000b). As nicotine directly evoked DA release from these so-called reward
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pathways, the conclusion was that they may have a central role in the development of 
addiction to tobacco in humans.
As stated above, a major component of the drug reward circuit is the NAcc. With regard 
to nicotine addiction, in vivo microdialysis has produced some contrasting results involving 
release of DA from the NAcc after chronic nicotine treatment. Some studies report that 
repeated exposure to nicotine induces sensitisation in the NAcc (Benwell and Balfour, 
1992) whereas others have seen no such sensitisation (Damsma et al., 1989; Nisell et a!.,
1996). These differences may be due to the length of nicotine pre-treatment, as Benwell 
and co-workers used 5 days whilst Damsa et al. and Nisell et al. used 12-15 days. Also, 
differential responses may be given by either the core or shell of the NAcc in response to 
nicotine. This was substantiated in a study by Cadoni and Di Chiara (2000) in which an 
acute dose of nicotine increased DA release in the shell but not the core. Conversely, 
repeated doses of nicotine followed by an acute dose increased DA release in the core 
but not the shell. These observations may implicate the shell in the initial recognition of 
novel stimuli and rewarding effects of nicotine, whilst the core is concerned with 
development of drug seeking behaviour and locomotor responses to the drug (Di Chiara, 
2000b). At this point it should be noted that the striatal dissection procedure followed in 
this thesis results in the inclusion of the NAcc in the slice preparation used in superfusion 
experiments.
Evidence also suggests that in vivo, DA release from the accumbens is not modulated 
by nAChR present in the terminal fields of these mesolimbic neurones, but rather 
somatodendritic nAChR located in the ventral tegmental area have been implicated. This 
interpretation arises from reports that local application of nAChR antagonists into the VTA 
reduced DA release in the NAcc in response to systemic nicotine, whereas infusion of the 
same antagonists directly into the NAcc did not affect DA release (Corrigall et al., 1994; 
Nisell et al., 1994). A neurochemical comparison of nicotine-evoked [3H]DA release from 
striatal synaptosomes and nigral dendrosomes suggests that the nAChR at these loci 
differ (Reuben et al., 2000). The mechanism by which somatodendritic nAChR actually 
increase DA release is not entirely understood. The principal mechanism may be related 
to the frequency of spike generation in dopaminergic neurones, with an increase in burst 
firing, a type of firing that is efficient in producing neurotransmitter release. Indeed, 
concentrations of nicotine, similar to those obtained from cigarettes, can induce increases 
in the firing rate of DA neurones in the VTA (Pidoplichko et al., 1997). There is less 
evidence concerning the in vivo responses of striatal DA neurones to chronic nicotine
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treatment. However, our laboratory has observed DA release in the striatum in response 
to a local application of nicotine via the microdialysis probe (Marshall et al., 1997). 
Additionally, constant infusion of nicotine (4 mg/kg/day) resulted in an increased response 
to the locally applied nicotine.
The behavioural sensitisation that accompanies repeated administration of the 
psychomotor stimulants cocaine and amphetamine is attributed to a potentiation of 
transmission at excitatory amino acid synapses onto DA neurones in the VTA (Clark and 
Overton, 1998). A comparison may be drawn between this and results shown in Chapter 
4, as nAChR can influence the activity of DA neurones indirectly through presynaptic 
modulation of glutamate release by an a l  nAChR. This has been demonstrated in vivo in 
the VTA (Schilstrom et al., 1998a,b), as local infusion of MLA or NMDA receptor 
antagonists reduced DA release in the NAcc. One concern regarding these experiments is 
that the local concentration of MLA in vivo can only be estimated, and so the involvement 
of the a7 nAChR is not adequately proven (given the results for the potency of MLA at 
non-a7 nAChR in Chapter 3; Klink et al., 2001).
The association of a7 nAChR with glutamate terminals and their participation in LTP- 
like processes makes them an attractive substrate for mediating some of the responses 
important for nicotine reinforcement. Some reports are compatible with this view: the 
NMDA antagonist MK801 prevented the development of locomotor sensitisation and 
upregulation of [3H]cytisine binding sites (a4|32* nAChR) in response to daily nicotine 
injections (Shoaib et al., 1997). Recently, in vitro, Mansvelder and McGehee (2000) 
demonstrated that nicotine can initiate synaptic plasticity in the VTA. They applied a low 
concentration of nicotine to a midbrain slice and saw an enhanced release of glutamate 
onto postsynaptic dopaminergic neurones. Release of glutamate was due to action of 
nicotine at presynaptic a7 nAChR but, more importantly, the authors found that if 
glutamate transmission occurred at the same time as depolarisation of the postsynaptic 
DA neurone, then LTP was induced, with the DA neurones remaining excited after the 
direct nicotine stimulation had ceased due to desensitisation.
In contrast to the studies described above that implicate the a7 nAChR in the 
development of the addictive process, Grottick and co-workers (2000a,b) proposed that 
the a7 nAChR has a negligible role in nicotine-induced hyperlocomotion and reward, as 
the a7 agonists AR-R17779 and DMAC failed to stimulate locomotor activity in both 
nicotine-nontolerant and -sensitised rats. In contrast, nicotine and the a4p2 nAChR 
selective agonist SIB1765F increased activity in both experimental conditions. This view is
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supported by measurements in 02 null mutant mice which indicate that 02* nAChR are of 
paramount importance for nicotine self administration and striatal DA release (Picciotto et 
al., 1998).
In order to explore the contribution of a l  nAChR to DA release and nicotine 
dependence, results presented in this chapter describe the effects of chronic nicotine 
treatment in vivo on [3H]DA release from striatal slices in vitro (responses from which have 
been previously defined in naive animals, Chapter 4). Of particular interest is whether 
modification of the a7-mediated DA-glutamate interactions occurs in the striatum after 
chronic nicotine exposure.
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5.3 Results
The results in this chapter are concerned with [3H]DA release from striatal slices and 
can be divided into three sections; those after treatment with nicotine by injections, those 
after treatment with nicotine by osmotic minipumps, and some preliminary experiments 
examining withdrawal after nicotine treatment. Anatoxin-a (AnTx-a, 25 pM -  a maximally 
effective concentration) was used as the agonist in these experiments rather than 
nicotine, as it was the more well-characterised agonist in the slice at the time these 
experiments were initiated (Kaiser et al., 1998; Kaiser and Wonnacott, 2000; Wonnacott et 
al., 2000).
5.3.1 Effects of chronic nicotine treatment by injection
The initial experiments in this section relate to the behavioural and neurochemical 
effects of daily injections of nicotine (0.4 mg/kg), for 7 days. Rats were killed on the eighth 
day and striata dissected for use in superfusion experiments.
5.3.1.1 Behavioural effects
Some behavioural changes were noted in rats that received daily injections of nicotine 
(0.4 mg/kg/day) when compared to rats that received saline. These have been previously 
described (Clarke and Kumar, 1983), but briefly, in the present study during the first 3 
days of injections, approximately 20 s after the injection, rats became lethargic with 
concurrent increases in observed respiratory and heart rates. These effects initially lasted 
from between 10 to 20 min but became shorter as treatment progressed. From day 3 to 
the end of treatment (day 7), the injection of nicotine produced increases in locomotor 
activity, specifically cage crossing, tail movement, and rearing. Again this occurred 20- 
30 s after the injection of nicotine and lasted from between 5 to 15 min.
5.3.1.2 Neurochemical effects
Superfusion was performed on striatal slices from the rats the day after they received 
their final injection. Figure 5.2 shows the levels of [3H]DA release obtained from treated 
animals compared to the responses from saline treated controls. No significant changes in 
the levels of basal or AnTx-a-evoked [3H]DA release were observed between the control 
and treated animals. To determine if the proportion of glutamate-mediated DA release 
may be altered by this regime of chronic treatment, DNQX (100 pM) was applied. 
Compared to stimulation by 25 pM AnTx-a alone, the inhibition of AnTx-a-evoked [3H]DA
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release by 100 pM DNQX was significant in the control animals but not in the treated 
animals, with decreases of 29 ± 8.1 % (p<0.05, n=6) and 27.1 ± 10.0 %, respectively. The 
levels of inhibition were similar to those seen in naive rats (Chapter 4). However, between 
control and treated animals there were no significant differences in the levels of [3H]DA 
release evoked by 25 pM AnTx-a alone nor in the magnitude of inhibition caused by 
DNQX.
+ DNQX + DNQX
Control T reated
25 pM Anatoxin-a
Figure 5.2 Inhibition of AnTx-a-evoked pH]DA release from striatal slices by the 
AMPA/Kainate antagonist DNQX after chronic nicotine treatment. Striatal slices from rats 
chronically treated for 7 days by injection with PBS (Control) or (-)nicotine (0.4 mg/kg/day; 
Treated) were loaded with pHJDA and superfused as described in section 2.1. The 
AMPA/kainate iGluR antagonist DNQX (100 (JM) was added to the perfusing buffer 10 min prior 
to stimulation for 40 s with 25 juM AnTx-a. Results are expressed as a percentage of the 
response from the corresponding control animal to 25 juM AnTx-a alone, determined in parallel. 
Values are the mean ±S.E.M. from six independent experiments, each comprising tissue from 
one control and one treated rat. Each condition consisted of two or more replicate chambers. 
(* p<0.05 significantly different from control response, Student’s t-test).
After superfusion had been performed on the striata, radioligand binding studies were 
carried out using the remainder of the brain (minus striatum and cerebellum), as described 
in section 2.3, and employed a saturating concentration of 20 nM [3H]nicotine (Figure 5.3). 
The purpose of these assays was to determine whether or not chronic nicotine treatment 
via injections had produced any discernible changes in the numbers of high affinity
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nAChR. Previous studies (see section 5.2.1 of this chapter) have demonstrated that 
chronic nicotine treatment evokes increases the number of [3H]nicotine binding sites.
After the regime of one daily injection of nicotine (0.4 mg/kg) for 7 days, no significant 
changes were observed in the levels of specific [3H]nicotine binding (Figure 5.3), either 
between individual animals or in overall binding levels (controls: 157.2 ± 5.4 fmol/mg 
protein; treated: 162.0 ± 2.7 fmol/mg protein). It should be noted that binding levels were 
high in these experiments compared to other assays in this section and those in the 
literature. This was due to the use of a crude P1 preparation (i.e. tissue was homogenised 
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Figure 5.3 Comparison of levels of fH]nicotine binding to brain membranes from 
rats chronically treated with (-)nicotine or PBS by injection. Rats were chronically treated 
for 1 days by injection with PBS (Control) or (-)nicotine (0.4 mg/kg/day; Treated). Data are 
presented as overall (A) or individual (B) levels of specific fHJnicotine binding from pairs of 
animals treated in parallel and sacrificed on the same day. Levels of specific pHJnicotine 
binding are shown as fmol pHJnicotine bound per mg/protein as measured in whole brain 
membranes (minus cerebellum and striatum) prepared from rats that had received nicotine 
(coloured bars) or PBS (open bars). Values in (B) represent those of individual animals and are 
the mean ±  range of the specific binding from 2 assays, each consisting of triplicate samples. 
No significant differences were found (Student’s t-test).
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5.3.2 Effects of chronic nicotine treatment by osmotic minipumps
As chronic nicotine treatment of rats by daily injection failed to produce any significant 
neurochemical changes, it was decided to employ a different method of nicotine 
treatment. Delivery of nicotine via osmotic minipumps was chosen, as these have 
previously been exploited in our laboratory to provide a constant infusion of a relatively 
low concentration of nicotine (4 mg/kg/day) that mimics the steady-state plasma 
concentrations found in smokers (Sanderson et al., 1993). Therefore, in the following 
experiments in this section animals were chronically treated for 14 days with nicotine (4 
mg/kg/day). Animals were sacrificed at the end of day 14 with the minipumps still 
implanted, and striata dissected for use in superfusion experiments.
t
5.3.2.1 Behavioural effects
No significant changes in the behaviour of the rats were noted during the days 
following minipump implantation, apart from a slight depression of general activity on days 
1 and 2, which could be attributed to recovery from surgery.
5.3.2.2 Neurochemical effects
5.3.2.2.1 Contribution of iGluR to [3H]DA release after chronic nicotine treatment
Initial experiments examined AnTx-a responses and the effect of the general iGluR 
antagonist kynurenic acid on AnTx-a-evoked [3H]DA release. Figure 5.4 shows results 
obtained from control animals that received PBS for 14 days and treated animals that 
received nicotine (4 mg/kg/day) via osmotic minipumps:
In rats treated with nicotine, release of [3H]DA evoked by 25 pM AnTx-a alone was 
lower than the release measured from control tissue (30.1 ± 8.3 % decrease). Moreover, 
the significant inhibition (p<0.05, n=6) of AnTx-a-stimulated [3H]DA release by kynurenic 
acid (Kyn A; 500 pM) in tissue from control animals was absent in tissue from those 
animals that were chronically treated with nicotine. This lack of effect of kynurenic acid 
suggested that during chronic nicotine treatment alterations in the nicotinic modulation of 
glutamate release had occurred. This prompted subsequent experiments that were 
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Figure 5.4 The effect of kynurenic acid on AnTx-a-stimulated fhiJDA release from 
striatal slices after chronic nicotine treatment by infusion. Striatal slices from rats 
chronically treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 
mg/kg/day; Treated) were loaded with ?H]DA and superfused as described in section 2.1. The 
iGluR antagonist kynurenic acid (Kyn A, 500 pM), was added to the perfusing buffer 10 min 
prior to stimulation for 40 s with 25 pM AnTx-a. Results are expressed as a percentage of the 
corresponding control animal’s response to 25 pM AnTx-a alone, determined in parallel. Values 
are the mean ±  S.E.M. from six independent experiments, each comprising tissue from one 
control and one treated rat. Each condition consisted of two or more replicate chambers. (* 
p<0.05, significantly different from control response, one-way ANOVA and Tukey’s post-hoc 
test).
5.3.2.2.2 The effect of nAChR antagonists on fHJDA release after chronic nicotine 
treatment
In the next series of experiments, stimulation of slices from nicotine treated animals 
with 25 |iM AnTx-a alone again resulted in significantly lower levels of [3H]DA release than 
from control rats (Figure 5.5; A, p<0.01, n=3; B, p<0.05, n=3). A decrease in [3H]DA 
release of 40.0 ± 8.4 % and a smaller reduction of 20.8 ± 5.4 % were obtained (Figure 5.5 
A and B, respectively). In addition, the effects of two nAChR antagonists were compared 
in control and treated rats. The data presented in Figure 5.5 A demonstrates the effect of 
the a7 nAChR antagonist MLA (50 nM) and results reflect the profile obtained with the 
iGluR antagonist kynurenic acid (Figure 5.4). Specifically, significant inhibition (p<0.05, 
n=3) of AnTx-a-stimulated [3H]DA release by 50 nM MLA was observed in control animals
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but this decrease was not mirrored in rats that had received nicotine. In contrast, the non­
et? nAChR antagonist DH(3E, used at a modest concentration of 1 pM, significantly 
inhibited (p<0.01, n=3) [3H]DA release evoked by 25 pM AnTx-a in both control and 
treated animals (Figure 5.5 B). Reductions of 48.2 ± 3.5 % and 33.6 ± 5.4 % were seen in 
control and nicotine treated animals compared to respective AnTx-a control responses.
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Figure 5.5 The effects of nAChR antagonists on AnTx-a-stimulated fHJDA release 
from striatal slices after chronic nicotine treatment by infusion. Striatal slices from rats 
chronically treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 
mg/kg/day; Treated) were loaded with fHJDA and superfused as described in section 2.1. The 
nAChR antagonists (A) MLA (50 nM) or (B) DHpE (1 pM), were added to the perfusing buffer 10 
min prior to stimulation for 40 s with 25 pM AnTx-a. Results are expressed as a percentage of 
the corresponding control animal’s response to 25 pM AnTx-a alone, determined in parallel. 
Values are the mean ±  S.E.M. from three independent experiments, each comprising tissue 
from one control and one treated rat. Each condition consisted of two or more replicate 
chambers. (** p<0.01, * p<0.05, significantly different from control response, one-way ANOVA 
and Tukey’s post-hoc test, tp<0.05, significantly different from response obtained with AnTx-a 
alone in the treated animal, one-way ANOVA and Tukey’s post-hoc test.)
5.3.2.2.3 Contribution of non-NMDA iGluR to [3H]DA release after chronic nicotine 
treatment
The results in Figure 5.5 provided more evidence that chronic nicotine treatment was 
possibly causing alterations in either modulation of glutamate release by the a7 nAChR 
subtype and/or sensitivity of glutamate receptors on the DA terminals themselves. Either
164
___________________________________________________________________________________ Chapter 5 |
of these could explain the observed reduction of [3H]DA release. To investigate these 
observations further, a series of assays was performed to investigate the activity of the 
iGluR present in the slice, specifically the AMPA subtype (see Chapter 4 for the effect of 
this agonist in naive animals). Figure 5.6 presents data from experiments performed using 
the agonist AMPA, the prototypic agonist at the eponymous subtype of iGluR.
140 -
+ AMPA + AMPA
Control Treated
25 pM Anatoxin-a
Figure 5.6 The effects of the iGluR agonist, AMPA, on AnTx-a-stimulated fhiJDA 
release from striatal slices after chronic nicotine treatment by infusion. Striatal slices from 
rats chronically treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 
mg/kg/day; Treated) were loaded with pHJDA and superfused as described in section 2.1. 
Stimulation was for 40 s with 25 pM AnTx-a alone or in combination with 1 mM AMPA. Results 
are expressed as a percentage of the corresponding control animal’s response to 25 pM AnTx-a 
alone, determined in parallel. Values are the mean ±  S.E.M. from three independent 
experiments, each comprising tissue from one control and one treated rat. Each condition 
consisted of two or more replicate chambers. (* p<0.05, significantly different from control 
response, one-way ANOVA and Tukey’s post-hoc test, t t  p<0.01, significantly different from 
indicated control, one-way ANOVA and Tukey’s post-hoc test).
In slices from nicotine treated animals, release of [3H]DA by 25 pM AnTx-a alone was 
significantly lower, by 43.7 ± 6.4 % (p<0.05, n=3) compared to PBS treated controls. 
Additionally, in the treated animals, 1 mM AMPA caused a significant increase in [3H]DA 
release of 54.7 ± 13.7 % (p<0.01, n=3) when co-applied with AnTx-a. Interestingly, this 
increased [3H]DA to the level of the response of the control animals to 25 pM AnTx-a
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alone. In the control animals 25 jiM AnTx-a plus 1 mM AMPA provoked a non-significant 
increase in [3H]DA of 26.6 ± 6.4 %, similar to the increase seen in naive animals (section 
4.7.5 of Chapter 4) where AMPA and nicotine were co-applied (36.6 ± 5.6 %).
To balance the experiments in Figure 5.6, the AMPA/kainate selective antagonist 
DNQX (100 pM) was used. In accordance with previous experiments, the results in Figure 
5.7 show a decrease of 29.3 ± 8.4 % between the levels of [3H]DA release from control 
and treated animals stimulated by 25 jxM AnTx-a alone. In the control animal, DNQX (100 
|iM) caused a decrease of 34.0 ± 7.1 % in AnTx-a-evoked [3H]DA release, complementing 
results from naive animals (see section 4.7.3 of Chapter 4). However, in the rats that 
received nicotine, AnTx-a-evoked [3H]DA release in the presence of 100 jiM DNQX was 
higher by 36.9 ± 9.9 % than that evoked by agonist alone. This was initially seen in 3 pairs 
of animals (n=3) and so the experiments were repeated (n=6) to verify the results.
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Figure 5.7 The effects of the AMPA/kainate antagonist, DNQX, on AnTx-a-stimulated 
fHJDA release from striatal slices after chronic nicotine treatment by infusion. Striatal 
slices from rats chronically treated for 14 days via osmotic minipumps with PBS (Control) or 
(-)nicotine (4 mg/kg/day; Treated) were loaded with fHJDA and superfused as described in 
section 2.1. The AMPA/kainate selective antagonist DNQX (100 pM), was added to the 
perfusing buffer 10 min prior to stimulation for 40 s with 25 pM AnTx-a. Results are expressed 
as a percentage of the corresponding control animal’s response to 25 pM AnTx-a alone, 
determined in parallel. Values are the mean ±S.E.M. from six independent experiments, each 




The effect of DNQX in the treated rats was difficult to explain and thus more evidence 
was needed to clarify what exactly was occurring in the nicotine treated animals. 
Additional experiments were performed to examine the NMDA component of [3H]DA 
release from striatal slices using the same paradigm as in Chapter 4, section 4.7.8. The 
NMDA receptor co-agonist glycine (1 pM) was included in the buffer, in addition to 
strychnine (1 pM), to block inhibitory glycine receptors. A lower concentration of 10 pM 
nicotine was used that should mainly stimulate those nAChR present directly on DA 
terminals, without significant glutamate release. This can be seen in section 4.7.3 of the 
previous chapter, where the extent of inhibition by DNQX of [3H]DA release evoked by 10 
pM nicotine was greatly reduced compared to that obtained at a maximally effective 
concentration of 100 pM nicotine.
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Figure 5.8 The effects of NMDA on nicotine-stimulated fHJDA release from striatal 
slices after chronic nicotine treatment by infusion. Striatal slices from rats chronically 
treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 mg/kg/day; 
Treated) were loaded with fHJDA and superfused as described in section 2.1 with buffer 
containing 1 pM glycine and 1 pM strychnine throughout the experiment. Stimulation was for 40 
s with 10 pM nicotine or 10 pM nicotine in combination with 1 mM NMDA. Results are 
expressed as a percentage of the corresponding control animal’s response to 10 pM nicotine 
alone, determined in parallel. Values are the mean ±  S.E.M. from three independent 
experiments, each comprising tissue from one control and one treated rat. Each condition 
consisted of two or more replicate chambers.
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The data in Figure 5.8 show [3H]DA release evoked by 10 pM nicotine alone is similar 
in both control and treated animals, supporting the notion that the reduction in AnTx-a- 
evoked [3H]DA release in rats chronically exposed to nicotine is not due to desensitisation 
of presynaptic nAChR on DA terminals. Furthermore, in control animals, [3H]DA release 
evoked by co-application of 1 mM NMDA and 10 pM nicotine replicated the responses 
seen in naive animals (Chapter 4) as it was increased by 45.6 ± 20.6 % compared to 
[3H]DA release triggered by nicotine alone (Figure 5.8). However, in the rats that received 
nicotine, the enhancement of [3H]DA release by co-application of 10 pM nicotine and 1 
mM NMDA was absent.
5.3.3 Radioligand binding studies *
5.3.3.1 Radioligand binding in cortex and striatum
As with rats treated with nicotine injections, radioligand binding experiments were also 
performed using saturating concentration of [3H]nicotine (20 nM) and also [3H]MLA (20 
nM). Rats were treated for 14 days with PBS or nicotine (4 mg/kg/day) via osmotic 
minipumps. Animals were sacrificed at the end of day 14, with the minipumps still 
implanted, and the frontal cortex and striatum were dissected. Radioligand binding was 
then performed on these discrete areas.
Binding levels of [3H]nicotine and [3H]MLA in the frontal cortex and striatum (Figure 5.9) 
of control animals were consistent with those found in previous, comparable, studies 
(Sanderson et al., 1993; Davies et al., 1999). Overall, [3H]nicotine binding levels in control 
animals were similar between brain regions, whereas striatal [3H]MLA binding was roughly 
50 % lower than [3H]MLA binding in the frontal cortex. Treatment of rats with nicotine 
produced significant (p<0.01, n=1-2) overall increases in cortical binding of both 
radioligands, with increases in binding of 93 % and 78 % for [3H]nicotine and [3H]MLA, 
respectively (Figure 5.9 A). Significant increases were also noted between individual pairs 
of control and treated animals (Figure 5.9 B).
Striatal binding levels of [3H]nicotine were significantly increased (p<0.01, n=3) by 
19.8% but only a small, non-significant increase in binding was seen using [3H]MLA 
(Figure 5.9 C). Significant increases in striatal [3H]nicotine and [3H]MLA binding between 
individual pairs of control and treated animals were not as prevalent as seen with cortical 
binding. Indeed, there was no difference in [3H]nicotine binding in one pair of animals, and 
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HJNicotine [3H]MLA [3H]Nicotine [3H]MLA
Figure 5.9 [*HJNicotine and fHJMLA binding in frontal cortex and striatum. Rats were
chronically treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 
mg/kg/day; Treated). Data are presented as overall (A & C) or individual (B & D) levels of 
binding from pairs of animals treated in parallel and sacrificed on the same day. Levels of 
specific fHJnicotine or pHJMLA binding are shown as fmol fHJIigand bound per mg/protein as 
measured in cortical (A & B) or striatal (C & D) membranes prepared from rats that had received 
nicotine (coloured bars) or PBS (open bars). Overall binding levels are shown in A & C (n=3, ** 
p<0.01, * p<0.05, significantly different from controls, Student’s t-test). Values in B & D are the 
mean +S.E.M. of the specific binding from 1 or more experiments, each consisting of triplicate 
samples, (cortex, fHJnicotine, n-1; fHJMLA, n-2; striatum, fHJnicotine, n-2; fHJMLA, n=1).
169
___________________________________________________________________________________ Chapter 5 |
5.3.3.2 Radioligand binding in whole brain
In all superfusion experiments in this chapter only the striatum was required. As a 
result, the remainder of the brain was available for radioligand binding experiments. The 
cerebellum was also discarded as it only contains low levels of nAChR. Binding was 
performed using 20 nM concentrations of [3H]nicotine and [3H]MLA, as well as 10 nM 
[3H]AMPA to measure levels of AMPA receptors (Figure 5.10).
] Control i i Control I ~~i Control
T reated] Treated Treated
[3H]Nicotine [3H]MLA [3H]AMPA
(20 nM) (20 nM) (10 nM)
Figure 5.10 Radioligand binding in whole brain (-striatum & cerebellum). Rats were 
chronically treated for 14 days via osmotic minipumps with PBS (Control) or (-)nicotine (4 
mg/kg/day; Treated). Data are presented as overall levels of binding from pairs of animals 
treated in parallel and sacrificed on the same day. Levels of specific pHJnicotine, pHJMLA, 
pH]AM PA binding are shown as fmol pHJIigand bound per mg/protein as measured in whole 
brain membranes prepared from rats that had received nicotine (coloured bars) or PBS (open 
bars). Values represent the mean ±  S. EM. of the specific binding from either 3 (p H]nicotine and 
pH]MLA) or 2 (pH]AM PA) experiments, each consisting of triplicate samples (** p<0.01 
significantly different from control animals, n-16, Student’s t-test).
In whole brain, increases in [3H]nicotine and [3H]MLA binding were observed between 
control and treated animals. Overall, there was a 45.9 % increase in [3H]nicotine binding 
and a 26.9 % increase in [3H]MLA binding, both of which were significantly different from 
control binding levels (p<0.01, n=16). In addition to the two nAChR radioligands used so 
far, the iGluR ligand [3H]AMPA (10 nM) was used in binding experiments on the remainder 
of the brain from superfusion experiments. Binding results for [3H]AMPA are shown in
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Figure 5.10 and are, on average, about 6-7 times higher than binding of the nicotinic 
radioligands. No significant differences were observed in overall binding levels. 
Unfortunately, time constraints prohibited further analyses of individual brain regions with 
[3H]AMPA or other iGluR radioligands.
5.3.4 The effects of nicotine withdrawal
This final section outlines preliminary experiments that were performed to determine 
whether the changes in [3H]DA release observed in rats chronically treated with nicotine 
underwent any modification after osmotic minipumps were removed. Superfusion 
experiments were performed at 1 and 7 days after minipump removal to examine AnTx-a- 
evoked [3H]DA release in the absence and presence of MLA (50 nM). Radioligand binding 
using [3H]nicotine and [3H]MLA was also carried out using the remainder of the brain 
(minus striatum and cerebellum).
5.3.4.1 AnTx-a-evoked [3H]DA release
The data presented in Figure 5.11 show that 1 and 7 days after pump removal, in 
control animals, 50 nM MLA caused reductions in AnTx-a-evoked [3H]DA release of 32.2 ± 
5.9 % and 25.5 ± 6.9 % respectively, compared to agonist alone. Only the reduction in 
[3H]DA release at 1 day withdrawal was significant (Figure 5.11 A; p<0.01, n=3) and was 
similar to the responses of control animals in Figure 5.5 A.
The situation pertaining to the nicotine treated rats was much more complicated. 
Firstly, no significant reductions in AnTx-evoked [3H]DA release were seen from slices 
from treated rats, as had been observed in section 5.3.2. Moreover, MLA (50 nM) did not 
inhibit this response. The data from nicotine treated animals were much more variable, 
compared to values from control rats. This can be seen by the plotted symbols which 
represent the mean responses from individual animals (Figure 5.11). In some treated 
animals, MLA (50 nM) caused a reduction of AnTx-a-evoked [3H]DA release, in others an 
enhancement was seen. The possible causes of this variability are discussed in the final 
section of this chapter.
171
Chapter 5 |













© *  80 * *
E c  
E <
o a- Q in 
^  CM
_L_ («—to O
Control Treated Control Treated
I-------------1 I------------- 1
25 pM Anatoxin-a 25 nM Anatoxin-a
Figure 5.11 The effects of the nAChR antagonist MLA, on AnTx-a-stimulated fHJDA 
release from striatal slices 1 and 7 days after cessation of chronic nicotine treatment by 
infusion. Rats were chronically treated for 14 days via osmotic minipumps with PBS (Control) 
or (-)nicotine (4 mg/kg/day; Treated). Minipumps were removed at the end of day 14 and 
animals sacrificed 1 (A) or 7 (B) days afterwards. Striatal slices were loaded with ?H]DA and 
superfused as described in section 2.1. The nAChR antagonist MLA (50 nM), was added to the 
perfusing buffer 10 min prior to stimulation for 40 s with 25 pM AnTx-a. Results are expressed 
as a percentage of corresponding control animal’s response to 25 pM AnTx-a alone, determined 
in parallel. Values are the mean ±  S. E M. from three independent experiments, each comprising 
tissue from one control and one treated rat. Each condition consisted of two or more replicate 
chambers. Symbols (■, # , ▲) represent the mean responses from individual animals (** 
p<0.01, significantly different from control response, Student’s t-test).
5.3.4.2 Radioligand binding
Several studies have noted that after withdrawal of nicotine treatment, [3H]nicotine 
levels return to those of controls (Schwartz and Kellar, 1985; Collins et al., 1988, 1990). 
However, the duration, dose and mode of nicotine treatment in the present study differ to 
those used in previous studies. It was, therefore, prudent to perform radioligand binding 
experiments to determine whether levels of [3H]nicotine and [3H]MLA binding did indeed 
decrease during withdrawal from nicotine.
As described previously, superfusion experiments in this section only utilised the 
striatum. Therefore, the remainder of the brain was used for radioligand binding 
experiments as in section 5.3.3.2. (Figure 5.10). Binding was performed using saturating 
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Figure 5.12 f  HJNicotine and fHJMLA binding to whole brain membranes from rats
previously treated with nicotine. Rats were chronically treated for 14 days via osmotic 
minipumps with PBS (Control) or (-)nicotine (4 mg/kg/day; Treated). Minipumps were removed 
at the end of day 14. At 1 or 7 days after pump removal, animals were sacrificed and brains 
removed. Levels of specific fH]nicotine or fHJMLA binding are shown as fmol fHJIigand bound 
per mg/protein as measured in whole brain membranes (minus striatum & cerebellum) prepared 
from rats that had received nicotine (coloured bars) or PBS (open bars). Values are the mean ±  
S.E.M. of the specific binding from 3 animals, each performed in thplicate (** p<0.01 
significantly different from control animals, n=3, Student’s t-test).
In whole brain (minus striatum and cerebellum), significant increases in overall levels 
[3H]nicotine and [3H]MLA binding were observed (p<0.01, n=3). Percentage increases are 
shown in Table 12. The increases in [3H]nicotine and [3H]MLA binding after 1 and 7 days 
withdrawal were comparable to those observed immediately after chronic nicotine 
treatment (section 5.3.3.2; Table 12). Overall, enhancements to the increases in binding 
levels of both radioligands were observed as withdrawal progressed (Table 12).
Table 12 Summary of fH]nicotine and fHJMLA binding results from rats withdrawn from
chronic nicotine treatment
% Increase of ^HJNicotine % Increase of fH]MLA
Binding Above Controls Binding Above Controls
0 Days Withdrawal 45.9 % 26.9 %
1 Day Withdrawal 55.2 % 37.4 %
7 Days Withdrawal 72.1 % 52.0 %
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5.4 Discussion
This chapter presents data that suggest that in rats, after a prolonged infusion of 
nicotine, striatal DA release evoked by the nicotinic agonist anatoxin-a is altered. 
Specifically, results show a possible modification of the indirect enhancement of DA 
release by glutamate. [3H]DA release from striatal slices evoked by a maximally effective 
concentration of AnTx-a was significantly reduced in animals that had been chronically 
treated with an infusion of nicotine via osmotic minipumps. Inhibition of AnTx-a-evoked 
[3H]DA release by the iGluR antagonist kynurenic acid and the a7 nAChR antagonist, 
MLA, was also abolished in these animals. In addition, the non-a7 nAChR, DHpE inhibited 
evoked [3H]DA release from striatal slices of both control and nicotine treated animals.t
Application of AMPA or, unexpectedly, DNQX was able to reverse the deficit in [3H]DA 
release from chronically treated animals. Interestingly, co-application of NMDA with 
nicotine caused an enhancement of [3H]DA release in control animals but not in treated 
animals, suggesting that processes involving NMDA receptors may also be modified 
during the course of chronic nicotine treatment. Radioligand binding also highlighted 
regional and overall differences of nAChR and iGluR that may be relevant in nicotine 
addiction.
5.4.1 Chronic nicotine treatment decreases anatoxin-a-evoked 
dopamine release
A search of the literature reveals that few reports exist regarding the effect of chronic 
nicotine treatment on DA release in vitro, with examination of DA release in vivo regarded 
as a more suitable system for studies of this type (Di Chiara, 2000b). However, in vitro 
studies such as those presented here may prove invaluable in dissecting the subtypes of 
nAChR and intracellular responses involved in the possible long-term neuronal changes 
due to nicotine addiction.
With regard to the present results, treatment of rats by injections of nicotine (0.4 mg/kg) 
produced no significant changes in [3H]DA release between control and treated animals 
nor were any changes in the extent of inhibition by DNQX (Figure 5.2). In addition, there 
were no significant changes in the number of [3H]nicotine binding sites. This is in 
agreement with a previous study that examined the same dose of nicotine over a much 
longer period of administration (39 days; Benwell and Balfour, 1985). Indeed, a more 
recent study by Rowell and Li (1997) suggests that the number of injections a day may be 
important. In fact, the authors found that two injections of 0.6 mg/kg nicotine for 10 days
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only produced significant upregulation in the hippocampus but not in the cortex or 
striatum. This suggests that either the injection regime or the dose of nicotine given (0.4 
mg/kg) in the present study were not enough to produce changes in either [3H]DA release 
or numbers of [3H]nicotine binding sites. However, the fact that behavioural changes and 
tolerance were noted during the period of nicotine treatment suggests the development of 
some neurochemical alterations which were unable to be measured in the assays 
described here.
Subsequently, osmotic minipumps were utilized to provide a more constant level of 
nicotine in the bloodstream, as opposed to the injections of the alkaloid. Previously, an 
infusion of 4 mg/kg/day in rats has been shown to simulate the ‘troughs’ of nicotine in the 
blood of smokers (Sanderson et al., 1993). One of the principal findings in this* chapter is 
that in those animals that had received nicotine via osmotic minipumps, significant and 
non-signifcant decreases in [3H]DA release were consistently noted in response to AnTx-a 
alone. This is in partial agreement with Marks et al. (1993), who determined that [3H]DA 
release from mouse brain synaptosomes declined after chronic nicotine infusion, 
suggesting desensitisation/ inactivation of nAChR directly on the DA terminal, rather than 
the involvement of an a7 nAChR. Nevertheless, a modest increase in striatal [3H]nicotine 
binding was observed, similar to that seen in this study (Figure 5.9). Contrary to the 
present study, an analysis of [3H]DA release from rat striatal slices found an increase in 
[3H]DA release after treatment with nicotine by daily injections (Yu and Wecker, 1994). 
Related in vivo studies have also shown that daily injections of nicotine enhanced the 
accumbal response to a single challenge with nicotine, whereas pre-treatment by constant 
infusion of the agonist abolished the response (Benwell et al., 1994, 1995). One could 
conclude that in the studies above, chronic treatment by injections of nicotine upregulated 
nAChR but without extensive desensitisation resulting in an increased response 
(sensitisation) to a subsequent dose of nicotine.
In contrast, the nature of the reduction in [3H]DA release seen in this study could, 
primarily, be due to desensitisation of the subtypes of presynaptic nAChR characterised in 
Chapter 3, that are involved in DA release from nigrostriatal terminals (Grady et al., 1994; 
Rowell and Hillebrand, 1994). However, this is unlikely as DHpE retained the ability to 
inhibit [3H]DA release from both control and treated animals (Figure 5.5 B). If the nAChR 
were desensitised then no such inhibition should have occurred and more dramatic 
decreases in [3H]DA release would have been seen. Moreover, a lower concentration of 
nicotine (10 ^M) caused a similar increase in [3H]DA release from both control and treated
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animals (Figure 5.8). Another explanation for the reduction in [3H]DA release may be due 
to the attenuation of the glutamatergic enhancement of DA release described in Chapter 
4. Initial evidence for this can be seen in Figure 5.4 and Figure 5.5 A, as neither kynurenic 
acid nor MLA inhibited the release of [3H]DA from animals treated with nicotine but caused 
significant decreases in AnTx-a-stimulated [3H]DA release from control rats. From these 
results alone it is not possible to determine whether the reduction of [3H]DA release is due 
to desensitisation of the a7 nAChR or inactivation/downregulation of the iGluR present on 
the DA terminals themselves. However, the iGluR agonist, AMPA, enhanced [3H]DA 
release from slices from nicotine treated animals to a greater degree than from PBS 
treated controls (Figure 5.6). The increased level of stimulation evoked by AMPA in the 
treated animals hints that chronic nicotine treatment prevents AnTx-a from eliciting 
glutamate release and results in lower [3H]DA release. AMPA is able to replace the 
missing glutamate, thus restoring [3H]DA release to the level seen in the controls. 
Down regulation of AMPA receptors is also unlikely as binding levels of [3H]AMPA were 
unchanged between control and treated animals, although this was measured in whole 
brain and not striatum alone (Figure 5.10). However, the AMPA/kainate antagonist DNQX 
produced an increase in [3H]DA release from the treated rats (Figure 5.7). This was quite 
unexpected and difficult to explain, although, as DNQX inhibits both AMPA and kainate 
receptors, its effect on [3H]DA release in Figure 5.7 may involve the latter subtype of 
iGluR. In summary, these results suggest that the a7 nAChR may be inactivated by 
chronic exposure to nicotine.
A recent study by Girod and Role (2001) provides supporting evidence for this 
hypothesis as they found that exposure of MHN-IPN co-cultures to low concentrations (0.5 
-  1 pM) of nicotine inhibited the responses of glutamatergic synapses to a subsequent 
stimulation by nicotine, even after 3 h in nicotine-free media. Moreover, the responses of 
the synapses only reverted to control levels after 24 h in nicotine-free media, thus 
supporting the hypothesis that similar, long-term inactivation, may also occur at 
glutamatergic synapses in the striatum. But how might this inactivation occur? From 
previous reports, one would expect the nAChR present on the DA terminal would become 
inactive, as they are more sensitive to nicotine than the a7 nAChR (Marks et al., 1993; 
Alkondon and Albuquerque, 1995; Rowell and Duggan, 1998). However, the 
submicromolar concentrations of nicotine in the brains of rats may only desensitise these 
receptors, allowing them to recover to an active state during the superfusion procedure 
(Sanderson et al., 1993; Rowell and Li, 1997; Rowell and Duggan, 1998). The allosteric
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transition model of the nAChR allows the receptor to proceed from the closed state to the 
high affinity long-term inactive state without entering into the active and desensitised 
states (see model in Chapter 1; Galzi and Changeux, 1995). If the putative presynaptic a7 
nAChR in this study entered this state it would no longer respond to elicit glutamate 
release. In addition, if such a transition occurred then it may explain why there was no 
significant upregulation of [3H]MLA binding in the striatum (Figure 5.9), as evidence 
suggests upregulation occurs after activation and desensitisation of the nAChR, at least 
for the a4p2* subtype (Fenster et al., 1999). Upregulation of the a7 nAChR after chronic 
nicotine treatment has been observed in vitro, but using higher concentrations of nicotine. 
For instance, in HEK cells transfected with a7 nAChR, significant upregulation was only 
seen when cells were treated with nicotine concentrations above 10 pM (Peng et al. 1997; 
Molinari et al., 1998). In SH-SY5Y cells, after chronic treatment with the same 
concentration of nicotine, upregulation of [125l]a-Bgt binding sites was also seen (Ridley et 
al., 2001). Interestingly, a recent report has shown that a7 nAChR on rat cortical neurones 
were upregulated but not inactivated after chronic treatment with 10 pM nicotine (Kawai 
and Berg, 2001). However, the authors did not examine functional responses in these 
neurones after treatment with lower concentrations of nicotine that did not cause 
upregulation.
This chapter has also presented data demonstrating the first use of [3H]MLA to monitor 
changes in nAChR after chronic nicotine exposure. The reason why [3H]MLA binding is 
unchanged in the striatum but is upregulated in the cortex is unknown, although this 
observation does concur with results of two previous studies, which found [125l]a-Bgt 
binding was upregulated in the cortex, but not in the striatum, of mice chronically exposed 
to nicotine by infusion (Marks et al., 1985; Pauly et al. 1991).
5.4.2 Involvement of NMDA receptors
The data presented in Figure 5.8 show a set of preliminary experiments that appear to 
suggest that chronic nicotine treatment can inactivate the enhancement of nicotine- 
evoked striatal [3H]DA release by NMDA (studied in naive animals in section 4.7.8 of 
Chapter 4). A similar phenomenon has recently been seen in hippocampal cultures 
(Fisher and Dani, 2000) where activation of nAChR increased glutamate release but 
decreased the NMDA R mediated component. The decrease was also insensitive to the 
calmodulin antagonist fluphenazine. Consequently the authors suggested that activation 
of postsynaptic receptors can initiate a Ca2+ signal that causes inhibition of the NMDA R.
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A similar phenomenon may occur at dopaminergic terminals in the striatum after chronic 
exposure to nicotine, and may representative of cellular processes resulting in a form of 
LTD.
5.4.3 Dopamine release and withdrawal from nicotine
The final section of results in this chapter detailed experiments that examined the effect 
of withdrawal on the chronic nicotine-induced changes in [3H]DA release from the 
striatum. The significant reductions in [3H]DA release seen in the previous results section 
were not observed at either 1 or 7 days after minipump removal. In addition, responses 
from the treated animals were extremely variable. Although these could be attributed to 
stress responses when the osmotic minipumps were removed, this is unlikely as 
responses from the tissue of control rats were much less erratic. Genetic differences in 
the response to withdrawal from nicotine could be a more feasible explanation, although 
there is little evidence to support this.
Levels of [3H]nicotine and [3H]MLA binding remained significantly elevated in nicotine 
treated animals at both time points studied. Previously, in mice, levels of [3H]nicotine 
binding return to those of controls after only 8 days, contrary to the results here, but this 
may reflect the higher metabolism of the mouse (Marks et al., 1985). Radioligand binding 
after cessation of chronic nicotine treatment was also examined in rats by Ksir et al. 
(1985), who only saw a reduction in [3H]ACh levels after 21 days of recovery from nicotine 
treatment. It would appear, therefore, that a longer time course of withdrawal from nicotine 
is needed to observe possible changes in [3H]DA release and/or radioligand binding. 
Unfortunately time constraints precluded initiation of these experiments.
5.5 Conclusions
In this chapter chronic nicotine treatment of rats produced consistent and significant 
reductions in AnTx-a-evoked [3H]DA release from striatal slices. A possible mechanism for 
this phenomenon may occur via inactivation of the presynaptic a7 nAChR on glutamate 
terminals, resulting in removal of the indirect enhancement of [3H]DA release by 
glutamate. However, further experiments using microdialysis would help address the 
question as to whether this situation occurs in vivo, including the effect of AMPA/kainate 
iGluR agonists and antagonists on DA release from dopaminergic neurones in striatum 
and accumbens.
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An analysis of nAChR involvement in the release of other neurotransmitters (e.g. 5-HT) 
in the striatum after chronic nicotine treatment would also be of use in unravelling the 
overall state of circuitry in this brain region. In addition, there are cholinergic neurones that 
project from the peduncular pontine nucleus to the VTA and are thought to be involved in 
the rewarding effects of natural stimuli. A role for these neurones in the rewarding effects 
and neuroadaptations to nicotine cannot be ruled out (Dani and de Biasi, 2001).
5.5.1 Validity of animal models of nicotine addiction
The neurochemical and behavioural changes that accompany chronic nicotine 
treatment appear to vary between studies and seem to depend on experimental variables, 
such as mode (injection or minipump), dose, time course of nicotine administration, and 
also the time point when measurements are made (see Di Chiara, 2000b, for 
comprehensive review). Therefore, are animal models of nicotine addiction relevant to 
human tobacco use? They have certainly supported the realisation of the central 
importance of nicotine in maintaining the tobacco habit -  the drug is self-administered by 
both rodents and humans (Di Chiara, 2000b). In behavioural tests some of the effects of 
nicotine parallel those seen in humans, as it appears to alleviate stress and reduce the 
consumption of sweet, high-calorie foods in both species (Clarke, 1987). However, is the 
administration of chronic nicotine treatment to animals by methods used in this chapter 
relevant to smoking? Chronic infusions of nicotine in rodents replicate steady-state 
plasma concentrations in the blood of smokers, though peaks in plasma nicotine 
concentrations seen after an individual smokes a cigarette are absent, as are overnight 
decreases due to abstinence (Russell, 1990; Sanderson et al., 1993). Conversely, and 
depending on the dose, injections of nicotine produce rapid increases in plasma 
concentrations that increase to levels that may never be achieved by even the most 
enthusiastic smoker. In addition, the high metabolic rates of rodents ensure that the half- 
life of nicotine elimination is much faster than in humans, resulting in periods of very low 
nicotine levels between injections (Sastry et al., 1995). Despite these drawbacks, the 
relatively simple methods of nicotine treatment described so far remain essential in 
helping to uncover some of the long-term changes that occur in nAChR-mediated 
pathways in the brain, some of which may be relevant to nicotine addiction in humans. 





6 Examination of Intracellular Ca2+ Stores After 
nAChR Activation
6.1 Calcium
The vast majority of cellular and physiological processes involve changes in the 
concentrations of a variety of ions. Calcium ions (Ca2+) are now recognised as one of the 
most important of these, indeed, 100 years ago Ringer and colleagues demonstrated that 
Ca2+ were required for the normal contraction of the frog heart. Since then, Ca2+ has been 
shown to be responsible for the control of such diverse processes as transmitter release, 
muscle contraction, cell proliferation, synaptic plasticity and gene expression (for reviews 
see Ghosh and Greenberg 1995; Berridge, 1998). The incredible versatility and signal 
specificity of this ubiquitous ion arises from the independent regulation of distinct 
signalling pathways linked to specific routes of Ca2+ influx (Ghosh and Greenberg, 1995). 
The spatial and temporal characteristics of a particular Ca2+ signal are determined by the 
combination of extracellular and/or intracellular Ca2+ sources, which can be triggered by 
an array of specific stimuli.
Many Ca2+ dependent signal pathways are initiated when intracellular calcium ion 
concentrations ([Ca2+]j) are raised from their resting levels of 10-100 nM, to levels of 
100 pM or more (Verkhratsky and Shmigol, 1996). Moreover, it has been shown that 
[Ca2+]i required to produce half-maximal rate of exocytosis range from 30 |aM in 
melanotrophs (Thomas et al., 1993) to 200 nM in synaptic terminals of retina bipolar cells 
(Heidelberger et al. 1994). With such increases in [Ca2+]j, the control of Ca2+ levels is 
tightly regulated by a number of membrane channels and proteins, each serving to either 
raise or lower [Ca2+]j (Figure 6.1).
Those that are able to increase Ca2+ concentrations in cells are:
• Channels located on the plasma membrane
• Channels located on the endoplasmic reticulum
And those that may act to decrease Ca2+ concentrations are:
• Ca2+ ATPases on the plasma membrane and endoplasmic reticulum
• Intracellular buffering components e.g. mitochondria
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Through the action of these last two components the diffusion of Ca2+ into the cell is 
impeded to a distance of roughly 0.5 -  1 pm before it is bound. Its action is, therefore, 




Figure 6.1 Cellular processes that modulate cytoplasmic Ca2* levels. The mechanisms 
that are responsible for raising [Ca2*]j concentrations are marked with orange arrows. Those 
which lower [Ca2*] are marked in blue. PMC A - plasma membrane Ca2*/ATPase; SERCA - 
sarcoplasmic/  endoplasmic reticulum Ca2*/ATPase; SOCC, ROCC, & VOCC, refer to 
store/receptorA/oltage operated Ca2* channels, respectively. Mitochondria and various other 






The first Ca2+ channels were discovered in crustacean muscle by Fatt and Katz in 
1953, who were examining the electrical properties of the muscle fibres. They established 
that in the absence of Na+ there was still evidence of action potentials, and that these 
were dependent on Ca2+.
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6.2.1 Voltage-operated Ca2* channels
To date, a wide variety of these influx channels have been described in vertebrate 
neuronal systems (Figure 6.2). These, so-called, voltage-operated Ca2+ channels (VOCC) 
are normally closed at resting membrane potentials but are activated upon depolarisation.
Figure 6.2 Structure of VOCCs. (A) Model of the subunits that form the VOCC. The a1 
subunit forms the pore whilst the other subunits (a2, 8, p, j j  control gating and modulation by 
secondary messengers. This subunit arrangement is known to occur in all high-voltage gated 
Ca2+ channels discovered so far. (B) Transmembrane topology of the a1 subunit that forms the 
pore. The folding of the a1 subunit is similar to the a subunits of Na+ and kC channels, with four 
internal repetitions, each containing six membrane spanning regions (S1-S6). Motifs that line 
the pore are shown in green and are located on domains S5 and S6. Glutamate residues are 
thought to form a Ca2+ binding site and are highlighted in red. (C) The spatial arrangement of 
transmembrane domains in the folded structure around the central pore, viewed from above 
(modified from Striessnig and Glossmann, 2001).
In many tissues two different types of Ca2+ current can be detected by 
electrophysiological methods. The first is activated by small depolarisations but then is 
rapidly inactivated, whilst the second is activated by large depolarisations. These have 
been termed low voltage activated (LVA; or T for transient), and high voltage activated 
(HVA), respectively (Table 13). HVA currents may be divided into further subtypes, 
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VOCCs represent only one of mechanisms by which neurones control [Ca2+]j as we 
shall see in the following sections.
6.2.2 Receptor operated Ca2* channels
In addition to voltage operated Ca2+ channels, another structurally and functionally 
diverse group of channels are present in the plasma membrane of nerve terminals and 
are known as receptor operated Ca2+ channels (ROCC). Both nAChR and NMDA R are 
well-defined examples of ROCCs, which share the similar characteristic that upon binding 
of an agonist to the extracellular domain of the receptor, allow the flow of sodium and, 
more relevant to this chapter, Ca2+ into the cell.
6.2.2.1 The neuronal nAChR -  an example of a ROCC
Due to the high relative permeability to Ca2+, the opening of the nAChR channel can 
directly increase cytoplasmic Ca2+ concentrations, as seen in the results presented in 
section 6.5 of this chapter. The overall Na+ influx can also cause neuronal depolarisation, 
activation of VOCCs and subsequent amplification of Ca2+ transients (Vijayaraghavan et 
al., 1992; Rathouz and Berg, 1994). Ca2+ entry after activation of nAChR has been 
reported to regulate a diverse array of cellular processes, such as neurotransmitter
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release (Soliakov and Wonnacott, 1996; Gray et al., 1996; Kulak et al., 2001), 
neuroprotection (Donnelly-Roberts et al., 1996; Dajas-Bailador et al., 2000), synaptic 
plasticity (Matsuyama et al., 2000; Mansvelder and McGehee, 2000) and the activation of 
key signalling molecules, with protein kinase C, Ca2+ calmodulin dependent kinase II, 
extracellular-signal regulated kinase 1/2 (ERK1/2) and cAMP response element binding 
protein (CREB; Messing et al., 1989; Tsutsui et al., 1994; Dineley et al., 2001) being the 
most well-defined examples. The evident versatility of nAChR-mediated cellular functions 
suggests that elaborate Ca2+ signalling systems, capable of integrating different sources 
of intracellular and/or extracellular Ca2+ signals may be involved. Indeed, the contribution 
of internal Ca2+ stores to the sustained Ca2+ signals activated by nAChR stimulation has 
been reported in chick cilliary ganglion cells and substantia nigra brain slices (Tsuneki et 
al., 2000; Shoop et al. 2001), whilst nicotinic activation of store-operated Ca2+-induced 
Ca2+ release has recently been reported in hippocampal astrocytes (Sharma and 
Vijayaraghavan, 2001). However, the precise relative contributions of different Ca2+ 
sources to the nicotine-evoked Ca2+ signals has not been fully explored.
Neurones also possess an elaborate membrane system, known as the endoplasmic 
reticulum (ER), that extends throughout the cell, and has been termed a neurone-within-a- 
neurone, as it plays an important role in intracellular signalling (Berridge, 1998). The 
network of the ER contains several types of intracellular Ca2+ channels, that differ from 
VOCCs and enable the ER to play an active role in neuronal Ca2+ signalling.
6.2.3 Intracellular Ca2* channels
There are two main families of receptors that have been given the designation of 
intracellular Ca2+ channels -  namely inositol triphosphate receptors (IP3R) and ryanodine 
receptors (RyR). Located on the membranes of the ER and sarcoplasmic reticulum they 
mediate the release of Ca2+ from intracellular stores (for reviews see Simpson et al., 1995; 
Berridge, 1998). When depleted of their Ca2+ both RyR and IP3R mediated stores are then 
rapidly refilled via the Ca2+/ATPase pumps present on the ER (Figure 6.1). A third Ca2+ 
release channel exists, known as SCaMPER (sphingolipid Ca2+-release mediating protein 
of the ER), about which little is known (Mao et al., 1996). Activated by 
sphingosylphosphocholine, it seems to be expressed in several tissue types, including the 
pancreas (Yule et al., 1993) but as yet there is no evidence for expression in the CNS. 
Little is known about the structure or function of this recently discovered channel and as 
such it is not described at length here.
185
Chapter 6 |
6.2.3.1 The inositol triphosphate receptor
These receptors respond to the ligand inositol-1,4,5- 
triphosphate (IP3; Figure 6.3), produced by the enzyme 
phospholipase C (PLC). IP3Rs are thought to function as 
homotetramers, comprised of 305-315 kDa monomers that 
are arranged to produce a central Ca2+-permeant channel in 
the membrane of the ER (Berridge, 1993; Simpson et a!.,
1995). At least 3 different isoforms are known at present 
(Furuchi and Mikoshiba, 1995). The IP3 binding site itself is 
thought to reside at the end of the large N-terminal domain, 
which projects into the cytoplasm, and is spatially far away 
from the channel forming C-terminal domain (Mignery and Sudhof, 1990). Unlike Ca2+,
which upon entering the cell are rapidly sequestered, IP3 is able to diffuse over a
considerable range (~ 24 urn compared to -  0.1 - 5 pm for Ca2+), and therefore has been 
suggested to be a global messenger within the cell (Verkhratsky and Shmigol, 1996).
Generation of IP3 can be accomplished by either one of two enzyme cascades 
involving different forms of the enzyme PLC (Figure 6.4). Activation of these pathways 
may be initiated by:
1. The activation of G protein-coupled receptors present in the plasma membrane by a 
number of neurotransmitters (acetylcholine, dopamine, glutamate, serotonin, ATP, 
adenosine), neuropeptides (neuropeptide Y, substance P), and oderants.
2. The activation of tyrosine-kinase linked receptors for growth factors (plasma derived 
growth factor, epidermal growth factor) and neurotrophins (NGF, BDNF, and 
neurotrophins 3, 4 and 5).
These pathways are summarised in the following figure (Figure 6.4):
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Figure 6.3 The 
chemical structure of 
inositol triphosphate (IP3)
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Activation of PLC-pi and 
protein tyrosine kinase
L . Breakdown of phosphatidylinositol- 4,5-bisphosphate (PIP2)
4
Production of IP3 and diacylglycerol
4
Induction of Ca2+ release from 
intracellular stores
After activation of the IP3R, IP3 itself is rapidly (within -  1 s) inactivated by the enzyme 
IP3-5-phosphatase or through a different pathway where IP3 is sequentially 
phosphorylated and dephosphorylated.
6.2.3.2 The ryanodine receptor
These types of receptors are so-called as they display a high affinity for ryanodine, a 
plant derived alkaloid. The RyR itself is structurally and functionally analogous to the IP3R, 
although it has twice the conductance and mass of the IP3R, consisting of 550-565 kDa 
monomers that aggregate into functional tetrameric complexes (see Berridge, 1993, 
1998). At present, three subtypes of RyR are known to 
exist, encoded by three genes which appear to be 
differentially expressed in a variety of tissues and cells.
Skeletal muscle cells express type 1 RyR whilst types 2 
and 3 are present in cardiac, brain and other tissues.
Another interesting difference between the subtypes is the 
manner in which they release Ca2+. Type 2 RyR are 
sensitive to changes in cytosolic levels of Ca2+ and, during 
a process known as Ca2+ induced Ca2+ release (CICR), are
Figure 6.5 The 




activated by Ca2+ entering through channels present in the plasma membrane, triggering 
release of Ca2+ from internal stores. However, Ca2+ release from stores in skeletal muscle 
is brought about by a direct coupling of the type 1 RyR to L-type Ca2+ channels present on 
the PM. This causes Ca2+ release from the SR without any initial Ca2+ entry through 
VOCCs. An endogenous activator of the RyR has also been identified, cyclic ADP ribose 
(cADPR; Galione et al., 1991; Patel et al., 2001).
Table 14 Modulators o f intracellular Ca2+ stores






















Both IP3Rs and RyRs have been localised in the rat brain by immunohistochemical 
methods (Sharp et al., 1993). Although labelling was observed in widespread and 
overlapping areas of the brain, distinct immunoreactivity was seen in a number of regions. 
The IP3R was in especially high concentrations in cerebellar Purkinje cells and 
hippocampal CA1 pyramidal cells, whereas the RyR was only at a low concentration in 
these areas. Conversely, high levels of the RyR were expressed in the dentate gyrus and 
CA3/4 regions of the hippocampus. Both receptors were found at moderate levels 
throughout the striatum.
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The Ca2+ release from the internal stores described above is often accompanied by 
influx of extracellular Ca2+, not through ROCCs or VOCCs, but through another class of 
Ca2+ channel - the store operated Ca2+ channel.
6.2.4 Store-operated Ca2+ channels
As stated above, activation of the RyR and/or IP3R triggers Ca2+ release from 
intracellular stores. Then, a poorly understood mechanism termed ‘capacitative Ca2+ entry’ 
(since it depends on depletion of the intracellular stores) is initiated. This permits Ca2+ 
entry through store-operated Ca2+ channels (SOCC; Petersen et al., 1995). These 
channels could possibly be some of the most ubiquitously expressed Ca2+ channels 
present on the plasma membrane, since many cell types have been found*to display 
elevated Ca2+ entry after store depletion. SOCCs display homology to a protein entitled 
"transient receptor potential", or TRP, that is involved in Drosophila photoreception. 
Mammalian homologues of this protein encode at least 20 different ion channel proteins, 
which are widely distributed in a variety of tissue types, but from a physiological 
perspective are poorly understood, as there does not appear to be a unifying focus to their 
function or mechanism of action (Clapham et al., 2001). They have tentatively been 
divided into three subfamilies based on sequence homology, named TRPC, TRPV and 
TRPM (Harteneck et al., 2000). The most well-defined channels are ones known to be 
involved in painful stimuli (TRPV subfamily). The channels themselves are composed of 
subunits with six membrane-spanning domains that probably form tetramers in which the 
pore is formed by the fifth and sixth transmembrane domains. In common with nAChR, 
most SOCCs will allow any cation, including Ca2+ to pass through the channel, although 
TRPV5 and TRPV6 are more selective for the Ca2+ ion than any of the other channels due 
to their ability to bind one Ca2+ per pore (as opposed to the two per pore of VOCCs). 
Knowledge of the exact function and regulation of the other channels is either poor or non­
existent and only the future will reveal the exact nature and purpose of this novel family of 
Ca2+ channels.
6.2.5 The role of intracellular Ca2+ stores
While there is a copious amount of literature describing the Ca2+ influx pathways 
present in the plasma membrane of the cell and their effect on intracellular signalling 
pathways, much less is known about the exact role of the Ca2+ that resides in the ER. 
However, there is increasing evidence that Ca2+ stores are involved in processes 
underlying synaptic plasticity. In the last couple of years, studies have demonstrated that,
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in certain regions of the brain, internal stores are involved in induction of LTP and/or LTD. 
As mentioned in the previous section, Ca2+ flux from these stores is controlled by RyRs, 
which respond to Ca2+ influx from outside the cell, or IP3Rs, which respond to IP3 
generated through the activation of metabotropic receptors.
One family of metabotropic receptors that has been implicated in this process is the 
metabotropic glutamate receptor family (mGluR). Compelling results from mGluRI null 
mutant mice show that the LTD normally present at cerebellar parallel-fibre-Purkinje cell 
synapses was absent in these mice, and responsible for a number of distinctive 
behavioural abnormalities associated with the cerebellum, such as ataxia and motor 
discoordination (Aiba et al., 1994; Conquet et al., 1994). An additional study, which 
involved the same type of null mutant mice, utilised an mGluRI transgene c<5upled to a 
Purkinje cell specific promotor to selectively rescue mGluRI expression in Purkinje cells 
(Ichise et al., 2000). Results showed that cerebellar LTD function and locomotor activity 
returned to normal. These results, coupled with the discovery that mice with a faulty IP3R 
type 1 gene in the same Purkinje cells also failed to display any signs of LTD (Inoue et al., 
1998), confirmed that both mGluRs and IP3Rs are vital for the induction of LTD in these 
cells.
Another example of the involvement of intracellular stores in synaptic plasticity occurs 
in the pyramidal neurones found in the CA1 region of the hippocampus, However, a more 
complicated situation can occur here, as either LTD or LTP can develop in synapses 
formed between these neurones and Schaffer collaterals. In contrast to Purkinje cells, 
these cells express RyRs on their spines and are thought to regulate the LTP and LTD 
initiated by Ca2+ entry through AMPA and NMDA receptors on the plasma membrane 
(Korkotian and Segal, 1998; Emptage et al., 1999).
With regard to nAChR, a recent paper has suggested that, via Ca2+ release from 
intracellular stores, nicotinic stimulation can produce long-term changes in the intracellular 
messenger, pCREB, and enhanced expression of targeted genes, without the involvement 
of VOCCs (Chang and Berg, 2001). In fact, the repeated activation of VOCCs inhibited the 
transcriptional effects of nAChR activation, suggesting a novel role for VOCCs in gene 
regulation.
In addition to being involved in synaptic plasticity, there is also evidence that Ca2+ 
stores may be involved in the release of several neurotransmitters (see Berridge, 1998). 
Classically, such release was thought to be initiated by influx of Ca2+ through VOCCs. It is 
only in recent years that release of Ca2+ from intracellular stores has been implicated in
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such exocytotic events. It is not inconceivable that activation of either IP3Rs or RyRs may 
be capable of creating localised elevations of [Ca2+]i high enough to initiate the processes 
leading to exocytosis and neurotransmitter release. However, for this to occur the plasma 
membrane must come into close contact with the ER. Such physical juxtapositioning was 
noted some 15 years ago (Westrum and Gray, 1986) and only now is this observation 
helping to explain how neurotransmitter release may occur following activation of 
intracellular Ca2+ stores. Several studies have noted exocytosis following release of Ca2+ 
from internal stores, with IP3 sensitive stores implicated in exocytosis from pituitary 
gonadotrophs (Tse et al., 1997) and ryanodine sensitive stores implicated in exocytosis 
from guinea pig sympathetic nerve terminals (Smith and Cunnane, 1996), bullfrog 
sympathetic ganglia (Peng, 1996) and rat chromaffin cells (Guo et al., 1996). With regard 
to DA release, intracellular stores have been implicated in DA release from PC12 cells 
(Koizumi and Inoue, 1998) and more recently, from human mesocortical derived 
synaptosomes (Bonanno et al., 2000). The mechanism proposed in the latter study 
involved a dantrolene and heparin sensitive mobilisation of Ca2+ from the ER evoked by 
caffeine. The authors concluded that caffeine-evoked DA release is caused by the 
mobilisation of Ca2+ from the ER which subsequently initiates exocytosis, an interaction 
shown to be independent of external Ca2+. These observations were partly responsible for 
prompting the present investigation as to whether a similar situation occurs to stimulate 
DA release from rat striatal synaptosomes (section 6.5.2). However, before performing 
these studies, we thought it judicious to first examine changes in [Ca2+]i in response to 
nicotine by direct monitoring in a neuronal cell line (section 6.5.1).
6.3 Measurement of changes in [Ca2+]i
With the discovery that Ca2+ is involved in some of the major cellular and physiological 
processes in vertebrates, attempts were made to measure concentrations of the ion inside 
cells. The first successful measurements were preformed by Ridgeway and Ashley in 
1967, in barnacle muscle using the photoprotein, aequorin (for a comprehensive review of 
Ca2+ indicators see Takahashi et al., 1999). However, the real quantum leap in the field of 
[Ca2+]j measurement came in the 1980s when Tsien and colleagues synthesised a variety 
of fluorescent indicators enabling the robust investigation of intracellular Ca2+ transients. 
Coupled with the development of the confocal laser scanning microscope, precise 
quantitative, temporal and spatial measurements of intracellular Ca2+ are now performed 
in a variety of living tissue types and cells, including cultured cells and cell lines.
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6.3.1 The principle of fluorimetry
Certain molecules, called fluorophores or fluorescent dyes, have the ability to fluoresce 
on exposure to an external source of energy. Fluorescence is the result of a three-stage 
process that occurs in certain molecules.
• Stage 1 : Excitation
A photon of energy hvEX is supplied by an external source such as an incandescent lamp 
or a laser and absorbed by the fluorophore, creating an excited electronic singlet state
(S i’)-
• Stage 2 : Excited-State Lifetime
The excited state exists for a short time (typically 1-10 x 10'9 seconds). During this time,
t
the fluorophore undergoes conformational changes and is also subject to a multitude of 
possible interactions with its molecular environment. These processes have two important 
consequences. First, the energy of Si' is partially dissipated, yielding a relaxed singlet 
excited state (Si) from which fluorescence emission originates. Second, not all the 
molecules initially excited by absorption (Stage 1) return to the ground state (S0) by 
fluorescence emission. Other processes such as collisional quenching, fluorescence 
energy transfer and intersystem crossing may also depopulate Si. The fluorescence 
quantum yield, which is the ratio of the number of fluorescence photons emitted (Stage 3) 
to the number of photons absorbed (Stage 1), is a measure of the relative extent to which 
these processes occur.
• Stage 3 : Fluorescence Emission
A photon of energy fwEM is emitted, returning the fluorophore to its ground state So. Due to 
energy dissipated during the excited-state lifetime, the energy of this photon is lower, and 
therefore of longer wavelength than the excitation photon hvEX.
With regard to these processes, many Ca2+-sensitive dyes have been developed (see 
section 6.3.5) that alter their spectral characteristics on binding of the ion, with this change 
forming the basis of detection of [Ca2+]j.
6.3.2 Fluorescence spectra
The entire fluorescence process is cyclical. Unless the fluorophore is irreversibly 
destroyed in the excited state, the same fluorophore can be repeatedly excited and 
detected.* With few exceptions, the fluorescence excitation spectrum of a single 
fluorophore species in dilute solution is identical to its absorption spectrum. Under the
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same conditions, the fluorescence emission spectrum is independent of the excitation 
wavelength, due to the partial dissipation of excitation energy during the excited-state 
lifetime. Additionally, the emission intensity is proportional to the amplitude of the 
fluorescence excitation spectrum at the excitation wavelength.
6.3.3 Fluorescence detection
Four essential elements of fluorescence detection systems can now be recognised 
from the points discussed above:
1. An excitation source
2. An excitable fluorophore
3. Wavelength filters to isolate emission photons from excitation photons
4. A detector that registers emission photons and produces a recordable output,
either as an electrical signal or video image
Compatibility of these four elements is essential for optimising fluorescence detection and 
a general diagram showing their layout in a typical fluorimeter is shown in Figure 6.6.













6.3.4 Ca2+ sensitive fluorophores
The development of indicator dyes selective for Ca2+ has enabled the accurate 
measurements of the changes in Ca2+ concentrations that occur within living systems to 
be monitored in real-time by a variety of methods including fluorescence microscopy, flow 
cytometry and fluorescence spectroscopy. The fluorescent indicator itself is normally a 
derivative of one of the Ca2+ chelators EGTA, APTRA or BAPTA. At present, a wide range 
of indicators for Ca2+ are available, each having their own distinct properties that must be 
taken into account in selecting the correct dye.
1. Indicator form (salt, AM ester or dextran conjugate)
The chemical form of the dye has a bearing on the method of cell-loading and may also 
effect the intracellular distribution and retention of the indicator. The salt and dextran 
forms of indicator dyes cannot enter cells by diffusion and so are typically loaded by 
microinjection, electroporation, or patch-pipette perfusion. In contrast, the cell permeant 
acetoxymethyl (AM) esters can be passively loaded into cells, where they are cleaved to 
cell impermeant forms by intracellular esterases.
2. Measurement mode
The requirement for qualitative or quantitative measurements of ion concentrations is 
also an important factor when considering the type of indicator. Ion indicators that exhibit 
spectral shifts upon ion binding can be used for ratiometric measurements of Ca2+ 
concentration, which are essentially independent of uneven dye loading, cell thickness, 
photobleaching and dye leakage. Excitation and emission wavelength preferences 
depend on the type of instrumentation being used, as well as on sample autofluorescence 
and on the presence of other fluorescent or photoactivatable probes in the experiment.
3. Dissociation constant (Kd)
This must be compatible with the Ca2+ concentration range of interest. Generally, 
indicators have a detectable response in the concentration range from approximately 0.1 x 
Kd to 10 x Kd. For ratiometric indicators, the Ca2+ response range is also somewhat 
dependent on the measurement wavelengths used. The Kd of Ca2+ indicators can fluctuate 
due to a variety of factors, including pH, ionic strength, viscosity, temperature, protein 
binding and the presence of Mg2+ and other ions. Consequently, Kd values for intracellular 
indicators are usually significantly higher than corresponding values measured in cell-free 
solutions.
194
___________________________________________________________________________________ Chapter 6 |
6.3.5 Ratiometric dyes
These indicators have the advantage of providing quantitative data on changes in 
[Ca2+]j. The foremost compounds in common use today are those based on fura-2, indo-1 
and to a lesser extent, quin-2.
6.3.5.1 Fura-2
Fura-2 is a widely used ratiometric dye based on the selective Ca2+ chelator, EGTA. 
Upon binding Ca2+, fura-2 exhibits an absorption shift that can be observed by scanning 
the excitation spectrum between 300 and 400 nm, whilst monitoring the emission at ~ 510 
nm (Figure 6.7). It has become the dye of choice for ratio-imaging microscopy, in which it 
is more practical to change excitation wavelengths than emission wavelengths. However, 
it is not commonly used in confocal scanning microscopy or flow cytometry as it is 
impractical to rapidly change excitation wavelengths using these types of instruments.
Figure 6.7 Chemical structure and absorbance/emission spectra of fura-2.
Fluorescence excitation (solid lines; detected at 510 nm) and emission (broken lines; excited at 
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6.3.5.2 lndo-1
The design of this indicator is based on the structure of the Ca2+ chelator BAPTA. 
When in a Ca2+-free environment, the emission maximum of indo-1 is -  475 nm and this 
shifts to ~ 400 nm when the dye is saturated with Ca2+ (Figure 6.8). Indo-1 has some 
advantages over fura-2 as it does not require specialised quartz optics for microscopy and 
may be less prone to compartmentalisation than fura-2. However, indo-1 is much more
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susceptible to photobleaching than fura-2, with the result being a potential increase in the 
signal-to-noise ratio (Wahl et al., 1990). Indo-1 is the preferred dye for flow cytometry, 
where it is more practical to use a single laser for excitation and monitor two emission 
wavelengths.
Figure 6.8 Chemical structure and absorbance/emission spectra of indo-1. Absorption 
and fluorescence emission (excited at 338 nm) spectra of Ca2*-saturated ( —) and Ca2+-free (—) 
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6.3.6 Non-ratiometric dyes
These types of indicator differ to ratiometric dyes as they are only excited at one 
wavelength, which does not change on binding of Ca2+. As a result [Ca2+]i in cells can only 
be estimated.
6.3.6.1 Quin-2
This was one of the first-generation dyes developed by Tsien and co-workers (Tsien, 
1980; reviewed by Tsien and Pozzan, 1989). Quin-2 has several disadvantages when 
compared to some of the other indicator dyes available, such as lower absorptivity and 
quantum yield values, with the resulting requirement of higher loading concentrations. 
Consequently, high intracellular concentrations of quin-2 may buffer Ca2+ fluxes.
6.3.6.2 Rhod-2
The use of this compound has proved advantageous in those tissues that exhibit high 
levels of autofluorescence and in detecting Ca2+ release generated by photoreceptors and 
photoactivatable chelators (Ranganathan et al., 1994). Recently it has been used to 
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membrane (Trollinger et al., 1997). This was achieved through modifications to the 
loading conditions (e.g. temperature, time), allowing the dye to be selectively loaded into 
the mitochondria. It is known as a long-wavelength Ca2+ indicator, as can be seen from its 
absorption/emission spectra in Figure 6.9.
Figure 6.9 Chemical structure and absorbance/emission spectra of rhod-2.
Absorption and fluorescence emission spectra o f Ca2+-saturated rhod-2 in pH 7.2 buffer (data 
modified from Haugland, 2001).




Fluo-3 was developed by Tsien and colleagues (Minta et al., 1989) and is essentially 
non-fluorescent unless bound to Ca2+, unlike the AM esters of fura-2 and indo-1. It also 
differs to fura-2 and indo-1 in that its excitation and emission spectra are within the optical 
spectrum, as opposed to UV spectrum, and so is detectable using conventional optical 
filters (Figure 6.10). It is the ideal Ca2+ indicator for use in CLSM and flow cytometry and 
as a result has become one of the most popular visible wavelength indicators. It has a 
of 400 nM and on binding Ca2+, undergoes a 40 to 100 fold increase in fluorescence. 
Ratiometric measurements may be made with the dye by dual-loading it with a longer 
wavelength dye such as fura red or with Ca2+-insensitive indicators, such as rhodamine 
and Texas red. Recently, an improved version of fluo-3, named fluo-4, has been 
developed, where the two chorine atoms have been replaced by fluorine (Gee et al., 
2000). The result of this substitution is a greater quantum yield to almost double that of 
fluo-3 without a significant change in baseline fluorescence. Fluo-4 also offers faster 
loading times than fluo-3. Several other indicators are available that are based on fluo-3. 
Fluo 3FF and fluo 5N have a lower affinity for Ca2+, whilst fluo-LR is a leakage resistant 
form of the dye.
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Figure 6.10 Chemical structure and absorbance/emission spectra of fluo-3. Absorption 










In section 6.5 results are presented using fluo-3 to monitor changes in [Ca2+]j in a 
model neuronal cell line. At the time these experiments were performed, fluo-4 was a 
novel compound and not well characterised, in addition to being expensive. For these 
reasons fluo-3 was used as the dye of choice.
6.4 Overall aims
A recent report has suggested that intracellular Ca2+ stores are involved in DA release 
from striatum (Bonanno et al., 2000). Therefore, it was decided to investigate the 
possibility that in addition to extracellular Ca2\  nAChR-evoked DA release may involve 
Ca2+ release from intracellular stores. However, before undertaking such work, it was 
prudent to characterise the relationship between nAChR and sources of Ca2+ in detail, in a 
model neuronal system using a high-throughput technique. Consequently, experiments 
presented in this chapter can be divided into two sections.
In the first section the relationship of particular nAChR subtypes and different Ca2+ 
sources in the nicotine-evoked modulation of intracellular Ca2+ signals is explored. The 
human neuroblastoma SH-SY5Y cell line is used here as a model neuronal system. This 
clonal cell line was initially derived through sequential subcloning from the SHSY cell line 
and the parental epithelial cell-like subclone of the SK-N-SH human neuroblastoma- 
derived cell line, cultured from a biopsied, metastatic tumour, diagnosed as a peripheral 
neuroblastoma (Lukas et al., 1993). This cell line, of sympathetic adrenergic ganglion 
origin, expresses two classes of nAChR.
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1. Ganglionic type nAChR, which are normally post-synaptic, and are tentatively 
composed of the a3, a5, 02 and 04 subunits (Wang et al., 1998)
2. Neuronal type nAChR that bind a-Bgt and are composed of a 7 subunits (Lukas et 
al., 1993; Peng et al., 1994b; Ridley et al., 2001)
Figure 6.11 Human neuroblastoma SH-SY5Y cell morphology (X 40 magnification).
Cells were cultured to 70 % confluency, as described in section 2.5.2, and photographed under 
bright phase contrast. Cell bodies and dendrites can be clearly seen.
Although it has been previously shown that stimulation of SH-SY5Y cells with nicotinic 
agonists can increase intracellular Ca2+ concentrations (Ridley et al., 2002), the sources of 
Ca2+ have not been well characterised. Therefore, in this chapter, results are presented 
that dissect the contributions of various subtypes of nAChR to the nicotine-evoked 
increase in intracellular Ca2\  and demonstrate that these subtypes are differentially 
coupled to specific sources of Ca2+. In particular, results show that besides Ca2+ influx 
through nAChR and VOCC, the stimulation of nAChR can also induce Ca2+ release from 
ryanodine- and IP3-dependent intracellular stores. These experiments allowed us to better 
define Ca2+ dynamics in these cells with a view to proceeding to examine the possible 
involvement of intracellular Ca2+ stores in DA release from striatal synaptosomes. Ca2+ 
fluorimetry experiments in this section were performed in conjunction with Dr Federico 
Dajas-Bailador. In the second section of this chapter the involvement of intracellular Ca2+ 
stores in the modulation of [3H]DA release from rat striatal synaptosomes is investigated. 
In this case some of the experiments were performed in conjunction with Mr Andrew 




6.5.1 Contribution of intracellular Ca2+ stores to increases in [Ca2+]j
after nAChR stimulation in SH-SY5Y cells
The protocol followed to monitor [Ca2+]j in SH-SY5Y cells is described in detail in 
section 2.5. Briefly, SH-SY5Y cells were grown on 96 well plates until confluent. They 
were loaded for 1 h with the Ca2+ sensitive dye, fluo-3 AM (10 pM). Cells were then 
washed and pre-incubated with drugs before stimulation with nicotine or KCI using a 
Fluoroskan Ascent™ fluorimeter equipped with filters to excite the dye at 485 nm and to 
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6.5.1.1 Intracellular Ca2+ changes in response to non-specific stimulation by 
KCI
Preliminary experiments were concerned with determining whether intracellular Ca2+ 
stores were involved after the non-specific stimulation of SH-SY5Y cells (Figure 6.12). 
The short term protocol was used in cells loaded with the Ca2+-sensitive dye fluo-3 AM, 
with stimulation by 20 or 50 mM KCI. Inhibitors were chosen that affected various Ca2+ 
sources (VOCCs or intracellular Ca2+ stores) that could be involved in the modulation of 
intracellular Ca2+. These were ryanodine, used at a concentration that blocks the RyR on 
the ER, CPA, an inhibitor of the Ca2+/ATPase pump that is responsible for refilling the
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stores, and cadmium chloride, a non-specific blocker of VOCCs in the plasma membrane 
of the cells (see section 2.5.1 for references regarding concentrations of the drugs used). 
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Figure 6.12 KCI stimulation and the 
contribution of various sources of Ca2+ to 
the increase in intracellular Ca2+. Two
concentrations of KCI (A; 20 & 50 mM) were 
compared in their capacity to evoke 
increases in [Ca2+]i in SH-SY5Y cells. Cells 
were also stimulated with (B) 20 or (C) 50 
mM KCI in the presence or absence of 
ryanodine (30 pM), CPA (20 pM), CdCI2 (100 
pM). Blocking agents were incubated with 
the cells for 15 min, before addition of KCI. 
Fluorescence was monitored for 20 s after 
KCI stimulation. Values at the 20 s time point 
are expressed as a percentage of the 
corresponding KCI control response, 
measured in parallel. Data represent the 
mean ±  S.E.M. of at least 3 independent 
experiments with quadruplicate repeats. ** p 
< 0.01, significantly different from KCI 
stimulation, one-way ANOVA with Tukey’s 
post-hoc test, f t  p < 0.01, significantly 
different from all other treatments; one-way 
ANOVA with Tukey’s post-hoc test.
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Responses to the higher concentration of KCI (50 mM) were approximately double that 
of the lower concentration of 20 mM, and rapidly reached a plateau ~ 10 s after KCI was 
applied (Figure 6.12 A). In the presence of Cd2+, levels of fluorescence evoked by both 
concentrations of KCI were dramatically reduced by over 80 % in both cases (Figure 6.12.
B & C), suggesting VOCCs are the main element that contributes to intracellular Ca2+ 
increases in this paradigm. Addition of ryanodine, a selective blocker of Ca2+-induced Ca2+ 
release from ryanodine-sensitive stores, also reduced the KCI-evoked increases in 
fluorescence, but in a non-significant manner (Figure 6.12. B & C). However, application 
of CPA, which causes depletion of Ca2+ from internal stores, significantly reduced 
increases in fluorescence induced by 20 mM and 50 mM KCI by 34.1 ± 5 and 16.0 ±
3.3 %, respectively (Figure 6.12. B & C) *
Results in Figure 6.12 provided initial evidence that VOCCs and intracellular Ca2+ 
stores can contribute to the rise in [Ca2+]i after stimulation. Therefore, in the following 
experiments the non-specific KCI depolarisation was replaced by nicotine, in order to 
specifically activate the nAChR present in SH-SY5Y cells. Initially, the concentration range 
over which nicotine elicited an optimum response was determined by application of 
increasing concentrations of the agonist to SH-SY5Y cells loaded with fluo-3 AM.
In Figure 6.13, nicotine (1 -  300 pM) caused a concentration dependent increase in 
[Ca2+]i with an EC5o value of 37 pM, similar to that determined previously in our laboratory 
with another Ca2+ sensitive dye, fura-2 (Ridley et al., 2002). From these findings, a modest 
concentration (30 pM) of nicotine was chosen for use in subsequent experiments as this 












Figure 6.13 Nicotine concentration-response curve. SH-SY5Y cells loaded with fluo-3 
AM were stimulated with concentrations of nicotine between 1 -  300 pM and fluorescence 
monitored at 538 nm for 20 s. The response to 100 juM nicotine was taken as 100 % and all 
other values expressed as a percentage of this. Data points for the concentration-response 
cun/e were fitted to the Hill equation. All values are the mean ±  S.E.M. from at least 3 separate 
experiments. Inset: A representative trace of the increase in fluorescence evoked by 30 juM 
nicotine.
6.5.1.2 Multiple subtypes of nAChR contribute to the initial increase in 
[Ca2*],
The relative contributions of a variety of nAChR subtypes and different [Ca2+]j sources 
to the initial (20 s) rise in fluorescence evoked by 30 pM nicotine were examined (Figure 
6.14). The dependence on extracellular Ca2+ was examined in buffer containing 0 [Ca2+] 
with the addition of the selective Ca2+ chelator, EGTA. Mecamylamine (10 pM) was used 
to inhibit all nAChR present. To define the nAChR subtypes involved, maximally effective 
concentrations (see section 2.5.1) of the a7 nAChR selective antagonists a-Bgt (40 nM) 
and a-CTx Iml (1 pM), the a3(34* selective antagonist a-CTx AulB (1 pM) or the a3|32*- 
selective antagonist a-CTx Mil (200 nM) were used.
In SH-SY5Y cells, the nicotine-evoked increase in fluo-3 fluorescence was totally 
dependent on extracellular Ca2+, as virtually no response was observed when cells were 
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Figure 6.14 Contribution of nAChR subtypes to the nicotine-evoked increase in 
intracellular Ca2+. SH-SY5Y cells loaded with fluo-3 AM were stimulated with 30 pM nicotine in 
the presence or absence of Ca2+ (0 [Ca2+]  + 5 mM EGTA), mecamylamine (mec; 10 pM), a-CTx 
Mil (200 nM), a-CTx AulB (1 pM), a-CTx Iml (1 /jM) or a-Bgt (40 nM). Nicotine stimulation was 
also carried out after co-incubation with a-CTx Mil plus a-CTx Iml or a-Bgt. Antagonists were 
incubated with the cells for 15 min, or 30 min in the case of a-Bgt, and a-CTx Mil plus a-Bgt, 
before addition of nicotine. Fluorescence was monitored for 20 s after nicotine stimulation. 
Values at the 20 s time point are expressed as a percentage of the nicotine control response, 
measured in parallel. Data represent the mean ±S.E.M. of at least 4 independent experiments 
with quadruplicate repeats. ** p <  0.01, *p< 0.05, significantly different from nicotine stimulation, 
one-way ANOVA with Tukey’s post-hoc test; or t  p < 0.05, significantly different from nicotine 
stimulation in the presence of a-CTx Mil, one-way ANOVA with Tukey’s post-hoc test.
In standard conditions (1.8 mM extracellular Ca2+), pre-incubation with mecamylamine 
(10 pM; Figure 6.14) also completely prevented the nicotine-evoked increase in 
fluorescence, confirming nicotine is acting through nAChR. In the presence of each of the 
other antagonists, nicotine-evoked responses were significantly inhibited by about 20 % 
(Figure 6.14). Co-application of a-CTx Mil plus a-Bgt or a-CTx Iml produced an additive 
effect, inhibiting the response to 30 pM nicotine by about 40 %, a level of inhibition 
significantly different from the inhibition caused by the antagonists alone (Figure 6.14). 
These results suggest that the a3p2*, a3(34* and a7* nAChR all contribute to the 
increases in [Ca2+]j. However, initial results with KCI suggested that VOCC were also
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involved in the response to nicotine, therefore the next series of experiments aimed to 
analyse this contribution further.
6.5.1.3 Contribution of VOCC dependent and independent Ca2+ influx
As mentioned above, this set of experiments aimed to dissect the contribution of 
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Figure 6.15 Contribution of VOCC-dependent and -independent Ca2* influx to the 
nicotine-evoked elevation of intracellular Ca2+. SH-SY5Y cells loaded with fluo-3 AM were 
stimulated with 30 pM nicotine after incubation with CdCI2 (100 pM) or nifedipine (nif; 5/jM), and 
after co-incubation with CdCI2 plus a-Bgt (40 nM) or a-CTx Mil (200 nM), and nifedipine plus a- 
Bgt or a-CTx Mil. Antagonists were incubated with the cells for 15 min, or 30 min in the case of 
a-Bgt plus CdCI2 and a-Bgt plus nifedipine. Fluorescence was monitored for 20 s after nicotine 
stimulation. Values at the 20 s timepoint are expressed as a percentage of the nicotine control 
response, measured in parallel. Data represent the mean ±  S.E.M. of at least 5 independent 
experiments with quadruplicate repeats. All drug treatments were significantly different from 
nicotine stimulation, (p < 0.01, one-way ANOVA with Tukey’s post-hoc test). ** p < 0.01 and * 
p< 0.05 significantly different from CdCI2 or nifedipine as indicated (Student’s t-test)
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As observed with KCI (Figure 6.12 B & C), CdCI2 (100 pM) blocked more than 80 % of
the nicotine-evoked increase in fluorescence (Figure 6.15), indicating that VOCCs
mediate the majority of the response. The residual nicotine-evoked increase in
fluorescence in the presence of CdCI2 was significantly decreased, by a further 9 %, by
co-application of a-Bgt and CdCI2 (Figure 6.15). The L-type VOCC blocker nifedipine (5
pM) inhibited almost 70 % of the nicotine-evoked increase in fluorescence. In the
presence of nifedipine, both a-Bgt and a-CTx Mil produced additional, statistically
significant, reductions of fluorescence of 9 % and 5 % respectively (Figure 6.15).
Together, these results suggest that a7 nAChR are the main mediators of the VOCC-
indeoendent increase in intracellular Ca2+, whereas a3[32* nAChR cause an increase in
*
[Ca2+]j that is dependent on VOCCs.
6.5.1.4 Nicotine-evoked increases in [Ca2+]i includes release from 
intracellular stores
In Figure 6.12 depletion of intracellular Ca2+ stores with CPA reduced the subsequent 
response to stimulation by KCI. To establish if intracellular Ca2+ stores also contributed to 
the overall increase in cytoplasmic Ca2+ evoked by nicotine we used selective inhibitors of 
IP3- and ryanodine-sensitive stores.
Pre-incubation with ryanodine (30 pM), a selective blocker of Ca2+-induced Ca2+ 
release from RyRs, produced a significant decrease (39 %) in the nicotine-evoked rise in 
fluorescence measured at 20 s (Figure 6.16). No further inhibition was observed when a- 
Bgt or a-CTx Mil was co-applied with ryanodine (Figure 6.16). Xestospongin-c (10 pM), a 
membrane permeant non-competitive inhibitor of IP3 receptors (Gafni et al., 1997), 
produced a greater level of inhibition than ryanodine (60 %, Figure 6.16), and when 
applied together, the two agents showed a partially additive effect, reducing the nicotine- 
evoked response by 77 % (Figure 6.16).
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Figure 6.16 Contribution of intracellular Ca2* stores to the nicotine-evoked increase in 
intracellular Ca2*. SH-SY5Y cells loaded with fluo-3 AM were stimulated with 30 pM nicotine 
after incubation with ryanodine (Rya; 30 pM), xestospongin-c (Xec; 10 pM), or after co- 
incubation with ryanodine plus a-Bgt (40 nM) or a-CTx Mil (200 pM) and ryanodine plus 
xestospongin-c. In a separate group of experiments, SH-SY5Y cells were also stimulated with 
30 mM caffeine (Caff). Antagonists were incubated with the cells for 15 min, or 30 min in the 
case of a-Bgt plus ryanodine. Fluorescence was measured for 20 s after nicotine stimulation. 
Values at the 20 s timepoint are expressed as a percentage of the nicotine control response 
measured in parallel. Data represent the mean ±  S.E.M. of at least 4 independent experiments, 
each carried out in quadruplicate. All drug treatments were significantly different from nicotine 
stimulation, p<0.05, Student’s t test. Significantly different from ryanodine is indicated ttp<0.01  
and tp<0.05. One-way ANOVA with Tukey’s post-hoc test.
6.5.1.5 Sustained responses in [Ca2+]i levels after nicotine stimulation
The results presented in the previous figure (Figure 6.16) describe the contribution of 
intracellular Ca2+ stores to the initial phase of the Ca2+ response to nicotine (20 s time 
point; Figure 6.13 inset). We also analysed the involvement of internal Ca2+ stores in the 












Max 10 min Max 10 min
Time (s) 30 nM nicotine
I-------------1
100 nM nicotine
Figure 6.17 Timecourse of fluorescence increase after nicotine stimulation. (A)
Representative traces from SH-SY5Y cells loaded with fluo-3 AM and stimulated with 30 pM 
(green) or 100 pM nicotine (red). Changes in fluorescence were monitored for 10 min. (B) The 
increase in fluorescence in response to 30 pM and 100 pM nicotine stimulation was determined 
at 10 min, as well as the respective maximum values (max). Data are expressed as the 
percentage of Fmax -  Fmin (mean ±S.E.M.), as described in the methods, from at least four 
independent experiments.
Nicotine (30 jxM or 100 pM) produced rapid and significant increases in fluorescence. 
The time course of the response to 30 pM nicotine indicated that maximal fluorescence 
levels were reached within 100 s, and were sustained for the duration of the recording in 
the continued presence of nicotine (10 min; Figure 6.17 A). In comparison, stimulation 
with 100 nM nicotine evoked more rapid increases in fluorescence values (Figure 6.17 A 
& B), with a slightly higher maximum level (Figure 6.17 B). Unlike 30 nicotine, 
stimulation with 100 nicotine did not produce a stable and sustained increase in 




6.5.1.6 Contribution of nAChR to the sustained increase in [Ca2+]j
Results presented in Figure 6.14 showed that pre-incubation with the general nAChR 
antagonist mecamylamine (10 pM) completely prevented the nicotine evoked increase in 
fluorescence, confirming that nicotine exerted its effect through nAChR. The contribution 
of nAChR activation to the sustained elevation in fluorescence after incubation with 30 pM 
nicotine was examined by applying mecamylamine (10 pM) during the nicotine stimulus 
(Figure 6.18 A; red bar).
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Figure 6.18 The effect of mecamylamine on the sustained elevation of intracellular 
Ca2* evoked by nicotine. SH-SY5Y cells were stimulated with nicotine 30 / jM  and fluorescence 
was monitored for 5 min. Then (A) mecamylamine (10 fM ) or (B) buffer was added and 
fluorescence was monitored for further 10 min. Representative traces are shown. (C) 
Percentage inhibition of the nicotine-evoked fluorescence signal after mecamylamine (mec) or 
buffer application, measured at the end of the 15 min recording period. Data represent the 
mean ±  S.E.M. of three independent experiments, each carried out in quadruplicate.
The addition of mecamylamine 150 s after nicotine stimulation (when the maximum 
response had been reached) produced an almost immediate and complete inhibition of 
the nicotine-evoked increase in fluorescence (Figure 6.18 A & C). This would indicate that 
nAChR activation is required throughout the response in order to sustain the long-term 
increase in fluorescence values. When the same application protocol was performed with 
buffer alone (Figure 6.18 B; purple bar), a modest decrease (15 %) in fluorescence was 
observed, which can be attributed to dilution and/or mechanical perturbation of the 
sample. The rapid decrease in the Ca2* signal observed in response to the application of 
mecamylamine indicates that the dye was not rate limiting in determining the duration of
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the response. In fact, the relatively low affinity of fluo-3 for Ca2+, which would give 
comparatively faster dissociation rates (Minta et al., 1989), should allow a good temporal 
resolution of Ca2+ signals, as the bound dye would not artificially extend the time course of 
intracellular Ca2+ elevations. As a result, the inhibition seen with mecamylamine indicates 
that nAChR activation is required throughout the response in order to sustain the long­
term increase in fluorescence.
6.5.1.7 The sustained elevation of [Ca2+]j : Involvement of intracellular Ca2*
In addition to the assessment of the involvement of internal Ca2+ stores in the initial 
response to nicotine (Figure 6.16), the involvement of such stores in the sustained, long­
term increase in fluorescence evoked by 30 t^M nicotine was investigated.
Figure 6.19 The involvement of intracellular Ca2* stores in the sustained elevation of 
intracellular Ca2* after nicotine stimulation. (A) Representative traces of long-term 
fluorescence measurements (10 min) of SH-SY5Y cells loaded with fluo-3 AM and stimulated 
with 30 /JM nicotine in the presence or absence of ryanodine (30 pM; green) or xestospongin-c 
(10 pM; blue). (B) Percentage inhibition of nicotine’s response in the presence of ryanodine or 
xestospongin-c, measured at 20 s or 10 min after stimulation. Data are expressed as a 
percentage of the corresponding nicotine control at that time point and bars represent the mean 
±  S.E.M. of at least 3 independent experiments, each carried out in quadruplicate. All drug 
treatments were significantly different from nicotine response, p<0.05, Student’s t test. 
Significantly different from ryanodine (20 s) or xestospongin-c (20 s) is indicated, tp<0.05, f t  
p<0.01, one-way ANOVA and Tukey’s post-hoc test.
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Pre-incubation with ryanodine (30 pM) produced a significant depression of the nicotine 
response throughout the time course monitored (Figure 6.19 A & B). However, 
comparison of the effect of ryanodine at the initial (20 s) versus the latter phase of the 
response (10 min) showed that it caused greater inhibition at the early stage than at the 
end of the 10 min incubation (Figure 6.19 B; green bars). In contrast, the response to 
nicotine in the presence of xestospongin-c showed a quite different profile (Figure 6.19 A; 
blue trace). The initial inhibition produced by xestospongin-c (60 %) was followed by a 
progressive decrease in the nicotine-evoked fluorescence, resulting in the complete 
abolition of the response by the end of the experiment (Figure 6.19 A & B).
6.5.2 Intracellular Ca2+ stores and DA release from rat striatal 
synaptosomes
In the previous section, we determined the existence of intracellular Ca2+ stores in SH- 
SY5Y cells, that are activated after stimulation of nAChR by nicotine and contribute to the 
majority of the increase in [Ca2+]j. SH-SH5Y cells have also been shown to release the 
neurotransmitter noradrenaline (NA) in response to nicotinic stimulation (Vaughan et al.,
1993). The release of NA was enhanced in the presence of a L-type VOCC agonist (Bay 
K 8644) and completely inhibited in the presence of nifedipine, suggesting that Ca2+ influx 
through VOCC is necessary for release. However, other sources of Ca2+ were not 
examined. Ideally, it would be pertinent to examine whether release of Ca2+ from internal 
stores is involved in NA release. However, in keeping with the focus of this thesis, it was 
decided to perform some preliminary experiments examining [3HJDA release from rat 
striatal synaptosomes. Especially in view of a recent report by Bonanno et al. (2000), who 
determined that caffeine-evoked release of Ca2+ from internal stores can stimulate DA 
release from human neocortical synaptosomes.
In initial experiments a high concentration of caffeine (30 mM) was applied as the 




Rat striatal synaptosomes were loaded with [3H]DA and stimulated for 90 s with 
caffeine or buffer alone. Figure 6.20 shows that caffeine produced a 5.1 % increase in 
[3H]DA release when compared to stimulation with buffer alone (1.4 % increase).
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Figure 6.20 Initial experiments to define caffeine-evoked fHJDA release from rat 
striatal synaptosomes. Synaptosomes were loaded with pHJDA and superfused as described 
in section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity. (A) Release of 
fHJDA over time. Representative traces from one experiment showing the response of 
individual chambers to a 90 s stimulation with either caffeine (30 mM; upper traces) or buffer 
(lower traces) (B) Quantification of responses from the same chambers. fhlJDA release was 
calculated as the area under the peak above basal release (dotted lines) and is presented as 
recorded CPM (left hand graph) or percentage of the total radioactivity remaining at the end of 
the experiment (right hand graph). Values are the mean ±S.E.M. from 3 replicate chambers for 
each condition.
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In the next set of experiments, synaptosomes were exposed to pulses of caffeine (30 
mM) that varied in duration (30, 90 and 180 s; Figure 6.21). This was to determine an 
whether increasing the time of stimulation would evoke a greater level of [3H]DA release.
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Figure 6.21 Comparison of the duration of stimulation with 30 mM caffeine against 
those of buffer. Synaptosomes were loaded with fH ]DA and superfused as described in 
section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity. fH ]DA release 
evoked by caffeine (30 mM) is expressed as a percentage of the response to buffer alone. 
Values are the mean ±  S. E.M. from at least three independent experiments, each consisting of 
two or more replicate chambers. * *p< 0.01, compared to buffer control, Student’s t-test.
Stimulation with caffeine for 90 or 180 s evoked significant increases in [3H]DA release 
compared to buffer only controls, consistent with the findings of Bonanno et al. (2000). 
[3H]DA released by buffer alone was consistently low (for 30 s, 0.212 %; for 90 s, 0.416 %; 
for 180 s, 0.291 %) and did not vary significantly (one-way ANOVA). The effects of 
caffeine on [3H]DA release also exhibited a duration-of-exposure dependent effect. The 
longest exposure time (180 seconds) was selected for use in subsequent experiments, as 
it evoked the most robust responses of all those tested.
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These initial experiments suggested that internal Ca2+ stores may indeed be involved in 
release of [3H]DA from synaptosomes. If intracellular Ca2+ stores are involved then release 
should be independent of the external [Ca2+].
Therefore, experiments were performed to examine the effect of varying the external 
Ca2+ concentration on caffeine-evoked [3H]DA release. Normal [Ca2+] (2.4 mM), low [Ca2+]j 
(nominally 0.1 pM) and Ca2+-free buffers (0 [Ca2+] + EGTA) were used in separate 
experiments as the superfusion buffer and as solvent for drug solutions. The low and 
Ca2+-free buffers were applied as antagonists, that is, after a 20 minute wash period in 
normal Krebs-bicarbonate buffer, the low and Ca2+ free buffers were superfused over the 
synaptosomes for 10 minutes before stimulation and also afterwards for a further 10 or 20 






6 normal [Ca2+] 












Figure 6.22 Effects of decreasing concentrations of Ca2* in the extracellular medium 
on caffeine evoked [*H]DA release. Synaptosomes were loaded with fH]DA and superfused 
as described in section 2.1; 2 min (1 ml) fractions were collected and counted for radioactivity. 
Low Ca2+ buffer (no EGTA) and Ca2*-free (+ 1 mM EGTA) was introduced into the perfusing 
buffer 10 min prior to stimulation for 180 s with caffeine (30 mM). (A) Evoked pHJDA release in 
the presence of the different buffers expressed as a percentage of the response to 30 mM 
caffeine in normal Krebs-bicarbonate buffer. (B) Representative traces from each Ca2* 
condition. Each fraction is calculated as a percentage of the total amount of radioactivity 
remaining at the end of the experiment. Values in both (A) and (B) are the mean ±S.E.M. from 
at least three independent experiments, each consisting of two or more replicate chambers. 
** p<0.01, one-way ANOVA and Tukey’s post-hoc test.
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Results from this experiment are presented in Figure 6.22 A & B. It was determined 
that there was no significant difference between the responses of caffeine in normal [Ca2+] 
and low Ca2+ buffer. However, the Ca2+-free condition significantly reduced the response 
to caffeine by around 80 % (Figure 6.22 A). Figure 6.22 B shows traces of the mean 
caffeine-evoked [3H]DA release in the three different extracellular Ca2+ conditions. The 
reduction in extracellular Ca2+ produced a marked decrease in the level of basal [3H]DA 
overflow. The Ca2+-free condition produced a very low and consistent release of [3H]DA of 
around 1 % of the total cpm. This could represent the ‘ground-state’ basal release caused 
by the random fusion of DA containing vesicles anchored to the presynaptic membrane. 
The additional release caused in the presence of Ca2+ containing media, is likely to 
represent transient, random, local increases in [Ca2+]if that perhaps artee through 
membrane channels or the general ‘leakiness’ of synaptosomal membranes. Further 
evidence for this can be seen in Figure 6.22 B, when normal Krebs bicarbonate buffer is 
re-introduced to the synaptosomes. The resulting elevation of extracellular Ca2+ restores 
the level of basal [3H]DA release to a level similar to that found prior to introduction of the 
Ca2+-free buffer (Figure 6.22 B).
Caffeine has been shown to activate RyRs in the membranes of intracellular Ca2+ 
stores by increasing their sensitivity to Ca2+ (Nehlig et al., 1992; Verkhratsky and Shmigol, 
1996). These receptors may, therefore, represent a potential target for the release of 
[3H]DA by caffeine. According to this hypothesis, blockade of these receptors should 
reduce Ca2+ efflux from intracellular stores and reduce the caffeine-evoked response. 
Ryanodine, as previously described, is a plant alkaloid that at high concentrations (> 1 
pM) is known to block activation of RyR that gate intracellular Ca2+ stores. However, 
Figure 6.23 shows that ryanodine (30 pM) applied in tandem with caffeine (30 mM) 
significantly increased (p<0.05, n=5) [3H]DA release by 31 ±15  %.
As the effects of caffeine were not attenuated by ryanodine, another drug was used 
that also inhibits RyRs, namely dantrolene which, like ryanodine, is known to inhibit Ca2+ 
release from intracellular stores (Verkhratsky and Shmigol, 1996). However, Figure 6.23 
shows that dantrolene also potentiated the caffeine-evoked [3H]DA release, with a 
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Figure 6.23 Blockade of the RyR 
potentiates the effects of caffeine.
Synaptosomes were loaded with fhlJDA 
and superfused as described in section 
2.1; 2 min (1 ml) fractions were collected 
and counted for radioactivity. Antagonist 
(ryanodine, 30 (M  or dantrolene, 1 pM) 
was introduced into the perfusing buffer 
10 min prior to stimulation for 180 s with 
caffeine (30 mM). Evoked fHJDA 
release in the presence of antagonist is 
expressed as a percentage of the 
response to 30 mM caffeine alone. 
Values are the mean ±  S. E M. from at 
least three independent experiments, 








6.5.2.1 Another mechanism for caffeine-evoked DA release?
From the results in Figure 6.22 & Figure 6.23 it appeared that activation of intracellular 
Ca2+ stores may not be the primary mechanism for the enhancement of [3H]DA release by 
caffeine, as it was sensitive to changes in extracellular [Ca2+] and not inhibited by 
ryanodine or dantrolene.
Another reported action of caffeine is antagonism of adenosine receptors (reviewed in 
Garrett and Griffiths, 1997). These receptors are known to be present in the striatum and 
may be located directly on dopaminergic terminals (Ferre et al., 1997). Antagonism of 
these receptors occurs with a much lower concentration (10 -100  pM) of caffeine (Garrett 
and Griffiths, 1997), so it was decided to determine whether lower concentrations of 
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Figure 6.24 The effects of adenosine receptor antagonism on fHJDA release.
Synaptosomes were loaded with fHJDA and superfused as described in section 2.1; 2 min (1 
ml) fractions were collected and counted for radioactivity. Stimulation was for 180 s with caffeine 
at the concentrations indicated (A) or the adenosine receptor antagonist ZM-241385 (B). 
Evoked fHJDA release is expressed as a percentage of the response to a buffer control. Values 
are the mean +S.E.M. from at least three independent experiments, each consisting of two or 
more replicate chambers. (* p<0.05, significantly different from buffer response, one-way 
ANOVA, Tukey post-hoc test).
Data are presented in Figure 6.24 and show that caffeine did indeed enhance [3H]DA 
release at much lower concentrations (30-300 pM) than previously used, although only the 
two highest concentrations of caffeine produced responses that were significantly different 
from the buffer control. In addition the degree of enhancement mirrored that obtained with 
the much higher concentration of 30 mM caffeine. Moreover, the selective adenosine 
receptor antagonist ZM-241385 also caused a significant enhancement of [3H]DA release 




The purpose of the experiments described in this chapter was to assess the role of 
intracellular Ca2+ stores in two different neuronal systems. Firstly, responses evoked by 
nicotine and KCI depolarisation in SH-SY5Y cells loaded with the Ca2+-sensitive dye fluo-3 
were examined, in order to evaluate the proportions of Ca2+ flux from various Ca2+ 
sources, which included a variety of nAChR subtypes, VOCCs, and [Ca2+]j stores. In 
keeping with the main theme of this thesis, superfusion experiments were performed to 
establish whether activation of intracellular Ca2+ stores by caffeine evokes [3H]DA release 
from rat striatal synaptosomes.
«
6.6.1 Activation of intracellular Ca2* stores in the SH-SY5Y cell line
In the first section, intracellular Ca2+ signals generated by the activation of nAChR in 
SH-SY5Y cells loaded with the Ca2+-sensitive dye fluo-3 were investigated. The results 
demonstrate that stimulation of nAChR produces rapid and sustained elevations in 
cytoplasmic Ca2+ levels, which are dependent on the mobilisation of different Ca2+ 
sources, including extracellular Ca2+ influx through nAChR and VOCCs and intracellular 
Ca2+ from internal stores.
Initial experiments were aimed at outlining the sources of Ca2+ that contribute to the 
rise in intracellular Ca2+ levels due to a non-specific stimulus, in this case a depolarising 
concentration of KCI. From the data presented in Figure 6.12 it appeared that both 
VOCCs and Ca2+ stores were involved in the response. The next step was to use a 
specific activator of nAChR. Nicotine was chosen as the agonist and a concentration- 
response curve was constructed demonstrating that nicotine caused a measurable rise in 
intracellular Ca2+ levels that increased with increasing nicotine concentration (Figure 
6.13). Further experiments aimed to analyse the components involved in the rise of 
[Ca2+]„ a modest concentration (30 pM) of nicotine was used that was close to the EC50 
value obtained (37 pM).
The rapid and sustained elevations of intracellular Ca2+ levels in response to nicotine 
stimulation were prevented by the general nAChR antagonist mecamylamine (Figure 6.14 
& Figure 6.18) or when carried out in the absence of extracellular Ca2+, demonstrating that 
activation of nAChR and extracellular Ca2+ influx mediate nicotine-evoked Ca2+ signals in 
SH-SY5Y cells. The persistence of the increase in Ca2+ levels during the 10 min nicotine 
application is in contrast with the rapid desensitisation of nAChR (McGehee and Role,
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1995). However, sustained elevations of intracellular Ca2+ in response to nicotine 
stimulation have been previously observed in hippocampal neurones (Dajas-Bailador et 
al., 2000), chick cilliary ganglia neurones (Shoop et al., 2001) and PC12 cells (Gueorguiev 
et al., 2000). The ability of mecamylamine, applied after Ca2+ levels had reached a 
plateau, to provoke the rapid return of intracellular Ca2+ to basal values, suggests that 
activation of nAChR is required throughout the response in order to maintain the 
sustained elevation in the Ca2+ signal (Figure 6.18 A). This is likely to reflect the inability of 
30 pM nicotine to fully desensitise the entire nAChR population concurrently. As a result, 
there is the probability that at any given time during the nicotine stimulation, a proportion 
of the nAChR population would be responsive to activation by the agonist. This 
interpretation is consistent with the failure to sustain maximum Ca2+ increased at higher 
nicotine concentrations (100 pM; Figure 6.17), which would desensitise a greater 
proportion of nAChR.
The use of selective nAChR antagonists disclosed the contribution of a7, a3(32*, and 
a3|34* nAChR subtypes to the initial Ca2+ increase in response to 30 pM nicotine 
stimulation (Figure 6.18). Although the co-application of a-CTx Mil with the a7 selective 
antagonists was additive, only 40 % of the response to nicotine was inhibited, indicating 
that other nAChR subtypes must also be involved. SH-SY5Y cells express a3, a5, a7, (32 
and (34 nAChR subunits (Lukas et al., 1993, Peng et al., 1994b), which can form a variety 
of nAChR subtypes. Immunoprecipitation studies showed that in SH-SY5Y cells, 56 % of 
the a3* nAChR also contained the (32 subunit (Wang et al., 1996); the presence of an 
a3(32 interface should make such nAChR susceptible to blockade by a-CTx Mil (Cartier et 
al., 1996). In the present study, we show that 20 % of the Ca2+ response is attributable to 
a3(32* nAChR and a3(34* nAChR, whereas 60 % is mediated by non-a7, non-a3(32* 
nAChR subtypes, with a3(34* nAChR as the obvious candidate. The relatively high Ca2+ 
permeability (Ragozzino et al., 1998) and slow rate of desensitisation (Cachelin and Jaggi, 
1991; Vibat et al., 1995) of heterologously expressed a3(34 nAChR may be relevant to the 
sustained Ca2+ changes observed in the present study. However, further experiments 
using the a3(34* selective conotoxin, a-CTx AulB, in combination with the other drugs 
were unable to be performed due to a limited supply and commercial unavailability of the 
toxin.
Despite the high relative Ca2+ permeability of neuronal nAChR, in SH-SY5Y cells, the 
vast majority of the nicotine-evoked increase in intracellular Ca2+ is dependent on the
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activation of VOCCs, as incubation with CdCI2 blocked more than 80 % of the response 
(Figure 6.15). This is consistent with previous studies in. other preparations, including 
hippocampal neurones (Barrantes et al., 1995), chick cilliary ganglia (Rathouz and Berg, 
1994; Shoop et al., 2001) and [3H]DA release from striatal synaptosomes (e.g. Soliakov et 
al., 1995; Soliakov and Wonnacott, 1996). The CdCI2 resistant increase in intracellular 
Ca2+ was not blocked further by a-CTx Mil (Figure 6.15), suggesting that a3f32* nAChR do 
not account directly for any measurable part of the Ca2+ increase. This is compatible with 
the elegant study by Shoop et al. (2001), which concluded that the role of a3* nAChR in 
generating sustained Ca2+ responses in chick cilliary ganglion somatic spines could be 
primarily that of a catalyst for the mediation of membrane depolarisation and VOCC 
activation. In contrast with a-CTx Mil, co-application of a-Bgt and CtiCI2 produced an 
additive effect, which suggests that, unlike a3p2* nAChR, the a7 nAChR subtype may be 
responsible for a component of the Ca2+ increase that is independent of VOCC activation. 
This is consistent with previous results found in chick ciliary ganglia (Rathouz and Berg,
1994) and hippocampal preparations (Gray et al., 1996).
SH-SY5Y cells have been shown to express both L- and N-type VOCC (Morton et al., 
1992). L-type VOCCs appear to be responsible for part of the CdCI2-sensitive response, 
as incubation with nifedipine significantly decreased the nicotine-evoked increase in Ca2+ 
levels (Figure 6.15). However, the ability of dihydropyridines to block the neuronal nAChR, 
especially a3* subtypes (Herrero et al., 1999, and references therein; Shoop et al. 2001), 
compromises the estimation of the extent of the L-type VOCC contribution. Nevertheless, 
co-application of nifedipine and a-CTx Mil resulted in significantly greater inhibition 
(Figure 6.15), implying that non-L-type VOCC are also associated with a3|32* nAChR. 
This is in agreement with the findings of Kulak et al. (2001), interpreted in favour of a 
functional association between a3|32* nAChR and N-type VOCC in rat brain 
synaptosomes.
It is widely recognised that neuronal Ca2+ signals initiated by voltage- or receptor- 
operated Ca2+ permeable channels can induce mobilisation from intracellular Ca2+ stores, 
which can play a crucial role in defining complex Ca2+ signals (for reviews see, Simpson et 
al., 1995; Berridge, 1998; Rose and Konnerth, 2001). SH-SY5Y cells have both IP3 and 
RyR (Mackrill et al., 1997), and we have shown that both contribute to the nicotine-evoked 
Ca2+ signals. Indeed, pre-incubation with ryanodine prevented a significant part of the 
nicotine-evoked elevation in cytoplasmic Ca2+, suggesting that Ca2+ influx (through the 
nAChR receptor itself, or through VOCCs), provokes Ca2+ induced Ca2+ release from
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ryanodine-dependent storage sites (Figure 6.16). Additional confirmation of the existence 
of functional ryanodine sensitive Ca2+ stores was provided by the observed increase in 
Ca2+ levels after caffeine, a widely used stimulator of RyRs (Verkhratsky and Shmigol,
1996). Although Ca2+ release from ryanodine dependent stores contributes to both the 
initial and sustained Ca2+ elevation in response to nicotine (Figure 6.16 and Figure 6.19 
A), the influence of Ca2+ release from this source seems to decrease with time, as 
ryanodine produced a larger inhibition during the initial phases (Figure 6.19 B). In 
contrast, Ca2+ released via IP3 receptors, disclosed by inhibition with xestospongin-c, 
plays a fundamental role in the maintenance of sustained Ca2+ responses evoked by 
nicotine (Figure 6.19). IP3 receptors are sensitive to both Ca2+ and the intracellular 
messenger IP3. In PC12 cells, it has been demonstrated that nicotine stimulation can lead 
to the production of IP3 (Gueorguiev et al., 1999), while IP3 dependent storage sites are 
involved in the long-term elevations of intracellular Ca2+ concentrations after activation of 
nAChR in the PC12 cell line (Gueorguiev et al., 2000). The functional interaction of 
ryanodine- and IP3-dependent Ca2+ stores has been described as a key signalling 
mechanism in neurones (Simpson et al., 1995; Berridge, 1998). Interestingly, the inhibition 
of the response to nicotine obtained after the simultaneous addition of ryanodine and 
xestospongin-c was only partially additive (Figure 6.16), suggesting that part of the store 
dependent Ca2+ release occurs through sequential activation of ryanodine- and IP3- 
receptor dependent Ca2+ stores.
It is increasingly assumed that the diversity of Ca2+ mediated signals is accomplished 
by the segregation of precise Ca2+ sources with particular intracellular signalling 
cascades. The functional and spatial heterogeneity of Ca2+ sources appears to be crucial 
for the simultaneous control of cellular functions by Ca2+ dependent mechanisms 
(Johnson and Chang, 2000). In this regard, the observation that a-Bgt produced no further 
inhibition in the presence of ryanodine, may indicate that the increase in Ca2+ levels 
mediated by the a7 nAChR is specifically coupled with ryanodine-sensitive Ca2+ stores 
(i.e. Ca2+ influx via a7 nAChR may directly activate RyRs, without the intervention of 
VOCC). The existence of a functional interaction between Ca2+ influx through a7 nAChR 
and Ca2+ induced Ca2+ release from RyRs may be pertinent to the particular activation of 
specific Ca2+-dependent signalling mechanisms by a7 nAChR, such as ERK1/2 and 
CREB signalling (Dineley et al., 2001; Dajas-Bailador et al., 2002).
The results presented here indicate that different nAChR subtypes and various Ca2+ 
sources, namely VOCC and ryanodine- and IP3-dependent Ca2+ stores, mediate the
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elevation of intracellular Ca2+ after nicotine stimulation of neuroblastoma cells. Using 
combinations of antagonists, we deduce that whereas a302* nAChR couple exclusively to 
VOCC, a portion of a l  nAChR-mediated Ca2+ influx may directly activate Ca2+ induced 
Ca2+ release from RyRs. Furthermore, analysis of the sustained elevations of Ca2+ 
indicate that continuous activation of nAChR is required and that IP3-sensitive stores play 
a greater role than RyRs in maintaining the long-term Ca2+ responses after nicotine 
stimulation. These data are summarised in Figure 6.25 and provide insights into the 
complexity of Ca2+ signals emanating from nAChR activation. They also paved the way for 
the initial analysis of the role of intracellular Ca2+ stores in [3H]DA release.
6.6.2 Intracellular Ca2* stores and DA release from rat( striatal 
synaptosomes
In the second section of this chapter, a preliminary investigation of the possible 
involvement of Ca2+ stores in the release of [3H]DA from rat striatal synaptosomes was 
performed. This was prompted by the results obtained from the preceding studies in SH- 
SY5Y cells, and also by the report by Bonanno et al. (2000) implicating intracellular Ca2+ 
stores in the release of [3H]DA by caffeine from human neocortical synaptosomes. In 
contrast to the experiments performed in SH-SY5Y cells, caffeine, rather than nicotine, 
was employed as the stimulus, as it should directly activate intracellular Ca2+ stores, 
namely those mediated by the RyR (Verkhratsky and Shmigol, 1996).
Application of caffeine produced a release of [3H]DA in a duration-dependent manner. 
However, removal of external Ca2+ abolished this effect, excluding a direct triggering of 
exocytosis by release of Ca2+ from intracellular stores. In addition, the RyR antagonists, 
ryanodine and dantrolene, applied in tandem with caffeine, augmented rather than 
reduced [3H]DA release. Further experiments using caffeine at lower concentrations that 
should not release intracellular Ca2+ stores and addition of a selective adenosine receptor 
antagonist hinted that a different mechanism, involving adenosine receptors, may be 
responsible for the increase in [3H]DA release.
Preliminary experiments identified a robust and reproducible release of [3H]DA evoked 
by 30 mM caffeine (Figure 6.20 & Figure 6.21) that increased with the duration of the 
caffeine stimulation, when normalised to buffer-only controls. Such responses mirrored 
those seen in various systems, in other studies examining neurotransmitter release (Guo 
et al., 1996; Tse et al., 1997; Bonanno et al., 2000). This initial result suggested that 
intracellular Ca2+ stores may indeed be involved in [3H]DA release. If this hypothesis is
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valid then the process should be independent of any changes in extracellular [Ca2+] (Guo 
et al., 1996; Bonanno et al., 2000). This was not the case, as removal of Ca2+ from the 
superfusion medium abolished the effects of caffeine completely (Figure 6.22). Caffeine- 
evoked [3H]DA release was examined in three different Ca2+ concentrations - normal 
[Ca2+] (2.4 mM), low [Ca2+] (~ 0.1 pM) and Ca2+-free. Caffeine, however, was unable to 
evoke [3H]DA release in Ca2+-free condition. The characterisation of the relative amounts 
of Ca2+ required for caffeine to affect [3H]DA release suggests that caffeine is stimulating 
[3H]DA release through an alternative mechanism that operates in low concentrations of 
extracellular Ca2+ but is ultimately dependent on the presence of Ca2+ in the buffer.
The kinetics of the response may also give a clue to the mechanisms involved (Figure 
6.22). Most studies examining caffeine-evoked Ca2+ efflux from intracellular stores report 
that release occurs over a timescale of milliseconds to seconds (Friel and Tsien, 1992; 
Korkotian and Segal, 1998) with caffeine-evoked neurotransmitter release occurring on a 
timescale of several seconds (Guo et al., 1996). More importantly, only a short (500 ms) 
application of caffeine was needed in the latter study to evoke a response. In Figure 6.21, 
however, even a 180 s stimulation with caffeine only evoked a moderate amount of [3H]DA 
release, compared to that evoked by a buffer pulse.
The results obtained when RyR antagonists were added were also inconsistent with 
idea that caffeine is activating intracellular Ca2+ stores. Surprisingly, addition of ryanodine 
did not reduce caffeine-evoked [3H]DA release, but rather augmented it (Figure 6.23), 
compared to the effect of caffeine alone. Dantrolene, another drug that prevents Ca2+ 
release from ryanodine-sensitive stores, also increased the caffeine-evoked overflow to 
an even greater extent, compared to that of ryanodine (Figure 6.23). These increases 
were not significant due to the small sample size. Basal release for the ryanodine plus 
caffeine and dantrolene plus caffeine conditions showed no significant differences 
compared to control base lines that lacked these antagonists. Therefore, the increased 
responses were not simply due to an increase in the baseline. These observations are 
contrary to other studies in which the response to caffeine was blocked with ryanodine 
(Guo et al., 1996; Korkotian and Segal, 1998; Bonanno et al., 2000; Sharma and 
Vijayaraghavan, 2001) and are thus difficult to explain as there are no reports in the 
literature of enhancement of responses when ryanodine or dantrolene are applied. 
Overall, these results seem to indicate that the effects of caffeine are at another site 
distinct from the RyR, although the enhancement of release by the blockers of this 
receptor suggests intracellular stores may still be involved.
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It is known that the pharmacological effects of caffeine are widespread, including its 
ability to mobilise intracellular Ca2+ (Verkhratsky and Shmigol, 1996) the inhibition of 
nucleotide phosphodiesterases (Howell et al., 1997) and antagonism of adenosine 
receptors (Carter et al., 1995, Fredholm, 1995). Initial experiments (Figure 6.24 A & B) 
suggest that caffeine elicits [3H]DA release by the latter mechanism, as stimulation with 
low concentrations of caffeine (10 -  300 pM) and by a high concentration of the selective 
adenosine receptor antagonist, ZM-241385 caused the same enhancement of [3H]DA 
release as seen with the high concentration of caffeine (30 mM).
Adenosine receptors are plasma membrane, G-protein coupled receptors of which 4 
subtypes are presently known (Ai, A2A, A2b and A3). Of particular interest is the inhibitory 
Ai subtype, which is known to be present in cortico-striatal and nigro-striatal dopaminergic 
neurones (Ferre et al., 1997) and has been shown to be involved in the modulation of DA 
release (Harms et al., 1979; Michaelis et al., 1979; Jin et al., 1993). If adenosine receptor 
antagonists increase release then conversely adenosine receptor agonists should 
decrease it. Indeed, adenosine has been shown to decrease DA release in both slices 
(Harms et al., 1979) and, with relevance to this study, in synaptosomes (Michaelis et al., 
1979). In vivo microdialysis experiments have demonstrated that infusion of caffeine into 
the striatum of rats increased the extracellular level of DA, an effect mirrored by the 
selective antagonist CPT (Okada et al., 1997). Additionally, infusion of an Ai selective 
agonist, decreased DA levels whilst A2 selective ligands did not effect DA levels (Okada et 
al., 1997). Thus, the Ai adenosine receptor would appear to be a potential substrate for 
the effects of caffeine.
Of course, for inhibition of adenosine receptors to occur they must first be active. This 
could occur during DA release due to the presence of the endogenous ligand, adenosine, 
generated in the following manner. ATP (or adenosine itself) can be co-released with DA 
from nerve terminals as a part of endogenous neurotransmission, the subsequent 
degradation of ATP by 5’nucleoside in the extracellular media could then generate free 
adenosine. The existence of endogenous adenosine in rat striatal synaptosomes is 
supported by a study in which an adenosine-metabolising enzyme (ADA) was added prior 
to a releasing stimulus. It was found that the level of DA release was increased by 75 % 
over controls (Michaelis et al., 1979). Furthermore, an inhibitor of adenosine uptake 
potentiated the inhibitory effects of ATP by 92 -124 % (Cunha et al., 1998). So it appears 
that, at least in vitro, adenosine receptors may tonically inhibit [3H]DA release from striatal 
terminals.
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Extending this hypothesis, the adenosine receptor effects the cAMP and IP3 signalling 
pathways through activation of the Gj subunit (Klinger et al., 2002). Activation of 
adenosine Ai receptors inhibits phospholipase C, the enzyme that cleaves PIP2 to 
generate IP3 and DAG (Okada et al., 1997). Both these products are important 
intracellular messengers, and have been implicated in the modulation of neurotransmitter 
release, IP3 through Ca2+ store release (Koizumi and Inoue, 1998), and DAG through the 
activation of protein kinase C (PKC; Soliakov and Wonnacott, 2001). Production of both of 
these would be dependent on external Ca2+, thus explaining the sensitivity to levels of 
Ca2+ in the buffer (Figure 6 .2 2 ). One implication of this is that caffeine could be indirectly 
stimulating the release of Ca2+ from IP3R-mediated intracellular stores. PKC, on the other 
hand, is believed to be a stimulator of the exocytotic machinery (Turner et*al., 1999). 
There is evidence that, in some systems, inhibition of PKC blocks neurotransmitter 
release (Soliakov and Wonnacott, 2001), whilst its activation enhances action potential 
evoked DA release from rat and rabbit brain slices (lannazzo et al., 1997) and rat striatal 
synaptosomes (Soliakov and Wonnacott, 2001). The inhibition of adenosine receptors by 
caffeine could, perhaps, influence exocytotic machinery indirectly, through increased PKC 
activity, with the result being enhanced release of [3H]DA.
The effects of RyR antagonists on caffeine-evoked [3H]DA release are hard to explain. 
Given that caffeine acts at the RyR to increase its sensitivity to Ca2+ it was unexpected 
that their blockade would increase DA release. It is unlikely that ryanodine is affecting 
targets elsewhere, as dantrolene, an antagonist of the same receptor, had similar 
consequences. Time constraints precluded further investigation of this phenomenon.
However, the primary action of caffeine does seem to be antagonism of adenosine 
receptors present on the DA terminal, possibly of the subtype. Without further study it 
is impossible to state with any certainty the mechanisms that follow to produce an 
increase in [3H]DA release, although activation of PKC or release of Ca2+ from IP3- 
sensitive intracellular stores are both plausible mechanisms that may occur (Figure 6.26).
An interesting quandary highlighted by this study concerns the use of caffeine as a 
pharmacological tool for the study of Ca2+ stores. It has been exploited as both an 
adenosine antagonist (e.g. Okada et al., 1997), and as a Ca2+ store activator (Koizumi and 
Inoue, 1998; Bonanno et al., 2000). However, the non-specific actions of caffeine could 
lead to misinterpretation of results, especially in in vivo systems, suggesting that it is, 
perhaps, an unsuitable drug for the type of studies performed here.
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6.7 Conclusions
The results presented in the first section of this chapter indicate that different nAChR 
and various Ca2+ sources, including Ca2+ influx through VOCCs and activation of 
ryanodine and IP3 dependent Ca2+ stores, mediate the elevation of intracellular Ca2+ after 
nicotine stimulation. In addition, it appears that a7 mediated Ca2+ signals are directly 
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Figure 6.25 The complexity of intracellular Ca2* dynamics initiated by nAChR activation.
Activation of VOCC constitutes a major component of the nicotine-evoked increase in [Ca2*],. In 
addition, the a l  nAChR increases [Ca2*] independently of VOCC with ryanodine and IP3 sensitive 
stores also involved in the rise in [Ca2*] after nAChR stimulation. Interestingly, the a7-evoked 
increase in [Ca2*] seems to be dependent on ryanodine sensitive Ca2* stores
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In the second section, evidence suggests that intracellular Ca2+ stores are not involved 
in [3H]DA release from rat striatal synaptosomes. Although caffeine did elicit [3H]DA 
release, primarily through the inhibition of presynaptic adenosine receptors, there may be 
several subsequent mechanisms responsible for the ensuing release of [3H]DA.
•  An increased production of DAG leading to enhancement of PKC activity, and 
increased [3H]DA release.
•  An increase in the concentrations of IP3 present in the terminal, through removal of 
inhibition of the enzyme phospholipase C, activating IP3 sensitive stores. The release 
of Ca2+ from intracellular stores could increase the local [Ca2+]j to a level that initiates 
DA release or simply increases the rate of basal release.
Caffeinev Metabotropic
X /A A c ,e n o s 'n e
^Receptor (A ^ )
Dopamine Release
Figure 6.26 Putative model showing the effects of caffeine on fHJDA release from rat 
striatal synaptosomes. Mechanisms are presented here showing the primary action of caffeine at 
adenosine receptors, causing the initiation of a number of possible intracellular pathways that may 
eventually result in initiation of DA release.
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7 Summary, Conclusions and Future Work
7.1 nAChR and modulation of dopamine release
Over the last thirty years, a great deal of progress has been accomplished regarding 
nAChR structure and function, in addition to revelations that nAChR are involved in such 
diverse phenomena as pain, learning and memory, and neuroprotection. The dualistic 
relationship between neuronal nAChR and neurotransmitter release has also been the 
subject of intensive research, especially with regard to the effects of nicotine and addiction 
to tobacco. Currently, it is known that nAChR in the brain are involved in the presynaptic 
modulation of release of several neurotransmitters. Therefore, the work presented in this 
thesis has attempted to extend the characterisation of striatal nAChR subtypes and their 
involvement in DA release, whilst also analysing their role in the relatively novel concept 
of Ca2+ release from intracellular stores.
The synaptosome allows the neuroscientist to study the responses of neurotransmitter 
receptors in isolated nerve terminals without interference from neurotransmitters released 
from neighbouring terminals. This was the preparation of choice to scrutinise presynaptic 
nAChR mediation of [3H]DA release from the striatum (Chapter 3). Previous evidence 
implicates two populations of nAChR in the modulation of DA release from this region, one 
sensitive to the marine snail toxin, a-CTx Mil and another which is insensitive to the toxin 
(Kulak et al., 1997; Kaiser et al., 1998). Results in Chapter 3 demonstrated that the 
nAChR antagonist MLA, which has previously been thought to selectively inhibit the a7 
nAChR at low nanomolar concentrations, also acts at the a-CTx Mil-sensitive population 
of nAChR in the striatum. The subunit composition of nAChR on DA terminals in the 
striatum was also extended through the use of the alleged a4p2 nAChR selective 
compound l-A-85380 (Mukhin et al., 2000), which proved extremely potent in evoking 
[3H]DA release from synaptosomes. However, release was partially blocked by a-CTx Mil, 
an observation that may indicate that either l-A-85380 also acts at a3/a6p2* nAChR or 
that an a4p2 interface is present in both nAChR populations in the striatum.
As mentioned above, interactions between neurotransmitters are not thought to occur 
in synaptosomes due to their spatial separation. If one wishes to examine such dynamics 
then a more holistic preparation is required. Therefore, experiments described in Chapter 
4 progressed to study [3H]DA release from striatal slices. Release from slices evoked by a 
maximal concentration of nicotine was sensitive to both AMPA/kainate iGluR and a7
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nAChR selective antagonists, which when combined did not produce any additive 
inhibition. These data support the model that proposed that a7 nAChR are located on 
glutamate terminals and are able to elicit the indirect enhancement of DA release through 
release of glutamate (Kaiser and Wonnacott, 2000).
Nicotine is also the psychoactive component in tobacco smoke and is thought to be the 
driving force behind addiction to tobacco products with DA release implicated in some of 
the rewarding and reinforcing properties of the drug. In Chapter 5, rats were chronically 
treated with nicotine prior to measurement of [3H]DA release from striatal slices by 
superfusion. A consistent and significant decrease in [3H]DA release was noted in those 
animals that received nicotine compared to saline treated controls. Moreover, the 
decrease was concurrent with the inability of MLA and kynurenic acid to inhibit release of 
[3H]DA from slices from chronically treated animals. These results suggested that the 
reduction in [3H]DA release was due to long-term inactivation of the oc7 nAChR controlling 
glutamate release. Interestingly, co-application of NMDA with nicotine caused an 
enhancement of [3H]DA release in control animals but not in treated animals, suggesting 
that a phenomenon involving inactivation of either NMDA receptors or subsequent 
intracellular signalling pathways may occur during the course of chronic nicotine 
exposure.
DA release and, indeed, neurotransmitter release in general, is intimately associated 
with increases in intracellular Ca2+ which trigger exocytosis. It now appears that Ca2+ may 
be released into the cytoplasm through a variety of mechanisms, including influx channels 
and from intracellular Ca2+ stores. By using a model neuronal cell line, the contribution of 
various Ca2+ sources to the nicotine-evoked elevation of intracellular Ca2+ was examined.
In addition to direct Ca2+ entry through nAChR themselves, a large portion of the Ca2+ 
influx occurred through VOCCs and from intracellular Ca2+ stores, the latter of which was 
essential to the sustained response to nicotine. After definition of this system, the 
involvement of internal Ca2+ stores in [3H]DA release was examined. Although no direct 
evidence was uncovered for the involvement of intracellular Ca2+ stores, experiments did 
establish the existence of presynaptic inhibition of [3H]DA release by adenosine receptors, 
which may exert a tonic modulation of DA release in vivo.
Extensive research has determined that the striatum and associated structures are 
intimately involved with forms of motor learning and addictive processes (Wise, 2000). 
This is in addition to the discovery that degradation of DAergic neurones in this region 
occurs during Parkinson’s disease (Gibb, 1992). nAChR modulate the release of a
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number of neurotransmitters in the striatum, including 5-HT, GABA, glutamate and DA 
and so could be expected to be involved in the processes described above. As stated 
previously, there appears to be at least three subtypes of nAChR that contribute to the 
modulation of DA release from the striatum (Chapters 3 & 4). If the distinct populations of 
nAChR observed by Klink et al. (2001) in the VTA and SN are extrapolated to the 
striatum, it would indicate that one nAChR population may be located on nigrostriatal 
afferents and another on neurones that project from the ventral tegmental area. The third 
population of putative a l  nAChR is probably located on corticostriatal glutamatergic 
afferents. Differences in these populations with regard to Ca2+ permeability and 
desensitisation times may allow them to subtly affect the extent and duration of DA 
release in response to their endogenous ligand, ACh. However, the complement of 
subunits that combine to form these nAChR is only partly known at present, and may 
differ from those located somatodendritically (Klink et al., 2001). Until this information 
becomes available we can only estimate the properties of nAChR in this region by 
comparison with heterologous expressed nAChR. With relevance to Parkinson’s disease, 
[3H]nicotine binding is reduced in the striatum of PD patients, but a3, a4, a7, and (32 
immunoreactivity is unchanged (Martin-Ruiz et al., 2000), suggesting that the decline in 
radioligand binding involves a nAChR population containing another subunit (e.g. a5 or 
a6). It would be an appealing hypothesis that this reduction involves the a-CTx Mil- 
sensitive population of nAChR on DA neurones. Nicotinic modulation of DA release may 
also be pertinent in light of the fact that there is a negative correlation between cigarette 
smoking and Parkinson's disease, although the explanation for this is not certain at 
present (Fratiglioni and Wang, 2000).
There is also significant interest in the part that nAChR in the striatum, in particular the 
nucleus accumbens, play in the rewarding and motor activating properties of nicotine. This 
has become more relevant in recent years due to the discovery that a l  nAChR can 
participate in LTP like phenomena which could invoke longer lasting synaptic changes 
during cigarette smoking (Radcliffe and Dani, 1998; Mansvelder and McGehee, 2000; 
Girod and Role, 2001). The combination of the high Ca2+ permeability and localisation to 
glutamatergic terminals supports the involvement of a l  nAChR in this proposition. A 
different situation may occur at DA terminals in the striatum, as in Chapter 5 a decrease in 
DA release was noted after chronic nicotine treatment. This may reflect desensitisation/ 
inactivation of the a7 nAChR, rather than the LTP-like process described at the level of 
the cell body.
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Intracellular Ca2+ stores have also received increasing amounts of interest with regard 
to activity-dependent synaptic plasticity (Rose and Konnerth, 2001). Therefore, it was of 
relevance to determine whether such stores were involved in DA release from the 
striatum, especially in light of a recent report that suggests that Ca2+ stores are involved in 
the release of DA from human cortical synaptosomes (Bonanno et al., 2000). Although no 
evidence for the involvement of ryanodine receptor-mediated stores was found (Chapter 
6), intracellular Ca2+ stores may still be present in other cell-types found in the striatum 
(e.g. GABAergic medium-spiny cells). Besides the report by Bonanno et al. (2000), the 
involvement of intracellular Ca2+ stores in neurotransmitter release has only been reported 
in certain regions of the nervous system such as adrenal chromaffin cells (Guo et al., 
1996), pituitary gonadotrophs (Tse et al., 1997) and sympathetic varicosities of guinea pig 
vas deferens (Smith and Cunnane, 1996). It remains to be established whether Ca2+ 
release from intracellular stores is widely involved in release of neurotransmitters in the 
brain, or is mainly confined to specialised groups of neurones.
7.2 Future Perspectives
Despite extensive research in the nicotinic field we are still some way from providing 
answers to several important questions. Those that are relevant to this thesis are outlined 
below.
•  What is the subunit composition of native nAChR?
The range of subtype-selective tools available to the nicotinic community has gradually 
grown over the last decade, but there is still a need for more nAChR subtype selective 
agonists and antagonists. In the future, these may be synthetically produced or derived 
from nature. Marine snails of the genus Conus have already provided some highly useful 
nicotinic ligands, and may still be a source of new compounds due to the large number 
(-50,000) of different peptides found in their venom (McIntosh et al., 1999). In addition, 
nAChR knockout mice have proven invaluable for confirming some of the previous 
speculations regarding subunit composition of native nAChR and should prove to be of 
continued use for dissection of nAChR composition and analysis of nAChR agonists and 
antagonists (Cordero-Erausquin et al., 2000; Champtiaux et al., 2002). Moreover, nAChR 
that contain the p2 subunit have been implicated in the reinforcing properties of nicotine 
(Picciotto et al., 1998) and further behavioural and neuropharmacological studies using 
these mutant mice may prove useful in the area of nicotine addiction. Future research
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involving inducible mutations that target specific nAChR subunit genes would also extend 
our knowledge of neuronal nAChR. They may also solve some of the problems in 
knockout mice that have been encountered regarding the lethality of certain null mutations 
(e.g. a3) and compensation by other nAChR subunits.
•  Where exactly are nAChR located on neurones and are particular nAChR
subtypes associated with specific neurotransmitters or neuronal circuits?
The location of nAChR on the neurone may be of great importance. It is known that
activation of presynaptic nAChR can enhance the release of a number of
neurotransmitters. However, preterminal nAChR may operate to direct action potentials by
<
locally depolarising the axon. This could inactivate Na+ channels present in the membrane 
leading to a block of conduction to specific portions of the axonal ‘tree’ (Khakh and 
Henderson, 2000). In addition, postsynaptic nAChR have only been detected in a few 
neuronal areas, but may be more widespread than first though due to the overwhelming 
presence of excitatory glutamatergic input.
To address these important questions work is currently underway by, amongst others, 
members of our group using electron microscopy and nAChR subunit specific antibodies, 
in order to determine the ultrastructural location of nAChR in the striatum, VTA and SN 
(Wonnacott et al., 2000; Jones et al., 2001). Through additional labelling of enzymes that 
serve as markers of specific neurotransmitters, this technique can also assign nAChR 
subunits to specific types of neurones. Results from these studies should also help to 
resolve the presynaptic and/or preterminal localisation of nAChR in the brain.
•  What is the purpose of presynaptic nAChR?
Although it is known that, in vitro, nicotinic agonists can activate presynaptic nAChR 
and evoke the release of a variety of neurotransmitters, a different situation occurs in vivo, 
as nAChR respond to the endogenous neurotransmitter ACh. However, immunoelectron 
microscopy studies indicate that cholinergic varicosities make few direct synaptic contacts 
(Izzo and Bolam, 1988). This suggests that stimulation of presynaptic nAChR in vivo may 
be through so-called ‘volume’ transmission of ACh, by diffusion from sites of release. If 
this does indeed occur, it suggests that ACh release does not solely effect a single 




Neuronal nAChR have also been implicated in several major brain dysfunctions, such 
as Alzheimer’s disease, suggesting that they may be involved in learning and memory 
processes. This hypothesis is supported by animal studies where nicotine enhances 
working memory (Levin and Simon, 1998). The Ca2+ entry mediated by nAChR may play a 
vital role in these processes, in regulating intracellular signalling pathways and 
enhancing/controlling the responses of other neurotransmitter receptor channels. 
However, we are undoubtedly some way from resolving the exact role of the different 
subtypes of native nAChR and whether certain subtypes regulate particular physiological 
processes.
•  Are nAChR a suitable target for treatment of nicotine addiction? t
Currently, the major treatment to assist smoking cessation is nicotine replacement 
therapy (NRT; Thompson and Hunter, 1998). The rationale behind NRT is to help relieve 
some of the withdrawal symptoms and sensations of craving individuals experience when 
they quit smoking by generating lower and more stable concentrations of nicotine in the 
bloodstream. On average, NRTs only raise your chances of quitting from about 10 to 
20% . Although this is an improvement, it would appear that, perhaps, a different 
approach is required. Indeed, clinical trials of the first widely available non-nicotine 
therapy, known as Zyban™, have produced slightly improved rates of smoking cessation 
(Hurt et al., 1997), especially when combined with the nicotine patch (Jorenby et al., 
1999). Interestingly the active compound involved, bupropion, is both a DA re-uptake 
inhibitor and a nAChR antagonist (Slemmer et al., 2000). Due to the widespread 
distribution of nAChR in the brain, it is plausible that a diverse range of neuronal 
transmitter systems and circuits are affected, some of which may not yet be known or 
understood. Therefore, more advanced therapies involving combinations of agonists 
and/or antagonists of specific neurotransmitter receptors and/or uptake systems, other 
than nAChR, may be required to address the myriad of problems, both physical and 
psychological, that smokers experience during abstinence from smoking.
In summary, research on nAChR has uncovered increasing evidence that they are 
involved in some of the more subtle and intriguing aspects of neuronal function as well as 
being implicated in some of the neurological and pathological disorders that afflict the 
human population today. The growing realisation that nAChR may represent valid targets 
for clinical therapies adds extra urgency to the quest for selective nAChR ligands that 
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"One minute they're in a 
nicotine deprivation experiment. 
Next minute they're gone. "
Natura in minima maxima
Nature is the greatest in the smallest things
Latin Proverb
